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i 
Abstract 
Opioid dependence and opioid related deaths are a public health problem which 
the United States Centers of Disease Control have declared an epidemic. While opioid 
agonist therapy for opioid addiction has been accepted as the most effective treatment 
for opioid dependence among academics, and office based buprenorphine treatment 
has been available in the Unites States for over 10 years, OB buprenorphine faces many 
barriers to widespread adoption. Empirical data on the geographic distribution of 
physicians able to prescribe buprenorphine and the prescribing patterns of those 
physicians show considerable unevenness in access and utilization of treatment 
services. 
 Federal-level policies have recently been implemented to expand access to 
opioid agonist therapy, but the medium and long term impacts of these policy changes 
on individual outcomes, public health, and geographic access equity are not yet clear. 
This dissertation compares two recent federal level policies on expanding access 
to buprenorphine treatment: raising the regulatory limit on the number of patients a 
provider can treat (implemented July, 2016), and extending prescribing privileges to 
nurse practitioners and physician assistants (implemented February, 2017), using an 
empirically supported Agent Based Simulation model.  Policies are assessed by a novel, 
at-a-glance, quantitative access equity metric: the Spatial Potential Access Gini Index, in 
addition to year-end treatment utilization, opioid overdose deaths, and the amount of 
illicit medication diversion.  
ii 
In the simulation, expanding access by increasing the patient limit did not result 
in more equitable spatial access, while extending prescribing to NPs and PAs increased 
both utilization and spatial access equity.  This is likely due to empirically supported 
model assumptions that NPs and PAs providing primary care often serve in medically 
underserved areas including rural and remote regions. Extending prescribing to these 
practitioners opens up new treatment locations changing the spatial distribution of 
treatment opportunities. Changing patient limits does not change the overall spatial 
distribution of services, so spatial access equity does not change even if overall 
treatment supply gets better or worse. 
The primary contribution of this work is the Spatial Potential Access Lorenz Curve 
and the Spatial Potential Access Gini Index, measures that aggregate individual-level 
Spatial Potential Access Scores commonly used in health care geography to map and 
identify areas of access disparity within a region. The equitability of Spatial Potential 
Access is calculated by using the Lorenz Curve, which is commonly used to characterize 
the distribution of wealth or income in a society, from which a Gini Index is 
calculated.  The Spatial Potential Access Gini Index allows for direct comparison of 
complex quantitative information about the geographic distribution of supply and 
demand in a region with other regions, or in response to policies that impact supply or 
demand within the region. The measure has potential applications in simulation studies 
on the spatial allocation of services, allowing equity assessment of policy alternatives, as 
iii 
well as in empirical work, allowing equity comparisons of different regions, or in hybrid 
studies in which policy experiments are conducted on data-rich maps. 
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1 
1 Introduction 
Opioid dependence and opioid related deaths are a public health problem which 
the United States Centers of Disease Control and Prevention (CDC) have declared an 
epidemic. While mediation assisted therapy (OAT) for opioid addiction has been 
accepted as the most effective treatment for opioid dependence among academics, and 
office based (OB) buprenorphine treatment has been available in the Unites States for 
over 15 years, OB buprenorphine faces many barriers to widespread adoption.  Policy 
makers at agencies and professional societies concerned with substance abuse and 
mental health have instituted federal-level policies that could expand access to and 
adoption of OB buprenorphine treatment. The CDC, the Substance Abuse and Mental 
Health Services Administration (SAMHSA), the National Institute on Drug Abuse (NIDA), 
the Health Resources and Services Administration (HRSA), and the Office of National 
Drug Control Policy (ONDCP) have not achieved consensus on changes in federal policy. 
This is not surprising because the medium and long term impacts of policy changes on 
individual outcomes and public health are often difficult to determine soon after 
implementation.  
An empirically supported system-level model and policy exploration tool could 
give stakeholders and policy makers a big picture understanding of the current state of 
OB buprenorphine provision, and allow for policy exploration that reveals probable 
outcomes of policy changes.  Models can leverage the considerable amount of research 
on treatment outcomes, barriers and facilitators to treatment access and provision, as 
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well as the lived experience of researchers, patients and practitioners and synthesize 
this research and experience into a high-level whole.  
Empirical data on the geographic distribution of physicians able to prescribe 
buprenorphine and the prescribing patterns of those physicians show considerable 
unevenness in access and utilization of treatment services. Measuring and comparing 
this access inequality in the context of a simulation-based policy exploration requires a 
simple at-a-glance, quantitative access equality metric because of the large number of 
simulated scenarios that need to be compared.  In this dissertation I define a metric and 
demonstrate its usefulness by comparing simulation outcomes of an agent-based model 
of buprenorphine treatment access. 
1.1 Background 
1.1.1 Opioid use disorder is a public health problem in the United States 
The opioid class of drugs is one of the oldest drugs known to man.  People have 
been using extracts of the opium poppy to relieve pain for thousands of years 
(Brownstein, 1993).  Opioids also induce euphoria, and opium abuse has been recorded 
as early as the 16th century (Brownstein, 1993).  In modern times, opioids are still used 
to relieve pain and still used for euphoria.  We now understand that sustained abuse can 
lead to fundamental and long-lasting changes in brain structure and function (Leshner, 
1997). While many believe that drug dependence is the result of bad choices or weak 
will, drug dependence is now recognized as a chronic relapsing brain disorder (Baler & 
Volkow, 2006; Volkow, Fowler, & Wang, 2004; Volkow & Li, 2004).  
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Under the American Psychiatric Association Diagnostic and Statistical Manual 
version IV (DSM-IV), opioid abuse and opioid dependence were regarded as two 
separate disorders (American Psychiatric Association & DSM-IV, 1994).  The latest 
Diagnostic and Statistical Manual (DSM-5) combines opioid abuse and dependence into 
opioid use disorder (OUD), which is a spectrum of problematic use from mild to severe 
depending on the number of criteria met (American Psychiatric Association & others, 
2013).  Opioid use disorder, which encompasses both prescription opioid analgesic 
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(POA) use disorder and heroin use disorder, is a significant public health problem in the 
United States and worldwide.  The number of people who have used opioids 
nonmedically as well as the number of people with opioid use disorders in the United 
States have risen dramatically since the early 1990s (See Figures 1-1 and 1-2, SAMHSA, 
2014b), reaching an estimated 2.14 million in 2016 (SAMHSA 2017).  
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Figure 1-2: Number of people who used POA nonmedically (left plot) and heroin (right plot) in the past 
year.  Note different scales.  As the number of past year users of POA flattened, the number of past year 
heroin users began to rise.  Source: NSDUH, SAMHSA. 
Figure 1-1: Number of people with POA or heroin use disorder.  Note the continued 
rise in POA use disorder despite the flattened trend in past year POA use above.  
Source: NSDUH, SAMHSA. 
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The problem of opioid use disorder is not restricted to cities. According to the 
2012 National Survey of Drug Use and Health (NSDUH), 50% of people with opioid use 
disorder live in large Metropolitan Service Areas (MSAs), 35% live in small MSAs, and 
15% live in non-metro areas (SAMHSA, 2013b).  Negative health outcomes associated 
with opioid use disorder include fatal and non-fatal overdose (Chen, Hedegaard, & 
Warner, 2013), higher all-cause mortality (Degenhardt et al., 2009), and HCV and HIV 
infection risk if using intravenously (Garfein et al., 1998; Schoenbaum et al., 1989; 
Thorpe et al., 2002).  The number of deaths involving POAs has also risen dramatically 
since the 1990s paralleling the rise in use and use disorder, and deaths attributed to 
heroin have nearly tripled since 2010 (see Figure 1-3; Centers for Disease Control and 
Prevention, 2015).  
 Figure 1-3: Opioid overdose deaths 1999-2013: Source: CDC Wonder Multiple Cause of Death, 
1999-2013 Query, http://wonder.cdc.gov/mcd.html 
6 
1.1.2 Opioid Agonist Therapy is Effective 
Pharmacotherapies, or Opioid Agonist Therapy (OAT) are highly effective 
treatments for opioid use disorder(i.e. POA use disorder and heroin use disorder; 
Mattick, Kimber, Breen, & Davoli, 2002).  Pharmacotherapy for OUD has two basic 
types, opioid antagonist treatment, and opioid agonist treatment.  Opioid antagonists 
(including naloxone and naltrexone) bind to opioid receptors in the brain but do not 
activate the receptors, effectively blocking the receptor—not allowing the brain to feel 
the effects of opioid drugs (Comer et al., 2002; Martin, Jasinski, & Mansky, 1973), 
reducing the risk of opioid overdose (Hulse et al., 2005), and reversing opioid overdoses 
(Kerr, Kelly, Dietze, Jolley, & Barger, 2009). 
Opioid agonists bind to opioid receptors in the brain and also activate the 
receptors, which is why agonist treatment was previously referred to as substitution or 
maintenance therapy. Opioid agonist treatment reduces cravings for opioids, reduces 
use of illicit opioids, and allows for normal functioning (Payte, 1997).  Until 2002 
methadone was the only drug approved for opioid agonist treatment, and only within 
highly regulated Opioid Treatment Programs (OTPs) (Payte, 1997).   Methadone was 
considered a good choice for MAT because of its high oral availability, slow onset of 
action and long-acting duration of action (Payte, 1997).  In 2000, the Drug Abuse 
Treatment Act of 2000 (DATA 2000) became law, allowing doctors to use schedule III – V 
controlled drugs for the treatment of addiction (Carl Levin & Orrin Hatch, 2000).  
Methadone is a schedule II drug and cannot be used to treat addiction in private 
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doctors’ offices.  Buprenorphine, a schedule III drug approved by the FDA in 2002 for the 
treatment of opioid dependence, is the only opioid agonist that meets the criteria of 
DATA 2000.  Like methadone, buprenorphine has a long duration of action which allows 
for daily or less than daily dosing, and a strong safety profile due to the ceiling effect on 
respiratory depression—the primary cause of opioid overdose deaths (Dahan et al., 
2006).  (A ceiling effect on respiratory depression means that higher and higher doses of 
buprenorphine do not result in a higher risk of respiratory depression.) 
Office-based (OB) OUD treatment has many potential benefits over traditional 
treatment in OTPs: greater treatment accessibility especially in areas without OTPs, less 
stigma, greater flexibility to tailor treatment to patients’ needs, and less exposure to 
drug dealers who may prey on those waiting to get treatment at OTPs (Fiellin & 
O’Connor, 2002a)(Fiellin & O’Connor, 2002).  However, there are still significant barriers 
to the widespread adoption of OB buprenorphine treatment, and many communities 
lack adequate access to OB buprenorphine treatment (Rosenblatt, Andrilla, Catlin, & 
Larson, 2015a; Stein, Pacula, et al., 2015).   
Michael Botticelli, the Director of the ONDCP through 2016; Pam Hyde, the 
Administrator of SAMHSA through 2015; Senators Orrin Hatch and Carl Levin, the 
sponsors of DATA 2000; Nora Volkow, the Director of the NIDA, and former President 
Barack Obama have all made public statements about the need to expand access to OB 
buprenorphine (ONDCP 2015; SAMHSA 2014c; Volkow, Frieden, Hyde, & Cha, 2014).  
The second point of the 2014 President’s Plan to Reform Drug Policy states that to 
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reform drug policy the nation must “expand access to treatment for Americans 
struggling with addiction” (ONDCP 2014), and the 2015 National Drug Control Strategy 
stresses “integrating treatment for substance use disorders into health care and 
supporting recovery” (ONDCP 2015).  
There are two policies within the DATA 2000 legislation that limited providers’ 
capacity to prescribe buprenorphine.  Physicians can only prescribe to a maximum of 30 
patients in the first year, and 100 or 275 patients thereafter (109th Congress, 2005; Carl 
Levin & Orrin Hatch, 2000; SAMHSA 2016a), and up until 2017 only physicians could 
prescribe buprenorphine, not other medical care providers who have prescribing 
authority including nurse practitioners (NPs) or physician assistants (PAs) (Fornili & 
Burda, 2009). Issues around access to buprenorphine including these policies are 
examined at length in the literature review section (Chapter 2). 
1.2 Research Questions 
 Question 1: What functional form should an aggregated individual-level access 
inequality metric have for it to be sensitive enough to detect differences in access 
equity in different regions or due to different policy choices?  
 Question 2: How equitably distributed is access to OB buprenorphine treatment 
spatially in the current OB buprenorphine treatment system given regulatory caps 
on patient numbers, physician preferences, and geographic distribution of 
treatment seekers and providers? 
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 Question 3: To what extent would changing the DATA 2000 patient limit per 
physician change utilization of buprenorphine, spatial access equity, opioid 
overdose deaths and medication diversion? 
 Question 4: To what extent would various levels of buprenorphine prescribing 
adoption by Nurse Practitioners and Physician Assistants change utilization of 
buprenorphine, spatial access equity, opioid overdose deaths, and medication 
diversion? 
1.3 Motivation and Significance 
Treatment capacity, accessibility of OB buprenorphine treatment, and gaps 
between treatment need and treatment capacity are complex and current national 
survey-based metrics do not capture this complexity. The number of buprenorphine 
providers, measured at the county level, serves as a proxy measure for inequality of 
access (Rosenblatt, Andrilla, Catlin, & Larson, 2015b; Stein, Gordon, Dick, Burns, Pacula, 
Farmer, & Leslie, 2015).  One standardized approach for identifying communities with a 
shortage of waivered physicians given demand was modeled after the Health Resources 
and Services Administration (HRSA) Health Provider Shortage Area (HPSA) metric (Dick 
et al., 2015).  The authors defined shortage at the county level which may obscure 
inaccessibility due to the long travel distances required to access services in sparsely 
populated rural counties, and inaccessibility faced by marginalized urban residents who 
may not be able to travel even modest distances to access services in the counties they 
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live in.  An individual level metric may capture this scarcity where there appears to be 
abundance by other metrics.  
However, individual level metrics cannot be used in data models.  The number 
and location of people requiring services is not known due to patient privacy and 
confidentiality concerns; therefore proxy measures must be used.  In a simulation, one 
can generate synthetic populations based on these proxy measures and national survey 
data, and place synthetic people in a plausible landscape.  One can then calculate how 
accessible services are to each individual demander based how many providers there 
are, the capacity of those providers, the distance to the providers, the number of other 
demanders, and the distance the individual is willing to travel. Aggregating all individual 
access measures into a single spatial access inequality index can allow for quick, 
quantitatively meaningful comparisons of simulated policy experiment outcomes. 
1.3.1 Potential Significance 
There are two distinct needs that this study addresses.  First policy makers and 
practitioners know that buprenorphine access is uneven across the country and within 
the states, but this unevenness has only been captured at the county level and through 
proxy measures.  An empirically informed agent based model can visually display the 
mismatch between supply of and demand for OB buprenorphine treatment and 
describe this mismatch quantitatively.  This will give a deeper understanding of 
treatment capacity and access through quickly conveyed visual information, and 
nuanced quantitative information.   
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Second, a metric that aggregates map-based measures of spatial potential access 
could be useful to researchers who study access disparities, such as unequal access to 
health providers, food outlets, parks, or affordable quality childcare.  Map based metrics 
convey detailed information, but can be difficult to use to compare access in different 
regions or after policy implementation. A single, aggregated metric could allow 
researchers to make quick comparisons.  Is spatial potential access better under policy A 
or B? Does region C or D locate services more fairly?  Spatial potential access will be 
defined more fully in Section 2.2. 
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2 Literature Review 
This review of literature and data is organized into four main sections:  
 Buprenorphine treatment capacity  
 Measuring potential spatial access and studies on regional differences in 
buprenorphine access  
 Two major buprenorphine policies: the patient limit, and the exclusion of 
non-physician prescribers in the DATA waiver system 
 Simulations for exploring substance abuse policy 
2.1 Opioid Agonist Therapy treatment capacity 
Prior to 2002, OAT was only available in highly regulated Opioid Treatment 
Programs (OTPs), or in clinical trials (Fiellin & O’Connor, 2002a). In 2000, the 106th 
Congress passed the Drug Addiction Treatment Act of 2000 (DATA 2000) which allowed 
qualified physicians to prescribe schedule III – V controlled substances for the treatment 
of OUD for up to 30 patients per practice (Carl Levin & Orrin Hatch, 2000). Physicians 
could qualify for a DEA waiver under DATA 2000 by taking an 8-hour training course, by 
being board certified in addiction medicine or addiction psychiatry, or by having 
participated in a buprenorphine clinical trial (Fiellin & O’Connor, 2002a).  It took an 
additional two years for buprenorphine to be approved by the FDA for the treatment of 
opioid dependence as a schedule III drug (Campbell & Lovell, 2012; Jaffe & O’Keeffe, 
2003). Office-based OAT with buprenorphine began in 2002.  Prior to office-based OUD 
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treatment with buprenorphine, only approximately 170,000 of the estimated 810,000 
(21%) opioid dependent patients in the US were receiving OAT through OTPs, compared 
to approximately 55% opioid dependent patients during the same period in France, 
which had implemented a general practitioner focused, office-based buprenorphine 
treatment system (Fatseas & Auriacombe, 2007). While more strictly regulated than the 
largely unregulated French system, DATA 2000 similarly enabled office-based treatment 
with buprenorphine, and was intended to increase treatment capacity (Boone et al., 
2004; Bridge, Fudala, Herbert, & Leiderman, 2003; Thomas et al., 2008), engage new 
kinds of patients in OAT (Fiellin, Rosenheck, & Kosten, 2001; Sullivan, Chawarski, 
O’Connor, Schottenfeld, & Fiellin, 2005), and reach patients unable to access OTPs (Egan 
et al., 2010; Mark, Woody, Juday, & Kleber, 2001; Rounsaville & Kosten, 2000) which 
were only operating in 44 out of 50 states (WESTAT & The Avisa Group, 2006) and 
tended to be located in urban areas. 
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SAMHSA maintains a record of all providers who completed buprenorphine 
training and obtained DEA waivers to prescribe each year since 2002.  These data are 
publicly available and searchable on the SAMHSA website1 (SAMHSA 2016b). The DEA 
maintains a list of all providers with waivers. This total number of providers with waivers 
has increased steadily since 2002 (see Figure 2-1).  The number of providers obtaining 
either a new 30 patient waiver or electing to increase to the 100 patient waiver each 
year increased from 2002 to 2007, held steady from 2008 to 2012, and again increased 
from 2012 to 2016 (see Figure 2-2).  The spike in 2007 was likely due to regulation 
change that allowed providers to treat up to 100 patients and pent up demand by 
providers who would have increased their patient loads in earlier years. In July, 2016, 
                                                     
1http://www.samhsa.gov/medication-assisted-treatment/physician-program-data/certified-
physicians?field_bup_us_state_code_value=All 
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 Figure 2-1: Total number of providers waivered to prescribe buprenorphine at three patient limit levels, 
30, 100, and 275. 
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board certified addiction specialists could apply to further increase their patient limits to 
275 patients if they met certain regulatory requirements (Federal Register, 2016).  By 
January 2018, 4151 practitioners opted to increase their patient limit (SAMHSA 2018). 
Multiplying the total number of waivered physicians by their certification level yields the 
total potential office-based buprenorphine capacity shown in Figure 2-3. This measure 
of total potential office-based buprenorphine capacity was used to define a treatment 
gap between the number of people who need opioid agonist treatment and the total 
capacity of the treatment system to meet that demand (Jones, Campopiano, Baldwin, & 
McCance-Katz, 2015). 
However, this definition of potential capacity does not capture the fact that 
some providers who complete training and get waivers never prescribe, or are not 
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 Figure 2-2: Number of new waivered providers per year.  2016 is and underestimate because it only 
counts those providers who obtained waivers through July (Substance Abuse and Mental Health 
Services Administration, 2016a). 
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currently prescribing buprenorphine.  Four studies suggest that the number of 
physicians who do not prescribe to any patients has fallen since 2002.  In a study of a 
nationally representative sample of addiction specialists in 2003, only 58% of 
respondents with waivers had prescribed buprenorphine to any patients (Kissin, 
McLeod, Sonnefeld, & Stanton, 2006). In early 2005, “The SAMHSA Evaluation of the 
Impact of the DATA Waiver Program” reported that 67% of physicians with waivers were 
prescribing (WESTAT & The Avisa Group, 2006). By 2008, the percentage of providers 
who had prescribed to patients in the last 90 day had risen to 75%2, and the percentage 
of providers who had never prescribed buprenorphine fell to 17%2 (Arfken, Johanson, di 
                                                     
2 Calculations by the author.  Arfken, et al, (2010) separates providers into those on the CSAT locator list 
and those not on the list, the 75% is a weighted average of the two provider populations. 
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Menza, & Schuster, 2010).  In rural areas of Washington state, Quest, et al. (2012) found 
that 83% of the 24 surveyed physicians were actively prescribing buprenorphine in 2010 
(Quest, Merrill, Roll, Saxon, & Rosenblatt, 2012). 
Even when providers do prescribe buprenorphine, many do not prescribe up to 
their certification level.  There have been few studies on how many patients providers 
typically treat, but there appears to have been an upward trend since 2002, particularly 
after 2007, when the patient limit was raised from 30 to 100.  Gordon, et al. (2007) 
found that on average waivered physicians at VA health facilities were prescribing to 4.3 
patients in 2005 (Gordon et al., 2007). Reif, et al (2007) found that in 2005, the surveyed 
sample of early adopter buprenorphine prescribers wrote an average of 15.6 
prescriptions a month.  They also found that the mean total number of patients ever 
treated was 72, and the median 30, meaning that the distribution of prescribing level 
was skewed (Reif, Thomas, & Wallack, 2007a). Arfken, et al. (2010), found that the 
average number of patients per provider among providers with at least one patient rose 
substantially from 2004 to 2008 in a nationally representative sample of waivered 
buprenorphine providers (see Figure 2-4; Arfken et al., 2010).  This was true for both 
providers who chose to be on SAMHSA’s Center for Substance Abuse Treatment (CSAT) 
locator list and for those who chose not to be on the list. In 2008, the average number 
of patients per provider regardless of list participation was 32.42.  This average drops to 
23.5 when including non-prescribers2 (Arfken et al., 2010). Quest, et al (2012) found that 
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rural providers in Washington 
State treating at least one 
patient were treating an 
average of 23 patients, with 
the top one third of providers 
treating an average of 51.6 
patients, the middle third 
treating 14.2 patients, and the 
lowest third treating an 
average of 2 patients (Quest et al., 2012). Stacey Sigmon (2015) analyzed Vermont 
Medicaid claims from February through April 2014 and found that providers treated an 
average of 14.8 patients with a range of 1 to 76.  However, as Reif and colleagues noted 
in 2005, she found the distribution of patients per provider was highly skewed, with 
29.3% treating only one patient and 48.1% treating under 5 patients.  
In the 14 years since office-based buprenorphine prescribing, substantial 
increases in OAT capacity have been achieved. Currently there is the potential to treat 
over 2.4 million people with buprenorphine under the office-based DATA 2000 waiver 
system. This new capacity is in addition to treatment capacity afforded through OTPs.  
From 2003 through 2013, though the number of OTPs has remained relatively stable, 
the number of patients receiving either methadone or buprenorphine at substance 
abuse treatment facilities rose 66% from 227,003 to 378,456 (SAMHSA 2014a). Using 
 Figure 2-4: Mean patients per provider. Filled points represent 
providers on the CSAT locator list, hollow points represent 
providers not on the list (Arfken et al., 2010). 
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the definition of “treatment gap” established by Jones, et al (2015) comparing the 
prevalence of opioid use disorder to total treatment capacity, the treatment gap 
appears to be shrinking.  Jones and colleagues found that the difference between the 
number of people with opioid abuse or dependence and total treatment capacity was 
914,000 people, or 40% of total treatment need in 2012 (Jones et al., 2015).  Currently 
the “treatment gap” has closed; as 2,140,000 people met criteria for opioid use disorder 
in 2016 (most recently available data: SAMHSA 2017) and total buprenorphine 
treatment capacity reached 2,416,000 in 2016. 
2.2 Spatial potential access: A spatially informed measure of relative shortage or 
surplus 
Spatial accessibility is defined as the potential for geographically dispersed service 
demanders (e.g. people with OUD) to reach geographically dispersed opportunities (e.g. 
OAT slots;(Páez, Scott, & Morency, 2012). Potential access, a measure of whether 
people have the opportunity to use a service differs from realized access, a measure of 
actual service utilization.  Spatial potential access measures are used to quantify 
regional differences in ability, or opportunity to use services and have been used to 
highlight regional differences in access various goods and services including: healthy 
food (Charreire et al., 2010; Leslie, Frankenfeld, & Makara, 2012; Ning, 2012; Ver Ploeg, 
Dutko, & Breneman, 2014; Walker, Keane, & Burke, 2010), day care providers (Páez et 
al., 2012), recreation or park facilities (Nicholls, 2001; Talen & Anselin, 1998), and health 
services (see, for example: Delamater, 2013; Guagliardo, 2004; Joseph & Bantock, 1982; 
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Khan, 1992; Knox, 1978; Li, Serban, & Swann, 2015; Lowe & Sen, 1996; W. Luo, 2004; W. 
Luo & Qi, 2009; McGrail & Humphreys, 2009; Ngui & Apparicio, 2011). 
The simplest measure of spatial potential access is the regional availability 
method, also called the “container” or ratio method (W. Luo & Qi, 2009).  When 
measuring regional availability, the region under consideration, such as a county or 
census tract, is pre-defined and a supply/demand ratio is calculated by summing up all 
supply opportunities and all demanders within that region. In the case of physicians, a 
physician/population ratio is generated and compared to a standard established by 
professional determination of physician need (Feldstein, 2012). The two measures of 
health provider shortage used by the Department of Health and Human Services—
Health Professional Shortage Areas (HPSAs) and Medically Underserved Areas (MUAs)—
are sophisticated container methods that make adjustments for need within the service 
regions and for resources in contiguous areas (U.S. Department of Health and Human 
Services, Health Resources and Services Administration, 2016b, 2016a).  
There are two critiques of the regional availability method.  First, the method 
assumes that people within the pre-defined region do not seek services outside the 
region.  To assure that this assumption is valid, the region under consideration must be 
fairly large. Second, one must assume that there is little variation in access across the 
region considered—that access is essentially equal at all points within the container.  
This assumption requires that the defined regions be fairly small (W. Luo & Qi, 2009).  
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Geographers and demographers have been addressing these limitations for 
decades. The gravity model of accessibility addresses the second limitation—that access 
is not uniform at different distances between demanders and opportunities.  In 1948, 
John Q. Stewart proposed formal laws of demographic gravitation, the application of the 
Newtonian laws of gravity to population groups.  He presents the equation for physical 
gravitational potential VA which a mass m at point a produces on a second mass M at 
point A (with gravitational constant G): 
 𝑉𝐴 =
𝐺𝑚
𝑑
 
 
(1) 
and then applies it to population groups.  The potentials of population 1 and population 
2 become: 
   𝑉1 =
𝐺𝑁2
𝑑
; 𝑉2 =
𝐺𝑁1
𝑑
     
(2) 
where V is the population potential, N1 and N2 are the number of people considered, d is 
the distance between them, and G is a constant “left for future determination” 
(Stewart, 1948, p. 34). Population potential is directly proportional to the size of the 
population and inversely proportional to the distance from it.  
Walter G. Hansen (1959) expanded Stewart’s population-over-distance 
population potential concept and defined a measure of population potential as the 
“intensity of the possibility of interaction…[or] the spatial distribution of activities about 
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a point, adjusted for the ability and desire of people or firms to overcome spatial 
separation” (W. G. Hansen, 1959, p. 73). Formally: 
 
𝑆2 =
𝑂2
𝑑1−2
𝛽1
 
 
(3) 
where 1S2 is the measure of the accessibility in zone 1 of an activity in zone 2.  O2 is the 
size of the opportunity in zone 2, which could be the number of jobs, parks, people, etc. 
d1-2 is either the travel time or distance between zone 1 and 2, and β is an exponent that 
determines the effect of distance or travel time between the zones.  The total 
accessibility in zone 1 to opportunity type O is the sum of the accessibility in each zone:  
 
𝑆𝑖 = ∑
𝑂𝑗
𝑑𝑖𝑗
𝛽
𝑗
  
(4) 
The addition of an exponent β to the distance function was a response to 
criticism that the original population potential model adhered too rigidly to the physical 
gravity model with an exponent of 1 on the distance term.  The author contends that “it 
is generally agreed” that an exponential function be used for the distance decay term, 
and that the choice of an exponential function is empirically justified (W. G. Hansen, 
1959, p. 74). Changing the exponent on the distance decay term alters how restrictive 
travel time or distance is for the activity in question. People are willing to travel 
different distances for different types of activities.  For example, a person might find it 
reasonable to travel 40 minutes to work, but unreasonable to travel more than 15 
minutes to buy groceries.  Different values for the distance decay exponent reflect the 
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differences in people’s willingness to travel. Hansen states that the value of the 
exponent, β, should be determined from empirical studies of people’s actual travel 
behavior. So even though the relative accessibility measure, 1S2, is a potential access 
measure, the exponent of the distance decay function is derived empirically from actual 
utilization data. 
Hansen’s claim that “it is generally agreed” that an exponential function be used 
for the distance decay or friction term in a relative accessibility measure may have been 
overstated. In D. R. Ingram’s article “The Concept of Accessibility: A Search for an 
Operational Form” (1971), a negative exponential distance decay term was one of 
several operational forms for accessibility.  Ingram’s definition of accessibility, “the 
inherent characteristic (or advantage) of a place with respect to overcoming some form 
of spatially operating source of friction (for example, time and/or distance)” (Ingram, 
1971, p. 73), is consistent with Hansen’s (1959) definition. He defines relative 
accessibility as the degree to which two locations are connected based on their 
separation, and integral accessibility as the interconnection (at a given location) of all 
other points on a surface. Generally: 
 
𝑆𝑖 =∑𝑠𝑖𝑗
𝑛
𝑗=1
  
(5) 
where Ai is the integral accessibility at location i, or the total accessibility of all 
opportunities at location i, and aij is the relative accessibility of location j at i. Unlike 
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Hansen, this functional form does not account for the attractiveness or the size of the 
activity at location j. Ingram explores various functional forms for relative accessibility, 
sij, including average straight line distance (a linear measure): 
 
𝑆𝑖 =
∑ 𝑑𝑖𝑗
𝑛
𝑗=1
𝑛
 
 
(6) 
where locations with lower S values have greater accessibility.  If we desire, instead, that 
larger S values imply greater accessibility, we can calculate the inverse, and the 
accessibility function is equivalent to Stewart’s (1948) original gravity potential measure. 
Ingram also explores several curvilinear functions for distance decay including the 
reciprocal exponential function (with locations at negligible distance having accessibility 
scores of 100): 
 𝑠𝑖𝑗 = 100𝑑𝑖𝑗
−𝑘 (7) 
If we substitute Sj, the size of the activity at location j for 100, this is equivalent 
to the accessibility measure in Hansen (1959). The reciprocal exponential function 
results in rapid decreases in accessibility with increasing distance. The negative 
exponential function: 
 𝑠 = 100𝑒𝑖𝑗
−𝑑 (8) 
results in a gentler decline of the effect of distance on accessibility.  Both functions (7) 
and (8) are limited by the fact that they have rapid declines in accessibility at short 
distances, meaning that place 5 minutes away, say, would be substantially less 
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accessible than a place 2 minutes away. Ingram argues that the Gaussian function meets 
intuitive requirements of a distance decay function: that accessibility be reasonably flat 
near the origin, that the decline in accessibility at increasing distance be smooth, and 
that accessibility approach zero at large distances. He defines a modified Gaussian 
function: 
 
𝑠𝑖𝑗 = 100𝑒
−
𝑑𝑖𝑗
2
𝑣
⁄
 (9) 
where v is a constant for the total area under consideration, and determines the width 
of the curve. The author offers various, somewhat arbitrary ways of determining v, 
including using average squared distance between all points, the radius of the smallest 
circle that contains all points, or empirical determination from actual trip frequency 
data.   
These early gravity models captured an observed phenomenon in service 
utilization, the distance decay effect.  However, they were limited because they only 
considered the supply side of accessibility measurement, not the demand side—
consumers’ competition for the opportunity, service or resource.  For example: a 
physician in a location closely surrounded by a high number of demanders may seem 
highly accessible because the distances are short, but might not really be available 
because she has insufficient capacity to meet the demand.  Qing Shen (1998) critiques 
the supply-side gravity models by stating that at least one of the following must be true: 
demand is spread uniformly across the space, or the opportunities have no capacity 
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limitation (Shen, 1998).  If demand is spread uniformly across the space, then there will 
be no areas where competition or high demand strains the capacity of the resource 
more than any other area.  If the opportunities or resources considered have no 
capacity limitation, such as very large public spaces, or broadcast TV signals, then 
competition is not a relevant concern when measuring accessibility.  Medical services, 
however, do not meet these criteria.  Demand is not uniform, and health service 
providers have finite capacity. 
To address differences in the demand side and competition for supply, Joseph 
and Bantock (1982) generated a two-step method that integrates both supply and 
demand while considering the friction of distance between the two (Joseph & Bantock, 
1982). They, and many of the authors who extended their measure, were concerned 
with modeling physician accessibility. So instead of using general language where 
suppliers are referred to as opportunities, resources and the like, they use specific 
language, referring to physicians and populations. They are concerned with how 
accessible spatially dispersed physicians are to the spatially dispersed people they 
purportedly serve. Like these authors, I will use the more specific physician/population 
language from this point forward.  First the supply-side accessibility of physicians is 
calculated using the reciprocal exponential form of the gravity model from equation (4): 
 
𝑆𝑖 = ∑
𝑂𝑗
𝑑𝑖𝑗
𝛽
𝑗
  
(10) 
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where Si is the potential spatial accessibility of area i to physicians; Oj is a physician at 
location j that is within the range of area i; dij is the distance between them; and β is the 
exponent on the distance function. Then the potential demand on a physician at 
location j is calculated: 
 
𝐷𝑗 =∑
𝑃𝑖
𝑑𝑗𝑖
𝛽
𝑖
   
(11) 
where Pi is the size of the population in area i. Therefore, the demand, Dj, is 
proportional to the size of the population within the physician’s catchment area, and 
inversely proportional to a function of the distance from that population. Combining the 
equations (4) and (10) yields a weighted relative accessibility measure:  
 
𝐴𝑖 =∑
(
  
 𝑂𝑗
(∑
𝑃𝑖
𝑑𝑖𝑗
𝛽𝑖 )
)
  
 
𝑑𝑖𝑗
𝛽
𝑗
 
(12) 
or:   
 
𝐴𝑖 = ∑
𝑂𝑗
𝐷𝑗𝑑𝑖𝑗
𝛽𝑗  , 𝐷𝑗 = ∑
𝑃𝑖
𝑑
𝑖𝑗
𝛽𝑖  
 
(13) 
 Q Shen (1998) generalized equation (11) further, to allow for alternative 
functional forms for the distance decay function (Shen, 1998):  
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𝐴𝑖 = ∑
𝑂𝑗𝑓(𝑑𝑖𝑗)
𝐷𝑗
𝑗  ,  𝐷𝑗 = ∑ 𝑃𝑖𝑓(𝑑𝑖𝑗)𝑖  
 
(14) 
This more general form allows researchers the flexibility to calibrate the distance 
decay function to the actual region they are studying.  By adding the potential 
population demand term to the original gravity model formulation, Joseph and Bantock 
(1982) and those that followed addressed one of the fundamental criticisms of gravity 
models: that they did not consider competition for available physicians by the 
population.   
With the advent and maturity of geographic information systems (GIS), 
geographers became able to map physician locations precisely, to map population data 
at a high level of granularity, and to estimate travel distances or travel times on actual 
road networks.  Geographers could then map potential access surfaces for areas 
studied, and represent differences in spatial potential access in a visually compelling 
way. These advances in mapping technology led to the development of the two-step 
floating catchment area (2SFCA) and kernel density measures of accessibility. 
Luo and Wang (2003) describe the 2SFCA method in this way:  
Step 1: For each physician location j, search all population locations (k) 
that are within a threshold travel time (d0) from location j (that is, catchment 
29 
area of j), and compute the physician-to-population ratio, Rj, within the 
catchment area: 
𝑅𝑗 = 
𝑆𝑗
∑ 𝑃𝑘𝑘 ∈{𝑑𝑗𝑘≤𝑑0}
 
 
(15) 
where Pk is the population of tract k whose centroid falls within the catchment 
(that is, djk ≤ d0), Sj is the number of physicians at location j, and dkj is the travel 
time between k and j. 
Step 2: For each population location i, search all physician locations (j) 
that are within the threshold travel time (d0) from location i (that is, catchment 
area i), and sum up the physician-to-population ratios, Rj, at these locations: 
𝐴𝑖
𝐹 = ∑ 𝑅𝑗
𝑗 ∈ {𝑑𝑖𝑗≤ 𝑑0}
= ∑
𝑆𝑗
∑ 𝑃𝑘𝑘 ∈{𝑑𝑗𝑘≤𝑑0}𝑗 ∈ {𝑑𝑖𝑗≤ 𝑑0}
 
 
(16) 
where  𝐴𝑖
𝐹represents the accessibility at resident location i based on the two-
step FCA method, Rj is the physician-to-population ratio at physician location j 
whose centroid falls within the catchment centered at i (that is, dij ≤ d0), and dij is 
the travel time between i and j (W. Luo & Wang, 2003, p. 872). 
Computation of physician to population ratios in step one is an intuitive 
extension of container-based methods of calculating regional availability.  However, the 
2SFCA method addresses the two major criticisms of the container method.  First, 
calculating each individual physician’s physician-to-population ratio within his or her 
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individual catchment area in step 1 addresses the second criticism, that access is 
assumed to be equal over the entire region considered.  In the 2SFCA, method, each 
physician location is considered individually, so there is no need to assume uniformity. 
The second step of the 2SFCA method addresses the first criticism of container-based 
regional availability methods, that patients are assumed not to seek services outside the 
region.  Summing the physician-to-population ratios of physicians reachable from each 
population location allows that patients may choose to visit any physician that is 
reachable.  In application, authors tend to use buffer zones around the region under 
consideration to allow for “edge correction” of estimation of accessibility at peripheral 
regions (see, for example Yang, Goerge, & Mullner, 2006).   
Though the steps employed calculating accessibility by the 2SFCA method and 
the gravity-based models are different, and may be conceptually dissimilar, it is clear 
that the final form of the 2SFCA accessibility equation (14), is a special form of the 
general gravity model equation (12) where the distance decay function is a dichotomous 
function, where: 
 
𝑓(𝑑𝑖𝑗) = {
1, 𝑖𝑓𝑑𝑖𝑗 ≤ 𝑑0;
0, 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 
} 
 
(17) 
Over the following decade, several authors modified either the gravity model or 
the 2SFCA model to address limitations in each.  The dichotomous function in the 2SFCA 
was criticized as too rigid in assuming that a person was as willing or able to travel short 
distances as long distances (W. Luo & Qi, 2009), so alternatives were proposed.  Luo and 
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Qi (2009) recognized the criticism of assumed uniformity of access across catchment 
areas, but also criticized gravity models as overemphasizing the distance decay term, 
resulting in concentric rings of access around physicians and excessive smoothing of the 
accessibility surface.  To address both limitations, Luo and Qi (2009) created the 
enhanced two-step floating catchment area E2SFCA by applying weights to three travel 
zones (z) to allow for distance decay effects.  The weights are calculated from the 
Gaussian function as follows: 
 𝑤𝑖𝑗 = 𝑓(𝑑𝑖𝑗) = 𝑓(𝑧) = 𝑒
(−(𝑧−1)2 𝛽⁄ )   (18) 
Beta must be determined empirically or through calibration or sensitivity testing 
methods.  Graphically, the difference between the 2SFCA and E2SFCA can be seen in 
Figure 2-5. 
Several modified forms of the 2SFCA method emerged over the years as 
researchers found limitations in the E2SFCA when applying the method.  In the simplest 
modifications, different forms were proposed for the distance decay function 
Figure 2-5: Weights, or values of the distance decay function in the 2SFCA and E2SFCA (Delamater, 2013) 
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(Schuurman, BéRubé, & Crooks, 2010), in others, steps were added to allow for variable 
sized catchment areas (W. Luo & Whippo, 2012), or to add a selection weighting term to 
account for competition among facilities (Wan, Zou, & Sternberg, 2012). Luo (2014) 
proposed integrating the Huff model of selection probability for demand into the 2SFCA 
method.  In this case the physician-to-population ratio would be modified by the 
probability that a person at a given location would select a given physician in their 
catchment area over another based on the distances to each (J. Luo, 2014). Delamater’s 
(2013) modified M2SFCA adjusted the number of beds available (the supply) based on 
distance to the population, multiplying the supply term by the distance function twice, 
arguing that inaccessible beds do not “count” as much as highly accessible beds 
(Delamater, 2013). McGrail and Humphreys (2009) modified the 2SFCA to include a 
distance decay term and a capping function that does not allow access at fringe rural 
populations to be dominated by demand from outer metropolitan areas (McGrail & 
Humphreys, 2009). Ngui and Apparicio (2011) modified the 2SFCA using carried 
centrographic analysis and density analysis to adjust the supply side for their 
“optimized” 2SFCA (Ngui & Apparicio, 2011). 
All of these gravity-based models or 2SFCA methods generate quantitative 
measures of relative accessibility for population locations within a given area, which can 
be used to generate maps that qualitatively demonstrate disparities in accessibility 
using heat mapping.  However, additional steps are required to quantify disparities in 
accessibility at each location. Wan and colleagues (2012) created the spatial access ratio 
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(SPAR), which is a ratio of the accessibility index of each location and the mean 
accessibility index of the entire area. A SPAR of greater than 1 indicates greater 
accessibility than the overall mean. In defining an optimization problem in which a new 
facility would be located to minimize the inequality in potential spatial access, Wang and 
Tang (2013) simply define this inequality as:  
 𝑣𝑖 = (𝐴𝑖 − 𝑎)
2 (19) 
where vi is the deviation from the average accessibility, and a is a constant equal to the 
total supply to total demand ratio for the entire area (Wang & Tang, 2013). In other 
words, the constant, a, is equal to the population weighted average accessibility of the 
entire region. This property of all (standard, unmodified) gravity models was proven by 
Shen in 1998 (Shen, 1998).  Simply aggregating the accessibility scores of all locations 
yields the regional availability ratio of supply to demand with the entire area under 
consideration as the “container.” This does not characterize the access disparity in the 
area being studied.  To date, there does not appear to be a single metric that quantifies 
the disparity in access in a region.  A single metric could allow for quick comparisons of 
policy implications in what-if exploratory studies of areas that have already been 
mapped using a gravity model or 2SFCA method, or for comparisons of access disparity 
in different regions that have been mapped using the same methods. In Chapter 3 I 
propose a method of aggregating access disparity, and in Chapter 4, I test its usefulness 
in a spatial agent based model of OUD treatment accessibility. 
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2.2.1 Spatial disparity in access to buprenorphine treatment 
Regional disparities in access to buprenorphine treatment exist and have been 
measured by several authors. In general, authors assess regional differences in access 
either by measuring regional or spatial differences in realized access (utilization) or in 
potential access through the regional availability “container” method. 
Hansen, et al. (2013, 2016) analyzed differences in buprenorphine and 
methadone utilization in New York City residential zip codes and “social areas,” 
residential zip codes aggregated into areas based on race/ethnicity and income variables 
(H. B. Hansen et al., 2013; H. Hansen, Siegel, Wanderling, & DiRocco, 2016). In both 
papers, the authors found that buprenorphine treatment rates, defined as the number 
of people receiving buprenorphine per 10,000 residents in the area, was highest (in 
2007) and rose most quickly (2004 – 2013) in social areas that were predominantly 
white and well off. By aggregating the zip codes into social areas, the authors chose not 
to highlight regional differences in buprenorphine utilization, but rather demographic 
differences in utilization as extracted from zip-code level data.      
Schmitt, Phibbs, and Piette (2003) found that inpatient substance abuse 
treatment patients who live farther from their source of mental health care were less 
likely to receive aftercare, and that those who did receive aftercare received a lower 
volume of care (Schmitt, Phibbs, & Piette, 2003).  The authors use their finding of a 
distance decay effect on utilization to support the statement that “lack of geographic 
35 
access (distance) is a barrier to outpatient mental health care following inpatient 
substance abuse treatment” (Schmitt et al., 2003, p. 1183).  
Beardsley, et al., (2002) found a strong distance decay effect on retention in 
outpatient drug treatment at very short distances.  Clients who traveled one mile or less 
to a treatment center in an urban area were 50% more likely to complete treatment 
than clients who traveled more than a mile, and clients who traveled over 4 miles were 
likely to remain in treatment for a shorter time than those that traveled less than a mile 
(Beardsley, Wish, Fitzelle, O’Grady, & Arria, 2003).  Similarly, Brian Lockwood (2012) 
found that among juveniles attending court mandated treatment programs in 
Philadelphia, every increase of 3 miles to treatment nearly doubles odds of dropout  
(Lockwood, 2012).  These suggests that there is a steep drop in treatment accessibility at 
short distances for urban residents. In each case, the authors did not measure 
geographic access directly, but this work does provide the type of empirical support on 
the effect of distance on utilization to inform the selection of a weighting scheme or 
distance decay function.  
Several authors noted differences in potential access using the regional 
availability container or ratio methods.  Kvamme, et al. (2013) compared the 
distribution of buprenorphine waivered physicians, and potential buprenorphine 
treatment slots (number of physicians x waiver level) to the distribution of population in 
Washington State (Kvamme, Catlin, Banta-Green, Roll, & Rosenblatt, 2013a). They found 
that the population to provider and population to treatment slot ratios differed based 
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on urbanity as measured by RUCA codes, with the lowest ratios in small rural areas, and 
the highest ratios in isolated rural areas.  While this appears to be a regional availability 
analysis, it is not. The authors used RUCA codes associated with the zip codes of 
physicians’ practice locations to differentiate practices by urban/rural designation, and 
calculated population to physician ratios of each type of region, not the specific regions 
themselves. To illustrate, the population to treatment slot ratio in small rural areas of 
the state is the lowest, at 279:1, indicating the best access.  However, if all 21 of these 
rural buprenorphine providers happened to practice in the southeastern corner of the 
state, people in the northwestern corner of the state might have no access to providers 
despite also living in a small rural area. 
Robenblatt, et al. (2015) conducted a similar county-level analysis on the number 
and distribution of DATA waivered physicians using the US Department of Agriculture 
Urban Influence Codes to differentiate counties by urbanity level (Rosenblatt et al., 
2015a). Like Kvamme, et al. (2013), they aggregated counties by urbanity level, and 
presented a high-level analysis of accessibility, for the most part.  Counties in 
metropolitan areas had the highest physician to 100,000 population ratio, 6.3, while 
rural areas had the poorest, 3.1.  They note that 82.5% of rural areas counties have no 
waivered providers.  Also, like Kvamme, et al (2013), their main findings on the 
differences in provider ratios by urbanity is not a regional availability analysis.  However, 
they do map all counties according to whether they have any buprenorphine providers 
at all, exposing large disparities in regional access to providers, which is, in effect, a 
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simple regional availability analysis.  However, like all container analyses, even this 
simple map can be criticized for the assumption that all people within counties with at 
least one provider have equal access to that provider, and that people in areas with no 
providers will not seek services outside of the county.  
Hirchak and Murphy (2016) analyzed differences in the number of opioid agonist 
treatment centers and DATA waivered physicians per 10,000 residents aged 16-84 in 
Washington State zip codes based on urban-rural classification and whether the land 
was designated American Indian reservation/trust land (Hirchak & Murphy, 2016).  They 
calculated, but did not report, physician to 10,000 resident ratios for every zip code, as 
the independent variable of a regression model on the association with rurality and AI 
reservation status, and found no relationship. 
Stein and colleagues (2015) calculated the number of DATA waivered physicians 
per 100,000 residents at the county level from 2008 to 2011 to predict the effects of 
state policies and county characteristics on the physician/population ratio (Stein, 
Gordon, Dick, Burns, Pacula, Farmer, Leslie, et al., 2015).  Like Hirchak and Murphy 
(2016), they calculated this provider to population ratio, but did not report it at the 
county level because this was an intermediate step in generating the models for their 
study.  They did report some trends in county level disparities in this availability metric.  
In 2008, 51% of counties had no buprenorphine providers, which dropped to 43% in 
2011. They reported that the distribution of providers per 100,000 residents was highly 
skewed, “with a mean of 3.3 (sd = 6.6) in 2008 and 4.82 (sd = 8.2) in 2011,  with only 5% 
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of counties having more than 13 waivered physicians per 100,000 residents in 2008 and 
17.6 per 100,000 residents in 2011” (Stein, Gordon, Dick, Burns, Pacula, Farmer, Leslie, 
et al., 2015, p. 106). 
In the only article specifically addressing spatial potential access, Dick and 
colleagues (2015) created a methadone, buprenorphine, and overall treatment shortage 
area metrics using a methodology similar to that used to calculate HPSAs (Dick et al., 
2015).  They defined a treatment shortage county as a county that either had 0 
providers, had a provider to population ratio that fell in the lowest 10%, or a provider to 
population ratio that fell in the lowest 20% and high need for treatment.  High need was 
determined by proxies of need: the number of opioid overdose deaths, heroin prices, 
and demographic characteristics.  They reported that the number of people residing in 
treatment shortage counties declined from about 49% to 10%, largely due to the 
dramatic increase in buprenorphine waivered physicians over that time period.  They go 
on to report that the increases in potential access were not uniform across all 
metropolitan status types, with small and medium non-metropolitan counties seeing 
the smallest increases in potential access, and large non-metropolitan counties seeing 
the greatest increases in potential access. Nor were these gains uniformly distributed 
across the country.  By 2011, large areas in the Midwest remained treatment shortage 
areas. 
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2.3 Two buprenorphine policies and their impacts on treatment capacity  
DATA 2000 established the regulatory framework to allow buprenorphine 
prescribing for the treatment of opioid use disorder in office-based settings. 
Buprenorphine prescribing for OUD differs from prescription of all other medications in 
two respects: prescribers are limited in the number of patients to whom they can 
prescribe, and nurse practitioners and physician assistants were not allowed to 
prescribe buprenorphine even when they had the prescribing authority for other 
controlled substances (until the passage of the Comprehensive Addiction Recovery Act 
in 2017).  
2.3.1 The history of the patient limit policy 
A limit on the number of patients to whom a provider could prescribe was a part 
of office-based OAT policy from the outset.  The Controlled Substances Act (CSA) of 
1970 allowed for dispensing, but not prescribing, of narcotic drugs for maintenance 
treatment or detoxification treatment and imposed strict regulatory requirements on 
dispensing providers (91st United States Congress, 1970). The first draft of legislation to 
allow for office-based buprenorphine prescribing, the Drug Maintenance and 
Detoxification Act of 1995, sought an exemption to the regulatory requirements of the 
CSA when physicians treated 20 or fewer patients with a Schedule V drug 
(buprenorphine was in Schedule V at the time due to its safety profile and perceived 
limited abuse potential) (Jaffe & O’Keeffe, 2003). When DATA 2000 was signed into law 
in 2000, prescribing was limited to 30 patients per practice (Carl Levin & Orrin Hatch, 
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2000). In 2005, congress passed a law to allow 30 patients per physician, rather than per 
medical practice (109th Congress, 2005).  
In studies that surveyed physicians on buprenorphine use, the 30 patient limit 
was often cited as a barrier limiting patient access to treatment (Barry et al., 2008; Join 
Together, 2003; Kissin et al., 2006; WESTAT & The Avisa Group, 2006).  In December of 
2006, congress again amended the CSA, this time to allow physicians to treat up to 100 
patients at one time (109th Congress, 2006), and in 2007 the DEA finalized the rule 
change that allowed waivered physicians to apply for a patient limit increase after one 
year (Drug Enforcement Administration, 2008). Finally, in 2016, SAMHSA finalized a 
regulatory rule change, without a preceding act of Congress, to allow certain board 
certified addiction specialists to increase their patient limit to 275 (SAMHSA 2016a).  
2.3.2 The intent of the patient limit policy 
No authors explicitly stated the reasoning behind the original 20 or 30 patient 
limit, but much can be inferred from OAT policy papers published around the time that 
DATA 2000 became law and buprenorphine prescribing began.  Two themes for why 
policy-makers may have chosen to limit patient numbers emerged from this literature: 
integrating addiction treatment into mainstream or primary medical care—as opposed 
to higher volume specialty care settings, and reducing the risk of diversion.   
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2.3.2.1 Integrating addiction medicine into mainstream or primary medical care 
In a primary care addiction treatment model, in which a provider would treat a 
patient’s addiction as part of that patient’s routine medical care, many providers would 
each treat few patients.  This was the case in France around the time that DATA 2000 
became law.  In 1995, in response to a heroin crisis, France allowed all physicians to 
prescribe buprenorphine for the treatment of opioid use disorder without requiring any 
special certification or education. Bell, et al. (2002) wrote that 29% of French General 
Practitioners (GPs) were prescribing to 1 patient (6% of patients) and that 12% were 
prescribing to 12 or more (50% of total patients; Bell, Dru, Fischer, Levit, & Sarfraz, 
2002).  In 1999, in a study of one French region, 20% of GPs were prescribing 
buprenorphine, 0.8% had 50 or more patients, while 84% had fewer than 6 patients 
(Auriacombe, Fatséas, Dubernet, Daulouede, & Tignol, 2004). Several studies through 
2002 showed that the “large majority of buprenorphine prescribers in France [were] 
office-based general practitioners” (Auriacombe et al., 2004, p. S18). This GP focused 
system was able to engage 50% of problem heroin users in OAT, and likely contributed 
to a dramatic reduction in opioid overdose deaths at the time (79% reduction from 1994 
to 1999; Auriacombe et al., 2004).  
In the United States, interest in integrating OAT into primary care pre-dated 
DATA 2000 and buprenorphine FDA approval. In the 1980s and 90s, there were several 
successful studies of “medical maintenance programs,” or office based methadone 
treatment for stable methadone patients (Fiellin, O’Connor, et al., 2001; Merrill, 2002; 
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Novick et al., 1988; Schwartz, Brooner, Montoya, Currens, & Hayes, 1999; Senay et al., 
1993).  Because of these successful studies and the French experience, by the time 
DATA 2000 became law, authors were calling for broadening the OAT prescriber base 
through primary care methadone or buprenorphine treatment (Rounsaville & Kosten, 
2000), for the reintegration of “methadone maintenance and other addiction 
pharmacotherapies into [office-based] medical practice” (Merrill, 2002, p. 1), for “the 
much needed medicalization or opioid agonist pharmacotherapy” (Kreek & Vocci, 2002, 
p. 102) , and for the expanded role of the primary care physician in “optimizing health of 
opioid dependent patients”  (Krantz & Mehler, 2004, p. 1).  
Buprenorphine prescribing under DATA 2000 was originally envisioned as a 
system in which opioid agonist treatment was integrated into the normal course of 
medical treatment. The manufacturer of buprenorphine, Reckitt Benckiser, needed 
buprenorphine “to reach the mainstream practice of medicine” (Jaffe & O’Keeffe, 2003) 
in order to make the investment in the FDA approval of buprenorphine worthwhile. 
SAMHSA generated a Treatment Improvement Protocol (TIP) to support DATA 2000 
prescribers with limited experience with addiction treatment. The TIP authors wrote of 
the vision of OB buprenorphine treatment, “Office-based treatment with buprenorphine 
promises to bring opioid addiction care into the mainstream of medical practice”, and 
“The promise of DATA 2000 is to help destigmatize opioid addiction treatment and to 
enable qualified physicians to manage opioid addiction in their own practices”  
(emphasis mine; Boone et al., 2004, p. xv and 2-3). Feillin and O’Connor (2002) wrote 
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“the current initiatives are designed to meet the dual objectives of treatment expansion 
and involvement of physicians in the care of opioid-dependent patients….increasing the 
participation of the medical community in the treatment of opioid dependent patients” 
(Fiellin & O’Connor, 2002b). 
The original vision of DATA 2000 conveyed by researchers at the time was a 
primary-care based addiction treatment system as a supplement to OUD treatment in 
specialty addiction treatment settings, in which addiction treatment was integrated into 
mainstream medical practices (Ling & Smith, 2002).  With the example of the French GP-
based system and the promise of a similar primary care based system, one could see 
how a 30-patient limit might have seemed like a non-issue from an access standpoint.     
2.3.2.2 Reducing the risk of diversion 
In crafting the law that would create the envisioned diffuse, primary care based 
system, the early policy makers had to balance access with against the risk of diversion. 
In the French system at the time, access was paramount, and diversion did occur 
(Auriacombe et al., 2004). Auriacombe et al. (2004) wrote of the largely unregulated 
French system that “a lack of regulation could increase the occurrence of…diversion to 
non-registered patients and thus limit the overall benefit of this medication” 
(Auriacombe et al., 2004, p. S18). In the United States, the addiction treatment system 
in place before DATA 2000 was highly regulated to prevent methadone diversion (Bridge 
et al., 2003; Campbell & Lovell, 2012; Jaffe & O’Keeffe, 2003; Merrill, 2002). In the 
balancing concerns about access against diversion, diversion concerns appeared to be 
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paramount, as “limiting diversion dominated discussion of methadone within the 
domestic drug control apparatus in the early 1970s” (Campbell & Lovell, 2012). 
By the late 1990s, treatment access was once again a major concern as opioid 
overdose deaths were on the rise. Buprenorphine was seen as a desirable product for 
office based treatment because it appeared to have lower potential for diversion and 
misuse than methadone (Bridge et al., 2003; Fiellin et al., 2002), especially when 
combined with naloxone, an abuse deterrent formulation that discourages medication 
injection. Even with a lower potential for diversion and abuse due to its pharmacological 
properties, there were continuing concerns about medication diversion.  Jaffe and 
O’Keefe (2003) that “The FDA was concerned that the system could get out of hand 
unless limits were place on the number of doctors and patients who could initially 
participate in the system” (Jaffe & O’Keeffe, 2003, p. S8). A congressional aide 
interviewed by Fornili and Burda (2009) remembered that there was opposition to DATA 
2000 from legislators concerned about “potential diversion of any opioid medication” 
(Fornili & Burda, 2009). This concern may have contributed to the inclusion of a patient 
limit in the legislation.   
2.3.3 The effects of and reaction to the patient limit policy    
In the early days after DATA 2000, uptake of office-based treatment was low 
(Netherland et al., 2009).  As predicted, the early adopters tended to be addiction 
specialists (West et al., 2004).  According to SAMHSA’s evaluation of the DATA waiver 
program, by 2005 44% of waivered providers were addiction specialists (WESTAT & The 
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Avisa Group, 2006), and 80% of all waivered physicians were prescribing to zero or very 
few patients, leaving 20% of waivered physicians to treat the majority of patients 
seeking buprenorphine treatment (Albright, Ciaverelli, Essex, Tkacz, & Ruetsch, 2010). 
Similarly, a 2005 national survey of all psychiatrists found that 86% were not 
comfortable with prescribing buprenorphine (West et al., 2004). And in a non-
representative survey of psychiatrists in 4 cities also conducted in 2005, only 13% of 
non-addiction specialist psychiatrists had received waiver training and 9% had 
prescribed buprenorphine (Thomas et al., 2008). 
In these early days, patient counts tended to be low or even zero, but 
distributions of patient counts were skewed, indicating that while most providers were 
treating few patients, a few were treating a lot of patients (Albright et al., 2010; Fiellin, 
2007; Reif, Thomas, & Wallack, 2007b; WESTAT & The Avisa Group, 2006). These few 
were likely the early adopting addiction specialists. Many providers at the time were 
frustrated by the patient limit policy and were vocal in opposition to it. Physicians were 
frustrated with two aspects of the patient limit—the limit on patients per practice, and 
the limit itself. The limit on the number of patients per practice did not differentiate 
between large medical practices that could have hundreds or thousands of providers, 
and single solo practices (Schackman, Merrill, McCarty, Levi, & Lubinski, 2006; WESTAT 
& The Avisa Group, 2006). Providers in large medical groups, or in groups that 
specialized in addictions were particularly frustrated by the 30 patient limit for medical 
groups (WESTAT & The Avisa Group, 2006). The 30 patient limit was cited as barrier to 
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access to buprenorphine in several physician surveys (Barry et al., 2008; Join Together, 
2003; Thomas et al., 2008). Addiction specialists who responded to open ended survey 
questions in the SAMHSA evaluation report were eager to convey to SAMHSA that the 
30-patient limit hampered their ability to provide care to patients who need treatment. 
Many stated that they maintained waitlists and turned patients away. Some called for 
the limit to be raised, others for it to be abolished for specialists (WESTAT & The Avisa 
Group, 2006). The American Society of Addiction Medicine wrote in its public policy 
statement that “arbitrary caps on the number of patients who can be treated by a 
physician….that are not supported by medical evidence, should not be imposed by law, 
regulation or health insurance practices” (American Society of Addiction Medicine, 
2006, p. 2).  
After changes to the patient limit policy in 2005 and 2007, the patient limit was 
still cited as a constraint on physician capacity and a barrier to access (Green et al., 
2014; Molfenter, Sherbeck, Zehner, & Starr, 2015; Stein, Pacula, et al., 2015), and 
several providers have reported demand that exceeds their 100-patient limit (ASAM 
staff, 2015; Molfenter et al., 2015). 
2.3.4 Post-hoc policy analysis of patient limit changes 
To date there have been two post-hoc policy analysis studies of lifting the 
patient limit from 30 to 100. Stein and colleagues found that the amount of 
buprenorphine dispensed and the number of waivered providers increased in general 
from 2004 to 2011, but that buprenorphine dispensing increased most from providers 
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with 100-patient waivers. They estimated 24 to 45 additional patients received 
treatment per 100-patient provider in urban areas and 57 additional patients received 
treatment per 100-patient provider in rural areas (Stein, Pacula, et al., 2015). The 
authors noted that many of the physicians waivered at the 30-patient level were 
prescribing to few or no patients. The same research group published a study on 
pharmacy retail transactions and found that among those that prescribed, the majority, 
69%, prescribed to 30 or fewer patients (Stein BD et al., 2016). Similarly, Hefei Wen 
(2016) found that “the availability of 100-patient waivered physicians was strongly 
associated with increase in Medicaid prescriptions for and spending on buprenorphine 
MAT,” but did not find a significant association between prescribing and the availability 
of 30-patient waivered physicians (Hefei Wen, 2016). These studies suggest that though 
most providers are prescribing to a small number of patients and were unaffected by 
the cap change policy, increasing capacity did afford greater access to treatment 
through the smaller proportion of providers who elected to increase their limits, and 
that this increase in access occurred in both rural and urban areas. 
2.3.5 Exclusion of Nurse Practitioners and Physician Assistants as eligible DATA 2000 
prescribers until 2016 
A provision of the Comprehensive Addiction Recovery Act (CARA) passed in 2016 
enabled Nurse Practitioners (NPs) and Physician Assistants (PAs) to prescribe 
buprenorphine for the treatment of OUD.  The original language of DATA 2000 explicitly 
stated that “qualified physicians may prescribe” schedule III, IV and V controlled 
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substances for the treatment of opioid use disorder. It is not clear whether NPs and PAs 
were excluded from the waiver program due to oversight or design (Fornili & Burda, 
2009). Senator Levin, one of the original sponsors of DATA 2000 and an advocate for 
expansion of buprenorphine treatment expansion was in favor of NP buprenorphine 
prescribing in 2014 (“Congress and SAMHSA look at ways to expand buprenorphine,” 
2014), so it is unlikely that he had intended that they be excluded when the law was 
originally written. Whatever the original intent, up until passage of CARA, NPs and PAs 
could not prescribe buprenorphine for the treatment of OUD.  
Advocates for extending prescribing authority to NPs and PAs note that NPs and 
PAs could expand OAT capacity to vulnerable populations because NPs and PAs working 
in primary care often serve in Health Provider Shortage Areas (HPSAs) or Medically 
Underserved Areas (MUAs), in safety-net settings, or as front line health care workers in 
rural areas (Fornili & Burda-Cohee, 2006; O’Connor, 2011; Strobbe & Hobbins, 2012). 
Three studies have been conducted on NP/PA attitudes toward buprenorphine 
prescribing.  Roose, et al. (2008) found that 48% of PAs and NPs surveyed at HIV 
educational conferences expressed interest in prescribing buprenorphine and that PAs 
and NPs (pooled) were more likely than infectious disease physicians to be interested in 
prescribing (aOR 2.89; Roose, Kunins, Sohler, Elam, & Cunningham, 2008). The authors 
note the limitations of their study: small sample size and possibility of selection bias—
NPs and PAs at HIV conferences may be more likely to show interest in buprenorphine 
prescribing than those who don’t go to conferences.  They should be commended in not 
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making general claims about NP and PA interest from this small sample of NPs and PAs 
that work in HIV settings.  However, authors of policy and advocacy papers have not 
always been so careful.  This study is widely cited as proof of a general claim that NPs 
and PAs are interested in prescribing buprenorphine.  Additionally, the odds ratio in the 
study is a little suspect because physicians who were already prescribing buprenorphine 
to their patients were excluded from the analysis.  PAs and NPs who can’t prescribe 
buprenorphine are compared to physicians who have already had the chance to 
prescribe buprenorphine and have chosen not to.  
In a study of all PAs in Kansas to which only 25% responded, Spiser and Dumolt 
(2011) found that 53% of respondents believe legislation should be changed to allow 
PAs to prescribe buprenorphine, while 32% are unsure.  29% of primary care PAs were 
interested in becoming certified if the legislation would allow, while 15% were unsure.  
50% believed there was a need for more certified buprenorphine prescribers in their 
communities, while 29% were unsure. 65% of primary care PAs reported having to turn 
patient away or recommend another location for opioid addiction treatment.  Average 
distance from their practice to the nearest certified provider site was 28.87 miles.  Of 
those who practiced in rural or frontier communities, the average distance was 42.6 
miles, with more than one response of 150 miles (Spiser & Dumolt, 2011).   
The biggest issue with this study is selection bias: the PAs who are interested in 
buprenorphine may also be interested in filling in the survey, and the ones who didn't 
respond might not have because they are not interested in buprenorphine.  However, it 
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does provide another data point (if not a perfect one) on interest in buprenorphine 
prescribing by a group of non-physician providers.  The average distance metrics also 
provide a good picture of how patients are currently being affected by the physician-
only legislation, and how extending prescribing to this group could benefit 
geographically isolated patients.   
In her dissertation on advanced practice nurses’ perspectives on DATA 2000, 
Dorothy Were (2014) reports on a survey of a convenience sample of 96 NPs in 32 
states. 64% of those surveyed felt a subspecialty in addiction medicine should be 
required for buprenorphine prescribing. 65% believe that NPs should be authorized to 
prescribe buprenorphine, and 24% though that maybe they should. 99% said NPs should 
go through the same training as physicians for buprenorphine prescribing (Were, 2014). 
The use of a convenience sample limits the conclusions that can be drawn from the 
study since NPs interested in prescribing buprenorphine may have been more likely to 
complete the survey, potentially biasing the results.  Also, recruitment via social media 
likely resulted in a young sample, while the median age of NPs is fairly high(American 
Association of Nurse Practitioners, 2016).  Further, the author’s interpretation of survey 
results may have been overzealous. She used survey results to support a broad assertion 
not gathered from survey.  Responding that NPs should be allowed to prescribe 
buprenorphine was interpreted as representing the surveyed NPs’ personal interest in 
prescribing buprenorphine, while it may instead indicate that NPs believe that they 
should have the same prescribing authority as physicians regardless of actual interest. 
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These studies, while limited by their use of convenience samples, do show that 
some NPs and PAs are interested in buprenorphine prescribing.  In fact, some NPs who 
work in practices with physicians prescribing buprenorphine have already completed 
waiver training (O’Connor, 2011). Because NPs and PAs often work with marginalized 
communities or people in rural communities, it may be that extending prescribing 
authority to these types of providers will alleviate some of the regional disparities in 
access.  
With the passage of the Comprehensive Addiction Recovery Act (see McCarty, 
Priest, & Korthuis, 2018), nurse practitioners and physician assistants may now prescribe 
buprenorphine for the treatment of opioid use disorder after completing 25 hours of 
training (compared to 8 hours for physicians) which some providers have identified as a 
barrier to adoption by NPs and PAs. 
2.4 Simulation for substance abuse policy analysis 
Researchers have been generating substance abuse policy simulations since the 
1970s. While this is not a comprehensive list of all substance abuse policy simulations, 
several examples are shown in Table 2-1, categorized by substance and methodology. 
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Table 2-1: Dynamic policy models of substance use grouped by substance and modeling methodology. 
 Modeling Methodologies 
Topic 
System Dynamics/ 
Differential or 
Difference 
Equations 
Markov/ State 
Transition 
Monte Carlo 
Simulation/ 
Discrete Event 
Simulation 
Microsimulation Agent Based 
Simulation 
Alcohol (H. D. Holder & 
Blose, 1987) 
(H. Holder, 1998) 
(Mortimer & 
Segal, 2005) 
(Chisholm, Rehm, 
Van Ommeren, & 
Monteiro, 2004) 
(Barbosa et al., 
2010) 
  (Garrison & 
Babcock, 2009) 
(Giabbanelli & 
Crutzen, 2012) 
Tobacco (Levy, Chaloupka, 
Gitchell, Mendez, 
& Warner, 2002) 
  (Levy & Friend, 
2001) 
(Levy et al., 2002) 
(Levy, Friend, 
Holder, & 
Carmona, 2001) 
(Tomintz, 2009) 
 
Heroin/Opioids (Levin, Roberts, & 
Hirsch, 1975) 
(White & 
Comiskey, 2007) 
(Nyabadza & 
Hove-Musekwa, 
2010) 
(Barnett, 2009) 
(Schackman, Leff, 
Polsky, Moore, & 
Fiellin, 2012) 
(Zarkin, Dunlap, 
Hicks, & Mamo, 
2005) 
(Zarkin et al., 
2011) 
 (Perez et al., 2006) 
(Hoffer, Bobashev, 
& Morris, 2012) 
(Heard, Bobashev, 
& Morris, 2014) 
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(Wakeland et al., 
2013) 
(Wakeland, 
Nielsen, & 
Geissert, 2015) 
Cocaine (Homer, 1993a) 
(Homer, 1993b) 
(Behrens, 
Caulkins, Tragler, 
Haunschmied, & 
Feichtinger, 1999) 
(Sohler 
Everingham, Peter 
Rydell, & Caulkins, 
1995) 
(Jonathan P. 
Caulkins, Rydell, 
Everingham, 
Chiesa, & 
Bushway, 1999) 
(Jonathan P. 
Caulkins, Behrens, 
Knoll, Tragler, & 
Zuba, 2004) 
   
Other Methamphetamin
es (Nyabadza & 
Hove-Musekwa, 
2010) 
Injection drug 
users (Peterson, 
Willard, Altmann, 
Gatewood, & 
Davidson, 1990) 
Drug use 
trajectories (J. P. 
Caulkins, Dietze, & 
Ritter, 2007) 
Injection drug 
users (Peterson et 
al., 1990)  
 Drug use in 
general (Galea, 
Hall, & Kaplan, 
2009) 
Injection drug 
users (Gutfraind et 
al., 2015) 
Recreational poly 
drug use (Lamy, 
Bossomaier, & 
Perez, 2015) 
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2.4.1 Model typologies for policy analysis 
As simulation is increasingly used for policy analysis, methodologists have 
developed simulation classification schemes and recommendations for best practices.  
Boero and Squazzoni (2005) defined three basic agent based simulation (ABS) model 
typologies and prescribe appropriate levels of empirical embeddedness for each (Boero 
& Squazzoni, 2005). Simulations may be theoretical abstractions, typifications, or case-
based models. Theoretical abstraction models aim to explain or explore a “wide range of 
general phenomena with no direct reference to reality” (Boero & Squazzoni, 2005, p. 4), 
such as the SugarScape models which explore economic concepts including wealth 
disparity and trade in a simple stylized artificial world (Epstein & Axtell, 1997). Case-
based models simulate a specific event or phenomenon such as the rapid disappearance 
of the Anisazi people in around 1300 modeled in the Artificial Anisazi Project (Dean et 
al., 2000). Typificiation models target a class of empirical phenomena that share certain 
properties, but not a single, specific case.  Theoretical abstractions require no empirical 
data, and case-based modes aim to replicate a phenomenon as faithfully as possible and 
require as much empirical support as is available. Typification models make use of 
empirical data to specify, calibrate and validate models, but aim at a more generalizable 
understanding of studied phenomena. The buprenorphine treatment capacity model in 
this research is a typification model.  The purpose of the model is not to explain or 
understand access to buprenorphine in a given region at a specific time, but rather how 
policy could impact treatment access for people who live in different kinds of 
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communities based on typical provider and patient preferences.  The choice of a 
typification model rather than a case-based model for policy analysis may allow for 
more generalizable policy recommendations, as outlined in Yücel and van Daalen 
(2009). 
 Yücel and van Daalen (2009) propose a conceptual framework for policy analysis 
simulations, specifically, based on the objective of the simulation (Yücel & van Daalen, 
2009).  They delineate six general model objectives: 
1. To research and analyze  
2. To design and recommend 
3. To advise strategically  
4. To mediate 
5. To democratize 
6. To clarify values and arguments 
The buprenorphine policy model in this research is type 2, intended to design 
and recommend policies that increase buprenorphine access and reduce geographic 
access inequality. As an “advisory model” the buprenorphine policy simulation 
“focus[es] on a particular problem context, rather than representing [the] dynamic 
phenomenon in general” (Yücel & van Daalen, 2009, p. 5). They go on to recommend 
best practices for advisory models beyond standard modeling practices, including 
boundary assessment, basis assessment, and representation assessment. I will include 
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specifics on how these assessments will be used here as the concepts are defined, 
rather than in chapter 4, where I propose the actual tests.  
Boundary assessment is the evaluation of the selection of what is left out of the 
model, or what can be modeled as an exogenous input. In advisory models decisions on 
boundary selection, these decisions must be defensible in reference to the particular 
problem context of the policy.  In the case of the buprenorphine policy model, the policy 
problem is one of provider capacity and access, not treatment adequacy, quality, or 
patient quality of life. As such, the model excludes rich modeling of relationships among 
potential patients, motivations to seek treatment, or medical decisions by providers. 
Further, the incidence of OUD and treatment seeking are exogenous constants because 
they change slowly compared to the time horizon in the model.   
Basis assessment is the extent to which a model should be based on empirical 
data, theory or the knowledge of experts.  The buprenorphine policy model is a 
typification model that makes heavy use of empirical data.  Because the model is a 
typification, broad, survey-based empirical data is sufficient, where a case-based model 
might require specific, high fidelity geographic data (such as tract-level census data, or 
geo-coded provider locations). Also, because the model is a typification, the fact that 
the model is ad hoc rather than strictly theory-based is not problematic (Boero & 
Squazzoni, 2005). The highest quality, most generalizable data was sought to empirically 
support model parameters, and the opinion of a wide array of expert stakeholders with 
different policy perspectives was sought to guide the specification of model structure.  
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Experts included addiction specialist physicians, a primary care physician, a nurse 
practitioner, a physician assistant, a patient advocate in OUD recovery.  Providers serve 
a variety of patient populations including rural residents, urban residents, pregnant 
women with OUD, and veterans; practice in a variety of settings including primary care 
clinics, OB clinics, university hospitals, addiction treatment centers, VHA clinics; and live 
and practice in different regions of the country including the Northeast, the Northwest, 
Appalachia, and the Mid-Atlantic.   
Representation assessment includes standard assessments of validity as well as 
whether the model represents the behaviors and structures of the modeled system 
sufficiently to build confidence in policy recommendations. A model should replicate 
both the underlying agent level processes (structures) the overall behavior of the 
system for advising on policies to be meaningful. Though “models heavily dependent on 
the participators’ depiction of the system are naturally validated and already approved 
by the participants/problem owners,” as the buprenorphine policy model will be, 
standard validation tests should also be used (Yücel & van Daalen, 2009, p. 13). To 
develop appropriate model structures while simultaneously replicating the overall 
behavior of the buprenorphine treatment system, I will use Grimm and Railsback’s 
(2012) “pattern oriented modeling” approach (Grimm & Railsback, 2012), in which I will 
attempt to fit multiple quantitative and qualitative patterns at both the agent and 
system levels. 
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The literature reviewed in Chapter 2 reviewed the limited access to opioid 
agonist therapy in the US, outlined historical approaches to assessing variation in spatial 
access, described the unique limits imposed on buprenorphine prescribing, and 
discussed prior simulation models used to assess policies related to treatment for 
substance use disorders. The stage is now set to address the methods used in the 
analysis of potential changes in policies controlling buprenorphine prescribing. 
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3 Methods 
This research uses Agent-Based Simulation (ABS), a modeling methodology in 
which heterogeneous agents act and interact in a dynamic environment according to 
individual rules of behavior. Population level outcomes of interest are generated by 
local interactions of agents acting in their own interest—in this case: providers 
interacting with people with OUD seeking treatment, and people with OUD interacting 
with providers and peers. 
Empirically-based simulation models have been used to model state alcohol and 
traffic policies, social influence on BMI, drinking behavior, and health behavior and drug 
use (see Table 2-1). There are many advantages of using Agent-Based Models (ABMs) as 
policy analysis tools.  ABMs allow for the exploration of policy options in silico, without 
putting people at risk, at lower cost, and often in less time than empirical studies. ABMs 
are not aggregate population-based models, but rather individual-based models which 
allow for exploration of the effects of individual heterogeneity including spatial 
heterogeneity. As in real target systems, population level dynamics arise from the 
interactions of these heterogeneous agents within the modeled environment.  In this 
study, issues of buprenorphine treatment capacity arise due to the interactions 
between people with OUD entering treatment and their prescribers, and due to the 
simulated geography which these actors inhabit.  This simulation method was selected 
specifically because of an apparent mismatch between simply-calculated buprenorphine 
treatment capacity numbers (the sum of waivered doctors times the three patient limit 
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levels) and the actual experience of providers: some of whom treat very few patients, 
and others who maintain waitlists and routinely turn patients away.  
It should be noted that in some research studies an ABM is the result of 
research, and in others, an ABM is a research method. The latter is the case in this 
research.  The ABM developed is used to research policy options in the context of future 
uncertainty, and to assess the usefulness and functional form of the proposed aggregate 
geographic accessibility metric. As such, the model is described in this methods chapter, 
while the results of metric exploration and policy analysis experiments are described in 
Chapter 4. 
The model was implemented in NetLogo 6.0.2 (Wilenski & others, 1999). 
3.1 Model development 
Simulation modeling is often a participatory and iterative process.  Subject 
matter experts are involved throughout the model development process, from 
conceptualization of the system to validating that the model represents the actual 
system.  As initial, simple models expand to include more detail in order to explore more 
outcomes or to assess a new set of policy questions, the modeling process is repeated.  
This iterative process is outlined in Figure 3-1, below.   
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Figure 3-1: The model development process is iterative, and a single model may require many cycles 
through the process. 
The model used to assess the research questions in this thesis is the fourth 
iteration of a modeling process focused on addressing the question of buprenorphine 
capacity. Early model iterations included simple simulated geographies and were 
presented at SAMSHA’s 2014 Buprenorphine Summit (iteration 1: SAMHSA 2014c), at 
the American Association for the Treatment of Opioid Dependence (AATOD) annual 
conference in 2015 (iteration 2: Alexandra Nielsen, 2015), and submitted to an 
academic journal (iteration 3).  In the third iteration, model geography was based on a 
real map, and the scope of the model expanded to include: 1) a greater number of 
relevant outcomes, 2) more detail on patients seeking treatment, 3) people not seeking 
treatment as agents, 4) methadone treatment offered at Opioid Treatment Programs 
(OTPs), 5) children and pregnant women, and 6) more policy options. Model revision 
followed each dissemination activity in response to reviewer comments and critique. In 
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the fourth modeling iteration, the model was streamlined and several outcomes and 
populations were removed. For example, because child buprenorphine poisonings are a 
significant public health concern, children and this outcome were included in iteration 3, 
to increase applicability, but removed in iteration 4, to address more targeted 
dissertation research questions.  
Each step of the modeling process detailed in Figure 3-1 is detailed below: 
3.1.1 Conceptualize the system 
I sought understanding of the target system to be modeled through extensive 
literature search and through interviews with experts in OB buprenorphine treatment. 
Prior to initial modeling, I interviewed two addiction medicine specialists who had 
experience developing the eight-hour training course for DATA 2000 waiver 
certification, Dr. Margaret Kotz, and Dr. Stephen Wyatt (Kraus et al., 2011).  In order to 
involve a broader base of stakeholders, I empaneled a diverse group of experts to guide 
model conceptualization and specification. Expert panel members consulted during 
model development for iterations 2 through 4 are listed below.  I interviewed each 
panel member at least twice using an unstructured format, and asked specific questions 
via email as they arose in the modeling process. Dr. Alane O’Connor and Dr. Andrew 
Saxon were also consulted to assess iteration 4 face validity. 
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3.1.1.1 Expert Panel Members 
• Dr. Todd Korthuis—Oregon Health and Science University, General internal 
medicine, HIV research program director—Primary Care Provider in Oregon 
• Timothy Lepak—president National Alliance of Advocates for Buprenorphine 
Treatment—Patient Advocate 
• Melvania Briggs, PA-C—Academic coordinator for the Duke University 
Physician Assistant Program. Co-Principal Investigator of a NIDA funded 
Buprenorphine Clinical Trial for a community based mental health 
organization and Duke University Medical Center—Physician Assistant in 
North Carolina 
• Dr. Kelly Clark—Chief Medical Officer of CleanSlate Addiction Treatment 
Centers, president of the American Society of Addiction Medicine (ASAM)—
Addiction Medicine specialty provider in Kentucky and Pennsylvania 
• Dr. Andrew Saxon—Center of Excellence in Substance Abuse Treatment and 
Education, VA Puget Sound Health Care System, Director Addiction Psychiatry 
Residency Program, University of Washington, associated with the American 
Association of Addiction Psychiatrists (AAAP)—Addiction Psychiatry provider 
in Washington 
• Dr. Alane B. O’Connor, DNP, FNP—Maine Dartmouth family Medicine 
Residency Faculty Adjunct Instructor, author of NP buprenorphine health 
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policy article, investigator of clinical trials of buprenorphine use in 
pregnancy—Family Practice Nurse Practitioner in Maine 
3.1.2 Build a model 
The operational model was developed in NetLogo 6.0.2, an ABS tool. I used the 
pattern oriented modeling technique (Grimm & Railsback, 2012), in which a model is 
developed to fit several quantitative and qualitative patterns. The Overview, Design 
concepts, and Details (ODD) protocol (Grimm et al., 2010) was employed to convert the 
understanding of the system into an operational model.  The model is documented in 
Section 3.2 using the ODD protocol, which is the gold standard for model reporting and 
replicability. 
3.1.3 Add data to the model 
Modeling best practice requires that all aspects of the system that are 
considered important in model conceptualization be included in an operational model 
whether or not high quality data are available to support them (Caro, Briggs, Siebert, & 
Kuntz, 2012).  When possible, I obtained empirical support for model parameters from 
peer-reviewed published literature through both comprehensive and targeted literature 
searches. I obtained empirical support for model parameters for which high quality data 
were not available from smaller studies that are not necessarily generalizable, “grey” 
literature, expert opinion, and through the process of model calibration.    
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3.1.4 Test the Model 
For models to serve as credible proxies for the target system, models should be 
calibrated, verified, and validated to the degree possible. The model should also be 
tested for sensitivity to specific parameter values and critical assumptions about model 
structure.  I calibrated the iteration 4 model manually to reproduce historical trends in 
opioid overdose deaths and the number of unique buprenorphine recipients for a given 
year. I conducted model verification—testing that the model performs as expected—
throughout the iterative modeling process, as model code was developed and as new 
data added to the model. The model was assessed for face validity by two panel experts, 
Dr. O’Connor and Dr. Saxon, and externally validated by comparing model-generated 
annual opioid overdose deaths and number of unique buprenorphine recipients against 
data that was not used in model calibration. I conducted one-way sensitivity testing by 
varying each model parameter by 30%. I tested the model’s sensitivity to the geography 
selected by conducting baseline model runs with 10 different maps. I tested sensitivity 
to assumptions about provider preferences for patient loads by running the model 
under several alternative assumptions about providers’ patient load preferences.   
In general, model testing built confidence that the model is a sufficiently faithful 
representation of the world to be able to consider the results of policy experiments to 
be meaningful. Calibration can show that a model is capable of generating known 
behavior, verification shows that the operational model matches the conceptual model 
developed with subject matter experts, and validation can show that the model is 
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capable of generating real world behavior in a way that conforms to experts’ 
understanding of the target system. Sensitivity testing builds confidence by showing the 
degree to which model performance is dependent on assumptions and on parameter 
values which may or may not have strong theoretical or empirical support.  While none 
of these tests can prove that a model is “right,” they do build confidence that a model 
may be useful for its intended purpose.   
Model testing specifics and results are reported in Section 3.4. 
3.1.5 Run Experiments 
I conducted policy experiments by systematically changing the values of policy 
variables and observing model outcome values after a year of modeled time.  Because 
the model contains several random variables, each experiment was repeated 35 times 
to establish the possible range of outcomes. One-way ANOVA power analysis indicated 
that with 35 replications, one could detect medium to large effects (f = 0.30), with an 
alpha of 0.05, beta of 0.1, and 5 variable levels.  Fewer replications would risk low 
power, or inability to detect differences in outcome variables that are present in 
simulation data. Policy experiments and results are detailed further in Section 3.7 and 
Section 5. 
I also conducted spatial potential access metric exploration experiments using 
alternative formulations of the aggregated spatial disparity metric to assess the relative 
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sensitivity and usefulness of each formulation. The process is further detailed in Section 
3.6, results detailed in Section 4. 
3.2 Model specification 
Model specification is detailed below using the ODD (Overview, Design concepts, 
and Details) protocol for ABS models (Grimm et al., 2010).  The ODD protocol is a 
standardized description protocol that facilitates rigorous formulation of ABS models, 
and allows for reproducibility of such models. Model overview is outlined in three 
sections: purpose; entities, state variables and scales; and process overview and 
scheduling. Major ABS design concepts are described in the design concepts section, 
and details are provided in the initialization, and input data sections. Full model code is 
attached as an appendix to support model replicability. Embedding a full model 
description using the ODD protocol in a dissertation results in some redundancy, but I 
include all sections for rigorous adherence to the reporting standard.   
3.2.1 Purpose 
The purpose of this model is to represent OB buprenorphine treatment capacity 
in the United States, and to assess policy options that impact treatment capacity. 
Specifically: Is OUD agonist treatment capacity sufficient to meet patient 
pharmacotherapy treatment demand, given: regulatory limits on patient numbers, 
barriers to provision of treatment, geographic dispersion of people with opioid use 
disorder, and geographic concentration of providers? Is treatment capacity equitably 
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distributed spatially? The simulation explores two policy areas to increase OB 
buprenorphine access: 
 How does changing the patient limits affect treatment access, access equity, and 
medication diversion? 
 How does extending buprenorphine prescribing authority to NPs and PAs affect 
treatment access, access equity, and diversion? 
My research also explores the usefulness of the proposed aggregate spatial 
accessibility metric. 
3.2.2 Entities, state variables, scales, and environment 
There are four types of entities in the model: people with opioid dependence, 
OAT treatment providers, OTPs, and spatial units.  
Agents with OUD, “agents” are characterized by the following state variables, or 
attributes: 
Table 3-1: Attributes of agents with OUD 
Attribute  Range Units 
Is the agent seeking OAT? True/False Boolean (yes, no) 
Is the agent receiving 
methadone? 
True/False Boolean 
Number of weeks receiving OB 
BUP 
[0, length of simulation) weeks 
Has the agent relapsed? 
(defined as no longer seeking 
treatment, not engaged in 
True/False Boolean 
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treatment, or not completed 
treatment) 
Is the agent stably abstinent 
from non-medical opioids, 
(including reduced use)? 
True/False Boolean 
Chance that agent will never 
achieve stable abstinence (or 
reduced use) 
50% -- 
Length of time in treatment 
required to attain stable 
abstinence (or reduced use) 
[10, ~400) weeks 
Distance willing to travel for 
treatment 
(0, ~150) miles 
Length of time will wait for 
treatment before relapsing 
[1, ~10) weeks 
Length of time currently 
waiting for treatment 
[0, ~10) weeks 
Is the agent currently on a 
waitlist? 
True/False Boolean 
Is the agent too far from a 
provider? 
True/False Boolean 
Provider the agent would like 
to establish with 
provider agent provider agent 
Group of referred or nearby 
providers 
unsorted list of provider 
agents 
list 
Sorted list of referred or 
nearby providers 
list of provider agents 
sorted by distance from 
agent 
list 
Has the agent purchased 
buprenorphine from an illicit 
source? 
True/False Boolean 
Source of illicit buprenorphine  “friend” or “street” list 
Has the agent sold/given away 
treatment buprenorphine 
True/False Boolean 
Reason for diverting “can’t afford treatment”, 
“wanted money”, 
“friend asked” 
list 
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Dose of buprenorphine 
needed 
[8, 32] mg per day 
Weeks of buprenorphine 
medication in the agent’s 
possession 
[0, 4] weeks 
Insurance held by agent “public”, “private”, 
“none” 
-- 
Coinsurance—percentage paid 
for treatment 
[0, 100%] percentage 
Poverty level of agent [1,3] Indicator of income 
relative to the poverty 
level.  1 is below 100% of 
poverty level, 2 is below 
200% of poverty level, 
etc. 
Income (0, ~$3000) $ per month 
Monthly treatment out-of-
pocket payment 
[0, ~$1300) $ per month 
Monthly medication cost [0, $480) $ per month 
Can the agent afford his/her 
treatment? 
True/False Boolean 
Sex Male/Female -- 
At the end of the current year, 
did the agent receive any OAT 
treatment? 
True/False Boolean 
At the end of the current year, 
did the agent receive OB BUP? 
True/False Boolean 
At the end of the current year, 
did the agent never receive OB 
BUP? 
True/False Boolean 
At the end of the current year, 
did the agent attempt to get 
OB BUP even once? 
True/False Boolean 
weighted sum of provider to 
agent ratios 
[0,  upper patient limit * 
number providers] 
dimensionless 
For model simplicity, some of these states are mutually exclusive.  For example: 
an agent cannot be receiving OB BUP and also seeking OAT treatment. 
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Provider agents, “providers” are characterized by the following attributes: 
Table 3-2: Attributes of provider agents 
Attribute Range Units 
Number of years the provider 
has had a waiver 
[0, 15] years 
Other waivered providers that 
a provider might refer a 
patient to 
list of provider agents list 
Population density of the 
provider’s practice location 
(depending on provider type) 
(0, ~15,000) people/mi2 
Provider type “doctor,” “NP,” “PA,” 
“methadone only 
doctor” 
-- 
Does the provider work at an 
OTP? 
True/False Boolean 
Does the provider have an 
addiction medicine specialty? 
True/False Boolean 
Does the provider have a high 
waiver (100 patients at 
baseline, in 2013)? 
True/False Boolean 
Is the provider on the 
SAMHSA searchable list? 
True/False Boolean 
Is the provider currently 
prescribing? 
True/False Boolean 
If the provider has a low 
waiver, will he or she then get 
a high waiver? 
True/False Boolean 
Number of patients the 
provider is willing to treat 
under ideal circumstances 
[0, ~2500) people 
Number of patients the 
provider is able to treat with 
patient limits 
[0, upper patient limit 
levels] determined by 
policy experiment 
people 
Number of patients a 
methadone prescriber can 
treat with methadone 
[0, ~650)  people 
72 
Number of patients a 
methadone prescriber is 
currently treating with 
methadone 
[0, ~650) people 
Total capacity for all OAT 
treatment types by OTP 
doctors 
[0, ~650 + upper patient 
limit levels) 
people 
Does a methadone provider 
have a no-pay option? 
True/False Boolean 
Does the provider offer 
telemedicine BUP treatment? 
True/False Boolean 
Types of insurance the 
provider accepts  
“Public,” “Private,” 
“None” 
Combinations are 
allowed 
Cost of a typical BUP office 
visit before insurance 
(60, ~$800)  $/month 
Physician to agent ratio in 
physician’s catchment area 
(0, upper patient limit 
level] 
dimensionless 
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Opioid Treatment Programs, OTPs are characterized by the following attributes 
Table 3-3: Attributes of OTPs 
Attribute Range Units 
OTP type Private for profit, Private 
non-profit, Government, 
Veteran’s Health 
Administration 
-- 
Types of insurance the OTP 
accepts 
“Public,” “Private,” 
“None” 
based on OTP type, one 
OTP may accept some, 
one or all types 
Does the OTP have a no-pay 
option? 
True/False Boolean 
Does the OTP provide 
buprenorphine? 
True/False Boolean 
Providers that work at the OTP List of providers list 
Methadone spots at the OTP (~5, ~1300)  people 
Methadone recipients at the 
OTP 
(~5, ~1300) depending on 
the number of spots at 
the OTP 
people 
Spatial Units: The spatial units are 1 square mile grid cells that are characterized 
by population density, the amount of “street” buprenorphine available for purchase in 
that square mile, and whether the 1 square mile cell is in a “medically underserved area 
(MUA).”                                                                                                                                                               
Scales: Time is measured in weeks; 52 weeks constitutes a year, and the model 
was run for one year.  Each spatial unit represents one square mile, and the total 
modeled environment is 150 units by 150 units, representing 22,500 square miles. 
Environment: The modeled environment contains a gradient of population 
densities, with more dense clusters representing cities and less dense areas 
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representing rural regions.  The population density of the modeled environment was 
derived from actual population density maps of 150 x 150 mile regions of the United 
States. 
Policy: Policy variables are as follows: the patient limit for providers waivered for 
greater than one year (patients), and the percentage of NPs and PAs who obtain DATA 
2000 waivers (percentage). 
3.2.3 Process overview and scheduling 
The process overview and scheduling section outlines which entities do what, 
and in what order things happen. In general, this describes what happens when we “run 
the model.”  
In one time step, first, the environment does its process, then agents not in 
treatment or seeking treatment do their processes.  Next the agents seeking treatment 
or in treatment do their processes, and finally, providers do their processes.  These four 
sets of processes are outlined in pseudo-code below: 
Environment process: 
Environment patches (1 mile grid cells) with diverted 
buprenorphine diffuse a fraction of the street buprenorphine 
to neighboring patches 
Out of treatment or not seeking treatment Agent processes:  
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A number of people develop opioid use disorder, and initialize 
state variables as non-treatment-seeking agents 
A fraction of people not in treatment die of overdose and are 
removed from the model 
Treatment seeking or in-treatment agent processes:  
A fraction of patients in treatment die and free up a treatment 
spot 
Agents who have been waiting for treatment longer than their wait 
threshold relapse, become non-treatment-seeking agents, 
update state variables 
Patients in methadone treatment either:  
Quit treatment: relapse, become non-treatment-seeking 
agents, update state variables 
Continue treatment: update state variables 
Patients in buprenorphine treatment either:  
Quit treatment: relapse, become non-treatment-seeking 
agents, possibly die due to post-treatment relapse, 
update state variables 
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Complete treatment: free up treatment spot, update state 
variables 
Continue treatment:  
Get medication:  
If it has been 4 weeks since the last office 
visit or this is the first office visit, 
get 4 weeks of buprenorphine medication  
Set monthly out-of-pocket treatment and 
medication costs based on: insurance, 
whether it is an initial or follow up 
visit, and provider charges 
Set affordability variable based on out-of-
pocket costs and income 
Divert medication: 
A fraction of patients who need money or can’t 
afford treatment divert a fraction of 
their medication to the “street”: 
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Subtract medication from myself, add medication 
to the environment 
Set diversion flag variable to true 
Use medication: decrement the amount of medication by 
1 weeks’ worth 
Update state variables 
Patients on waitlists start treatment if possible: 
If the closest provider IS NOT within the distance the 
patient is willing to travel try to get diverted 
buprenorphine: 
Ask nearby people, “friends” in treatment for 
medication directly. If obtained: update 
diversion variables of self and friend, DO NOT 
increment time waiting variable 
If not obtained from friends, look for “street” 
buprenorphine in the environment patches in the 
neighborhood. If obtained: update diversion 
variable of self, update amount of buprenorphine 
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in the local environment, DO NOT increment time 
waiting variable 
If couldn’t get diverted buprenorphine, increment 
time waiting variable, update state variables 
If the closest provider IS within the distance the patient 
is willing to travel, check capacity of provider 
If the provider does not have a spot, get a list of 
other providers who may have spots 
If either a buprenorphine or methadone provider on the 
referral list has a spot, start treatment, take 
treatment spot, update state variables 
If no providers have spots, try to get diverted 
buprenorphine (as above) 
If can’t get diverted buprenorphine, increment weeks 
waiting, update state variables  
Patients NOT on waitlists start treatment if possible (same as 
waitlisted patient code), except that if no providers have 
capacity, become waitlisted 
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A number of non-treatment-seeking agents become treatment-seeking 
agents and start seeking treatment, update state variables  
There are a few scheduling issues that merit mention: a patient could quit 
treatment and begin seeking treatment again in the same time step.  This represents 
leaving treatment for a period of time shorter than a week.  Patients cannot start 
seeking treatment and get treatment in the same time period with this schedule.  And 
finally, patients seeking treatment will attempt to enter treatment before using diverted 
buprenorphine to avoid relapse. 
Provider Processes:  
Age all providers by one week: 
If a provider’s time providing buprenorphine is now > 1 year 
and the provider wants to have a higher patient limit, 
change to higher patient limit, update state variables 
Add more providers and initialize new providers 
It should be noted that providers update their patient limit levels and that new 
providers are added after the patient processes in a given week. So, a provider will get 
more patients due to a limit change in the time step after the limit level variable 
changes. 
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3.2.4 Design concepts 
ABS models tend to incorporate the design concepts below to some degree.  This 
model is a more top down, probabilistic ABS model than many ABS models and as such 
does not fully employ some of the design concepts.  Learning and prediction (by agents 
within the model) are not employed. 
3.2.4.1 Emergence 
The model is a top down, probabilistic model, so much of the dynamics are “built 
in” rather than emergent.  However, the heterogeneous geography, placement of 
waivered providers, and patients’ willingness to travel do result in the emergence of 
groups of unserved individuals even in more urban locations with many providers. These 
emergent groups do not arise out of the actions and interaction of agents, but more due 
to a confluence of many random properties of geography, treatment seekers and 
physician siting. 
3.2.4.2 Adaptation 
Again, as a top-down, probabilistic model the proposed model treats adaptation 
only lightly.  Patients seek to establish treatment with the closest provider, and if this 
fails, seek to establish with referred providers, failing that, they will use diverted 
buprenorphine or wait.  This could be construed as adaptive behavior in treatment 
seeking.  Use of diverted buprenorphine could be construed as an adaptive behavior in 
prolonging treatment seeking through self-medication.  Patients in treatment may be in 
treatment long enough to reach stable abstinence or reduced opioid use.  Once this 
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threshold is reached, a patient no longer uses a provider’s OAT treatment spot.  This 
could be construed as an adaptive behavior in recovery.  Patients who cannot afford 
their treatment or who need money will divert some of their medicine to the street 
(presumably for money).  This is an adaptive behavior in treatment retention.   
3.2.4.3 Objectives 
Treatment-seeking agents in the model want to get into treatment. Most people 
with opioid dependence do not want to enter treatment, their implied objective is to 
use opioids.  As in actual treatment, attrition out of treatment is high, but retention in 
treatment and possibly reaching stable abstinence or reduced opioid use is also an 
objective of agents.  While “success” per se is not modeled from the agent perspective, 
from the model observer perspective, an agent in treatment or stably abstinent is 
considered “successful.”   
Providers in the model want to provide treatment but only up to patient limit 
levels or to the level that they are comfortable.  
3.2.4.4 Sensing 
Treatment-seeking agents do not have complete information on all providers 
within the radius they are willing to travel, but they are assumed to know the closest 
provider.  They are able to query whether a provider has an open treatment spot and 
act according to this information.  Agents are also aware of their own internal states, 
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such as how long they have been waiting for treatment, or how long they have been in 
treatment.   
Providers know how many patients they have, what the patient limits are, and 
how many patients they are willing to treat.  They also know how long they have been 
waivered.  Providers know that patients have left treatment.  If a provider is in a densely 
populated area, a provider has complete information on all providers within a given 
radius.  If a provider is in a rural area, the provider may only know the closest provider. 
For this model purpose—determining capacity and access, it is not necessary for 
providers to know patient details.  
3.2.4.5 Interaction 
Interaction between agents is simple, and much of it is indirect.  Treatment-
seeking agents and providers interact when patients take up provider treatment spots.  
This results in indirect interaction among treatment-seeking agents.  Indirect interaction 
occurs when a treatment spot is occupied and a potential patient is denied treatment, 
or when a treatment spot opens up and another patient can receive treatment. 
3.2.4.6 Stochasticity 
Stochasticity is the driving force behind this model.  Providers and OTPs are 
placed on the map using a random process.  A statistical distribution is fit to the actual 
population densities of the zip codes of waivered physicians and OTPs.  Modeled 
providers select the density of their own practice location by drawing from this 
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probability distribution and matching their practice location population density to a 
close population density on the map.  The location of agents with OUD is also randomly 
selected based on the percentage of NSDUH respondents with dependence in different 
metro area types.  The proportion of large MSA, small MSA, and non-MSA are fixed at 
initialization, but the actual location of agents with OUD on the map is random.  This is 
because the actual locations of people with dependence is protected information, and 
not known to modelers.  The distance a patient is willing to travel for treatment is 
determined by 10 empirical probability distributions based on population density of 
patient zip code obtained from the NAABT patient locator data file (www.naabt.org), 
with a greater proportion of rural residents willing to travel large distances to receive 
treatment. Treatment retention is treated probabilistically based on retention in 
treatment studies.   
To model capacity and access, I have chosen to fit certain variables to empirically 
observed distributions to be both general and empirically grounded, specifically 
willingness to travel based on urban/rural designation.  I have also chosen to simulate 
decisions as probabilities based on aggregate survey and study data because it is simple 
and more nuanced decision making logic is likely not necessary to address the research 
aims.    
3.2.4.7 Collectives 
While different agent types are aggregated into collectives for observation (see 
below), agents act as individuals and do not interact with groups of agents.  For 
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example: there are no professional societies of providers that share a common desired 
cap level. 
3.2.4.8 Observation 
Observation refers to what data are collected from the model.  The following 
metrics are recorded at the end of a model year: 
 Total population in the modeled environment 
 Number of people who received  BUP treatment in the past year per 100,000 
population 
 Number of people who received ANY OAT treatment in the past year per 100,000 
population 
 Milligrams of diverted buprenorphine in the region 
 The number of opioid overdose deaths in the past year per 100,000 population 
 Spatial Potential Access Gini Indices (see Section 3.5 for derivation of these 
measures) 
3.3 Data 
3.3.1 Initialization 
Initialization varies from one simulation run to the next as described above in 
Section 3.3.1.  Initialization consists of 4 steps: geography, OTPs, providers, and agents 
with OUD are each initialized in turn. 
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Geography is initialized by importing population density maps into the 
simulation environment and by assigning densities to 1 square mile “patches” 
accordingly. Similarly, a map of medically underserved areas (MUAs) is imported and 
overlaid on the population map to determine for which patches the “medically 
underserved area” variable is “true.” MUAs maps are generated by the HRSA to identify 
regions which have a shortage of primary care health services and are publicly available 
for GIS analysis (Health Resources and Services Administration, 2018). Figure 3-2 shows 
the initial population density and MUA maps. The model is initialized with nine other 
sets of maps to explore the effect of geographic variation on outcomes and measures.  
This is described in Section 3.4.4.3.  
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Figure 3-2: Population density (left) and Medically Underserved Area (right) maps. Blue-grey regions 
represent MUAs. 
 
  
87 
OTPs are initialized with the following random and calculated parameters: 
Table 3-4: OTP initial parameter values and empirical support 
Parameter Value Support  Comment 
Number of OTPs  1368 * total model 
population / US 
population 
SAMHSA Opioid 
Treatment Program 
Directory (Division 
of Pharmacologic 
Therapies, 2015) 
The number of 
OTPs is scaled to 
the size of the 
model geography 
Location of OTPs Random: 
Lognormal 
distribution (mean 
9050 sd 32900) for 
density of OTP 
location 
SAMHSA Opioid 
Treatment Program 
Directory 
The lognormal 
distribution is the 
best fit to the 
actual densities of 
OTP locations on 
the OTP directory.  
Model OTPs select 
a population 
density from the 
distribution and 
then are sited on a 
patch with a similar 
population density. 
VA     
accepts cash 64% 2011 OTP Survey 
(SAMHSA 2013a) 
 
accepts private 
insurance 
91% 2011 OTP Survey 
 
accepts public 
insurance 
35% 2011 OTP Survey 
 
have a no-pay 
option 
94% 2011 OTP Survey 
 
offer 
buprenorphine 
94% 2011 OTP Survey 
 
methadone spots Mean 103 sd 89 2011 OTP Survey 
 
number of 
physicians 
Random: 1 or 2 2011 OTP Survey 
 
Government OTP 
   
accepts cash 92% 2011 OTP Survey 
 
accepts private 
insurance 
49% 2011 OTP Survey 
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accepts public 
insurance 
71% 2011 OTP Survey 
 
have a no-pay 
option 
70% 2011 OTP Survey 
 
offer 
buprenorphine 
35% 2011 OTP Survey 
 
methadone spots Mean 362 sd 469 2011 OTP Survey 
 
number of 
physicians 
2 2011 OTP Survey 
 
Private Non-profit 
   
accepts cash 96% 2011 OTP Survey 
 
accepts private 
insurance 
58% 2011 OTP Survey 
 
accepts public 
insurance 
92% 2011 OTP Survey 
 
have a no-pay 
option 
44% 2011 OTP Survey 
 
offer 
buprenorphine 
44% 2011 OTP Survey 
 
methadone spots Mean 235 sd 213 2011 OTP Survey 
 
number of 
physicians 
Random: 1 or 2 2011 OTP Survey 
 
Private For-Profit 
   
accepts cash 100% 2011 OTP Survey 
 
accepts private 
insurance 
33% 2011 OTP Survey 
 
accepts public 
insurance 
46% 2011 OTP Survey 
 
have a no-pay 
option 
8% 2011 OTP Survey 
 
offer 
buprenorphine 
48% 2011 OTP Survey 
 
methadone spots Mean 255 sd 204 2011 OTP Survey 
 
number of 
physicians 
Random: 1 or 2 2011 OTP Survey 
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Providers are initialized with the following random and calculated parameters: 
Table 3-5: Provider initial parameter values and empirical support 
Parameter Value Support  Comment 
Number of years 
the physician 
provider has had a 
waiver 
Random: Uniform 
distribution [0, 15] 
SAMHSA list of all 
waivered 
physicians, 
obtained 20143 
Uniform 
distribution best fits 
data 
Population density 
of physician 
practice location 
(for geographic 
placement) 
Random: 
Lognormal mean 
9460 sd 46300 for 
physicians with 
high waiver; 
lognormal mean 
5570 sd 19600 for 
physicians with low 
waiver 
SAMHSA list of all 
waivered 
physicians, 
obtained 2014 
Lognormal is best 
fit to actual 
population density 
of waivered 
physicians’ zip 
codes. 
Location and 
population density 
of NP or PA 
practice 
30% in Medically 
Underserved Areas 
(MUAs), 25% of 
those in “isolated 
small rural” areas 
with density < 20. 
Otherwise with a 
BUP physician. 
Cross sectional 
analysis of 
administrative and 
survey of primary 
care providers 
(Grumbach, Hart, 
Mertz, Coffman, & 
Palazzo, 2003), 13 
state survey of a 
random sample of 
rural physicians, 
NPs and PAs 
(Doescher, Andrilla, 
Skillman, Morgan, 
& Kaplan, 2014) 
Between 26% and 
42% NPs and PAs in 
Washington and 
California practice 
in HPSAs.  HPSAs 
may be rural or 
urban in the model 
and in the US. 
Co-locating NPs and 
PAs not in 
HPSA/MUAs with 
other BUP 
providers was 
suggested by the PA 
expert.  
Theoretical patient 
capacity 
Random: 30 + 
random 
exponential  mean 
220 for providers 
who are 
Calibrated to: 
Healthcare 
Analytics Retail 
Data4 and (Stein BD 
et al., 2016). 
See Section 3.4.5: 
Recalibration. 
Calibrated to fit 
total number of 
unique 
                                                     
3 A full de-identified list of providers with a DATA 2000 waivers was provided directly by SAMHSA 
in 2014. 
4 Data obtained from a representative of Reckitt Benckiser in personal communication. 
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prescribing, non-
specialists, have or 
will get a high 
waiver; Normal(20, 
7) for providers 
who are 
prescribing, non-
specialists, don’t 
have or want a high 
waiver, 30 + 
random 
exponential mean 
250 for providers 
who are addiction 
specialists. 
Supported by 
expert opinion. 
buprenorphine 
recipients per year, 
and so that 
physicians’ actual 
patient census 
numbers 
approximate mean, 
median, IQR of 
Stein, et al (2016). 
With some 
specialists willing to 
treat very large 
numbers, and other 
willing to treat 
fewer than 100.  
Experts supported 
that specialists with 
good infrastructure 
could treat a very 
large number of 
patients, and that 
primary care 
providers are 
unlikely to treat 
very many. 
Patient capacity 
with current 
patient limits 
Range[0, high 
patient limit], 
theoretical capacity 
truncated at 
patient limit 
 Providers willing to 
treat more than the 
high patient limit, 
are forced to treat a 
maximum of 100 or 
275, depending on 
model year 
Percentage of 
physicians that do 
not prescribe 
7% Upper limit 
established from a 
national survey of 
buprenorphine 
providers 2004 -
2008 (Arfken et al., 
2010), calibrated to 
fit (Stein BD et al., 
2016) 
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Number of 
physicians 
Calculated: 22631 / 
model population 
in 2013;  
22218 in 2014;  
25504 in 2015;  
29961 in 2016 
SAMHSA list of all 
waivered physicians  
Converted to 
doctors/person and 
multiplied by the 
model population 
Number of NPs 71% * 220,000 * 
model 
population/US 
population  
2013 NP survey:  
71% of 220000 NPs 
are in adult primary 
care or psychiatric 
fields (American 
Association of 
Nurse Practitioners, 
2013).  
192000 NPs in 
2013, with 
approximately 
14,000 graduates 
per year gives 
220,000. 
Number of PAs 26.5% * 101318 * 
model 
population/US 
population 
2013 PA survey: 
26.5% of 101318 
PAs are in adult 
primary care or 
psychiatric fields 
(American 
Academy of 
Physician 
Assistants, 2014). 
 
Insurance types 
accepted by all 
providers 
90% cash 
77% private  
60% public 
21% cash only 
Small survey of 
physicians 
(Wisniewski, 
Dlugosz, & Blondell, 
2013) 
Model parameters 
are set so that the 
resulting 
distribution of 
insurance accepted 
fits the empirical 
data. NP and PAs 
are assumed to 
take the same 
insurance as 
physicians. 
Cost of physician 
office visit 
Random normal 
(mean $150 sd 
$150), redrawn for 
visit costs less than 
$60. 
Expert opinion of 
buprenorphine 
treatment patient 
advocate, and 
patient advocate 
website (Timothy P. 
Lepak, 2014) 
Initial visit is double 
the maintenance 
office visit.  Costs 
vary considerably 
from provider to 
provider and region 
to region.  The 
random function 
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allows for a large 
range of visit costs. 
Cost of NP or PA 
office visit 
70% * cost of 
physician office visit 
Assumed. Primary 
care NPs are often 
reimbursed at a 
lower rate than 
primary care 
physicians by 
managed care 
payers (Hansen-
Turton, Ware, 
Bond, Doria, & 
Cunningham, 
2013). 
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Agents with OUD are initialized with the following random and calculated 
parameters: 
Table 3-6: Agent initial parameters and empirical support 
Parameter Value Support Comment 
Number of people 
with opioid use 
disorder 
3556000 * model 
population / US 
population in 
2013; 3400000 in 
2014; 3418000 in 
2015; 3538000 in 
2016 
 
2013, 2014, 2015, 
and 2016 NSDUH 
(SAMHSA 2014b) 
and ONDCP “What 
Americans Spend 
on Drugs” (ONDCP 
2012) 
Opioid use disorder 
is defined as opioid 
abuse or 
dependence per 
the NSDUH 
definitions. The 
number of people 
who primarily use 
opioid analgesics is 
estimated from the 
NSDUH, while 
heroin use is 
estimated from the 
ONDCP document 
since many heroin 
users are hidden 
from the NSDUH 
survey. 
Percentage of 
patients that are 
female 
30% 2013 NSDUH Assumed to be the 
same proportion as 
people with OUD. 
Distance willing to 
travel for treatment 
drawn from 
empirical 
distributions of 
patient willingness 
to travel based on 
zip code 
(presented in 
Appendix B) 
National Alliance of 
Advocates for 
Buprenorphine 
Treatment (NAABT) 
treatment locator 
data 
Dataset is not 
publicly available. 
Number of patients 
at baseline (seeking 
treatment or in 
treatment) 
35% of total OUD 
population  
2013 NSDUH, 
Calibrated to: 
Healthcare 
Using the highest 
estimate of 
receiving treatment 
in the NSDUH, 
“received 
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Analytics Retail 
Data5 
treatment in past 
year.”  
Percentage of 
patients in 
treatment at 
baseline 
60% in 2013 
70% in 2014 
80% in 2015 
 
Calibrated to: 
Healthcare 
Analytics Retail 
Data5 
Calibrated to 
reproduce 
estimated number 
of unique 
recipients of BUP. 
Number of weeks 
in treatment for 
those initialized in 
treatment 
Random: 
exponential mean 
10 
Assumed  
Stable abstinence 
threshold (time to 
achieve abstinence 
or reduced opioid 
use after opioid 
agonist therapy) 
Random: normal 
distribution (200, 
200), redrawn for 
weeks < 10. 
Assumed  
Geographic 
distribution of 
patients 
Random: 49.9% 
areas with 
population density 
> 1000, 35.5% in 
areas with 
population density 
between 35 and 
1000, 14.5% areas 
with population 
density less than 
35 with 48% of 
rural residents in 
areas with 
population density 
> 35 
SAMHSA, 2012 
NSDUH, (Kvamme, 
Catlin, Banta-
Green, Roll, & 
Rosenblatt, 2013b) 
To protect privacy, 
NSDUH only 
reports if a 
respondent lives in 
a large MSA, small 
MSA, or non-MSA.  
We assume that 
this roughly maps 
onto population 
density.  Kvamme 
reported that in 
Washington, 52% 
of rural residents 
live in small towns 
while 48% live in 
remote areas. 
Willing to wait 
threshold 
random-
exponential mean 
4 weeks 
Harm reduction 
expert opinion  
A random-
exponential 
distribution with a 
mean of 4 results in 
a median 
willingness to wait 
of about 2.5 weeks. 
                                                     
5 Data obtained from a representative of Reckitt Benckiser in personal communication. 
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Agents with waiting 
times less than 1 
week will seek 
treatment in the 
given week, but will 
relapse if they 
cannot 
immediately access 
treatment. 
Number of weeks 
waiting 
0 All initialized to 0 
weeks waiting for 
simplicity 
 
Percentage of 
patients who divert 
because they need 
or want money 
14 % of people 
below 200% of the 
poverty line per 
year 
Calibrated to fit 
buprenorphine 
patient survey 
(Genie L. Bailey, 
Monique Ziebro, 
Timothy P. Lepak, 
Richard G. Soper, & 
Michael M. Miller, 
2015).  
Setting the 
parameter to 14% 
results in 
approximately 29% 
of patients listing 
“needed money” as 
a reason for 
diversion 
Percentage of 
patients who can’t 
afford treatment 
who divert 
medication 
54% of people who 
can’t afford 
treatment per year 
Calibrated to fit 
buprenorphine 
patient survey 
(Genie L. Bailey et 
al., 2015).  
Setting the 
parameter to 54% 
results in 
approximately 47% 
of patients listing “I 
needed it to afford 
my treatment” as a 
reason for 
diversion 
Percentage of 
patients who say 
yes when a friend 
requests diverted 
buprenorphine 
35% per year Calibrated to fit 
buprenorphine 
patient survey 
(Genie L. Bailey et 
al., 2015). 
Setting the 
parameter to 35% 
resulted in 
approximately 38% 
of patients listing “I 
was pressured to 
divert by a friend or 
because someone 
else needed it 
more than I did” as 
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a reason for 
diversion 
Amount of 
medication 
diverted to the 
“street” 
1, 2, or 3 days’ 
worth out of a 
week selected at 
random 
Assumed  
Poverty level of 
people with OUD 
30% are below the 
poverty level, 26% 
are below 200% of 
the poverty level, 
44% are above 
200% of the 
poverty level 
2011-2013 NSDUH 
analysis of full data 
set 
 
Insurance of people 
in poverty 
47% have public 
insurance,  
20% have private 
insurance,  
33% have no 
insurance 
2011-2013 NSDUH 
analysis of full data 
set 
Insurance types for 
people with opioid 
abuse or 
dependence 
calculated based on 
poverty level. 
Insurance of people 
to 200% of poverty 
level 
30% have public 
insurance, 
34% have private 
insurance,  
36% have no 
insurance 
2011-2013 NSDUH 
analysis of full data 
set 
 
Insurance of people 
above 200% of 
poverty level 
11% have public 
insurance, 
72% have private 
insurance, 
17% have no 
insurance 
2011-2013 NSDUH 
analysis of full data 
set 
 
Coinsurance 0 for public 
insurance, 
50 – 70% for 
private insurance, 
100% for no 
insurance 
Assumed Medication 
coinsurance and 
office visit 
coinsurance were 
assumed equal for 
simplicity 
Buprenorphine 
dose 
 
18% 8 mg, 
63% 16 mg, 
15% 24 mg, 
4% 32 mg 
2011 OTP survey The SAMHSA OTP 
survey gives ranges 
of doses. For 
simplicity, doses 
were rounded up 
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to the highest dose 
in the range 
 
  
Figure 3-3: Graphical display of the simulation after model initialization. Maroon squares represent OTPs; 
large red triangles are OB BUP providers; small triangles represent people seeking OAT. 
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3.3.2 Input data 
Input data are those empirical data that are used when the model is running to 
update the state of the model.  The geography, population density and OTP values are 
static.  Provider and agent variables are updated with the following input data:    
Table 3-7: Input data for updating provider and patient variables 
Parameter value support comment 
Number of new 
providers obtaining 
waivers 
2500* (total model 
population / total 
US population) per 
year 
SAMHSA list of 
number of 
waivered physicians 
by state 2007-2015 
Data show near 
linear growth in 
providers since 
2007   
Buprenorphine 
treatment retention 
76% week 1, 64% 
week 2, 50% in 
week 6, mean days 
in treatment 214 
Randomized 
controlled trial of 
buprenorphine 
retention (Bell, 
Trinh, Butler, 
Randall, & Rubin, 
2009) 
The model was 
configured to 
simulate a closed 
cohort to 
reproduce the 
retention in 
treatment from this 
closed cohort study 
as a verification 
test 
Methadone 
treatment retention 
74% retained at 6 
months, 
50% at a year 
Multisite 
randomized 
controlled trial 
(Hser et al., 2014) 
 
 
Crude mortality 
rate: in treatment 
3/1000 patient 
years 
Randomized 
controlled trial, 
cohort study, of 
buprenorphine 
retention and 
mortality (Bell et 
al., 2009) 
 
Crude mortality 
rate:  stable 
abstinence 
3/1000 patient 
years 
Assumed assumed equal to 
in-treatment 
mortality 
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Crude mortality 
rate:  people taking 
diverted BUP 
3/1000 patient 
years 
Assumed Assumed equal to 
in-treatment 
mortality 
Crude mortality 
rate: not in 
treatment 
8/1000 patient 
years in 2013,  
10.5/1000 patient 
years in 2014, 
12/1000 patient 
years in 2015 
Calibrated to fit 
national opioid 
related deaths data: 
CDC Wonder 
Multiple Cause of 
Death Database for 
opioid and heroin 
deaths (NIDA, 2017)   
See Section 3.4.5: 
Recalibration 
Crude mortality 
rate:  relapsing out 
of treatment 
8/1000 patient 
years 
Randomized 
controlled trial, 
cohort study, of 
buprenorphine 
retention and 
mortality (Bell et 
al., 2009) 
 
Rate of growth of 
people with opioid 
use disorder 
10% 2002-2012 NSDUH 
Surveys 
Fit to rate of 
increase of 
prevalence of 
opioid use disorder 
Incidence of 
treatment seeking 
40% of people with 
OUD including 
multiple attempts 
by one person 
2013 NSDUH Calibrated to fit the 
unique recipients 
of BUP per year. 
3.3.3 Outcome variables 
Policies were assessed by their impact on the following outcome variables at 
year end: Population adjusted unique recipients of buprenorphine, opioid overdose 
deaths, and milligrams of diverted buprenorphine.  Population adjusted unique 
recipients of buprenorphine was normalized to the model population: total 
buprenorphine recipients/model population * 100,000.  This outcome variable will be 
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referred to as Unique BUP recipients, for short. Access equity was assessed using the 
Spatial Potential Access Gini Indices.   
3.4 Model Testing 
3.4.1 Calibration 
To establish the baseline model scenario, I initialized the model the model with 
2013 data and calibrated to fit two outcome variables: unique buprenorphine recipients 
and opioid overdose deaths; a pattern of buprenorphine diversion assessed by patient 
survey; and a pattern of buprenorphine prescribing based on pharmacy survey. Values 
and data sources for these calibration targets are detailed in Table 3-8.  
Prior to final model calibration, I conducted sensitivity analysis to highlight 
tunable parameters. I didn’t calibrate or validate against the medication diversion 
outcome directly because the quantity of diverted buprenorphine in the US is not 
known.  While there are several surveillance systems that can estimate trends in 
diversion including NFLIS (US Drug Enforcement Administration, Office of Diversion 
Control, 2013), or the RADARS system (see, for example: Dart et al., 2015), these rely on 
proxy measures such as calls to poison centers or seizures by law enforcement, and 
don’t generate estimates of total quantity diverted.  
I chose to calibrate the model against the provider patient census pattern 
reported by Stein, et al (2016) because provider preferences for patient loads are not  
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Table 3-8: Calibration targets and data sources 
known empirically, and these preferences play an important role in model dynamics. It 
was difficult for the model to generate a large enough number of unique buprenorphine 
recipients while tuning provider preferences for patient loads to fit the provider census 
pattern. Even when attempting to fit the prescribing pattern loosely, allowing a greater 
percentage of providers to have higher patient census levels than recorded in Stein’s 
group’s analysis, the number of unique buprenorphine recipients was 7-10% low.  It is 
worth noting that Stein reported that regression analysis showed an increase in 
prescribing levels in later years, though they did not report specifics on the census in 
                                                     
6 Data obtained from a representative of Reckitt Benckiser in personal communication. 
Parameter National value Support 
2013 unique 
buprenorphine recipients 
1,300,824 Healthcare Analytics Retail 
Data6 
2013 opioid overdose 
deaths 
24,492 CDC Wonder Multiple 
Cause of Death Database 
for opioid and heroin 
deaths (NIDA, 2017) 
Diversion by patients to 
non-patients 
9% of patients 
(47% to afford treatment) 
(29% needed money) 
(38% friend wanted or 
needed) 
Buprenorphine patient 
survey (Genie L. Bailey et 
al., 2015) 
Use of non-prescribed BUP 27% have used non-
prescribed BUP 
Buprenorphine patient 
survey 
Provider patient census Median 13, IQR 5-36; 
22% had 1-3 patients 
49% had 4-30 patients 
20% had 31-75 patients 
9% had more than 75 
Analysis of Symphony 
Health Solutions’ 
Integrated Dataverse retail 
pharmacy transactions 
(Stein BD et al., 2016) 
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later years. As discussed in Section 3.4.5, I found it necessary to calibrate the model 
further after validation tests.  
3.4.2 Face Validation 
 I reached out to all expert panel members via email for face validation 
interviews, received four responses, and conducted interviews with two panel 
members: Dr. Alane O’Connor, and Dr. Andrew Saxon. Interviews were two hours long, 
and covered boundary, basis, and representation assessment (see Section 2.4.1), as well 
as critical model assumptions, policies, and future conditions that should be considered 
in policy analysis.   
   At the outset of the interview, I introduced Drs. O’Connor and Saxon to the 
research questions, to the basic structure of the spatial ABS capacity model, and 
explained that the purpose of the interview was to check assumptions about model 
scope (boundary assessment), assumptions that informed the use of data (basis 
assessment), and model logic that drives key dynamics (representation assessment), and 
to share early findings prior to final external validation. 
In general, the experts were comfortable with the boundary of the model, 
agreeing that a model that is narrowly investigating questions of capacity might not 
need rich details on patient experience, for example. They were both interested in the 
spatial dimension of the model since they both had experience working with rural 
communities. As to basis assessment, they seemed comfortable with populating a real 
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map with people with OUD and providers placed plausibly according to population 
density and the NSDUH survey.  However, this may have stemmed more from a lack of 
familiarity with ABS methods and a reluctance to “red flag” something unfamiliar.  They 
agreed that there was a large variance in the patient loads of providers, which was 
reported by Stein, et al (2016) and suggested several reasons that some providers 
choose to serve different numbers of patients. Dr. O’Connor’s practice experience did 
not conform to the data used for patient retention, which was several years old.  In her 
experience, by the time patients are admitted to her program, they are heavily invested 
in treatment and are better retained, and suggested that retention in the model may be 
overly conservative.   
Regarding key model logic, both agreed that diversion was likely primarily not for 
recreational purposes but for self-treatment, or to maintain active opioid use when 
preferred drugs might not be available.  This supports model assumptions about reasons 
for diversion, which has implications for diversion outcomes of policies that expand 
access. They also agreed that many people self-treat with buprenorphine while waiting 
to start formal treatment, sometimes for years.  On the other hand, both also 
questioned the validity of the assumption that people with OUD select providers on the 
SAMSHA searchable list.  Dr. O’Connor asserted that word of mouth was a much more 
likely source of information on potential providers, especially in rural areas. 
Interviews concluded with open questions about the impact of policies 
implemented since modeling began in 2014, including the patient limit expansion policy 
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and NP/PA prescribing policy, and what unforeseen circumstances may have had 
outsized impact on their practices and patients.  Dr. O’Connor had already obtained her 
DATA 2000 waiver by the time the interview took place.  The model was originally 
intended to test very modest penetration of NP and PA prescribing, at the 3-5% level, 
mirroring the uptake among primary care physicians. Dr. O’Connor expects much higher 
uptake by NPs, and suggested testing the impact of uptake among 50-70% of primary 
care NPs in states with high NP autonomy. She also expects that initially patients will be 
shifted from overloaded specialty providers to less distant NPs resulting in a reallocation 
of treatment without apparent expansion until those specialist spots are backfilled and 
word of mouth brings new patients to NP prescribers.  
Both providers were not surprised that early model experiments with the patient 
limit policy didn’t produce large gains in the number of people who receive 
buprenorphine in a given year, though Dr. Saxon was dismayed by it.  In Dr. O’Connor’s 
experience, while some providers, such as those who run intensive outpatient recovery 
programs, may have expanded their practices dramatically after increasing their patient 
limit, many may have elected to expand to 275 patients as a safety valve just in case 
they approach the 100 patient limit.  Dr. Saxon also explained that even addiction 
medicine specialists may be reluctant to build their practices around buprenorphine 
prescribing, preferring a more diverse patient mix in part because practice barriers such 
as high paperwork burden and low reimbursement remain.   
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I closed by asking what surprised them in 2014-2017 and what to look out for 
when modeling future policy.  The emergence of synthetic fentanyl as a street drug was 
completely unanticipated and resulted in increased opioid deaths. State policies 
squeezing down on prescription opioid diversion and the resultant uptick in heroin use 
wasn’t totally unanticipated, but it did drive up overdoses and would not have been 
captured in a policy model that doesn’t differentiate between opioids, including this 
one. I was made aware of a major change in insurance that could have a large impact on 
access to treatment.  A person with an extremely high deductible insurance plan may be 
insured on paper, but that insurance wouldn’t pay for treatment, leaving that person 
effectively uninsured and paying out of pocket, making treatment unaffordable. 
3.4.3 External Validation 
I performed external validation by initializing the model in week 1 of 2013, 2014, 
2015, and 2016, and running the model for 52 weeks thirty times for each model year. I 
also initialized the model in 2013 and 2014 and ran for 104 weeks (two years) thirty 
times for each model year. I scaled up the model-generated number of unique 
buprenorphine recipients and opioid overdose deaths to the total national population, 
by dividing by model population and multiplying by the national population for that 
year. I generated 95% confidence intervals around the simulation means and compared 
these model ranges to the real world target values. The number of opioid overdose 
deaths in 2016 was not available at the time of writing.  Results are shown in Table 3-9. 
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Table 3-9: External validation results, simulation compared with data for 2013, 2014, and 2015. 
 Simulation Data 
One year 
runs 
Model year 
Unique BUP 
recipients: mean 
[95% CI] 
Opioid 
overdose 
deaths: mean 
[95% CI] 
Unique BUP 
recipients  
(%  deviation 
from mean) 
Opioid OD 
deaths 
(% deviation 
from mean) 
2013 1178147  
[1155141, 
1201152] 
23819  
[23050, 
24589] 
1300824 
(9.43%) 
24492  
(2.74%) 
2014 1065499  
[1045661, 
1085337] 
20574  
[20006, 
21143] 
1294715 
(17.7%) 
28647  
(28.18%) 
2015 1166551  
[1147081, 
1186021] 
20931  
[20452, 
21411] 
1387815 
(15.9%) 
33091 
(36.75%) 
2016 1242834 
[1220505, 
1265164] 
21375  
[20802, 
21948] 
1380616  
(9.9%) 
Not reported 
Two year 
runs 
Model year 
    
2013-2014 1132527  
[1103229, 
1161825] 
25257  
[24562, 
26153] 
1294715 
(12.5%) 
28547  
(11.5%) 
2014-2015 1087457  
[1062895, 
1112020] 
21736  
[21080, 
22392] 
1387815 
(21.6%) 
33091 
(34.3%) 
The 7-10% under-calculation of total unique buprenorphine recipients at the end 
of calibration resulted in a systematic low estimate of total unique buprenorphine 
recipients in each modeled year.  This was compounded by a change in the estimation 
method for the starting number of people with OUD in each modeled year.  The model 
was calibrated to an initial population with OUD of 3,895,621 in 2013, rather than an 
estimate of 3,556,000 using the estimation method for 2014 forward.  The fit to 2014 
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year end data when starting the model in 2013 and running for two years was likely 
better than when the model was initialized in 2014 and run for one year because of the 
higher starting population with OUD in 2013. 
Opioid overdose deaths in 2013 were calibrated to fall within the 95% 
confidence interval of simulated overdose deaths.  However, the fit 2014 onward was 
poor. This is unsurprising given that the opioid overdose death rate was held fixed in the 
model. The introduction of synthetic fentanyl and the shift in use of diverted 
prescription opioids to counterfeit prescription pills and heroin reported by Dr. 
O’Connor likely increased the risk of opioid overdose despite an apparent level trend in 
people with prescription OUD recorded in the NSDUH at that time. 
3.4.4 Sensitivity Analysis 
Sensitivity analysis consisted of three processes: one-way sensitivity analysis, 
structural sensitivity analysis to the provider patient load preference assumption, and 
structural sensitivity analysis to the map selected for simulation.   
3.4.4.1 One-way sensitivity analysis 
Holding all other parameter values fixed, I systematically increased and 
decreased each parameter value by 30% and recorded the impact on model outcome 
variables: unique BUP recipients, opioid overdose deaths, and diverted buprenorphine. I 
report the percentage difference of the means of 30 replications of these outcome 
variables from baseline level means and present results as tornado diagrams on each 
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outcome variable to highlight the sensitivity of model outcomes to changes in particular 
parameters (Eschenbach, 1992). If confidence intervals on the mean for outcome levels 
of tested parameters overlapped with the baseline mean, the difference in the mean is 
not detectable due to random variation in the model.  These parameters are in not 
included in the diagrams.   
The number of buprenorphine recipients was sensitive to three treatment 
seeking parameters, and three provider specific parameters, as shown in Table 3-10.  
The number of buprenorphine recipients was sensitive to the incidence of treatment 
seeking—the percentage of people with OUD who would seek treatment in the model 
year starting the year uninterested in treatment, and the initial percentage of people 
with OUD who start the year in treatment or seeking treatment, but only when these 
parameters were reduced. Increasing these parameter values did not significantly 
increase the number of buprenorphine recipients at year end.  The relative percentage 
of people with OUD who start the model year in or seeking treatment who 
Table 3-10: Tornado diagram of sensitivity analysis on the number of unique buprenorphine recipients. In 
general, an increase (or decrease) in the parameter value resulted in an increase (or decrease) in the number 
of buprenorphine recipients, with the exception of the number of OTPs (*), for which a 30% increase in the 
number of OTPs resulted in a 5% decrease in unique recipients of BUP 
  
+/-30% change in paramter value
25-
30%
20-
25%
15-
20%
10-
15%
5-
10%
0-
5%
0-
5%
5-
10%
10-
15%
15-
20%
20-
25%
25-
30%
incidence of treatment seeking -10%
initial % people with OUD in/seeking tx -8%
% providers = specialist high-cap -6%
initial % seeking vs in tx -5% 4%
number of OTPs * -5%
% providers accept private insurance -4%
Unique BUP recipients: percentage difference from baseline 
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.   
are assigned into treatment increases buprenorphine recipients when increased, and 
decreases it when decreased. 
Decreasing the percentage of providers who are addiction medicine specialists 
with high waivers and replacing those providers with an equal number of non-specialists 
who have low waivers resulted in a 6% decrease in buprenorphine recipients. Even 
though the percentage of specialist providers was only reduced from 12% to 9% of all 
providers, providers of this type were initialized with preferences for the highest 
number of patients (often over 100) and were replaced by providers with the lowest 
preference levels (around 10). 
Increasing the number of OTPs in the model decreased the number of 
buprenorphine recipients significantly, but did not affect the number of people who 
received any OAT. Conversely, decreasing the number of OTPs by 30% did result in a 7% 
decrease in OAT treatment overall, while having no detectable effect on the number of 
people receiving buprenorphine. This suggests that increasing OTPs results in a 
treatment substitution effect in the model.     
The amount of diversion in the model was sensitive to three types of parameters 
(see Table 3-11): diversion-specific parameters, poverty and affordability parameters, 
treatment seeking parameters, and two parameters that didn’t fall into those 
categories: number OTPs, and % patients with 16 mg BUP daily dose. 
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Table 3-11: Tornado diagram of sensitivity analysis on the amount of buprenorphine diverted to non-
patients. An increase (or decrease) in the parameter value resulted in an increase (or decrease) in the 
amount of diversion, with the exception of parameters marked with an (*). 
 
Not surprisingly, increasing the percentage of patients who divert medication for 
various reasons resulted in large increases in diversion.  This is due to model logic that 
does not require that an increase in one reason for diversion be offset by a decrease in 
another reason.  A person may divert medication both because she can’t afford 
treatment and because she wants money. Increasing the weeks a person is willing to 
wait to begin treatment before relapsing increases diversion because of the way the 
demand for diverted buprenorphine is coded.  People who are waiting for treatment will 
ask friends in treatment to divert, and will stop asking for diverted medication when 
they stop self-treatment and treatment seeking and resume regular opioid use. So in the 
model, relatively quick abandonment of treatment seeking results in less diversion 
demand.   
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Incidence of treatment seeking increases demand for diverted buprenorphine as 
people self-treat with diverted buprenorphine while waiting for formal treatment spots 
to open.  Decreasing incidence of treatment seeking also likely reduces the supply of 
diverted buprenorphine since it also decreases the unique number of buprenorphine 
recipients. 
Changes to poverty parameters affect diversion because most of the reasons for 
diversion are due to poverty.  People with incomes below two times the poverty level 
might divert because they can’t afford treatment or need money.  In the model, people 
whose incomes are above those levels will not divert due to affordability or money 
issues.  The cost of treatment and medication did affect diversion because they impact 
affordability logic.  A patient who pays less for treatment is less likely to find treatment 
unaffordable, and hedge the cost of treatment by selling medication.   
Changes in the number of OTPs affects diversion from the supply side, by 
changing the relative proportion of people receiving methadone versus BUP for OAT. 
Finally, the amount of diverted buprenorphine decreases when the percentage 
of people who require 16 mg per day of buprenorphine increases because of how 
required dosages are set. Increasing the number of people who require 16 mg doses 
squeezes down on the number of people getting 32 mg per day, followed by 24 mg per 
day, while decreasing the number of people who need 16 mg per day increases the 
number of people who need 8 mg per day. When diverting medication in the model, 
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people give up a fraction of what they receive.  So if most people get less medication, 
less is diverted per diversion occasion.  
The number of opioid overdose deaths was only affected by changes in the crude 
mortality rate for people not in treatment, and the change was approximately 1:1.  A 
30% increase in the mortality rate resulted in 27% more overdose deaths overall, and a 
30% decrease resulted in a 28% decrease. That no other parameter impacted opioid 
overdoses is likely due to the fact in the model, the vast majority of people with OUD 
are not in treatment. 
3.4.4.2 Structural sensitivity analysis: provider preferences 
The baseline model was run with provider preferences tuned to roughly match 
the provider census reported in Stein, et al (2016) and the number of unique 
buprenorphine recipients (Stein BD et al., 2016). I assumed that providers have a 
maximum patient number above which they would not accept new patients, no matter 
the patient limit.  For some providers this maximum lay above the patient limit level, for 
other, it lay below the limit.  In baseline runs, an individual provider’s maximum was 
drawn from a random distribution based on provider type.  These baseline distributions 
are reported in Table 3-5 as “Theoretical Patient Capacity.”  
I conducted one-way sensitivity analysis by provider type with three different 
sets of parameters for determining the patient maximum for each provider: a low 
uniform random distribution, a high uniform random distribution, and a fixed constant 
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at the patient limit for the waiver type held (30 or 100, in 2013). I conducted a five-way 
analysis by setting patient preferences to the maximum waiver level (30 or 100) for all 
provider types. Sensitivity analysis parameter values are shown in Table 3-12. 
Table 3-12: Distributions for provider preference sensitivity analysis 
  
 Baseline 
distribution 
Alternative 
random 
distribution 
(low) 
Alternative 
random 
distribution 
(high) 
Fixed constant 
Specialist, low 
waiver 
30 + 
exponential 
(250) 
Uniform[0, 
150] 
Uniform[0, 
1000] 
100 
Specialist, high 
waiver 
30 + 
exponential 
(250) 
Uniform[0, 
150] 
Uniform[0, 
1000] 
100 
Non-specialist, 
high waiver, 
on SAMSHA 
list 
30 + 
exponential 
(120) 
Uniform[0, 
100] 
Uniform[0, 
1000] 
100 
Non-specialist, 
low waiver, on 
SAMHSA list, 
will get high 
waiver 
20 + 
exponential 
(40) 
Uniform[0, 
100] 
Uniform[0, 
200] 
100 
Non-specialist, 
low waiver, on 
SAMHSA list, 
will NOT get 
high waiver 
Normal (3.5, 7), 
redraw for 
values below 0 
Uniform[0, 10] Uniform[0, 30] 30 
Non-specialist, 
low waiver, 
not on 
SAMHSA list 
Normal (3.5, 7), 
redraw for 
values below 0 
Uniform[0, 10] Uniform[0, 30] 30 
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Changing provider preference did not result in significant differences from 
baseline in medication diversion or opioid overdose deaths. However, there were 
significant changes in the number of buprenorphine recipients, as shown in Table 3-13.  
Only parameter settings with detectable differences are shown, and differences are 
expressed as percentage difference in means.   
 Table 3-13: Impact of changing assumptions about provider preferences on total number of buprenorphine 
recipients after a year. 
 
In the model, if all providers are willing to treat up to the regulatory limit 
depending on demand, the number of people who receive buprenorphine at year end 
increases by around 21%.  The greatest impact comes from changes in preferences of 
non-specialists, each of which increase utilization by around 10% alone.  This is likely 
because these two groups represent 20% and 48% of buprenorphine providers 
respectively, and because the maximum number of patients treated by non-specialists 
with low waivers was held very low at baseline. 
Parameter setting Percentage difference 
between mean and 
baseline 
All parameters to maximum level for waiver type +21% 
Fixed Constant (100) Non-specialist, high waiver, on list  +11% 
Fixed Constant (30) Non-specialist, low waiver, not on list +10.9% 
Random, Low (uniform[0, 100]) Non-specialist, high 
wavier, on list  
-10% 
Random, High (uniform[0, 1000]) Non-specialist, high 
waiver, on list 
+9.8% 
Random, Low (uniform[0, 150]) Specialist, high wavier -5.1% 
Random, High (uniform[0, 30]) Non-specialist, low waiver, 
not on list 
+4.3% 
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3.4.4.3 Structural sensitivity analysis: model map 
To test the model’s sensitivity to the selected geography, I generated 9 
additional population density maps based on the 2010 United States Census merged 
with HRSA Medically Underserved Area maps using the QGIS GIS mapping software 
(QGIS, 2017).  The population density maps are shown in Figure 3-4 and the underlying 
MUA maps are shown in Figure 3-5.  I selected the maps from a wide array of regions in 
the US including the North East, South East, Midwest, Mountain West and California, 
and include highly urbanized regions (such as Figure 3-4, bottom middle), and rural 
regions (such as Figure 3-4, bottom left).  Models were run 30 times each for one year, 
initialized at the start of 2013, and buprenorphine recipients, opioid overdose deaths 
and diversion outcome variables were compared against baseline model runs.  I 
normalized diversion and opioid overdose death outcome variables to the population 
size to allow for direct comparison. The buprenorphine recipients outcome variables for 
each set of runs was also compared against 2013 unique buprenorphine recipient data. 
There were no significant differences in opioid overdose deaths when using 
different starting maps.  Regions 1, 3 and 6 had significantly fewer buprenorphine 
recipients than the baseline Region 0 (Figure 3-4 top left, top right and middle right, 
respectively), with mean values 12%, 6% and 7% lower than the mean number of 
recipients per 100,000 population.  Regions 1, 3, 5, and 7 (Figure 3-4 top left, top right, 
middle middle, bottom left) had significantly lower diversion (mg per 100,000 
population) than the baseline region,  with mean values 14%, 10%, 7% and 15% lower. 
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Regions 4 and 8 (Figure 3-4 middle left, bottom middle) had significantly higher 
diversion (mg per 100,000 population) than the baseline region, with mean values 7% 
and 6% higher. In general, more densely populated regions had higher diversion than 
less densely populated regions despite normalization, and may signal a systematic bias 
in how demand for diverted buprenorphine is modeled in remote and urban areas.   
The number of unique buprenorphine recipients at year end was low for all 
regions.  Model confidence intervals did not cover the actual year-end value adjusted 
for model population in any region. Inadequate calibration to the year-end target in the 
baseline region reported in Section 3.4.3 resulted in the use of poorly calibrated 
parameter values in all regional model runs.    
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Figure 3-4: Alternative population density maps for geographic sensitivity testing.  Population density is 
measured in people per square mile. Maps are numbered sequentially left to right, top to bottom. 
  
118 
   
   
   
Figure 3-5: Additional Medically Underserved Areas (MUA) maps for geographic sensitivity analysis. Darker 
regions are MUAs. Maps correspond to population density maps in Figure 3-4. 
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3.4.5 Recalibration 
The original research plan called for calibration on 2013 data, external validation 
on 2014-2015 data, and sensitivity analysis followed immediately by policy 
experimentation. Rather than perform policy experiments on a model that failed tests of 
external validity, I chose to iterate and use all available data for model calibration and to 
perform policy experiments on a better calibrated, though non-validated model. Failure 
to validate large simulation models or poor results on tests of model fit tend to be a 
challenge when striving to simulate complex social systems. 
To recalibrate the model, I made three choices— 
1. to initialize the model in 2013 with the number of people with opioid 
dependence calculated the same way as the 2014 and 2015 populations,  
2. to tune provider preference parameters to privilege fit to total unique 
buprenorphine recipients over fit to provider patient census in Stein, et al (2016),  
3. to use a non-stationary opioid overdose death rate (the death rate changes 
over time). 
I chose to recalculate the initial population with OUD in 2013 because calculating 
the population in a different way resulted in an apparent decrease in people with OUD 
from 2013 to 2014 due to a modeling artifact. I removed this spurious effect by 
calculating the population the same way for all model years. The modeling artifact was 
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introduced in the first place because of the considerable lag between early modeling 
efforts in iterations 1-3 of the model and validation efforts on model iteration 4. 
I chose to recalibrate the model by tuning provider preference variables because 
these variables have considerable leverage over the unique buprenorphine recipients 
outcome measure as shown in structural sensitivity analysis (see Section 3.4.4.2). 
Further, Stein’s regression model on 2009-2011 patient census data showed that patient 
census levels were rising even in 2011 (Stein BD et al., 2016). 
Lastly, to fit trends in opioid overdose deaths in 2013-2015, I chose to 
parameterize the model with a non-stationary opioid overdose mortality rate. It may 
have been possible for a non-stationary opioid overdose mortality rate to have arisen 
endogenously by introducing considerable model complexity.  I could have chosen to 
model people’s shift from prescription opioids to heroin, from oral to injection drug use, 
and other transitions from lower risk to higher risk behaviors, but I would likely still have 
had to introduce exogenous factors that drove up overdose mortality, such as changes 
to price and purity of heroin and the introduction of synthetic fentanyl (see Section 
3.4.2, Face Validation).  Rather than introduce this complexity, which I felt would have 
little relevance to capacity and access equity research questions, I chose the simpler 
option of a time-varying opioid overdose mortality rate. 
The following parameters were tuned to fit the number of unique 
buprenorphine recipients in 2013, 2014 and 2015: theoretical patient capacity for non-
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specialists with a high waiver and for non-specialists with a low waver not on the 
SAMHSA searchable list, and percentage of patients in treatment at baseline each year. 
Table 3-14 shows all post-recalibration parameter values including crude mortality rates. 
The initialization data and input data parameterizations reported in Sections 3.3.1 and 
3.3.2 record parameter settings after calibration and recalibration was complete.  
Table 3-14: Parameter values changed during recalibration and the final values of these parameters. 
Theoretical patient capacity 
        Non-specialist, high waiver, on 
SAMSHA list 
        Non-specialist, low waiver, not on 
SAMHSA list 
 
30 + random exponential(220) patients 
random normal(20, 7) patients 
Percentage of patients in treatment at 
baseline 
        2013 
        2014 
        2015 
 
60% 
70% 
80% 
Opioid overdose crude mortality rate (not 
in treatment) 
        2013 
        2014 
        2015 
 
8/1000 patient years 
10.5/1000 patient years 
12/1000 patients years 
 
3.5 Spatial Potential Access Aggregate Measure 
To generate an aggregate access equity metric for OAT in the simulation model, I 
took advantage of the following simulation properties:  
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 the simulation generates plausibly sited synthetic individual demanders 
with opioid use disorder along with plausibly sited sources of OAT supply—
providers with limited treatment capacity 
  each demander has an empirically informed distance he or she is willing 
to travel to get OAT based on the population density of his or her location.  
Using these model properties, I modified the two-step floating catchment area 
(2SFCA) method (see Equations 13 and 14) in the following manner. Substantive 
differences from Luo and Wang (2003) are italicized.  
Step 1: For each provider j, search all individuals (i) that are within i’s 
willingness to travel distance (di0) from the location j (that is, the individualized 
catchment area of j), and compute the weighted provider capacity-to-population, 
Rj, within the catchment area:  
𝑅𝑗 = 
𝑆𝑗
∑ 𝑤𝑗𝑖𝑖𝑖 ∈{𝑑𝑗𝑖≤𝑑𝑖0}
 
 
(20) 
where Sj is the capacity of provider j (the number of patients that j is willing to 
treat given patient limits and preference), dji is the Euclidean distance between i 
and j. The weight, wji, is calculated by various distance decay functions described 
in Section 3.5.1, below. 
Step 2: For each individual, i, search all provider locations (j) that are 
within the threshold willingness to travel distance (di0) of i (that is, the reachable 
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provider region of i), and sum up the weighted provider-capacity-to-population 
ratios, Rj, at these locations: 
𝐴𝑖
𝐹 = ∑ 𝑤𝑗𝑖𝑅𝑗
𝑗 ∈ {𝑑𝑗𝑖≤ 𝑑𝑖0}
= ∑
𝑤𝑗𝑖𝑆𝑗
∑ 𝑤𝑗𝑖𝑖𝑘 ∈{𝑑𝑗𝑖≤𝑑𝑖0}𝑗 ∈ {𝑑𝑗𝑖≤ 𝑑𝑖0}
 
 
(21) 
where 𝐴𝑖
𝐹represents the potential access of individual i, Rj is the OAT treatment 
capacity of provider j, who is within the reachable provider region of i (that is djk 
< di0). The weight, wjk is the same distance weight as used in step 1. (Modified 
from W. Luo & Qi, 2009, p. 1102; W. Luo & Wang, 2003, p. 872) 
Changing the numerator of the first step to total provider capacity, and the 
demand from populations at census tract centroids to individuals preserves an 
important property of the 2SFCA method. The population weighted average of the 
accessibility values of a system will equal the provider-population ratio of that system 
(Shen, 1998).  Put another way, if you multiply the accessibility values of the population 
units by their population and sum, you get the total supply in the system (Delamater, 
2013).  In the individualized version, each population unit is one person, so the sum of 
the individuals’ potential accessibility scores equals the total capacity in the considered 
region:  
 ∑𝐴𝑖
𝐹
𝑖
= ∑ 𝑆𝑗
𝑗
 
(22) 
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This property allows us to consider one individual agent’s potential accessibility 
score as its fraction of the total supply. As such, we can quantify the equitability of the 
distribution of accessibility using the Lorenz curve and Gini coefficient (Gini, 1912; 
Lorenz, 1905).  
The Lorenz curve and Gini coefficient (or Gini Index) are usually used to quantify 
unequal distributions of wealth or income in an economy.  A Lorenz curve is constructed 
with the x axis representing the cumulative proportion of the population, and the y axis 
representing cumulative proportion of wealth or income. The population is indexed in 
increasing order of wealth or income.  The x value of the function is equal to the 
cumulative fraction of the population, and the y value of the function is equal to the 
cumulative fraction of total wealth or income.  If wealth is distributed perfectly, with 
each person having a proportional share, the function becomes the straight line y = x. If 
one person has all the wealth or income and everyone else has none, the function is a 
stepwise curve with y = 0 for x < 1 and y = 1 for x = 1.  In all other cases, the curve is  
Index is 0, because the area A is 0.  In the case in which one person has all the wealth, 
the Gini Index is 1 because A+B = A. The US Central Intelligence Agency publishes Gini 
Indices for household income in The World Fact Book (Central Intelligence Agency, 
2018).  Lethoso and South Africa have the most unequal distribution of income at Gini 
Index = 63.2 and 62.5 respectively, and Slovakia and Finland have among the most equal 
distribution of income at Gini Index = 23.7 and 21.5, respectively. The United States’ Gini 
Index is ranked 41st highest out of 156 nations at 45.0. The Gini Index of income 
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distribution does not give any information on individuals’ actual income, or the total 
income in the system.  Income in the United States is distributed about as equally as 
income in Cameroon (ranked 42nd out of 156, Gini Index = 44.6), but per capita income 
differs by an order of magnitude ($58,030 in the US, and $3,250 in Cameroon, 2018).  
I use the same general method to generate a Lorenz Curve and Gini Index for 
spatial potential access—the Spatial Potential Access Lorenz Curve (SPALC) and the 
Spatial Potential Access Gini Index (SPAGI).  The x axis represents the cumulative 
fraction of the total population of demanders, and the y-axis the fraction of the total 
OAT supply in the system. Agents are indexed in increasing order of spatial potential 
accessibility scores, 𝐴𝑖
𝐹 , and the y value is calculated by dividing the spatial potential 
accessibility score by the sum of all spatial potential accessibility score, which is 
equivalent to the total amount of supply in the system: 
𝐴𝑖
𝐹
∑ 𝑆𝑗𝑗
 . The area of region 
A 
B 
Figure 3-6: Typical Lorenz curve with the line of perfect equality in black. The Gini coefficient summarizes 
the unequal distribution represented by the curve in an index given by the ratio A/(A+B). 
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between the resultant Spatial Potential Access Lorenz Curve (SPALC), and the line of 
perfect equality of access is the Spatial Potential Accessibility Gini Index, or SPAGI for 
short.  
Like the Lorenz Curve and Gini Index for income does not give information of the 
adequacy of income to meet peoples’ needs, neither does the SPAGI give information 
on the adequacy of OAT supply to meet treatment demand, only the equitability of the 
distribution of that supply based on location and travel preferences.  Adding treatment 
supply to the system could cause the SPAGI to increase, decrease, or stay about the 
same depending on the location of that supply. 
  
Figure 3-7: Eight demanders equidistant to one provider. In the left figure, the provider has excess capacity, 
and in the right figure, the provider has inadequate supply. 
Figure 3-7 shows an idealized case.  In both the left and right figure, using a 
dichotomous weighting scheme with dij < di0, SPAGI = 0. In the Capacity = 16 case,   
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𝑅𝑗 =
16
8
= 2 
𝐴𝑖
𝐹 = 2 ∀𝑖 
𝐴𝑖
𝐹
∑ 𝑆𝑗𝑗
=
2
16
∀𝑖 
Each demander has a 1/8 proportional share of the 16 units of supply, and 
therefore the area of the region between the curve and the line of perfect equality is 0.  
In the Capacity = 4 case,   
𝑅𝑗 =
4
8
= 0.5 
𝐴𝑖
𝐹 = 0.5 ∀𝑖 
𝐴𝑖
𝐹
∑ 𝑆𝑗𝑗
=
0.5
4
∀𝑖 
 And again, each demander has a proportional share of the 4 units of supply, and 
again SPAGI is 0. 
3.5.1 Weighting schemes for the Spatial Potential Access Gini Index (SPAGI) 
As emphasized in Section 2.2, the distance decay weights 2SFCA models can take 
on various forms. I tested the range, sensitivity, and differences among five different 
weighting schemes: dichotomous 2SFCA at an individual’s stated willingness to travel 
distance, inverse logistic distance decay, Gaussian distance decay, exponential distance 
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decay, and at three cut off distances (10, 30 and 60 miles) per the E2SFCA method in 
equation (18). All weights are calculated based on Euclidean distances because the 
simulation model maps do not include road systems, or actual geo-located individuals, 
and because  travel times and straight line distances are highly correlated (Phibbs & 
Luft, 1995). 
3.5.1.1 Dichotomous weighting 
When using the dichotomous weighting scheme, (hereafter designated 
“2SFCA”), an individual regards all providers within his or her willingness to travel 
distance as equally reachable and all those outside that distance as unreachable. 
Provider catchment areas are determined by whether that provider is reachable by the 
patient. Individuals in the model have heterogeneous distances they are willing to 
travel, so one demander at a given location may be inside a provider’s catchment area, 
while another demander at the same location may be outside that provider’s catchment 
area.  The individualized dichotomous measure becomes: 
 
𝑓(𝑑𝑖𝑗) = {
1, 𝑖𝑓𝑑𝑖𝑗 ≤ 𝑑𝑖0;
0, 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 
} 
 
(23) 
where dij is the distance between the provider j and individual i, and d0, the population-
wide catchment cutoff distance is replaced by di0, an individualized cutoff value. 
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3.5.1.2 Continuous distance decay functions: Inverse Logistic, Gaussian, and 
Exponential decay 
The three continuous distance decay functions are also based on individuals’ 
willingness to travel distances. In these weighting schemes providers within the 
willingness to travel radii of demanders are reachable, but not equally desirable.  Those 
that are near are assigned high weights, and those that are further, but still within the 
willing-to-travel radius are assigned low weights.  Providers outside the willing-to-travel 
radius are unreachable and are assigned a weight of 0. The inverse logistic weight 
(designated “Logistic” hereafter) is calculated as follows: 
 
𝑓(𝑑𝑖𝑗) = {
1 −
1
1 + 𝑒
−10
𝑑𝑖0
(𝑑𝑖𝑗−
𝑑𝑖0
1.5
)
, 𝑖𝑓𝑑𝑖𝑗 ≤ 𝑑𝑖0;
0, 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 
}  
(24) 
where, dij is the distance between the provider j and individual i, and di0 is individual i’s 
willing-to-travel distance, and the constants -10 and 1.5 tune the shape of the curve.  
 The Gaussian weight function (designated “Gaussian”) is calculated as follows: 
  
𝑓(𝑑𝑖𝑗) = {𝑒
−
𝑑𝑖𝑗
2
0.3𝑑𝑖0
2
, 𝑖𝑓𝑑𝑖𝑗 ≤ 𝑑𝑖0;
0, 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 
}  
(25) 
where dij and di0 are defined as previously, and the constant, 0.3, is used to tune the 
shape of the curve. 
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 The exponential weight function (designated “exponential”) is calculated as 
follows: 
 
𝑓(𝑑𝑖𝑗) = {𝑒
−
𝑑𝑖𝑗
0.3𝑑𝑖0 , 𝑖𝑓𝑑𝑖𝑗 ≤ 𝑑𝑖0;
0, 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 
} 
 
(26) 
where dij and di0 are defined as previously, and the constant,0.3, is used to tune the 
shape of the curve. 
 The tuning parameters were selected so that each curve would have a weight of 
.0357 at the maximum travel distance, and a weight of 1 if the provider and demander 
were within a mile. The four curves are shown below for an individual with a maximum 
travel distance of 60 miles. 
Figure 3-8: The dichotomous and continuous distance decay functions for 60 mile travel willingness. The 
orange curve is inverse logistic, which penalizes small deviations from collocation less than the other 
continuous measures: blue for Gaussian and green for exponential.  The red region is reachable under the 
dichotomous scheme, and the region to the right of 60 miles is unreachable under all weighting functions. 
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3.5.1.3 Enhanced Two-Step Floating Catchment Area (E2SFCA) weighting zones 
For the final measure, I chose the three weighting zones proposed by Luo and Qi 
(2009). Any distance less than 10 miles is assigned weight 1, 10 to 30 miles 0.6, and 30 
to 60 miles 0.123 per the Gaussian function in equation (18).  Any provider outside of 60 
miles is unreachable.   
This weighting function differs from the others because it is not based on 
individuals’ stated willingness to travel or their geographic placement.  City dwellers are 
assumed equally willing to travel 50 miles as country residents. 
3.6 Exploratory Analysis Experiments 
Because the Spatial Access Gini Index (SPAGI) is a novel metric, I needed to 
understand more about its applicable range in idealized as well as plausible scenarios 
before using the measure to compare research scenarios. To answer Research Question 
1—What functional form should an aggregated individual-level access inequality metric 
have for it to be sensitive enough to detect differences in access equity in different 
regions and/or due to different policy choices?—I performed simple scenario 
exploration exercises and tests, as detailed in Section 3.6.1.   
3.6.1 Exploring the Spatial Potential Access Gini Index (SPAGI) with six test scenarios 
To explore the range and applicability of SPAGI with the five different weighting 
functions, I generated six test cases.  In five of the six cases, I explored the effect of 
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different geographies, using the ten maps generated for spatial sensitivity analysis (see 
Section 3.4.4.3). The six cases are as follows:  
 “Baseline”—Placement of people with OUD and providers according to model 
assumptions (see Section 3.3.2). 
 “Random”—Initial placement as “Baseline” (to generate willingness to travel 
distances in people with OUD and patient capacity for providers), 
reassignment to random locations.  
 “Baseline Double”—Placement as “Baseline,” but all providers at double 
baseline capacity. 
 “Hotspots”—Placement as “Baseline” with the addition of small regions of 
high demand with the following characteristics: 
o “Rural hotspot”—an additional 20% of the population in a 625 square 
mile rural region have OUD. 
o “Rural hotspot, low transport”—as “Rural hotspot,” but with 
willingness to travel restricted to 10+uniform(20) miles. 
o “Urban hotspot”—an additional 10% of the population in a 225 square 
mile urban region have OUD. 
 “High capacity provider closure”—Placement as “Baseline” with 1-5 of the 
highest capacity providers removed from the model, simulating the sudden 
closure of one or more high capacity providers. 
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 “Rural provider closure”—Placement as “Baseline” with 1-5 of the most 
remote providers removed from the model, simulating the sudden closure of 
one or more rural/remote providers. 
The “Hotspot” scenarios were only explored on the baseline map, all others were 
repeated on all 10 simulation maps.   
I conducted the following analyses on the six scenarios: 
3.6.1.1 Full Range of SPAGI  
For each weighting scheme (2SFCA, E2SFCA, Logistic, Gaussian, Exponential—
referred to as “weight” for short), I combined the datasets for each map and graphed 
the full range of the Spatial Potential Access Gini Index (SPAGI) for plausible allocation 
geographies.  
3.6.1.2 Allocation Exploration 
For each region and weight, I tested the difference in the SPAGI with respect to 
two population allocation scenarios, “Random,” and “Baseline.”  This tested the ability 
of the SPAGI to detect large differences in the spatial allocation of populations of the 
same size.  This tests the basic question: Does spatial allocation matter when calculating 
SPAGI, or just population sizes?  
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3.6.1.3 Exploration of Regional Differences 
For each region, I plotted all five SPAGI measures and tested the differences 
among the measures to see if the measures are different for each other, and if they are 
systematically different from each other across all ten regions.  
Additionally, for each measure, I also plotted and tested the difference in the 
SPAGI dependent variable with the region as the dependent variable.  This tests 
whether SPAGI can detect differences between regions with different spatial features 
and plausible population allocations. 
3.6.1.4 Double Capacity Exploration 
For each map and each weight, I tested the difference in the SPAGI between the 
“Baseline” scenario and “Baseline Double” scenario. This tests whether the SPAGI 
necessarily tracks with supply expansions. Colloquially: is more always more equal, as 
measured by SPAGI?   
3.6.1.5 Hotspot Exploration 
For each weight, I tested the difference in the SPAGI for each hotspot scenario.  
This tests whether SPAGI can detect unusual concentrated demand within a broader 
region. 
3.6.1.6 Supply Shock Exploration 
For each map and each weight, I tested the difference in the SPAGI for one to 
five high-capacity provider closures, and for up to five of the remotest providers.  This 
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tests whether SPAGI can detect the effect on access equity of the loss of individual 
providers. 
To test the response of the five parameterizations of the SPAGI in these 
scenarios, I had intended to perform one-way ANOVA tests (or t-tests in the Allocation 
and Double Capacity analyses).  However, when checking that the analyses met criteria 
for ANOVA, I found that the SPAGI often fails the Shapiro-Wilk normality test of 
residuals, and one-way linear models of the SPAGI often fail the Bartlett test of 
homoscedasticity.  Because I could not assume homogeneity of variance or normality of 
residuals, I opted to use the Kruskal-Wallis test as a non-parametric alternative to 
ANOVA, Dunn tests for post-hoc pairwise comparisons. For the Allocation Exploration 
and Double Capacity Exploration experiments I used the modified two-sample-t 
confidence interval procedure, also called the Welch confidence interval approach, set 
out in Simulation Modeling and Analysis (2005), a gold standard text on the construction 
and analysis of simulation models with random inputs and outputs (Law, 2013).    
3.7 Policy Analysis Experiments 
Because the model is complex and SPAGI is a novel measure, I kept policy 
research experiments simple.  
3.7.1 Model Baseline including Spatial Potential Access Gini Indices 
Research Question 2—How equitably distributed is access to OB buprenorphine 
treatment in the current OB buprenorphine treatment system given: regulatory caps on 
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patient numbers, physician preferences, and geographic distribution of treatment 
seekers and providers?—was answered simply by calculating SPAGI measures on the 
fully calibrated and tested baseline scenario in addition to generating other baseline 
outcome measures.  No tests were performed to answer this question; the outcome 
variables including SPAGI measures serve as a baseline foundation for comparing 
changes in outcomes including spatial potential access in the policy analysis. Because 
outcome measures are the results of a random process, I report 95% confidence 
intervals on all model outcomes. 
3.7.2 Patient Limit Change Experiments 
To answer Research Question 3—To what extent would changing the current 
DATA 2000 patient limit per physician change utilization of buprenorphine, equality of 
access, opioid overdose deaths and medication diversion?—I set patient limit levels to 
100, 275 (baseline), 500 and 4000, initialized the model in 2016, and ran it 35 times at 
each patient limit level. The SPAGI measures were calculated at the end of the year. 
Because the patient limit has already been expanded to 275, this is the baseline 
scenario, and a patient limit of 100 represents a policy roll-back to the previous patient 
limit prior to 2016. I chose to use patient limit level of 4000 as a proxy for the complete 
removal of the patient limit because this exceeded the maximum unlimited patient 
capacity of modeled providers. 
To test the impact of different patient limits on outcome variables including 
SPAGI measures, I used ANOVA tests where heteroscedasticity was absent and residuals 
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were normally distributed, Welch one-way tests with Games-Howell post hoc tests 
where heteroscedasticity was present and residuals were normally distributed, and 
Kruskall-Wallis non-parametric tests with Dunn post hoc tests where both assumptions 
were not valid.  
3.7.3 NP and PA Buprenorphine Adoption Experiments 
To answer Research Question 4—To what extent would various levels of 
buprenorphine prescribing adoption by Nurse Practitioners and Physician Assistants 
change utilization of buprenorphine, equality of access, opioid overdose deaths, and 
medication diversion?—I set the percentage of NPs and PAs who prescribe 
buprenorphine to 0, 5, 10, 20 and 30 percent, initialized the model in 2016, and ran it 35 
times at each patient limit level. The SPAGI measures were calculated at the end of the 
year. Because patient limit regulations were changed in July 2016, the patient limit for 
physicians was held to 100 for the first 26 week of the modeled year, and expanded to 
275 in week 27.  
To test the impact of different levels of NP PA buprenorphine adoption on 
outcome variables including SPAGI measures, I conducted ANOVA tests when 
assumptions were met, and Welch one-way test or Kruskall Wallis rank sum tests when 
assumptions were not valid, along with post hoc tests as described in Section 3.7.2.  
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4 Exploratory Analysis Results 
In Chapter Four I report the results of exploratory analyses of the Spatial 
Potential Access Gini Indices and the Spatial Potential Access Lorenz Curves. Because 
this section reports on my efforts to understand what these novel measures mean when 
used in practice, the tone in Chapter 4 is more conjectural and inquisitive than in 
Chapter 5, when the measures are used to make inferences on the spatial equity 
impacts of policy. Also, rather than wait to discuss the implications of the SPAGI 
exploration  experiments in the discussion section after they are used for policy analysis, 
I have chosen to dig deeper into the exploratory analysis of the measures in Chapter 4. 
In Chapter 5, I return to the more traditional format, in which I present results with little 
commentary in Chapter 5, followed by discussion in Chapter 6 
In this Chapter, some of the SPAGI exploration exercises required testing of five 
measures on ten maps, generating fifty separate analyses.  In these cases, I present a 
single case which shows a typical result, and any non-typical cases. 
4.1 Descriptive Statistics of 10 Regions 
Table 4-1 includes a brief list of descriptive statistics about the regions and the 
accompanying map. Mean and standard deviation of 35 replications are reported for 
random inputs. 
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Table 4-1: Descriptive statistics of 10 regions used for exploratory analysis. 
Region 0 
Total population (people) 2,666,164(19520) 
 
Proportion of population 
living in a MUA (dml) 
0.157 (0.002) 
Proportion of population 
living in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.638 (0.0028) 
Average population density 
(people/mi2) 
124.32 (0.91) 
Total number of providers at 
initialization (people) 
255.5 (3.02) 
Proportion of providers with 
high waiver (dml) 
0.316(0.022)* 
Total number of people with 
OUD at initialization (people) 
29,194 (213.7) 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 11 
Region 1 
Total population (people) 1,088,659 (4162) 
 
Proportion of population 
living in a MUA (dml) 
0.33 (0.0015) 
Proportion of population 
living in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.041 (0.0023) 
Average population density 
(people/mi2) 
54.9 (0.21) 
Total number of providers at 
initialization (people) 
103.5 (2.03) 
Proportion of providers with 
high waiver (dml) 
0.315 (0.05)* 
Total number of people with 
OUD at initialization (people) 
11,920 (45.6) 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 4 
*value fixed prior to simulation 
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Region 2 
Total population (people) 3,435,904 (10160) 
 
Proportion of population living 
in a MUA (dml) 
0.22 (0.0011) 
Proportion of population living 
in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.30 (0.0024) 
Average population density 
(people/mi2) 
152.7 (0.45) 
Total number of providers at 
initialization (people) 
328.6 (3.49) 
Proportion of providers with 
high waiver (dml) 
0.303 (0.02)* 
Total number of people with 
OUD at initialization (people) 
37,623 (111.2) 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 14 
Region 3 
Total population (people) 1,185,966 (5912) 
 
Proportion of population living 
in a MUA (dml) 
0.749 (0.0026) 
Proportion of population living 
in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.179 (0.004) 
Average population density 
(people/mi2) 
52.7 (0.26) 
Total number of providers at 
initialization (people) 
113.6 (2.03) 
Proportion of providers with 
high waiver (dml) 
0.303 (0.035) 
Total number of people with 
OUD at initialization (people) 
12,986 (64.7)* 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 4.8 (0.4) 
*value fixed prior to simulation 
  
141 
Region 4 
Total population (people) 5,319,913 (23025) 
 
Proportion of population living 
in a MUA (dml) 
0.25 (0.0013) 
Proportion of population living 
in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.69 (0.0018) 
Average population density 
(people/mi2) 
237.1 (1.03) 
Total number of providers at 
initialization (people) 
509.3 (3.5) 
Proportion of providers with 
high waiver (dml) 
0.31 (0.017)* 
Total number of people with 
OUD at initialization (people) 
58,253 (252.1) 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 22 
Region 5 
Total population (people) 1,062,685 (7522) 
 
Proportion of population living 
in a MUA (dml) 
0.22 (0.0024) 
Proportion of population living 
in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.469 (0.003)  
Average population density 
(people/mi2) 
47.69 (0.33) 
Total number of providers at 
initialization (people) 
100.9 (1.8) 
Proportion of providers with 
high waiver (dml) 
0.32 (0.035)* 
Total number of people with 
OUD at initialization (people) 
11,636 (82.3) 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 4 
*value fixed prior to simulation 
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Region 6 
Total population (people) 732,390 (4303) 
 
Proportion of population living 
in a MUA (dml) 
0.24 (0.0018) 
Proportion of population living 
in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.15 (0.004) 
Average population density 
(people/mi2) 
32.6 (0.19) 
Total number of providers at 
initialization (people) 
69.8 (1.52) 
Proportion of providers with 
high waiver (dml) 
0.30 (0.05)* 
Total number of people with 
OUD at initialization (people) 
8,019 (47.2) 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 3 
Region 7 
Total population (people) 248,524 (2681) 
 
Proportion of population living 
in a MUA (dml) 
0.92 (.001) 
Proportion of population living 
in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.209 (0.008) 
Average population density 
(people/mi2) 
11.1 (0.11) 
Total number of providers at 
initialization (people) 
23.6 (1.04) 
Proportion of providers with 
high waiver (dml) 
0.319 (0.102)* 
Total number of people with 
OUD at initialization (people) 
2720 (29.3) 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 1 
*value fixed prior to simulation 
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Region 8 
Total population (people) 6,920,384 (22035) 
 
Proportion of population living 
in a MUA (dml) 
0.14 (.001) 
Proportion of population living 
in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.71 (.001) 
Average population density 
(people/mi2) 
315.5 (1.0) 
Total number of providers at 
initialization (people) 
663.8 (5.3) 
Proportion of providers with 
high waiver (dml) 
0.31 (0.20)* 
Total number of people with 
OUD at initialization (people) 
75,778 (241.2) 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 29 
Region 9 
Total population (people) 2,524,241 (12268) 
 
Proportion of population living 
in a MUA (dml) 
0.23 (0.0017) 
Proportion of population living 
in an urban area with 
population density > 1000 
people /mi2 (dml) 
0.702 (0.002) 
Average population density 
(people/mi2) 
114.4 (0.54) 
Total number of providers at 
initialization (people) 
242.5 (3.3) 
Proportion of providers with 
high waiver (dml) 
0.31 (0.027)* 
Total number of people with 
OUD at initialization (people) 
27,640 (134.2) 
People with OUD per 100,000 
population (1/100000) 
1095* 
Total number OTPs (number) 10 
*value fixed prior to simulation 
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4.2 Full Range of Five Weighted SPAGI 
The full range of each of the five is shown in Figure 4-1.  The three SPAGI with 
continuous weighting have similar medians and ranges as shown in Table 4-2.  E2SFCA 
weighting has consistently lower SPAGI values, and 2SFCA has the largest potential 
range of values.  E2SFCA SPAGI is much lower than the other measures because access is 
not discounted by individuals’ ability to travel. Providers that are up to 60 miles away 
are considered reachable but distant for urban residents by E2SFCA, are unreachable by 
most urban residents by the other measures since many urban residents are willing to 
travel only 5 or 10 miles. 2SFCA SPAGI tends to be lower than the other willingness-
weighted measures because all reachable providers are assigned a weight of 1, while 
 
E2SFCA          Gaussian 
Figure 4-1: Box plots of the full range of each SPAGI measure over all regions. Plots left to 
right: 2SFCA, E2SFCA, Exponential, Gaussian, Logistic. 
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the other willingness-weighted measures discount more distant providers that are still 
reachable.  
Because E2SFCA is different from the other measures, in experiments that 
follow, I will discuss E2SFCA results first followed by willingness-weighted SPAGI results, 
noting any substantive differences among the willingness weighted measures. 
Table 4-2: Median, IQR and full range of each SPAGI measure. 
Measure  Median  IQR Range 
2SFCA 0.447 0.102 [0.137, 0.563] 
E2SFCA 0.29 0.079 [0.180, 0.459] 
Exponential 0.503 0.101 [0.328, 0.603] 
Gaussian 0.495 0.118 [0.278, 0.602] 
Logistic 0.512 0.124 [0.269, 0.621] 
4.3 Allocation Exploration 
Does spatial allocation matter when calculating SPAGI in a region? For each 
SPAGI measure and each region, can SPAGI detect a difference between the random 
allocation of the region-appropriate number of people with OUD and treatment 
providers, “Random,” and a plausible allocation of the same number of people and 
treatment providers, “Baseline?”  The null hypothesis is that the simulation mean for 35 
replications at “Random” and “Baseline” are equal, and was tested using the Welch 
Confidence Interval Approach (see Section 3.6.1 for specifics on how the populations 
were allocated randomly).  I ran 50 tests: the 5 SPAGI measures for 10 regions. Mean 
differences in confidence intervals did differ significantly from zero in 48 out of 50 tests 
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at p < 0.001.  Differences between E2SFCA SPAGI for “Radom” and “Baseline” allocation 
could not be detected in region 5 or 6. 
4.3.1 E2SFCA Typical Results 
Region 4 results are typical, and are featured in Figure 4-2. Typically, where a 
significant difference was detected in E2SFCA SPAGI, “Random” allocation resulted in 
substantially better E2SFCA SPAGI scores than “Baseline” allocation, as shown for region 
4 in Figure 4-2a. In region 4, under the “Random” allocation rule almost all people are 
within 10 miles of a provider. For the remaining tiny fraction of the population the 
closest provider is between 10 and 30 miles. Further, “Random” allocation means the 
catchment areas of each provider has about the same number of individuals, so the 
population denominator of the treatment supply to population ratio is about the same 
for all providers. Further, when populations are large, each person can reach a large 
number of providers, diluting the impact of high treatment capacity of individual 
providers.  Deviation from perfect equality is due to chance placing slightly more 
providers near some demanders, to the variation in provider capacity, or due to edge 
effects. These effects combined result in near perfect spatial access equity when 
populations are large. When populations are smaller, each person can reach fewer 
providers variation in the capacity of individual providers becomes more important, 
resulting in more heterogeneity in access. However, when population density is greater 
than 50 people/mi2, E2SFCA SPAGI scores are still higher than “Baseline” allocation. 
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4.3.2 Willingness-weighted Typical Results 
 “Baseline” allocation resulted in substantially better willingness-weighted SPAGI 
than “Random” allocation in all region. The box plots for 2SFCA, Logistic, Gaussian and 
Exponential SPAGI for region 4 shown in Figure 4-2(b-e) are typical. By random 
allocation, people with large willingness to travel radii aren’t relegated to provider-
scarce regions rural regions, so they have a disproportionately large share of the spatial 
potential access pie. Further, people who are willing to travel very short distances are 
not concentrated in regions of denser provider locations, so providers are more likely to 
be unreachable.  Slow growth at the low access end of the Spatial Potential Access 
Lorenz Curve coupled with as steep rise at the high access end of the curve results in 
high inequality as measured by SPAGI. 
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b. 2SFCA  
 
a. E2SFCA 
 
c. Logistic 
 
d. Gaussian 
 
 
e. Exponential 
Figure 4-2: Region 4 boxplots comparing SPAGI of the two population allocation scenarios using 5 
different weights. The willingness-weighted measures show the same trend, and are grouped to the 
right in plots (b-e), while E2SFCA shows the opposite trend and is high 
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4.3.3 E2SFCA Atypical Results 
Region 5, 6, and 7 results for E2SFCA are not typical.  These regions have small 
populations (47 people/mi2, 32 people/mi2, and 11 people/mi2, respectively). In region 5 
and 6, no difference could be detected between “Random” and “Baseline” allocation. In 
region 7, the most sparely populated region, “Random” allocation resulted in worse 
E2SFCA SPAGI, as shown in the boxplot in Figure 4-3. At low population levels, each 
individual may only be able to reach one or two providers, making the effect of the 
treatment capacity much more important when calculating equity. If one person can 
reach a provider with 20 treatment spots, and another person can reach an OTP which 
has 2 providers who can treat 150 people each, their access is not equal, despite the 
fact that the providers have about the same number of people in their catchment areas.  
4.3.4 Implications of Allocation Exploration  
This set of simple, stylized tests show that the Spatial Potential Allocation Gini 
Indices can detect differences from random spatial allocation. It is encouraging that the 
 
 Figure 4-3: Region 7 E2SFCA does not have the characteristic pattern of lower E2SFCA SPAGI for 
“Random” allocation. 
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differences between “Baseline” population allocation and “Random” allocation are 
much larger than the random run to run variation inherent in spatial agent based 
models. As a first test of a spatial potential access equity measures, this is encouraging.  
Failure to detect a difference between totally random allocation of supply and demand 
and geographically plausible allocation of supply and demand would mean that the 
measures are aspatial. Rejecting the null hypotheses in most cases means that, yes, 
spatial allocation does matter when calculating SPAGI. 
The analysis also highlights that SPAGI results that appear to be typical may not 
generalize to regions with particularly low population density.  
The attempt to understand the regional differences between regions where 
“Random” allocation resulted in higher E2SFCA SPAGI than “Baseline” allocation 
highlighted the importance of considering the capacity of reachable providers, distance 
from those providers, and the number of reachable providers. With “Random” 
allocation, provider catchment areas contained about the same number of people, so 
differences in competition for supply did not need to be considered. Even without 
competition and willingness to travel, understanding the source of a regional difference 
in the metric required careful consideration of three pieces of information. SPAGI 
compresses a lot of information about individual differences in spatial potential access 
into a single measure. Understanding SPAGI results requires the unpacking of that 
compressed information.  
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4.4 Exploration of Differences among SPAGI Measures in a Given Region 
Are the five SPAGI measures different, and are they different from each other in 
the same way in all regions?  For each region, are there detectable differences in 
medians of the 5 SPAGI measures as measured by Kruskall-Wallis rank sum tests? The 
null hypothesis is that all medians are equal, and rejection of the null hypothesis implies 
that at least one of the SPAGI measures gives different information about the region. 
Figures 4-4 through 4-8 show maps of each region, the allocation of people with OUD 
and providers in that region, and a boxplot of SPAGI by weighting scheme. In all regions 
differences in medians were detected at p < 0.0001. Post hoc tests showed that in all 
cases E2SFCA is different from all other measures.  Typically, 2SFCA is different from the 
other willingness-weighted SPAGI measures, and typically differences could not be 
detected among the Logistic, Gaussian and Exponential SPAGI measures. 
4.4.1 Typical Results 
All regions but region 7 show the same general trend: E2SFCA SPAGI is far lower 
than the other measures, and 2SFCA SPAGI is lower than the other willingness weighted 
measures.  The reasons for this were discussed in Section 4.2. Regions with lower 
population density have larger run-to-run SPAGI variation, so in some cases differences 
between 2SFCA SPAGI and the other willingness measures could not be detected, as in 
regions 1, 3 and 6.  
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Population density map Typical provider, population allocation SPAGI plots 
Region 0 
   
Region 1 
   
Figure 4-4: Regions 0 and 1.  Left, regional map; center, providers (red), OTPs (maroon), and people with OUD (black); right, Box plots of SPAGI by weight 
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Region 3 
   
Figure 4-5: Regions 2 and 3.  Left, regional map; center, providers (red), OTPs (maroon), and people with OUD (black); right, Box plots of SPAGI by weight 
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Figure 4-6: Regions 4 and 5.  Left, regional map; center, providers (red), OTPs (maroon), and people with OUD (black); right, Box plots of SPAGI by weight 
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Figure 4-7: Regions 6 and 7.  Left, regional map; center, providers (red), OTPs (maroon), and people with OUD (black); right, Box plots of SPAGI by weight 
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Region 8 
   
Region 9 
   
Figure 4-8: Regions 8 and 9.  Left, regional map; center, providers (red), OTPs (maroon), and people with OUD (black); right, Box plots of SPAGI by weight
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4.4.2 Atypical Results  
In region 7, 2SFCA has the lowest SPAGI.  To understand why the trend is 
different in region 7, I inspected the map shown in Figure 4-7(bottom), and the Spatial 
Potential Access Curves (SPALCs) shown in Figure 4-9.    
Lower SPAGI means supply is more equitably allocated among demanders. In 
region 7, the majority of people live in one small urban center or in rural areas. The 
small number of suppliers are also located in the urban centers where people are not 
willing to travel far.  Virtually everyone else is willing to travel large distances to the two 
more densely populated zones. The few people in small towns can’t access any provider, 
so the SPAGI curves are horizontal near the origin. Then, by 2SFCA, providers are far, but 
reachable for almost everyone else, hence the steep, linear curve.  With the E2SFCA 
providers who are between 30 and 60 miles away are less preferable, so the curve is 
more bowed out.  
However, at this very low population level, the SPAGI are sensitive to the actual 
allocation of the small number of providers, which is why several simulations resulted in 
outlier SPAGI values. Counterintuitively, when a provider is allocated to a small town in 
Figure 4-9:Spatial Potential Access Lorenz Curves for region 7. The 2SFCA weighting scheme results in the 
lowest SPAGI in this region only. 
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the west, as in Figure 4-10, the SPAGI values go down. Inspection of the curves gives a 
clue as to why.  It is easiest seen in the 2SFCA curve. The curve is still flat near the origin, 
rises linearly until about the 80% mark, and then rises dramatically. So the increase in 
inequality is not to more people having worse access, which would be indicated by a 
longer flat region near the origin, but instead by some people having much better 
access, indicated by the steep rise near the right axis. 
 
 
 
Figure 4-10: Region 7 map and Spatial Potential Access Lorenz Curves (SPALCs) with random allocation of 
a provider to the small town in the west. 
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4.4.3 Implications of Exploring Differences among SPAGI measures in a Given Region 
The SPAGI measures are different.  E2SFCA SPAGI is consistently much lower 
than the other measures because it does not include ability to travel in its calculation of 
individual spatial potential access. 2SFCA is typically slightly lower than the other 
willingness-weighted measures because there is no distance decay discounting of 
reachable providers. The Logistic, Gaussian and Exponential willingness-weighted SPAGI 
are the most complex measures because they include both ability to travel and a 
distance decay weighting within the willingness to travel radius. The subtle differences 
in the weighting curves typically do not result in detectable differences in SPAGI. 
The fact that results were again atypical in the lowest density region 7 highlights 
the need for special consideration in measuring Spatial Potential Access in low density 
regions. Analysis of an outlier simulation run in region 7 highlighted an important aspect 
of SPAGI—Spatial Potential Access Equity can get worse because a small, select group of 
individuals gets particularly good access. If we say that supply within a region is a pie, 
SPAGI calculates whether everybody is getting a fair and proportional piece of the pie. If 
a lucky few get large slices, there is less to go around for everyone else.  Changes in 
equity are zero sum. 
4.5 Exploration of Regional Differences: Comparing the Ten Regions for Each SPAGI 
Measure 
Can SPAGI detect differences between regions with different spatial features and 
plausible population allocations? For each SPAGI measure, I tested for differences in 
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SPAGI medians using Kruskall-Wallis rank sum tests.  The hull hypothesis is that medians 
are indistinguishable, and rejection of the null hypothesis would mean that SPAGI can 
detect differences in Spatial Potential Access equity based on regional differences. 
Figure 4-11 shows a plot of population density and boxplots of each of the 5 
SPAGI measures. The population density plot is included for comparison. Kruskall-Wallis 
rank sum tests for each measure were significant at p <0.001, and the results of Dunn 
post-hoc pairwise comparison test are shown in Table 4-3. In general, as was found 
when comparing the five SPAGI measures within each region, the trends across regions 
for the four measures based on willingness to travel were very similar.  Figure 4-11 
shows similar trends in the box plots, though note the slightly different y-axis scaling. 
Table 4-3 shows that most differences detected by one continuous measure were 
detected by all of the continuous measures.  When detecting differences among these 
particular simulations, the Gaussian weighed SPAGI was the most discriminating of the 
continuous measures, but all measures performed about the same.  All differences 
detected by the willingness-to-travel based measures were in the same direction: no 
region appeared less equitable than another by one measure, and more equitable than 
another by another, as indicated by the (+) and (-) notation in Table 4-3. 2SFCA detected 
differences in spatial potential access between some regions not detected by the 
continuous measures in some pairwise comparisons.   
E2SFCA SPAGI is different from the other measures both in magnitude, as shown 
in Section 4.2 but also in whether it detects differences between regions, and the 
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direction of the differences. Even when E2SFCA and another measure both detect 
differences in spatial potential access between two regions, the direction of the 
difference may not be the same, as indicated by opposite signs (+/-) in Table 4-3.  For 
example, SPAGI is higher for region 8 than 1 by all willingness-weighted measures (here 
8 appears to have less equitable allocation than region 1), but lower by E2SFCA. This 
same reverse trend was seen in the simple allocation exploration in Section 4.3. 
  
162 
 
 
 b. 2SFCA SPAGI by region  
 
 
 
 
 
 
 
 c. E2SFAC SPAGI by region 
 
 
a. Average population density by region d. Logistic SPAGI by region 
 
 
 e. Gaussian SPAGI by region 
 
 
 f. Exponential SPAGI by region 
Figure 4-11: SPAGI measures by region (right column), and population density by region (left). Differences 
among all plots but E2SFCA are small. E2SFCA has a substantially different trend 
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Table 4-3: Results of Dunn post-hoc pairwise comparison tests for each SPAGI, comparing the 10 regions. 
Kruskall-Wallis rank sum tests were significant, p <0.001. (+/-) indicate that SPAGI was higher (+) or lower  
(-) in the second region than the first. 
Regions  2SFCA 
p-value; +/- 
Logistic  
p-value; +/- 
Gaussian 
p-value; +/- 
Exponential 
p-value; +/- 
E2SFCA  
p-value; +/- 
1 vs 0 n.s. n.s. n.s. n.s. <0.001; + 
2 vs 0 <0.001; + <0.001; + <0.001; + <0.001; + <0.001; + 
3 vs 0 n.s. n.s. n.s. n.s. <0.001; + 
4 vs 0 <0.01; + <0.001; + <0.001; + <0.001; + n.s. 
5 vs 0 n.s. <0.05; - n.s. n.s. n.s. 
6 vs 0 n.s. n.s. n.s. n.s. n.s. 
7 vs 0 <0.001; - <0.001; - <0.001; - <0.001; - n.s. 
8 vs 0 <0.001; + <0.001; + <0.001; + <0.001; + n.s. 
9 vs 0 n.s. n.s. n.s. n.s. n.s. 
2 vs 1 n.s. <0.001; + <0.001; + <0.001; + n.s. 
3 vs 1 <0.01; - n.s. n.s. n.s. n.s. 
4 vs 1 n.s. <0.01 + <0.01 + <0.001 + n.s. 
5 vs 1 <0.001; - <0.01; - <0.01; - n.s. <0.001; - 
6 vs 1 <0.001; - <0.01; - <0.05; - n.s. n.s. 
7 vs 1 <0.001; - <0.001; - <0.001; - <0.001; - <0.001; - 
8 vs 1 <0.01; + <0.001; + <0.001; + <0.001; + <0.001; - 
9 vs 1 n.s. n.s. n.s. n.s. <0.01; - 
3 vs 2 <0.001; - <0.001; - <0.001; - <0.001; - n.s. 
4 vs 2 n.s. n.s. n.s. n.s. n.s. 
5 vs 2 <0.001; - <0.001; - <0.001; - <0.001; - <0.001; - 
6 vs 2 <0.001; - <0.001; - <0.001; - <0.001; - n.s. 
7 vs 2 <0.001; - <0.001; - <0.001; - <0.001; - <0.001; - 
8 vs 2 n.s. n.s. n.s. n.s. <0.001; - 
9 vs 2 <0.001; - n.s. n.s. n.s. <0.001; - 
4 vs 3 <0.001; + <0.001; + <0.001; + <0.001; + n.s. 
5 vs 3 n.s. n.s. n.s. n.s. <0.001; - 
6 vs 3 n.s. n.s. n.s. n.s. n.s. 
7 vs 3 <0.01; - n.s. <0.05; - <0.05; - <0.001; - 
8 vs 3 <0.001; + <0.001; + <0.001; + <0.001; + <0.001; - 
9 vs 3 n.s. <0.01; + <0.01; + <0.01; + <0.01; - 
5 vs 4 <0.001; - <0.001; - <0.001; - <0.001; - n.s. 
6 vs 4 <0.001; - <0.001; - <0.001; - <0.001; - n.s. 
7 vs 4 <0.001; - <0.001; - <0.001; - <0.001; - <0.001; - 
8 vs 4 n.s. n.s. n.s. n.s. <0.001; - 
9 vs 4 <0.05; - n.s. n.s. n.s. n.s. 
6 vs 5 n.s. n.s. n.s. n.s. n.s. 
7 vs 5 n.s. n.s. n.s. n.s. n.s. 
8 vs 5 <0.001; + <0.001; + <0.001; + <0.001; + n.s. 
9 vs 5 <0.05; +  <0.001; +  <0.001; +  <0.001; +  n.s. 
7 vs 6 n.s. n.s. n.s. n.s. <0.001; - 
8 vs 6 <0.001; + <0.001; + <0.001; + <0.001; + <0.001; - 
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9 vs 6 n.s. <0.001; + <0.001; + <0.001; + n.s. 
8 vs 7 <0.001; + <0.001; + <0.001; + <0.001; + n.s. 
9 vs 7 <0.001; +  <0.001; +  <0.001; +  <0.001; +  <0.01, + 
9 vs 8 <0.001; - n.s. <0.05; - n.s. n.s. 
 
 E2SFCA SPAGI Results  
Because E2SFCA SPAGI is not based on individuals’ willingness to travel, two 
people in the same location will always have the same Spatial Potential Accessibility 
Score, entirely determined by distance to providers, the treatment capacity of those 
providers, and the overall demand on those providers. To explore the differences 
between regions using E2SFCA, I first used the Dunn pairwise comparisons from the 
Kruskall-Wallis rank sum test post hoc procedure to identify differences in Spatial 
Potential Access equity as measured by SPAGI, compared Spatial Potential Access Lorenz 
Curves (SPALC) and summaries of the information conveyed by the curves, which I call 
SPALC decile summaries, and finally, generated and compared heat maps of individual 
Spatial Potential Accessibility Scores.  
Among other significant differences detected reported in Table 4-3, regions 1, 2 
and 3 have higher spatial inequity than most other regions (0, 5, 7, 8, and 9), though 
they cannot be distinguished from each other or regions 4 and 6. For illustration, I am 
analyzing region 3. 
I found that region 3 SPAGI was significantly higher than regions 0, 5, 7, 8 and 9.  
E2SFCA SPALCs and decile summaries for the curves are presented in Figures 4-12 and 4-
13.  Often Lorenz curves are interpreted by stating what fraction of the population owns 
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a given percentage of the total, for example: 80% of the population owns 20% of a 
nation’s wealth. In this case, I report which fraction of the population lays claim to a 
given percentage of total potential access in the system, subtracting out all groups who 
have lower access.  Each SPALC and SPAGI in Figures 4-12 and 4-13 are generated by a 
single model run.  I am comparing them to better understand why significant differences 
were detected over multiple runs, though different runs do produce different curves 
and accompanying indices. 
In all cases, a disproportionately large percentage of the population are in the 
bottom decile of access. In this particular model run of region 3, 27% of the population 
shares 10% of the capacity, weighted by distance, and each of the top 4 deciles have 
about 4% to 5% of the population in each.  This near-linear increase indicates that there 
is relative access equity among the 20% of people with the best access, but that this 
20% of the population have the highest 10% of Spatial Potential Access Scores. In the 
case of E2SFCA weighting this means they either fall within the 10 mile catchment area 
of high capacity providers, that they live where many catchment areas overlap, or that 
their reachable providers have low demand from others or combinations of these 
factors.     
When compared to region 3, region 0 has about same fraction of the population 
in the lowest access decile, but a more even distribution of access in the remainder of 
the population.  Regions 9 shows the same trend: a disproportionate fraction of the 
166 
population has very poor access, but there is near equality in all deciles above the first, 
indicating near equal access for all but the worst off.  Regions 5 and 7 show the same  
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Region 3 
 
SPALC decile Population at decile 
1st decile 27.0% 
2nd decile 16.0% 
3rd decile 11.9% 
4th decile 10.1% 
5th decile 9.6% 
6th decile 6.8% 
7th decile 4.7% 
8th decile 4.6% 
9th decile 4.4% 
10th decile 4.4% 
Region 0 
 
SPALC decile Population at decile 
1st decile 28.5% 
2nd decile 13.6% 
3rd decile 10.4% 
4th decile 8.3% 
5th decile 7.2% 
6th decile 6.7% 
7th decile 6.5% 
8th decile 6.3% 
9th decile 6.1% 
10th decile 5.8% 
Region 5 
 
SPALC decile Population at decile 
1st decile 22.2% 
2nd decile 12.8% 
3rd decile 11.6% 
4th decile 9.7% 
5th decile 8.8% 
6th decile 8.3% 
7th decile 7.8% 
8th decile 7.6% 
9th decile 6.7% 
10th decile 4.0% 
Figure 4-12: Along with following Figure (4-13), SPALC and SPALC decile summary for region 3 and the 5 
regions with significantly different SPAGI—regions 0, 5, 7, 8, and 9. SPALC and summaries are from 1 
model run. 
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Region 7 
 
SPALC decile Population at decile 
1st decile 24.3% 
2nd decile 11.3% 
3rd decile 9.1% 
4th decile 8.6% 
5th decile 8.6% 
6th decile 8.6% 
7th decile 8.6% 
8th decile 8.4% 
9th decile 8.2% 
10th decile 3.8% 
Region 8 
 
SPALC decile Population at decile 
1st decile 19.9% 
2nd decile 12.6% 
3rd decile 10.5% 
4th decile 9.4% 
5th decile 8.9% 
6th decile 8.4% 
7th decile 8.02% 
8th decile 7.6% 
9th decile 7.3% 
10th decile 6.9% 
Region 9 
 
SPALC decile Population at decile 
1st decile 26.9% 
2nd decile 10.6% 
3rd decile 9.1% 
4th decile 8.3% 
5th decile 7.9% 
6th decile 7.7% 
7th decile 7.5% 
8th decile 7.3% 
9th decile 7.2% 
10th decile 7.0% 
Figure 4-13: Along with previous Figure (4-12), SPALC and SPALC decile summary for region 3 and the 5 
regions with significantly different SPAGI—regions 0, 5, 7, 8, and 9.  SPALC and summaries are from 1 
model run. 
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basic trend with a difference in the top decile.  A disproportionate fraction of the 
population has very poor access (at or near zero in the case of region 7). The access 
curve is then nearly linear from the 3rd through 9th deciles indicating near equal access 
for that segment of the population, a small fraction of the population have the very best 
access, as indicated by the sharp uptick at the right-most side of the curve. 
Region 8, on the other hand, has a smaller portion of the population with the worst 
access a gentle concavity to the Spatial Potential Access curve. Relative to region 3, 
access is more equally distributed across all populations. 
 Figure 4-14 shows a heat map for each region by individual E2SFCA Spatial 
Potential Access Scores.  The color coding represents deviation from equal proportional 
share.  The warm, red end of the spectrum represents having less than one’s 
proportional share, and the cool, blue end of the spectrum represents having more than 
one’s proportional share. If every person were allocated his or her proportional share of 
the total supply in the system, there would be no deviation from equal proportional 
share, and all individuals would be green.  In an extremely unequal allocation, most 
people would be orange and red and a small number of people blue. 
Examination of the heat maps gives some insight into the sharp uptick at the 
highest access decile in regions 5 and 7.  There is a deep blue area in the Southwest 
quadrant of region 5 and a small deep blue area in the Southeast quadrant of region 7. 
In these areas there is less competition for the treatment spots and those spots are  
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a. Region 0 b. Region 1 
  
c. Region 2 d. Region 3 
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e. Region 4 f. Region 5 
  
g. Region 6 h. Region 7 
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i. Region 8 j. Region 9 
 
Figure 4-14: Heat maps generated by individual deviation from equal proportional share of the total capacity 
in the system as measured by E2SFCA weighted Spatial Potential Access Scores 
 within ten miles of where those relatively privileged people live. However, like SPAGI 
and SPALC, the heat maps of Spatial Potential Access Scores do not give information 
about the adequacy of supply to meet demand.    
In general, the heat maps show that when ability to travel or preference for 
travel is not considered, assumptions about provider and demander locations generally 
result in city center residents having access to more than their proportional share of the 
limited supply of treatment capacity, rural residents having less than their proportional 
share, and residents of the suburbs having about their proportional share.  This is not 
always the case, as when a provider happens to practice in a small community with less 
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demand pressure for her limited capacity, as in regions 5 and 7.  The assumptions that 
result in these trends are that high waiver, high capacity providers tend to practice in 
the most densely populated regions; that OTPs are also located in dense population 
centers; and that rural and remote areas have more people with OUD than might be 
expected by population density alone. 
4.5.1 Willingness-weighted SPAGI Results 
Box plots of willingness-weighted SPAGI in Figure 4-11(a, c-e) show similar trends 
for each measure. Clearly, region 7 is different from the other regions, with the lowest 
population density and the lowest SPAGI, and region 8 has the highest population 
density and SPAGI.  These apparent differences in SPAGI are significant by Dunn 
pairwise comparison tests after a significant Kruskall-Wallis rank sum test of difference 
in medians for region 7, but not necessarily so for region 8.  In region 8 no significant 
differences can be detected between region 8 and regions 2 and 4, which have the 
second and third highest populations and a large, dense urban region, nor between 
region 8 and 9 by 2SFCA and Exponential SPAGI.  
Visual inspection of SPAGI box plots and the population density bar chart show 
apparent correlation between population density and SPAGI. Pearson correlation tests 
between total population and SPAGI are significant and high, at 0.68, 0.74, 0.75, and 
0.76 for 2SFCA, Logistic, Gaussian and Exponential weighted SPAGI respectively. This 
begs the question, do SPAGI measures tell us anything about the allocation of the 
population inside the regional container that is not summarized by the population 
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density? The Allocation exploration in 4.1.2 suggests they do, but can they detect equity 
differences in plausible allocations? 
Comparison of actual geographies suggests that SPAGI can, in fact, detect 
differences between regions with similar population levels, but different population 
allocations.  To analyze differences detected by willingness-weighted SPAGI post hoc 
pairwise comparison tests, I compared SPALCs, and SPALC decile summaries.  For 
illustration, I present two analyses of regions with similar population levels, but 
differences in SPAGI scores.  
Regions 3 and 1 have similar population densities, but different 2SFCA SPAGI 
scores, as do regions 5 and 1. Both region 5 and 3 have more equitable spatial allocation 
of supply than region 1. Comparison of SPALCs and SPALC decile summaries suggest that 
SPAGI is different for different reasons, and are shown in Figure 4-15. Region 3 has a 
much smaller fraction of the population in the lowest access decile than region 1. The 
region 3 curve is nearly parallel to the line of prefect equality for the middle 50% of the 
population, and bowed out for region 1.  This suggests that the proportion of access 
apportioned to the 50% of the population with neither the best nor the worst spatial 
potential access scores is shared approximately equally within that group.  Whereas in 
region 1, there are substantial differences in access equity within this subpopulation. 
This may be because providers are spread fairly evenly across the population in small 
urban pockets, rather than in a concentrated zone as in region 1. 
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SPALC decile Population at 
decile 
1st decile 42.0% 
2nd decile 16.5% 
3rd decile 10% 
4th decile 6.8% 
5th decile 5.8% 
6th decile 4.4% 
7th decile 4.2% 
8th decile 3.7% 
9th decile 3.4% 
10th decile 3.1% 
a. Region 1 2SFCA SPALC 
 
 
SPALC decile Population at 
decile 
1st decile 34.0% 
2nd decile 11.2% 
3rd decile 10.8% 
4th decile 8.8% 
5th decile 7.9% 
6th decile 7.7% 
7th decile 7.1% 
8th decile 5.3% 
9th decile 4.1% 
10th decile 3.1% 
b. Region 3 2SFCA SPALC 
 
 
SPALC decile Population at 
decile 
1st decile 40.0% 
2nd decile 10.7% 
3rd decile 7.8% 
4th decile 7.2% 
5th decile 6.9% 
6th decile 6.8% 
7th decile 6.0% 
8th decile 5.5% 
9th decile 5.0% 
10th decile 3.9% 
c. Region 5 2SFCA SPALC  
Figure 4-15: SPALCs (left) and SPALC decile summaries (right). Region 1 (a) is different from region 3 (b) and 
region 5 (c), but regions 3 and 5 are not different from each other. 
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Region 5 has fewer people in the lowest access decile, but the difference is not 
large (comparing Figure 4-15a and 4-15c). The SPALC curves are similar for the lowest 
40% of the population, after which the curve for region 5 becomes nearly linear.  Access 
is nearly equally distributed among this subpopulation. 
The willingness-weighted measures can also detect a difference in spatial access 
equity between region 0 and region 2, which have similar population densities. SPALCs 
and SPALC decile summaries for both regions are shown in Figure 4-16.  There are no 
linear regions in the curves, so Spatial Potential Access inequity is present across all 
populations.  
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Heat maps of deviation from proportional access are difficult to interpret for 
willingness-weighted Spatial Potential Access because people with high and low ability 
to travel are randomly mixed.  However, mapping the people with the lowest access is 
instructive.  About the same fraction of people in both regions have no reachable 
providers. Region 2 has many more people who have access to a tiny fraction (~0.01%) 
of total supply as shown in Figure 4-17. (Recall that individuals are indexed on the 
Spatial Potential Accessibility Lorenz curve by their Spatial Potential Accessibility Score 
 
 
SPALC decile Population at 
decile 
1st decile 38.5% 
2nd decile 14.3% 
3rd decile 11.3% 
4th decile 9.2% 
5th decile 7.2% 
6th decile 5.6% 
7th decile 4.6% 
8th decile 3.8% 
9th decile 3.1% 
10th decile 2.3% 
 
 
 a. Region 0 Logistic SPALC   
 
 
SPALC decile Population at 
decile 
1st decile 49.1% 
2nd decile 14.5% 
3rd decile 9.3% 
4th decile 6.9% 
5th decile 5.5% 
6th decile 4.4% 
7th decile 3.5% 
8th decile 2.8% 
9th decile 2.3% 
10th decile 1.7% 
 
 
 b. Region 2 Logistic SPALC   
Figure 4-16: Region 0 and region 2 Logistic SPALCs and SPALC summaries 
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divided by the total supply in the system, detailed in Section 3.5.)   Region 2 has two 
corridors of low access, in the South-west and the North-central regions.  Those regions 
have a few low capacity providers, but a large number of fellow demanders, taxing that 
supply. The people with the lowest access in those regions are likely penalized for being 
near their willingness-to-travel limit, unlike other people needing services in the same 
region. 
 
a. Region 0                                                                     b.      Region 2 
Figure 4-17: Maps of region 0 and region 2, with low access agents highlighted. Agents represented by 
white triangles have no access, while those represented by black triangles have access to ~.01% of the 
total provider capacity. 
4.5.2 Implications of Exploration of Detecting Regional Differences in Equity using 
SPAGI 
SPAGI measures can detect differences in Spatial Potential Access equity among 
regions.  SPAGI measures are highly correlated with population density, especially the 
willingness weighted measures.  This means that SPAGI will tend to find that regions 
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with high populations have more disparity is Spatial Potential Access than regions with 
low populations.  However, SPAGI does not always detect differences where regions 
have dramatically different population densities (as with regions 8 and 9), and can 
sometimes detect differences in regions where overall population density is about the 
same, but the geography is different in character. So, I argue, even though SPAGI tends 
to track with population density, it does give additional spatial information, and can be a 
useful addition to a spatial analysis of a region. 
E2SFCA and willingness weighted SPAGI measures do not necessarily give the 
same information about potential access equity. E2SFCA clearly gives information on 
equity based on location. By adding heterogeneity in ability to travel that is random but 
partially determined by location type (e.g. remote, rural, high density urban) into the 
calculation of Spatial Potential Access, access equity comparisons based on the 
willingness weighted SPAGI point to disparities in access that are not entirely based on 
location, but on the many factors considered when people state how far they can travel 
for treatment.  
Because of this, heat maps of deviation from proportional access are useful visual aids 
when analyzing differences in E2SFCA SPAGI, but not necessarily useful when analyzing 
differences in willingness weighted SPAGI measures. When individuals’ Spatial Potential 
Access scores are weighted by their stated willingness to travel, heat maps do not show 
a smooth rural to urban equity gradient. Heat maps by Logistic weighted Spatial 
Potential Access Scores are shown in Figure 4-18. People who are willing and able to 
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travel long distances live side by side with people who are unable or unwilling to reach 
many (or any) providers. This is due to a critical assumption, the validity of which I 
discuss at length in Section 6.4.2. At high population density, people overlap and the 
visual information conveyed by the heat map becomes muddied.   
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a. Region 0 b. Region 1 
  
c. Region 2 d. Region 3 
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e. Region 4 f. Region 5 
  
g. Region 6 h. Region 7 
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i. Region 8 j. Region 9 
 
Figure 4-18: Heat maps generated by individual deviation from equal proportional share of the total capacity 
in the system as measured by Logistic weighted Spatial Potential Access Scores 
4.6 Exploration of Doubling Capacity 
Does expanding capacity without adding new supply locations result in changes 
in Spatial Potential Access Equity? Do SPAGI measures detect differences in Spatial 
Potential Access equity when the treatment capacity of each provider is doubled? The 
null hypothesis is that the simulation mean for 35 replications at baseline capacity and 
double capacity are equal, and was tested using the Welch Confidence Interval 
Approach. 
Results of whether each of the SPAGI measures can detect differences in access 
equity when doubling the capacity of each provider are presented in Table 4-4. In most 
cases, no significant difference between baseline and doubled capacity was detected.  
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4.6.1 Typical Results 
It is not surprising that most regions showed no difference in SPAGI measures 
when doubling capacity. Recall from Figure 3-7, that SPAGI of a system with one 
provider with capacity 4 and 8 equidistant demanders was equal to the same system 
when the capacity of the provider was increased four-fold.  
Table 4-4: Results modified two-sample-t confidence interval Welch procedure on the difference in mean 
SPAGI when doubling capacity. Confidence intervals greater than 0 indicate that doubling capacity resulted 
in lower (more equal) SPAGI. Confidence intervals that span 0 indicate that a difference could not be 
detected between SPAGI at α = 0.05. Significant differences noted in grey. 
 95% Confidence Interval of difference in SPAGI when doubling supply (p-value) 
region 2SFCA E2SFCA Logistic Gaussian Exponential 
0 [-0.001, 0.014] (p 
= 0.104) 
[0.0009, 0.041] 
(p = 0.040) 
[-0.001, 0.020] 
(p = 0.085) 
[-0.001, 0.019] 
(p = 0.087) 
[-0.0018, 0.017] 
(p = 0.109) 
1 [-0.026, 0.005] 
(p = 0.179) 
[-0.058, -0.003] 
(p = 0.026) 
[-0.364, 0.005] 
(p = 0.148) 
[-0.036, 0.0047] 
(p = 0.126) 
[-0.039, 0.001] 
(p = 0.064) 
2 [-0.004, 0.007] 
(p = 0.64) 
[-0.01, 0.023] 
(p = 0.44) 
[-0.0057, 
0.009] 
(p = 0.589) 
[-0.005, 0.009] 
(p = 0.60) 
[-0.005, 0.009] 
(p = 0.54) 
3 [0.0026, 0.034] 
(p = 0.023) 
[-0.014, 0.045] 
(p = 0.318) 
[0.0039, 0.041] 
(p = 0.019) 
[0.0024, 0.039] 
(p = 0.027) 
[0.0003, 0.035] 
(p = 0.046) 
4 [-0.003, 0.007] 
(p = 0.48) 
[-0.008, 0.02] 
(p = 0.41) 
[-0.004, 0.009] 
(p = 0.51) 
[-0.004, 0.009] 
(p = 0.509) 
[-0.004, 0.009] 
(p = 0.49) 
5 [-0.006, 0.015] 
(p = 0.42) 
[-0.024, 0.024] 
(p = 0.995) 
[-0.008, 0.024] 
(p = 0.423) 
[-0.009, 0.019] 
(p = 0.47) 
[-0.01, 0.017] 
(p = 0.637) 
6 [-0.014, 0.02] 
(p = 0.605) 
[-0.040, 0.010] 
(p = 0.232) 
[-0.016, 0.025] 
(p = 0.676) 
[-0.017, 0.022] 
(p = 0.810) 
[-0.018, 0.021] 
(p = 0.88) 
7 [-0.048, 0.026] 
(p = 0.558) 
[-0.037, 0.022] 
(p = 0.61) 
[-0.042, 0.030] 
(p = 0.72) 
[-0.040, 0.026] 
(p = 0.68) 
[-0.039, 0.019] 
(p = 0.511) 
8 [-0.002, 0.0039] 
(p = 0.73) 
[-0.012, 0.016] 
(p = 0.812) 
[-0.004, 0.005] 
(p = 0.80) 
[-0.004, 0.005] 
(p = 0.78) 
[-0.004, 0.005] 
(p = 0.81) 
9 [-0.004, 0.006] 
(p = 0.663) 
[-0.010, 0.016] 
(p = 0.702) 
[-0.006, 0.010] 
(p = 0.651) 
[-0.006, 0.0092] 
(p = 0.677) 
[-0.006, 0.008] 
(p = 0.723) 
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4.6.2 Atypical Results 
The particular distribution of supply and demand in regions 0, 1 and 3 resulted in 
discernable, though small, differences in SPAGI when doubling the treatment supply of 
all providers.  To unpack these differences, I inspected the SPALCs, considered the 
SPALC deciles, and the relative Spatial Potential Access heat maps for one run at 
baseline capacity and one run at double capacity, shown in Figure 4-19.  In region 0, 
random allocation of more providers to the small city in the Southeast and doubling the 
capacity of all providers resulted in a smaller fraction of people in the lowest SPALC 
decile, more people with near proportional share of the treatment supply over all 
(broader swath of yellow and green in the urban corridor), and a new region of near 
proportional access in the Southeast.  
On the other hand, in region 1, doubling provider capacity resulted in an increase 
in E2SFCA SPAGI, meaning less equitable distribution. Inspection of SPALCs, SPALC 
deciles, and heat maps for one run at baseline capacity and one run at double capacity 
show subtle differences. About the same proportion of the population is in the lowest 
SPALC decile. In the double capacity scenario, a higher proportion of the population is in 
the second and third access deciles.  In both cases SPALCs are near linear thereafter.  
The heat map shows a much larger yellow region of less than proportional access and a 
contraction of the green proportional access band to the north of the city center. 
In region 3, doubling provider capacity resulted in detectable decreases in all 
willingness-weighted SPAGI—indicating greater equity. Inspection of SPALCs and SPALC 
186 
deciles for a single run at baseline capacity and a single run at double capacity show that 
the bottom three deciles are essentially unchanged, but that access is more equally 
distributed among the higher deciles in the double capacity case as shown in Figure 4-
20. 
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SPALC decile Population at 
decile 
1st decile 30.2% 
2nd decile 12.2% 
3rd decile 10.2% 
4th decile 8.5% 
5th decile 7.3% 
6th decile 6.8% 
7th decile 6.5% 
8th decile 6.3% 
9th decile 6.1% 
10th decile 5.9% 
a. Region 0 baseline capacity 
 
 
 
SPALC decile Population at 
decile 
1st decile 22.4% 
2nd decile 12.2% 
3rd decile 10.3% 
4th decile 9.5% 
5th decile 8.7% 
6th decile 8.2% 
7th decile 7.8% 
8th decile 7.4% 
9th decile 7.1% 
10th decile 6.7% 
b. Region 0 double capacity 
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SPALC decile Population at 
decile 
1st decile 32.6% 
2nd decile 12.7% 
3rd decile 9.8% 
4th decile 7.8% 
5th decile 7.1% 
6th decile 6.8% 
7th decile 6.2% 
8th decile 5.6% 
9th decile 5.6% 
10th decile 5.6% 
c. Region 1 baseline capacity 
  
 
SPALC decile Population at 
decile 
1st decile 32.2% 
2nd decile 14.0% 
3rd decile 12.0% 
4th decile 6.5% 
5th decile 6.0% 
6th decile 6.0% 
7th decile 5.9% 
8th decile 5.9% 
9th decile 5.8% 
10th decile 5.8% 
d. Region 1 double capacity 
Figure 4-19: Heat maps, SPALCs and SPALC decile summaries. Region 0 and 1 showed a significant difference by E2SFCA SPAGI. 
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4.7 Exploration of High Demand Hotspots 
Can SPAGI detect hotspots, small concentrated regions of high demand? I 
conducted Kruskall-Wallis rank sum tests comparing the three high demand “hotspot” 
scenarios—rural hotspot, rural low-transportation hotspot, and urban hotspot—in 
region 0 for each SPAGI measure. The null hypothesis is that medians for 35 replications 
of baseline, and the “hotspot” scenarios are equal. Rejection of the null hypothesis 
 
SPALC decile Population at 
decile 
1st decile 41.0% 
2nd decile 12.8% 
3rd decile 8.8% 
4th decile 7.5% 
5th decile 6.9% 
6th decile 6.3% 
7th decile 5.2% 
8th decile 4.3% 
9th decile 3.8% 
10th decile 3.3% 
 
a. Region 3 baseline capacity 
 
SPALC decile Population at 
decile 
1st decile 41.7% 
2nd decile 12.2% 
3rd decile 8.7% 
4th decile 7.0% 
5th decile 5.9% 
6th decile 5.4% 
7th decile 5.2% 
8th decile 5.0% 
9th decile 4.8% 
10th decile 4.1% 
 
b. Region 3 double capacity 
Figure 4-20: SPALCs and SPALC decile summaries for region 3 for one run at 
baseline capacity and double capacity. 
190 
means that the SPAGI measure can detect small regions of high demand within a larger 
region.  Scenario details were presented in Section 3.6.1.5. Significant differences in 
medians were detected by each of the 5 SPAGI measures. For simplicity, I present 
results of the Dunn pairwise post-hoc tests for comparisons to baseline in Table 4-5, 
rather than all pairwise comparisons. No difference between the rural hotspot scenario 
and baseline could be detected by any SPAGI measure.  In cases where differences were 
detected from baseline, SPAGI measures were larger, indicating less equitable access. 
Table 4-5: Dunn pairwise comparisons for hotspot scenarios versus baseline. Scenarios where significant 
differences were detected are highlighted in grey, and differences from baseline were positive—indicating 
greater inequity in hotspot scenarios.  
 mean rank difference (p-value) 
 2SFCA E2SFCA Logistic Gaussian Exponential 
baseline—rural  15.03 
(p=0.565) 
12.7 
(p=0.937) 
2.83 
(p=2.83) 
2.96 
(p=1.0) 
-1.6 
(p=1.0) 
baseline— 
rural-low-transport 
41.3 
(p=2.5e-5) 
16.3 
(p=0.410) 
31.0 
(p=0.003) 
32.56 
(0.0017) 
33.9 
(p=0.00096) 
baseline—urban  64.3 
(p=4.9e-
12) 
61.0 
(p=6.5e-
11) 
55.36 
(p=4.2e-9) 
56.2 
(p=2.3e-
9) 
56.1 
(p=2.5e-9) 
4.7.1 E2SFCA SPAGI Results 
E2SFCA could not detect difference between the rural hotspot-low-transport 
scenario and baseline because E2SFCA does not account for individuals’ transport 
ability.  Figure 4-21 shows heat maps, SPALCs and SPALC decile summaries for the urban 
scenario and baseline as measured by E2SFCA weighted spatial potential access.  
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SPALC decile Population at 
decile 
1st decile 25.7% 
2nd decile 11.3% 
3rd decile 9.9% 
4th decile 8.8% 
5th decile 8.0% 
6th decile 7.7% 
7th decile 7.5% 
8th decile 7.2% 
9th decile 7.0% 
10th decile 6.8% 
a. Baseline scenario 
 
 
 
SPALC decile Population at 
decile 
1st decile 30.4% 
2nd decile 13.1% 
3rd decile 9.2% 
4th decile 7.8% 
5th decile 7.2% 
6th decile 6.9% 
7th decile 6.6% 
8th decile 6.4% 
9th decile 6.3% 
10th decile 6.1% 
b. Urban hotspot (marked red) 
Figure 4-21: Baseline (a) and urban hotspot (b) heat maps, SPALCs and SPALC summaries for E2SFCA weighted Spatial Potential Access 
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Inspecting SPALCs and SPALC decile summaries comparing the urban hotspot 
scenario and baseline for E2SFCA weighted spatial potential access shows that a greater 
proportion of the population is in the lowest decile in the urban hotspot scenario.  Both 
curves are approximately linear in the top five deciles.  The heat maps show that 
capacity that was already strained in the baseline scenario, showing less than 
proportional access (50-90% of equal share) in the southeastern city, which becomes 
overwhelmed with a demand spike. Competition for strained capacity results in far less 
than proportional access for the whole southeastern region (25-50% of equal share). 
4.7.2 Willingness-weighted SPAGI Results 
Figure 4-22 shows heat maps, SPALC and SPALC decile summaries for the four 
scenarios as measured by Logistic weighted spatial potential access (as there is little 
difference among the willingness-weighted measures). 
Inspection of SPALCs and SPALC decile summaries for the urban hotspot scenario 
(Figure 4-22d) compared to baseline (Figure 4-22a) in the Logistic weighted Spatial 
Potential Access analysis, shows that in the urban hotspot case 50% of the population is 
in the lowest access decile, as compared to 40% in the baseline scenario.  This results in 
a SPAGI score that is twenty percent higher than baseline.  The entire southeast 
quadrant of region 0 has extremely low access. In the baseline scenario, some of the 
best access occurs in the rural zone between the western urban corridor and the small 
eastern city.  In this zone people who are willing to travel long distances have access to 
many providers.  In the urban hotspot scenario, when supply in the eastern urban region 
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SPALC decile Population at 
decile 
1st decile 39.8% 
2nd decile 14.9% 
3rd decile 10.3% 
4th decile 8.1% 
5th decile 6.9% 
6th decile 5.8% 
7th decile 4.7% 
8th decile 3.9% 
9th decile 3.1% 
10th decile 2.4% 
a. Baseline scenario 
  
 
SPALC decile Population at 
decile 
1st decile 42.3% 
2nd decile 15.2% 
3rd decile 10.8% 
4th decile 7.9% 
5th decile 6.1% 
6th decile 4.9% 
7th decile 4.1% 
8th decile 3.5% 
9th decile 2.9% 
10th decile 2.4% 
b. Rural hotspot (marked red) 
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SPALC decile Population at 
decile 
1st decile 42.4% 
2nd decile 15.7% 
3rd decile 11% 
4th decile 7.8% 
5th decile 6% 
6th decile 4.8% 
7th decile 4% 
8th decile 3.3% 
9th decile 2.7% 
10th decile 2.2% 
c. Rural hotspot low transport (marked red) 
  
 
SPALC decile Population at 
decile 
1st decile 50% 
2nd decile 13.7% 
3rd decile 9.4% 
4th decile 6.8% 
5th decile 5.3% 
6th decile 4.3% 
7th decile 3.4% 
8th decile 2.8% 
9th decile 2.3% 
10th decile 1.9% 
d. Urban hotspot (marked red) 
Figure 4-22: Baseline (a), rural hotspot (b), rural hotspot low transport (c) and urban hotspot (d) heat maps, SPALCs and SPALC summaries. Hotspot regions 
are marked by a red square.  No significant difference was detected between baseline (a) and rural hotspot (b) scenarios.  Differences in SPAGI between the 
rural hotspot scenario (b) and rural hotspot low-transport (c) and urban hotspot (d) were significant at p<0.05, Dunn pairwise comparisons not shown.
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is overwhelmed by high demand, rural residents who are willing to travel far have less 
choice. So a spike in urban demand has implications for people who live in the 
surrounding rural regions. 
Inspection of SPALCs and SPALC decile summaries for the rural hotspot scenario when 
residents are unable to travel long distances, shows small increase in the proportions of 
the population in the lowest three deciles.  The increase in the lowest decile is much 
smaller than in the urban hotspot case because the hotspot population is one quarter 
the size. The heat map shows that in the rural low-transportation hotspot case, people 
in the eastern two thirds of the hotspot region can’t reach any providers because there 
are no providers in the community.  Those in the eastern third of the hotspot region can 
reach providers located in the suburbs of the urban corridor, but because those 
providers are outside the community, they are likely highly discounted by the distance 
decay function.  Furthermore, all of the people in the hotspot are competing for the 
same treatment spots, driving each provider’s supply to demand ratio down. 
Because no significant difference was detected between the rural hotspot 
scenario and baseline, I am not comparing SPALCs, but the heat map is still interesting 
(Figure 4-22b).  Even though there is a greater density of demanders in the hotspot 
region, the mix of greater than proportional and lower than proportional access appears 
to be about the same as in other rural zones about the same distance from dense urban 
centers.  There may be strain on small local providers, but it can’t be detected as a 
difference in the aggregated SPAGI. 
196 
4.7.3 Implications of High Demand Hotspot analysis 
In general E2SFCA SPAGI cannot detect changes in region-wide Spatial Potential 
Access equity of a rural hotspot. The willingness weighted measures can detect changes 
in Spatial Potential Access equity when the people in the rural hotspot are unable to 
travel above 30 miles for treatment.  This means that SPAGI may not detect spatial 
potential access equity in real regions where heavy rural demand is a known issue. 
All measures did detect differences in region-wide Spatial Potential Access equity 
with an urban demand spike. The willingness weighted SPAGI showed that local strain 
on supply caused by a hotspot can have implications for the broader community. This is 
because competition for supply is a factor in Spatial Potential Access calculations. 
Overstrained providers are technically reachable, but far less desirable than providers 
with less competition. So local strain is felt as a diminution in choice by people outside 
the hotspot region. 
4.8 Exploration of Supply Shocks 
Can SPAGI detect the removal of particular providers? Specifically, can 
differences in median values of the five SPAGI measures be detected with the removal 
of up to 5 of the highest capacity providers, and up to 5 of the most remote providers? 
Rejection of the null hypothesis means that removing some providers does have 
implications for Spatial Potential Access equity in a region.  Rather than report on all 
fifty analyses (ten regions, 5 measures) for both sets of experiments, I will report only 
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those cases where differences in SPAGI medians were detected by Kruskall-Wallis rank 
sum tests.   
4.8.1 High Capacity Provider Closures 
Differences were detected by rank sum tests in Regions 1, 3, 5, and 6, as shown 
in Table 4-6. Some differences detected by Kruskall-Wallis rank sum tests could did not 
appear as detectable differences in the conservative post hoc tests. Dunn pairwise tests 
failed to show pairwise differences at p <0.05 in Region 3 by 2SFCA weight, or Region 5 
by Exponential weight (lighter grey highlighting). 
Table 4-6: Kruskall-Wallis rank sum test results for Regions 1, 3, 5, and 6. Results significant at p<0.05 are 
highlighted in grey. 
 Kruskall-Wallis chi-squared (p-value) 
 2SFCA E2SFCA Logistic Gaussian Exponential 
Region 1 7.78 
(p=0.162) 
5.12 
(p=0.400) 
15.22 
(p=0.009) 
13.80 
(p=0.016) 
14.78 
(p=0.011) 
Region 3 11.41 
(p=0.043) 
16.72 
(p=0.005) 
16.77 
(p=0.005) 
15.76 
(p=0.0075) 
18.59 
(p=0.002) 
Region 5 3.19 
(p=0.669) 
12.62 
(p=0.027) 
8.296 
(p=0.140) 
8.49 
(p=0.131) 
14.29 
(p=0.013) 
Region 6 18.55 
(p=0.002) 
16.61 
(p=0.0052) 
17.25 
(p=0.004) 
18.26 
(p=0.0026) 
16.70 
(p=0.005) 
4.8.1.1 Typical Results 
In six of ten regions, removing up to 5 high capacity providers did not result in 
detectable differences in Spatial Potential Access equity across the whole region by any 
SPAGI measure. 
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4.8.1.2 Atypical Willingness Weighted Results 
Because the willingness-weighted measures showed similar pairwise differences, 
I am electing to analyze the Gaussian weighted results, commenting how results differ 
for the other measures.  Figure 4-23 shows boxplots of Gaussian weighted SPAGI for 
regions 1, 3, and 6, and the caption notes pairwise difference results of Dunn’s post hoc 
tests. 
   
a. Region 1 significant 
differences from baseline at 
2 and 4 
b. Region 3 significant 
differences from baseline at 
4. 
c. Region 6 significant 
differences from baseline at 
1, 2, 4, and 5. 
Figure 4-23: Boxplots for Gaussian SPAGI measures for regions 1, 3, and 6. 
To dig deeper into these counter-intuitive results, I inspected Gaussian weighted 
SPALCs and SPALC deciles and heat maps for Region 6 and compared baseline and the 
‘closure of 4 providers’ scenarios (showing one run of each in Figure 4-24). In the 
baseline scenario, there were 71 providers and the mean treatment capacity was 56.35 
patients per provider. In the closure scenario, there were 67 providers and mean 
treatment capacity was 38 patients per provider. In the closure scenario, there were 
fewer treatment spots in the whole system, but the spatial allocation of this supply was 
more equitable as measured over 35 replications at each closure level.
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SPALC decile Population at 
decile 
1st decile 41.3% 
2nd decile 11.7% 
3rd decile 8.8% 
4th decile 7.5% 
5th decile 6.7% 
6th decile 6.2% 
7th decile 5.7% 
8th decile 5.2% 
9th decile 4.1% 
10th decile 2.9% 
a. Baseline scenario (71 providers, mean capacity 56.35) 
 
 
 
SPALC decile Population at 
decile 
1st decile 32.5% 
2nd decile 11.8% 
3rd decile 10.3% 
4th decile 9% 
5th decile 8.1% 
6th decile 7.4% 
7th decile 6.8% 
8th decile 5.9% 
9th decile 4.6% 
10th decile 3.6% 
b. 4 high capacity providers removed (67 providers remaining, mean capacity 38.3) 
Figure 4-24: Region 6 heat maps (left), SPALCs (center), and SPALC decile summaries (right). Maps and plots show one possible allocation of providers and 
demanders each.
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In these particular allocations of supply and demand, a concentration of 
providers in the small city in the northeast in baseline afforded people in that region a 
disproportionate share of potential access. Region 6 has many small cities surrounded 
by rural areas; (refer to Figure 4-1 for a population density map). In regions with small 
high density towns, equality of access is sensitive to the particular allocation of high 
capacity providers.  If a few high capacity providers locate in a small city, access for that 
fairly small population is much greater than proportional—as in the northeast in Figure 
4-24a. It also means that access for some other small, dense community is going to be 
disproportionately low if it has few low capacity providers or none, since Gini-style 
indices are essentially zero sum. See, for example, the city in the north central region, in 
which people have much lower than proportional access. If one population gets 
disproportionately more than its fair share, some other population gets 
disproportionately less.  Allocating fewer providers with lower capacity means that it is 
less likely any particular allocation of providers results in a super high capacity blip.  
Regions 1, 3, and 5 have similar geography to region 6, with tiny dense regions dotting 
the map, which may explain why differences were detected in these regions and not in 
others.  
4.8.2 Remote Provider Closures  
Kruskall-Wallis rank sum tests only showed differences from baseline in Region 
7, the region with the lowest population by far, and then only with 2SFCA, E2SFCA and 
Exponential weighted SPAGI.  Dunn post hoc tests showed significant differences from 
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baseline when the 5 most remote providers were removed from the region, at p <0.05. 
Figure 4-25 shows boxplots of Region 7 2SFCA, E2SFCA and Exponential weighted SPAGI 
when 0-5 remote providers are removed from the simulation. Differences are small 
because remote providers tend to have low numbers, and most people in this rural 
region a willing to travel to the urban center. 
   
d. 2SFCA, significantly better 
SPAGI at 5 closures 
e. E2SFCA, significantly worse 
SPAGI at 5 closures 
f. Exponential, significantly 
worse SPAGI at 5 closures 
Figure 4-25: Region 7 boxplots showing SPAGI when 0 to 5 of the remotest providers are removed from the 
simulation. Differences are detectable when 5 providers are removed, but the differences are small. 
4.8.3 Implications of Supply Shock Exploration 
In general, SPAGI cannot detect region-wide equity implications of removals of 
individual providers. This is likely because there is considerable run-to-run variation in 
the actual locations of providers which makes it difficult to detect that a few providers 
are missing. In regions with a dense urban center or two, highest capacity providers are 
in high provider-density regions.  So when total supply goes down, the overall spread 
remains about the same because people in dense urban zones can reach a large number 
of providers. 
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The fact that in regions dotted with small cities removing the highest capacity 
providers can result in more equitable access has an important implication to consider.  
There are ways to increase equity which may not be desirable or particularly fair. 
Removing a provider from a small city because people in that city have it too good when 
considering equity in broader defies a commonsense notion of fairness. The broader 
implication is this: equity shouldn’t be the only criterion of goodness when allocating 
scarce supply to meet demand.   
4.9 Reflections on Exploring SPAGI in Idealized Test Cases 
To answer research question 1—What functional form should an aggregated 
individual-level access inequality metric have for it to be sensitive enough to detect 
differences in access equity in different regions and/or due to different policy 
choices?—I generated individual Spatial Potential Access Scores using gravity model of 
spatial potential access with 5 different weighting schemes (specifically, by using the 
weighted 2 Step Floating Catchment Area method). I aggregated these individual Spatial 
Potential Access Scores into a Spatial Potential Access Lorenz Curve (SPALC) for a given 
region.  I then further condensed the information captured in the Lorenz curve into a 
single index, the Spatial Potential Access Gini Index (SPAGI). I then tested differences in 
SPAGI across a wide variety of idealized test scenarios using simple statistical tests of 
differences in medians. If statistical tests showed a difference in medians across several 
simulation replications, I disaggregated the measure to understand the possible reasons 
behind the difference. 
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Research question 1 is exploratory, and its answer requires quantitative analysis 
and argumentation. For this, I break the question into the following parts:   
 Is SPAGI useful and what information does SPAGI provide? 
 What does it mean when SPAGI is higher or lower in the context of an experiment? 
 How are the five weighting schemes different, which should be used for an 
experiment? 
 What is a good analytic strategy for integrating spatial potential access analysis 
into the current simulation study? 
4.9.1 Is SPAGI useful? 
The aggregation of individual level Spatial Potential Access Scores using the 
Lorenz Curve and Gini Coefficient calculations results in an index that can summarize the 
distribution of Spatial Potential Access within a region. The index is not particularly 
informative on its own, but can be used along with simple statistical tests to discern 
differences in the equitability of access distribution due to spatial allocation of supply 
and demand (as shown by the allocation experiments in Section 4.3), regional 
differences (as shown in Section 4.5), spikes in demand (as shown in Section 4.7) and 
shocks to supply (as shown in Section 4.8). It does not provide information on the 
adequacy of supply to meet demand (as shown in Section 4.8.1.2). It also tends not to 
be able to detect differences at the regional level (150x150 square mile) of the removal 
of a small number of individual providers (as shown in Section 4.8.2).  This may also be 
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an artifact of simulation, in which simulation-to-simulation variability masks small 
regional effects that could be detected if SPAGI were used for empirical analysis. 
These comparisons of Spatial Potential Access in simulations would be difficult 
without aggregating the diffuse, individual-level access scores. Simulations that include 
random inputs have random outputs, and comparisons across simulation scenarios 
requires multiple runs of each.  This precludes side-by-side visual comparison of heat 
maps because of run-to-run variability. SPAGI is one way of aggregating and comparing 
spatial potential access and its response to policy. 
4.9.2 What does it mean when SPAGI is higher or lower in the context of an 
experiment? 
Sometimes interpreting differences in SPAGI is difficult.  SPAGI can get worse 
when overall capacity in the system gets better, (as shown when total capacity doubled 
in Region 1 in Section 4.6), or better when overall capacity in the system gets worse (as 
shown with high capacity provider closures in Region 6 in Section 4.8.1.2). When SPAGI 
is better, Spatial Potential Access is more equitably distributed; each person has closer 
to his or her proportional share of the supply in the system, considering all the factors 
that go into calculating that person’s spatial potential access score: how close he or she 
is to providers, the capacity of those providers, the other demand on those providers, 
and in some calculations, how far he or she is able to go to reach providers. 
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If the people were the same from one simulation to the next, improvement in 
SPAGI from one scenario to the next would mean that some people who had greater 
than their proportional share of access to supply in the system would have less in the 
new scenario. Colloquially, there is no way for everyone to be above average. Since the 
simulated people are not the same from one simulation to the next, improvement of 
SPAGI from one scenario to the next means that the proportion of the people who have 
less than their proportional share decreases, and the people with the best access have a 
smaller piece of the total.  This is easier to see in the context of wealth disparity. “The 
poorest 50% have 10% of the total wealth” is clearly worse than “the poorest 50% have 
40% of the total wealth.”  “The richest 5% have 20%” of the total wealth is less equal 
than the richest “5% have 10% of the wealth.” 
In the access to treatment context, if 50% of the population with the lowest 
Spatial Potential Access scores are in the lowest access decile, it means that the “access-
poorest” 50% has access to just 10% of the total supply in the system. And when 1.5% of 
the population is in the highest access decile means that the “access-richest” 1.5% has 
access to 10% of the total supply in the system. 
4.9.3 How are the five weighting schemes different and which should be used in the 
context of an experiment? 
The five weighting schemes for calculating individual Spatial Potential Access 
scores are of two types: those that are based on how far an individual is willing to travel, 
and one that is strictly based on distance. The four willingness-based weights: 
206 
dichotomous (2SFCA), Logistic, Gaussian, and Exponential, appear to be equally sensitive 
and give similar results in most experiments.  I would recommend the dichotomous 
weighted measure for experiments in mostly urban regions, and any single continuous 
measure for more rural, or rural/urban mixed regions. But I would not recommend using 
more than one willingness-based measure in one experiment, as an additional measure 
does not seem to give more information. 
 The dichotomous measure assumes that all providers within a persons’ stated 
travel range are equally accessible. People in the densest population areas tended to 
pick the smallest search radii possible, five or ten miles. Continuous weighting results in 
heavy discounting of providers that are within two or three miles, which may not be 
reasonable. On the other hand, dichotomous weighting may be problematic in rural or 
mixed urban/rural areas, because the assumption that a provider that is 100 miles away 
affords the same treatment access as a provider that is 10 miles away may be 
untenable. 
 The E2SFCA measure is not based on travel preference, and doesn’t provide the 
same information as the other measures. Median SPAGI values are incomparable to the 
other SPAGI values, as shown in Section 4.2. Differences in SPAGI may be detected by 
E2SFCA and not by the willingness-weighted measures, vice versa, or the differences 
detected by each type of measure may be of opposite sign, as shown in Section 4.5, 
Table 4-3.  
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 Spatial Potential Access as measured by E2SFCA removes individual 
heterogeneity and provides more general information about residents of a region. 
Because it gives different, and sometimes clearer information than the preference-
weighted measures, I recommend including one willingness-weighted measure along 
with E2SFCA in a Spatial Potential Access analysis. 
4.9.4 What is a good analytic strategy for integrating Spatial Potential Access analysis 
into the current simulation study?  
In order to answer research questions 3 and 4 in Chapter 5, I integrated Spatial 
Potential Access analysis into policy analysis that also measured treatment utilization, 
medication diversion, and opioid overdose deaths. Spatial Potential Access analysis 
complements but does not replace the direct analysis of utilization, a possible side 
effects and outcomes.  This is because SPAGI and SPALCs only provide information on 
the distribution of access, not whether access is adequate to meet need, or if any of the 
treatment capacity is used. 
To integrate SPAGI and SPALCs into the policy analysis, simulations were run 35 
times at each policy level, and Logistic SPAGI and E2SFCA SPAGI calculated for each set 
of simulation runs. Differences in SPAGI at different policy levels were tested with 
Kruskall-Wallis rank sum tests and Dunn pairwise post hoc tests.  When pairwise 
differences from baseline were detected, I inspected SPALCs, SPALC decile summaries, 
and heat maps for one baseline simulation run and one policy simulation run to get a 
better understanding of what lay behind the statistically significant differences. Because 
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there can be considerable run-to-run variation, for this stage of the analysis, I chose 
runs whose SPAGI values lay near the median SPAGI for 35 runs for both the baseline 
simulation run and the policy simulation run.  
 Aggregating individual-level spatial potential access information into a curve, and 
further into a single index allows for policy impact comparisons using simple statistical 
tests.  Disaggregating from the index to the curve to the individual-level potential access 
information allows examination and understanding of the spatial supply and demand 
factors that generated the difference at the highest aggregation level.  This analysis of 
the disaggregated information is important, but not statistically rigorous. Comparing 
single runs of simulations with random inputs always risks that the particular runs 
compared are not representative. Generation of statistical tests at lower levels of 
aggregation of spatial potential access information is a direction for future research. 
 In summary, the answer to Research Question 1—What functional form should 
an aggregated individual-level access inequality metric have for it to be sensitive enough 
to detect differences in access equity in different regions and/or due to different policy 
choices?—is as follows:  
The Spatial Potential Access Gini Index is an aggregated individual-level access 
inequality metric that can detect differences in access equity in different regions and 
due to different policy choices that effect total supply, total demand, or the spatial 
allocation of supply or demand within a given region. The Spatial Potential Access Gini 
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Index is generated by the two-step floating catchment area method of calculating 
spatial potential access scores, as detailed in Section 3.5, using either a willingness-to-
travel based weighting scheme, or a weighting scheme based on Euclidean distance, as 
detailed in Section 3.5.1.  It is then aggregated by generating a Spatial Potential Access 
Lorenz Curve and Spatial Potential Access Gini Index, as detailed in Section 3.5. Both a 
willingness-weighted Index and a Euclidean distance weighted Index should be 
generated because they convey complementary information about access equity in a 
region.  
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5 Policy Analysis Results  
In Chapter 5, I present the results of policy analysis addressing research 
questions two, three, and four with little commentary.  Research Question 2 establishes 
the baseline scenario including SPAGI measures, and Research Question 3 and 4 analyze 
specific policies to increase buprenorphine access and access equity through supply 
expansion.  Discussion of policy analysis results follows in Chapter 6. 
5.1 Model Baseline including Logistic and E2SFCA SPAGI 
 Descriptive statistics for the baseline simulation region are presented in Table 4-
1 (Region 0). I initialized the 35 baseline simulation runs using the Initialization data 
detailed in Section 3.3.1, and the model was run with input data detailed in Section 
3.3.2, and the specific input and policy parameter settings detailed in Table 5-1. The 
patient limit for providers with the high waiver was raised from 100 to 275 in week 26 
because the regulation raising the patient limit went into effect in mid-2016. 
All model outputs, including SPAGI measures, were calculated at year end. As 
reported in Section 3.3.3, unique BUP recipients was adjusted to the model population: 
Table 5-1: Parameter settings for input and policy variables for baseline model simulation 
parameter value 
High waiver patient limit weeks 1-26 100 people/provider 
High waiver patient limit weeks 27-52 275 people/provider 
Opioid Overdose Crude Mortality Rate 12/1000 person-years 
Percentage NPs, PAs prescribing 
buprenorphine 
0% 
Percentage of providers accepting 
Medicaid 
59% 
Percentage of uninsured with Medicaid 0% 
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total unique BUP recipients/ model population * 1000,000.  Milligrams diverted BUP and 
Opioid overdose deaths are year-end model totals for the studied region.  Means and 
95% confidence intervals are presented in Table 5-2.  
Table 5-2: Model outcome variables for 35 baseline model simulations. 
Outcome variable 
measured year end 2016 
Mean [95% CI] Scaled nationally 
Mean [95% CI] 
Population Adjusted 
unique BUP recipients  
469.72 [465.29, 474.15] 
people/100,000 population 
1,516,000  
[1,504,000; 1,529,000] 
Milligrams diverted BUP  8580 [8373, 8787] mg -- 
Opioid overdose deaths  283  [277, 290] people 34673 
[33949, 35397] 
E2SFCA SPAGI 0.31 [0.30, 0.32] dmnl -- 
Logistic SPAGI 0.54 [0.53, 0.55] dmnl -- 
Answering Research Question 2—How equitably distributed is access to OB 
buprenorphine treatment in the current OB buprenorphine treatment system given: 
regulatory caps on patient numbers, physician preferences, and geographic distribution 
of treatment seekers and providers?—provides a baseline against which to compare 
supply expansion policies.  As discussed in Section 4.9.1 (Is SPAGI useful?), SPAGI 
measures are not very informative on their own. However, in the context of the 
explorations conducted in Chapter 4, SPAGI results indicate that there is substantial 
inequity in spatial potential access in this region. 
5.2 Patient Limit Change Policy Analyses 
Results of the analysis to address Research Question 3—To what extent would 
changing the current DATA 2000 patient limit per provider change utilization of 
buprenorphine, spatial access equity, opioid overdose deaths and medication 
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diversion?—follow. Details of the experiment setup are presented in Section 3.7.2.  For 
this analysis, I set the patient limit to 100 (for the entire year, in contrast to the baseline 
scenario presented in Section 4.3), 275, 500, and 4000. Because the purpose of the 
analysis is to test the impact of changing policy, the 275 person patient limit is taken to 
be the status quo, and the 100 patient limit the implementation of a policy roll-back to a 
more restrictive limit level. Boxplots of outcome variables and post hoc pairwise 
comparisons against the status quo when significant differences were detected are 
presented in Figure 5-1.  The Cohen’s d effect size was medium for the change in unique 
buprenorphine recipients (d = -0.695). To summarize results: the policy rollback to a 100 
patient limit resulted in a small but significant decrease in utilization, but no detectable 
changes in opioid overdose deaths, medication diversion, or spatial potential access 
equity. 
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Differences in means detected by one-
way ANOVA (p = 3.9e-9) 
 
Tukey’s post hoc pairwise comparisons 
Pairwise 
comparison 
Difference in 
mean 
adj p-value 
100-275 -15.5 0.00000 
500-275 n.s. 0.701 
4000-275 n.s. 0.740 
a. Unique buprenorphine recipients 
 
No significant differences in means 
detected by Kruskall-Wallis rank sum 
test (p=0.507) 
b. Milligrams diverted buprenorphine 
 
No significant differences in means 
detected by one-way ANOVA 
(p=0.583) 
c. Opioid overdose deaths 
 
No significant differences in means 
detected by one-way ANOVA 
(p=0.958) 
d. E2SFCA SPAGI 
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No significant differences in means 
detected by one-way ANOVA 
(p=0.963) 
e. Logistic SPAGI 
Figure 5-1: Boxplots (left) and statistical tests (right) for the patient limit policy  
5.3 NP PA Buprenorphine Adoption Policy Analysis 
Results of the analysis to address Research Question 4—To what extent would 
various levels of buprenorphine prescribing adoption by Nurse Practitioners and 
Physician Assistants change utilization of buprenorphine, equality of access, opioid 
overdose deaths, and medication diversion?—follow. For this analysis, I allowed the 
patient limit to rise to 275 for providers who qualified for a high waiver in week 26 of 
the simulation, because this reflected the actual policy in place at the time.  So the NP 
PA 0% prescribing level is equivalent to the baseline scenario presented in Section 5.1. 
Significant differences were detected at all NP PA adoption levels for the number of 
unique buprenorphine recipients, above 10% adoption for E2SFCA SPAGI, and above 
20%for logistic SPAGI.  No differences were detected in diversion and opioid overdose 
deaths at any policy level. Boxplots, tests for differences in medians or means, and post 
hoc pairwise tests are presented in Figure 5-2.  Unlike the patient limit policy, the SPAGI 
measures improved (decreased) at higher levels of NP PA adoption, as shown in 5-2d 
and 5-2e. Cohen’s d calculations for the smallest detectable difference indicate   
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Differences in means detected by one 
way ANOVA (p <2e-16) 
 
Games Howell post hoc comparisons 
Pairwise 
comparison 
Difference in 
mean 
p-value 
5%-0 13.3 <0.0001 
10%-0 27.7 <0.0001 
20%-0 37.5 <0.0001 
30%-0 50.5 <0.0001 
a. Unique buprenorphine recipients 
 
No significant differences in medians 
detected by Kruskall-Wallis rank sum 
test (p=0.6796) 
b. Milligrams diverted buprenorphine 
 
No significant differences in means 
detected by one-way ANOVA 
(p=0.309) 
c. Opioid overdose deaths 
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Differences in means detected one-
way ANOVA (p=7.25e-9) 
 
Tukey’s post hoc pairwise comparisons 
Pairwise 
comparison 
Difference in 
mean 
p-value 
5%-0 n.s. 0.749 
10%-0 n.s. 0.056 
20%-0 -0.029 <0.0001 
30%-0 -0.039 <0.0001 
d. E2SFCA SPAGI 
 
 
Differences in medians detected by 
Kruskall-Wallis rank sum test 
(p=0.00032) 
 
Dunn’s post hoc pairwise comparisons 
Pairwise 
comparison 
Difference in 
median 
p-value 
5%-0 n.s. 0.36 
10%-0 n.s. 0.21 
20%-0 -0.0099 0.0008 
30%-0 -0.0112 0.0003 
e. Logistic SPAGI 
Figure 5-2: Boxplots (left) and statistical tests (right) for the NP PA prescribing adoption policy   
that all effect sizes are large: unique recipients 5% vs 0, d = -0.84; E2SFCA SPAGI 10% vs 
0, d = 3.65; Logistic SPAGI 20% vs 0, d = 0.987.  
To summarize the results of the NP PA buprenorphine expansion policy: 
Adoption of buprenorphine prescribing by NPs and PAs resulted in increases in 
utilization at all levels of adoption (5%, 10%, 20% and 30%) and in improvements in 
Spatial Potential Access equity at high levels of adoption (20%, 30%). Medication 
diversion and opioid overdose deaths were not affected by this treatment supply 
expansion policy. 
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6 Discussion 
The implications of individual exploration experiments to address Research 
Question 1 were presented alongside each exploration in Sections 4.3 through 4.8. 
Section 4.9 closed with a discussion of how to interpret differences in SPAGI and how to 
use SPAGI in policy analysis.  This Chapter begins with a discussion of the results of 
policy analysis experiments presented in Chapter 5 in Sections 6.1 through 6.3, presents 
limitations in Section 6.4, areas for future research in Section 6.5, implications for 
research in Section 6.6, implications for substance abuse treatment research practice in 
Section 6.7, and closes with a brief conclusion in Section 6.8. 
6.1 How equitable is the spatial distribution of treatment supply (RQ2) 
In the simulated area, a mixed rural-urban 225,000 square mile region of the 
country with providers and people with OUD sited in accordance with national trends, 
two measures of Spatial Potential Access equity—the E2SFCA weighted Spatial Potential 
Access Gini Index and the Logistic willingness-to-travel weighted Spatial Potential Access 
Gini Index—give different information about the how equitably distributed OB 
buprenorphine access is in the current treatment system.   
6.1.1 E2SFCA weighted SPAGI discussion 
E2SFCA takes into account 1.) provider locations, 2.) the number of people those 
providers are willing to treat given personal preference and patient limits, 3.) the 
locations of people with OUD, and 4.) competition for the scarce provider resource, but 
not the willingness or ability of people to travel. Providers within 10 miles are 
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considered 100% accessible, providers between 10 and 30 miles are 60% accessible, 
providers between 30 and 60 miles are 12.3% accessible.  
The E2SFCA SPAGI for the region at the end of 2016 after the patient limit rose 
to 275 is 0.31 (95% CI is [0.30, 0.32]). This is higher than the median E2SFCA SPAGI (0.29, 
IQR 0.079) for all regions explored in this study, as shown in Table 4-2.  Like the Gini 
Index for wealth or income, the Index on its own is only useful for comparison. To 
understand how access is apportioned, I examined the heat map of deviation from 
proportional access, Spatial Potential Access Lorenz Curve (SPALC), and SPALC decile 
summary, shown in Figure 6-1a.   
The heat map shows that almost no people with OUD in the region have 0 access, but 
the SPALC decile summary shows that in this model run about 32% of the population is 
in the lowest access decile and 44% of the population is in the lowest 20% access decile. 
E2SFCA weighted Spatial Potential Access considers both distance effects and 
competition for scarce supply. The heat map shows that in this region with this 
particular allocation of providers, the source of inequity for the worst off appears to be 
due to distance decay and demand competition for limited rural provider spots in the 
northeast, the west coast, and the southwest corner of the region. Heavy demand on 
providers at the southern tip of the western urban corridor and outside of two pockets 
in the southeastern city mean that people there have less than proportional demand 
even though there are providers near by.  
 
2
1
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SPALC decile Population at 
decile 
1st decile 32.3% 
2nd decile 12.1% 
3rd decile 10.3% 
4th decile 8.8% 
5th decile 7.2% 
6th decile 6.5% 
7th decile 6.1% 
8th decile 5.8% 
9th decile 5.6% 
10th decile 5.5% 
a. E2SFCA Heat map, SPALC and SPALC decile summary  
 
 
 
SPALC decile Population at 
decile 
1st decile 47.1% 
2nd decile 13.4% 
3rd decile 9.9% 
4th decile 7.3% 
5th decile 5.7% 
6th decile 4.7% 
7th decile 3.9% 
8th decile 3.2% 
9th decile 2.7% 
10th decile 2.1% 
b. Logistic Heat map, SPALC and SPALC decile summary  
Figure 6-1: One simulation run of the baseline region after one modeled year. 
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Similarly, people with access to 25% to 50% of their proportional share of supply 
(brown) and 50-90% of their proportional share of supply (yellow) are distributed in all 
types of communities. The lowest decile of access includes people in the red (12%), 
orange (13%), brown (11%), and yellow (24%) groups.  
Far fewer people have near their fair share or greater than their proportional 
share of access to supply. People on the periphery do not have near equal or greater 
than proportional access to the supply in the region.  This is likely due to edge effects 
because providers outside the 150x150 mile region aren’t represented.  People with the 
most choice of providers and greatest access to treatment spots are either those who 
live in rural regions around the urban corridor but can travel far and can reach almost all 
providers in the urban corridor, or those who live closer to the densest urban center in 
the north and can reach all providers in that city. 
People in the periphery of southeastern city (but not the suburbs) have about 
their proportional share of total supply. And in the densest population center in the 
North, people have better than their proportional share of the total supply in the region. 
Here people have about 50% more than their proportional share. If the total supply in 
the system were known to be adequate to meet demand, this would suggest oversupply 
of treatment providers in that region. However, this is a problematic interpretation.  
One cannot infer adequacy of treatment supply in a region (or a sub-region, such as the 
city in the southeast) based how close to an equal proportional share of the supply 
people in the region can access. The people in the western central region appear to 
221 
have more choice and less competition for treatment spots than people elsewhere, 
even though the population of demanders is dense.   
This interpretation is just one possible allocation of treatment supply and 
demand in this region. Close examination of heat maps and SPALCs can give a feel for 
the supply and demand pressures in a simulated region, but policy analysis using 
simulation requires comparison of E2SFCA SPAGI over several simulations to 
discriminate between policy effects and run-to-run variation. 
6.1.2 Logistic Willingness Weighted SPAGI Discussion 
Logistic willingness-to-travel weighted SPAGI tells a more complex story because 
it incorporates how far people are willing to travel into the individual Potential Spatial 
Access scores.  Using the Logistic willingness-to-travel weighting scheme means that 
providers closer than 1/6 * stated willing-to-travel distance are 100% accessible, about 
1/3 * willing-to-travel distance are ~95% accessible, 2/3 * willing-to-travel distance are 
~50% accessible, and exactly at willing-to-travel distance is about 10% accessible, refer 
to Section 3.5.1.2 for the mathematical formulation. This means for many people in 
densely populated regions, a provider must be within about 3 miles to be 100% 
accessible, since many people in the model cities are willing to travel 10 miles for 
treatment. It also means that many people in cities find providers greater than 10 miles 
away completely inaccessible. 
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Logistic SPAGI for the study region at the end of 2016 after the patient limit rose 
to 275 is 0.54 (95% CI is [0.53, 0.55]). This is higher than the median (0.512, IQR 0.124) 
for Logistic SPAGI for all regions explored in this study shown in Section 4.2.  Again, like 
other Gini Indices, Logistic SPAGI is primarily used for comparison and gives little 
information on its own.  Again, I examined a heat map of deviation from proportional 
access, the SPALC, and SPALC decile summary for one simulation replication, shown in 
Figure 6-1b.  The same simulation run was used to generate the E2SFCA heat map 
discussed above.  Providers and people with OUD are located in the same places; all that 
has changed is the weighting term in the Spatial Potential Access Score calculations.  
    The SPALC has a near zero slope near the origin, and 47% of the population is 
in the lowest access decile. 60% of the population has access to 20% of the supply in the 
system, taking into account weighting and preference.  Because two people occupying 
the same square mile of the model can have completely different travel preferences, 
their Spatial Potential Access scores can be different. The heat map becomes too 
crowded in urban areas for easy interpretation.  To aid interpretation, I generated 
Figure 6-2, in which each heat map color is shown separately.   
People with zero access (red) tend to live in rural areas outside the large city 
centers.  However, people with non-zero access scores under a quarter of what would 
be their proportional share (orange) are present in every community.  The lion’s share 
of these people with poor access are in the dense urban region in the north, where 
there is high demand and low willingness to travel, and a large population.   
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Figure 6-2: Heat map of deviation from proportional access in Spatial Potential Access Scores with colors 
separated out. 
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Similarly, people with access to 25% to 50% of their proportional share of supply 
(brown) and 50-90% of their proportional share of supply (yellow) are distributed in all 
types of communities. The lowest decile of access includes people in the red (12%), 
orange (13%), brown (11%), and yellow (24%) groups.  
Far fewer people have near their fair share or greater than their proportional 
share of access to supply. People on the periphery do not have near equal or greater 
than proportional access to the supply in the region.  This is likely due to edge effects 
because providers outside the 150x150 mile region aren’t represented.  People with the 
most choice of providers and greatest access to treatment spots are either those who 
live in rural regions around the urban corridor but can travel far and can reach almost all 
providers in the urban corridor, or those who live closer to the densest urban center in 
the north and can reach all providers in that city. 
6.1.3 Summary Regarding Baseline Spatial Potential Access Equity (RQ2) 
The Spatial Potential Access Gini Indices, Spatial Potential Access Lorenz Curves 
and heat maps indicate that treatment access is not equitably distributed in the current 
treatment system. If ability to travel is not considered, there seems to be relative 
oversupply in dense urban zones and undersupply in rural zones, some small cities and 
exurbs. When ability to travel is considered, the situation is more complicated.  People 
with the best access live alongside people with the worst access, in all community 
types—rural, urban, center city, suburban, exurban zones.  Some of this may reflect 
reality, as people with high incomes and means to travel may live very close to people of 
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very limited means.  This makes it difficult to devise strategies to reduce inequality of 
access.  Increasing the number of urban providers in the dense city center would 
certainly improve access for people with limited ability to travel located near the city 
center, but it would also improve access for the people who already have more than 
their proportional share. SPAGI scores could go up, down or remain the same by 
increasing supply in these zones. 
However, it’s important to remember that the random collocation of people 
with high and low ability to travel is due to simplifying model assumptions.  The model 
does not specify affluent or impoverished neighborhoods. If it did, the apparent random 
mixing might be replaced by clear pockets of high demand with low ability to travel as in 
the hot-spot exploration experiments in Section 4.7, and strategies to target people 
living in specific small areas could emerge. 
6.2 Discussion of Results for the Patient Limit Policy (RQ3) 
As shown in Section 5.2, under model assumptions of individual provider 
preferences for patient loads, a roll back to 100 patient per provider resulted in a 5% 
decrease in the number of unique buprenorphine recipients in the model year. Further 
expansion of the patient limit did not result in statistically detectable differences in 
utilization.  There were no differences detected in medication diversion, opioid 
overdose deaths among, or SPAGI measures at any of the patient limit levels. 
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6.2.1 Patient Limit and Buprenorphine Utilization 
To generate an individual provider’s personal patient preference level, a provider 
agent generates a random variable from a random distribution based on provider type. 
A provider’s capacity may then be truncated at the patient limit, if the limit is lower than 
the preferred patient number. To understand the relative impact of patient limits and 
provider preference on total OB BUP utilization, I compared the population sizes of two 
types of providers: those whose patient census counts are within 10% of the patient 
limit, those whose patient census counts are within 10% of their preference level. 
Results of 35 replications at each patient limit level are shown in Table 6-1.  Preferences 
are unchanged for each simulation run, so 95% confidence intervals for the number of 
providers near maximum preferred capacity are pooled from all 140 runs. 
Table 6-1: Number and percentage of providers within 90% of either their personal maximum patient levels 
or the regulatory patient limit. 
At each patient limit level, about 27% of providers are treating about their 
maximum preferred level of patients.  For some providers this number may be zero. 
When the patient limit is 275 only one provider is treating up to the 275 limit in about 
 Number providers >= 90% 
capacity [95% CI] 
Percent providers >= 90% 
capacity [95% CI] 
Preferred (unlimited) 
capacity 
70.36 [68.73; 71.98] 27% [26%; 28%] 
Capacity given limits   
100  17.43 [16.42; 18.44] 7% [6%; 7%] 
275 0.4 [0.23; 0.57] 0% 
500 0.03 [-0.03; 0.09] 0% 
4000 0.00 [0.00; 0.00] 0% 
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40% of the replications.  When the patient limit is 500, this drops to 1 provider in only 1 
of the simulation runs. At 4000, no providers are near the patient limit. 
This explains why the number of unique buprenorphine recipients dropped 
when the patient limit policy was dropped to 100, but remained unchanged when 
patient limits were further relaxed.  At higher patient limit levels, the patient limit is not 
meaningfully constraining utilization. This is despite the fact that patient limits are lower 
than the number of patients some providers are willing to treat at all limit levels, as 
shown in Table 6-2.   
Table 6-2: Total and mean unconstrained capacity, and capacity given patient limits. 
 Total treatment spots  
Mean 100 replications 
[95% CI] 
Mean treatment spots 
Mean 100 replications [95% 
CI] 
Preferred (unlimited) 
capacity 
26,900 [26,300; 27,600] 105 [103; 108] 
Capacity given limits   
100  10,200 [10,100; 10,300] 40 [39; 40] 
275 17,300 [17,000; 17,600] 67 [66, 69] 
500 21,700 [21,200, 22,100] 84 [83, 86] 
4000 23,700 [23,200; 24,300] 93 [91; 95] 
This is likely due to simplifying assumptions about how patients select providers. 
Patients simply choose providers that are close, who accept the right insurance, starting 
with providers on who are on the SAMHSA online provider list.  Advertising, word of 
mouth, or reputation effects are absent from the model.  Word of mouth and positive 
reputation are known positive reinforcement effects that could drive potential patients 
to high capacity providers who already have a lot of patients.  This provider selection 
effect was highlighted in the face validity interview with Dr. O’Connor.  It is possible that 
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more providers would be closer to the regulatory limits if the model included these 
kinds of effects. 
Though Cohen’s d suggests that the effect size of rolling back to a 100 patient limit 
is medium, a 5% effect seems small, given the 40% reduction in capacity given patient 
limit shown in Table 6-2. The patient limit was raised in 2016, and many providers did 
elect to apply for the 275 waiver.  Theoretical capacity (patient limit x number of 
providers) nearly doubled from 2015 to 2016 as shown in Figure 2-3. If there were a 
large reservoir of providers “capped out” at the 100 patient limit, the number of unique 
buprenorphine recipients should have jumped from 2015 to 2016. Estimates of unique 
buprenorphine recipients in 2016 were roughly the same as the number of unique 
providers in 2015. Analysis conducted by Indivior, the maker of Suboxone estimated 
1,387,815 total buprenorphine recipients in 2015 and 1,380,616 recipients in 2016. The 
data seem to support the finding of a modest change in utilization despite a much larger 
change in capacity.  The model may be showing a small effect where none was seen in 
the data because in the model the limit levels persisted for the whole year, without any 
adoption implementation phase, or practice change rollout among providers. 
Even at the 100 patient limit, only 17% of simulation providers were at or near the 
patient limit, while 27% of providers were up against their personal practice limits.  This 
is consistent with literature on barriers to buprenorphine adoption and utilization, in 
which many providers list other barriers as equally or more important in their decisions 
around buprenorphine use (see for example Hutchinson, Catlin, Andrilla, Baldwin, & 
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Rosenblatt, 2014).  In the simulation these barriers are not modeled explicitly, but are 
assumed to be latent factors that drive preferences for patient loads.   
6.2.2 Patient Limit and Opioid Overdose Deaths 
It is not surprising, though distressing, that changes in buprenorphine utilization 
due to patient limit changes do not appear to result in changes in opioid overdose 
deaths.  This is consistent with the sensitivity analysis (Section 3.4.4.1) which showed 
that only changes in the opioid overdose crude mortality rate resulted in changes in the 
number of opioid overdose deaths.  Again, this is due to model assumptions.  Opioid use 
disorder incidence is held to a constant rate, as is the rate of treatment seeking.  
Changes in policy alter how many people who seek treatment actually get treatment, 
not the total number of people who seek treatment. Modeled changes in policy effect 
only about 10% of the population with OUD, the 10% seeking but not yet receiving 
treatment.  Even if all of these people seeking treatment got treatment, the number of 
overdoses avoided would be small. Further, people who seek treatment may self-treat 
with buprenorphine, reducing their risk of overdose death. Transitioning these people 
from informal self-treatment to formal treatment might not result in much change in 
modeled overdoses. 
For policies to affect the number of opioid overdose deaths, they would have to 
impact the 70% of the model population at highest overdose risk—those who are not 
interested in treatment. Sensitivity analysis showed that a 30% change in the incidence 
of treatment seeking (from 10% to 13%) was not enough to see significant changes in 
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overdose deaths. In fact, the only parameter that impacted overdose deaths was the 
opioid overdose crude mortality rate.  Increasing the mortality rate directly, due to the 
influx of potent opioids such as fentanyl, or because of random fluctuations in heroin 
purity, results in more deaths.  Decreasing the mortality rate directly, through such 
strategies as increased adoption naloxone for overdose reversal, results in fewer deaths. 
6.2.3 Patient Limit and Diversion 
In the analysis of changes in the level of diversion with changes in the patient 
limit I could not reject the null hypothesis that the mean diversion levels were all equal. 
This is not surprising, given model assumptions.  The people who sell or give away their 
medication are a fraction of those who are in treatment who need money. Utilization 
was about the same at three of the four patient limit levels.  At the lowest patient limit 
level, utilization was only 5% lower, which means the fraction of people who divert 
buprenorphine would have gone down by perhaps 2%. Diversion model logic involves a 
lot of random processes, a small reduction in the population of people diverting would 
likely be obscured by random variation in the model.  
Sensitivity analysis in Section 3.4.4.1 suggests that policies which impact 
treatment cost and the number of people in treatment are likely to impact diversion, if 
model assumptions regarding the reasons for diversion are valid. The patient limit policy 
only affects the number of people in treatment, but not to a large enough degree to see 
changes in diversion supply.   
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6.2.4 Patient Limit and Spatial Potential Access 
Changes in the patient limit did not result in detectable differences in either 
E2SFCA SPAGI or Logistic SPAGI despite the large differences in total capacity, shown in 
Table 6-2.  New capacity (or in the case of the 100 patient limit rollback, removal of 
capacity) is located in the same places at each policy level. The supply is divided the 
same way, even though the size of the total supply expands or contracts.  This echoes 
the findings in the Doubling Capacity Exploration in Section 4.6, and the toy example in 
Section 3.5, Figure 3-7. In general, changes to treatment capacity that do not change the 
allocation of treatment supply are unlikely to change Spatial Potential Access equity. 
Policy-makers interested in spatial equity should be aware that expanding capacity for 
everyone does not necessarily mean that previously disadvantaged areas are less 
disadvantaged when compared to all others. More does not necessarily mean more 
equal.  However, exclusive focus on equity could miss the important fact that in this 
case, return to a more restrictive patient limit level means that everyone gets less.  The 
allocation of that smaller supply is no more or less equal spatially than at other patient 
limit levels, but fewer people get treatment.
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6.3 Discussion of Results of NP PA Buprenorphine Adoption Policy (RQ4) 
As shown in Section 5.3, increasing adoption of buprenorphine prescribing by 
NPs and PAs resulted in increases in the number of unique buprenorphine recipients at 
all levels of adoption, and improved Spatial Potential Access equity at higher adoption 
levels. The policy did not result in detectable differences in opioid overdose deaths or 
medication diversion.  
6.3.1 NP PA Adoption and Buprenorphine Utilization 
When I added NP and PA buprenorphine prescribers to the model, I did so under 
the following assumptions: NPs and PAs buprenorphine prescribers are primary care 
providers; they may prescribe under their own authority; 30% practice in medically 
underserved areas (MUAs) and 25% of those practice in isolated rural areas; and they 
are willing to treat the same number of patients as primary care physicians. I also 
assumed that all NP or PA providers were new providers, which meant that they could 
treat a maximum of 30 patients.  As in the discussion of the Patient Limit policy, I 
examine how much capacity was added to the region at each adoption level, which is 
shown in Table 6-3. 
For every percentage point increase in NP PA prescribing, there is about a 2 
percentage point increase in the number of treatment spots in the simulated region.  
Because NPs and PAs are new providers and are constrained to at most 30 patients, the 
mean number of treatment spots per provider steadily decreases as the number of NPs  
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Table 6-3: Total capacity, increase in capacity, and mean capacity per provider given a 30 patient limit for 
new providers, a 275 patient limit for high waiver holders, and provider preferences for patient case-loads 
at 4 adoption levels of NP and PA prescribing. 
 Total treatment spots  
Mean 100 replications [95% 
CI] 
% 
capacity 
increase 
Mean treatment 
spots 
Mean 100 
replications [95% CI] 
Baseline 18,300 [18,100; 18,600]  70 [69; 71] 
% NP and PA 
prescribing 
   
5% 20,400 [20,100; 20,700] 11% 60 [60; 61] 
10% 22,100 [21,800; 22,500] 20% 53 [52; 54] 
20% 26,000 [25,700; 26,300] 41% 46 [45; 46] 
30% 30,100 [29,800; 30,500] 64% 42 [41; 42] 
and PAs increases.  Unlike in the patient limit expansion, all these increases in capacity 
also resulted in increases in utilization.  The number of unique buprenorphine recipients 
increased by 2.8%, 5.9%, 7.9%, 10.7% at each of the five levels of prescribing adoption. 
Since increasing treatment capacity doesn’t feedback into treatment seeking, the 
increased utilization arises when people seeking treatment are able to get into 
treatment rather than wait or return to use.  As shown in Table 6-4, at high levels of NP 
and PA adoption there seems to be some shifting of patients from overburdened 
physician providers to the large pool of NP and PA providers.  The percentage of 
providers within 10% of their personal limit drops from 26% at baseline to 21% at 20% 
NP/PA adoption, and 15% at 30% NP/PA adoption.  However, at lower NP/PA adoption 
levels, the percentage of providers near their personal limits increases because the 
decrease in physician providers near their limit is outpaced by NPs and PAs near their 
limits. This supports the Dr. O’Connor’s assumption that NPs might relieve some of the 
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pressure on busy addiction medicine practices initially, until those freed up spots are 
backfilled by new patients.  In the model, the backfilling process does not occur because 
the rate of treatment seeking is held fixed. 
Table 6-4: Mean patient census levels for NPs and PAs, and physicians, and the percentage of providers who 
are within 10% of their personal limit on the number of patient they are willing to treat. 
 Mean NP PA 
patient census  
Mean physician 
census 
% providers within 
10% of personal limit 
Baseline 0 26 [26; 27] 26% [26%; 27%] 
% NP and PA 
prescribing 
   
5% 21 [20; 21] 21 [20; 21] 31% [30%; 31%] 
10% 19 [18; 19] 16 [16; 16] 29% [29%; 30%] 
20% 15 [15; 15] 11 [11; 11] 21% [21%; 22%] 
30% 12 [12; 12] 8 [8; 8] 15% [15%; 15%] 
Because NP and PA providers in the model are limited to 30 patients, capacity 
would rise in the second and third modeled years, as higher capacity NPs and PAs 
choose to apply for the higher level DEA waivers.  This would likely have an impact at 
the lower adoption levels because the mean patient census level for NPs and PAs is high, 
indicating that some of these providers are at their 30 patient limit. 
I was initially reluctant to model buprenorphine prescribing adoption by over 10% 
of primary care NPs and PAs because there has been such resistance to buprenorphine 
prescribing among primary care physicians, where adoption has stalled at 3-5%.  I was 
encouraged to model high adoption by Dr. O’Connor, a primary care Nurse Practitioner 
with long experience working with patients with OUD in the context of primary care.  If 
the enthusiasm she has seen among her colleagues translates into high adoption of 
buprenorphine prescribing among NPs and PAs, the OAT treatment system might come 
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closer to resembling a diffuse, primary care based system that may have been the 
original vision of DATA 2000.  However, the same barriers that may be preventing higher 
adoption of buprenorphine prescribing among primary care physicians are present for 
primary care NPs and PAs, and may even be more severe. NPs and PAs tend to be 
reimbursed at lower rates than physicians for the same services. Low reimbursement 
may make offering OAT cost prohibitive for some practices. Adoption may also be 
hampered by laws limiting the prescribing authority of non-physician prescribers. All 
states allow NPs to prescribe Schedule III drugs, and all states but Kentucky allow PAs to 
prescribe Schedule III drugs, but most states limit prescriptive authority in some way. It 
is not yet clear how limitations on prescriptive authority and requirements for physician 
supervision may impact the ability of NPs and PAs to provide OAT. 
Given the barriers and unanswered questions regarding high adoption of 
buprenorphine prescribing by NPs and PAs, it is encouraging that the model shows 
increased utilization at the lowest level of adoption—5%.  If model assumptions on NP 
and PA practice locations are valid, 30% of these new providers may serve patients in 
medically underserved areas, including remote areas where community-based OAT may 
not currently exist. 
6.3.2 NP PA Adoption and Opioid Overdose and Diversion 
As was the case in with the patient limit policy, no changes in opioid overdose 
deaths or diversion were detected with changes in policy. The fact that opioid overdose 
deaths did not change despite increases in treatment utilization underscores the 
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reasons given in Section 6.2.2, above.  Under model assumptions, expansions in 
treatment supply meant that people already seeking treatment were able to get a 
treatment spot. In the model, these people represented only 10% of the people with 
OUD and were already at lower risk due to self-treatment with illicit buprenorphine. The 
70% of the population at high risk did not change, so overdose deaths did not change.  If 
the model were coded so that increasing treatment capacity and availability induced 
more people to seek treatment, I would expect the number of opioid overdose deaths 
to decrease with increases in treatment capacity. 
I had expected to see some change in diversion with the changes in utilization 
because of the logic governing diversion demand. Demand for diverted buprenorphine 
has two sources: explicit demand by people seeking and waiting to begin treatment, and 
implicit demand as people who need money can divert medication to “the street.” 
Increases in supply allow people who are seeking treatment to enter treatment, 
reducing the size of the population explicitly requesting diverted buprenorphine from 
friends in treatment. Reducing explicit demand should reduce total diversion. 
However, it may be that decreasing demand is obscured by more people in 
treatment who may need money.  Implicit demand is not modeled directly.  I assume 
that “the street” will always demand buprenorphine from people in treatment, so that 
people who need money will always get money for diverted medicine. In early 
interviews with Dr. Clark, ASAM president and addiction medicine specialist treatment 
provider, she predicted that a curve relating diversion and the number of people in 
237 
treatment would be roughly hill shaped.  As more people get treatment, there would be 
more diversion because there are more patient sources of diverted medicine, but after a 
certain threshold level of people in treatment, diversion would go down because there 
would be less demand as people who would be self-treating are folded into the formal 
treatment system.  
  It could be that in the model, both processes are occurring, canceling out the 
effects of each.  Explicit demand from treatment seekers reduces demand, but 
increased utilization increases supply to the ever-present implicit “street” demand for 
people who are in treatment but need money. 
6.3.3 NP PA Adoption and Spatial Potential Access Equity 
In addition to increasing utilization of buprenorphine, the NP PA buprenorphine 
adoption policy also resulted in detectable improvements in the two SPAGI measures.  
Statistical tests for differences when the NP PA adoption levels were treated as factors 
only found significant differences at the 20% and 30% adoption levels.  However, if NP 
and PA prescribing adoption were treated as a continuous variable, linear regression 
models predicting E2SFCA SPAGI and Logisitic SPAGI from NP PA prescribing are 
significant.  The model predicting E2SFCA SPAGI: 
E2SFCA SPAGI = 0.305 – 0.0012 (NP/PA pct adopting) 
is significant (p = 4.81e-11), and 21% of the variance in E2SFA SPAGI can be explained by 
NP PA prescribing level. The model predicting Logistic SPAGI: 
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Logistic SPAGI = 0.5374 – 0.000364 (NP/PA pct adopting) 
is significant (p = 1.37e-5), and explains 9% of the variance in Logistic SPAGI. 
The linear models show that at low adoption levels, changes to SPAGI measures 
would be very small, and analyses treating the adoption levels as factors show that 
these small changes to SPAGI are not detectable above the considerable run-to-run 
variation, even though we may observe a linear trend in the plots.   
To understand the response of E2SFCA SPAGI to changes in NP and PA prescribing, 
I examined the heat maps, SPALCs and SPALC summaries for the 20% and 30% adoption 
levels and compared each to baseline, as shown in Figure 6-3.  There is no statistically 
significant difference between 20% and 30% adoption, so I did not compare these two 
scenarios directly.  In the model run shown in Figure 6-3a, 32.1% of the population is in 
the lowest spatial potential access decile, and 44.4% in the lowest 20%.  People whose 
spatial potential access scores are below one quarter of their proportional share of 
supply are concentrated in the northeast and southwest corners.  The large population 
living at the southern tip of the urban corridor have less than proportional access, while 
those in and around the dense urban core have much greater than their proportional 
share of access. 
E2SFCA SPAGI is almost 5 percentage points better with 20% NP and PA adoption, 
but the differences in distribution of spatial access equity are diffusely spread over all 
SPALC deciles. A smaller fraction of the population is in the lowest decile meaning that 
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the new allocation of supply is felt by the population that previously had the least 
choice and the most competition for distant providers. In the 20% adoption heat map, 
there are no people with “orange level” disparity in the small city in the northeast, nor 
on the central western coastal cities. 
In the SPALC decile summary, when we consider the 50% of the population that 
has the best access, larger populations in each decile means that allocation is more 
equitable.  Using the income metaphor, if the top 5% of earners earn 10% of the 
income, they have more equal a share of total income than if 1% of earners earned 10%. 
At the 5th decile and up, each access decile contains a slightly larger proportion of the 
population, so the area between the line of perfect equality and the Spatial Potential 
Access Lorenz Curve is smaller. The best access is shared by more people, which means 
that access is less skewed to the “access-rich.”  
In a heat map, a society with totally equal spatial potential access would be 
entirely green.  Changes toward the center of the color legend indicate greater access 
equity. In the heat map of Figure 6-3b, high concentration orange areas were eliminated 
as discussed above, a brown region in the south central area changed to yellow.  Striking 
changes can be seen in the urban corridor. Access equity improved for the suburbs and
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Figure 6-3: E2SFCA Spatial Potential Access heat maps (left), SPALCs (center) and SPALC decile summaries (right) for baseline (a), 20% NP PA buprenorphine 
adoption (b) and 30% NP PA buprenorphine adoption (c) 
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exurbs as shown by the expansion outward of the yellow region, especially to the west. 
More people are closer to their proportional share of access at the southern tip of the 
urban zone, and the number of people enjoying disproportionately high choice and less 
competition for nearby providers in the dense urban center contracted. 
The 30% penetration SPALC and SPALC summary tell a similar story by the 
numbers.  There are small reductions in the size of populations with the worst access, 
and the best access is shared among a larger fractions of the populations resulting in a 
smaller areas between the SPALC and the line of perfect equality.  The heat map tells a 
story that is different in the details, but similar in its implications.  Random allocation of 
providers in the rural zone in the north east improved access for those residents.  The 
orange zone in coastal cities is again eliminated.  The urban corridor expanded, access 
improved at the southern end, and the access richest region in the dense urban core 
contracted. 
If the simulations were run again, providers would be allocated differently and 
the particular story told by the heat maps would be different.  However, the heat maps 
do tell the same general story. Allocation of providers in new places according to a 
different allocation rule results in changes in the geographic concentration of treatment 
availability, which means treatment spots are newly accessible to those who previously 
didn’t have many options (orange  brown  yellow  green). Changes to geographic 
concentration by adding supply outside of treatment dense areas increases equity by 
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diluting the influence of high concentration zones. More access elsewhere means high 
access areas are less exceptional (blue  cyan  turquoise  green). 
It is notable that increasing the patient limit did not result in allocation of new providers 
in new places, so the supply that was added to the system did not noticeably change the 
concentration gradient of treatment supply. 
Despite a Cohen’s d indicating a large effect on Logistic SPAGI at 20% NP PA 
adoption, at 20% adoption the mean of Logistic SPAGI decreases by less than 1 
percentage point. At 30% adoption, the mean of Logistic SPAGI decreases by a little 
more than 1 percentage point. The difference is detectable even considering run-to-run 
variation. However, because the difference is so close to the normal range of variation 
in the Logistic SPAGI measure at baseline I concluded that SPALC, SPALC decile, and heat 
map analysis of individual replications are not useful. 
As I opined in Section 6.1.3, I believe the model assumption regarding the random 
mixing of people with highest and lowest ability to travel based on population density 
muddies the spatial distribution of access picture. This limitation is further discussed in 
Section 6.4.2, below. 
Even though SPALC and heat map analysis are not illuminating, and the effects are 
small, there is a measurable impact on SPAGI weighted by people’s ability to travel.  
When NP and PA adoption is at high levels and new sources of supply are spread more 
evenly in the region, including to MUAs and remote areas, spatial potential access 
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equity improves.  Limited ability to travel still puts treatment out of reach, or nearly out 
of reach, for many. This suggests that treatment accessibility policies that increase 
people’s ability to travel or reduce the distance they have to go can have a positive 
impact on spatial potential access equity given ability to travel, as well as utilization and 
retention (see for example: Friedmann, Lemon, & Stein, 2001; Hall et al., 2014).  
6.4 Limitations 
The chief limitations of this study are its simplifying assumptions. Because the 
research questions were narrowly focused on buprenorphine treatment capacity, 
several important aspects of the treatment system were left out of the model.  Though 
all modeling requires selection of model boundaries and each model assumption could 
be discussed in turn, I did not conduct exhaustive boundary assessment.  However, 
several simplifying choices should be discussed because they have implications for the 
measurement of utilization, diversion, and equity, the primary foci of the research 
questions. I cover three main limitation areas: homogeneous population, homogeneous 
population allocation, and homogeneous providers and treatment experiences. 
6.4.1 Population homogeneity 
First, the population with OUD is generic. Agents are coded as male or female, 
but agent sex has no influence on other variables. Agents do not have variables for age, 
substance use history, treatment history, race or ethnicity, language, pregnancy status, 
employment status, criminal justice involvement, or comorbid physical or mental health 
problems. Several of these individual factors do impact retention in treatment, how long 
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treatment may last, which OAT type a person is likely to get. However, the research 
questions in this study are narrow and don’t necessitate heterogeneous agents, that is: 
“Do supply side changes in capacity result in greater utilization in general, given spatial 
considerations?” The impact of characteristics of people with OUD on treatment 
outcomes is assumed to underlie the heterogeneity in the two primary patient 
outcomes: time to abstinence or reduced use, and treatment retention. Heterogeneity 
is also assumed to inform people’s willingness or ability to travel. Some of the empirical 
data informing model parameters could have been stratified by any number of 
population characteristics, and a diverse, heterogeneous synthetic population 
generated through microsimulation techniques.  I argue that this dramatic increase in 
agent complexity would not better answer the general questions on general utilization 
levels and spatial equity. 
There are racial and ethnic disparities in access to treatment services, which 
must be included in studies of treatment access equity writ large. Racial and ethnic 
disparities are not included in this study of access equity, because questions of equity 
are narrowly limited to Spatial Potential Access. Equity is only assessed in this narrow 
Spatial Potential Access context. I do not consider equity in utilization, or outcomes, nor 
do I consider access equity across population groups.  This is not because these studies 
would be unimportant, they are simply outside the narrow focus of this work. No non-
spatial aspects of accessibility are included in the model. There is great potential to 
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expand the calculation of potential access to include non-spatial determinants of access, 
which is a promising thread for future work. 
6.4.2 Population allocation homogeneity 
While the regional population density maps represent real regions, people are 
placed on the maps in a plausible fashion and not directly from empirical data.  There 
were two major reasons for this decision.  First, there aren’t good data on that would 
allow geo-coding of people with OUD, although there are ways to estimate populations 
by proxy measures such as those used by Dick and others (Dick et al., 2015). Second, the 
original impetus for the research was to model the national implications of policy.  So 
rather than generate a single high resolution, high fidelity representation of a real 
region, which might not be suitable for a national analysis, I chose to generate a high-
resolution (1 square mile), low-fidelity, plausible allocation of individuals. 
People with OUD were initialized with randomly assigned poverty levels based 
on NSDUH, and insurance type based on poverty level.  Then they were placed on the 
map so that population distribution in different types of regions (large MSA, small MSA, 
etc.) matched NSDUH survey data. Once people were placed on the map, willingness to 
travel were drawn from the empirical distribution for the population density of the 
person’s residence (see Appendix A). This population allocation algorithm assumes 
independence of poverty level and willingness to travel. 
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This assumption of independence makes analysis of willingness to travel based 
SPAGI problematic. People with limited ability to travel are not spatially grouped. 
In future research, this shortcoming could be addressed by better methods for 
generating synthetic populations. Rather than using population density to place agents 
and providers, providers could be placed by zip code, and agents generated by matching 
high-resolution census data and zip code data on willingness to travel and then merging 
this data with representative survey data from NSDUH using iterative proportional 
fitting. The resultant synthetic population would much better represent a plausible 
allocation of individuals with OUD, and would vastly improve willingness to travel based 
SPAGI analyses. 
The resulting analyses would be regional, not national, however. National scaling 
of individual-level dynamic models is an active area of research in the Agent Based 
Simulation research community. 
6.4.3 Provider and treatment homogeneity 
The model does include some provider heterogeneity, but only on factors that 
impact capacity and utilization, such as accepted insurance and cost, and especially 
number of patients a provider is willing to treat. In the model, the number of patients a 
provider is willing to treat depends on whether the provider is a specialist, whether they 
have a high or low waiver, and whether they are on the SAMHSA searchable list. There 
are many other factors that determine how many patients a provider is willing to treat, 
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including practice barriers and facilitators (Barry et al., 2008; Gordon et al., 2011; 
Hutchinson et al., 2014; Roman, Abraham, & Knudsen, 2011; Schackman et al., 2006) 
and practice models (see SAMHSA 2014c for examples).  A rich policy model could 
include barriers, facilitators, and practice models and their impact on how many 
patients a provider is willing to treat.  However, there are no data on how many people 
a provider is willing to treat. Rather than model the impact of these variables on 
preference, the magnitudes of which are not known, I chose to simplify and generate 
preferences by drawing from probability distributions based on specialty and waiver 
level, and calibrating to patient census data. 
Testing the impact of adopting different practice models could be a fruitful 
avenue for simulation research in OUD treatment. 
6.5 Future Directions 
There are several fruitful future directions for research using SPAGI measures 
and spatial agent based models of OUD treatment access.  The current research could 
be strengthened substantially by using spatial synthetic population generation 
techniques to generate the population with OUD. The model could then be used to 
assess regional spatial potential access using geocoded provider locations.  The model 
could be extended to allow exploring the spatial implications of any number of 
experiments for changing access and utilization, including different practice models and 
regional policy models such as hub and spoke, in which stable patients are transferred 
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to primary care providers closer to where they live; or telemedicine adoption for 
reaching people with limited ability to travel. 
The Spatial Potential Access Gini Index itself could be developed in future 
research to incorporate methodological improvements in floating catchment area 
gravity models, including edge correction, different distance decay functions for urban 
and rural residents.  Research could explore whether non-spatial aspects of accessibility 
could be incorporated into spatial potential access measures and SPAGI to give a richer 
picture of access disparities. Careful attention must be paid to whether changing how 
spatial potential access is measured preserves the property of 2SFCA measures which 
allows for aggregation using SPAGI by assuring that the weighted average of accessibility 
scores equals the total number of opportunities in the system. 
More robust statistical analysis of differences in Spatial Potential Access Lorenz 
Curves could be explored in future research.  I compared SPALCs and SPALC decile 
summaries of individual model runs to understand statistically significant differences in 
SPAGI measures. However, these analyses were informal comparisons of deciles rather 
than a statistically robust comparisons of all the information contained in the curves 
themselves. Development of formal curve analysis could allow better understanding of 
the nature of the inequity in systems described by Lorenz Curves. 
Future research could explore whether SPAGI measures are useful in empirical 
analyses using standard floating catchment area estimates of demand at the census 
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tract level.  Initial exploration could be used to compare regions for which spatial 
potential access analyses have already been conducted. Once initial exploration shows 
that SPAGI can detect differences between regions, SPAGI could be used to compare 
supply allocation experiments in real regions. 
Finally, scaling of dynamic agent based models is an active area of research. How 
can researchers make national level inferences based on agent based simulation models 
when spatial heterogeneity is an important driver of dynamics? Must one agent 
represent one person, or can simulated individuals be “statistical individuals?” Can a 
population centroid of a census tract represent a person in an agent based simulation, 
allowing for a direct synthesis of empirical spatial potential access research and agent 
based simulation? Can an agent based simulation of a region represent similar regions in 
a statistically robust way, in the way that a statistical individual represents a large 
number of people in survey research? I am currently involved in research on how to 
scale individual models and spatial representativeness, which has grown from the 
current work.  
6.6 Implications for Research 
Development of a method to aggregate complex Spatial Potential Access 
information into a single metric grows the field of spatial potential access measurement 
in a new direction.  It addresses a fundamental question in spatial potential access 
measurement: how can researchers compare mapped regions? To date, much attention 
has been paid to identification of supply shortages, or supply deserts, using census-
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based spatial potential access mapping (see, for example: Lee & Lim, 2009; Sharkey, 
Horel, & Dean, 2010; Wan, Zhan, Zou, & Chow, 2012). Methodological improvements 
have focused on how to improve the catchment area methods (Delamater, 2013; 
McGrail & Humphreys, 2009; Wan, Zou, et al., 2012), how to optimize allocation of new 
supply (Ngui & Apparicio, 2011; Wang, 2012; Wang & Tang, 2013), and how to choose 
distance measures and aggregation levels (Apparicio et al., 2017) or representations of 
populations (Langford & Higgs, 2006). Equity is assessed within the mapped region, and 
quantitative information is displayed in rich maps.  However, researchers appear not to 
have compared equitability of access across regions, or within regions after a policy 
experiment. 
The Spatial Potential Access Gini Index and Spatial Potential Access Lorenz Curve 
compresses the rich information of access equity present in individual maps to allow for 
direct comparison of Spatial Potential Access across maps.  Spatial potential access must 
be assessed the same way in all regions to be compared, and the weighted average of 
spatial potential access scores must equal the total supply in the system for Lorenz 
Curve aggregation to be mathematically sound. Care should also be taken to interpret 
differences in SPAGI across regions because of issues in interpretation noted in Section 
4.9.2. The ability to compare equitability of Spatial Potential Access across regions could 
allow for hybrid empirical simulation studies, in which supply allocation policies are 
tested directly on data rich, empirical maps. 
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6.7 Implications for Substance Abuse Treatment Research Practice 
This study shows the promise of simulation research in substance abuse 
treatment policy analysis.  An earlier iteration of the simulation model had a larger 
scope, allowing for the exploration of more policies and policy impacts on more 
outcomes.  The vision of the earlier model was as a flight simulator, in which treatment 
models could be swiftly operationalized, and the potential impacts explored in a 
participatory process with researchers and stakeholders working together. Simulations 
can be useful for testing simple what-if ideas for improving access to treatment, such as 
how could people with OUD in Oregon benefit primary care providers contracted with 
the Coordinated Care Organizations got and used DATA waivers to prescribe for people 
receiving Medicaid. It is a simple idea, but one that has met with resistance from 
providers as reported by Lucy Zammarelli, Health Equity Officer for Trillium, a 
Coordinated Care Organization and health insurer operating in several counties in 
Oregon. A simulation showing improved utilization and access equity when adding 
primary care providers and no improvement in equity from addiction specialist supply 
expansion could build evidence to support advocacy in treatment expansion in primary 
care. 
6.8 Conclusions 
If we as a society believe that equity is important, then we should measure it. 
This simulation exercise showed that if we allocate supply of OAT treatment services as 
it is allocated in the United States, and we allocate people with OUD in a way that it 
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consistent with representative surveys of OUD, there is substantial inequity in the 
spatial allocation of OAT. If we as a society believe that equitable access to OAT is 
important, then we should work to improve it.  We can use simulation that includes 
measurement of Spatial Potential Access to take the first steps in improving equity. We 
can see what might work in simulation studies like this one, before post-hoc empirical 
policy analyses have been conducted. And then we could also use empirical policy 
evaluation tools, including mapping, measuring and comparing equity measures in post-
hoc analyses to evaluate policies after the fact. 
As we do these analyses, we should ask ourselves the difficult ethical questions 
that come with work to improve equity.  Is it OK for things to get better for some people 
before it gets better for other people?  Is it OK to define equity narrowly—can we pat 
ourselves on the back for improvements in Spatial Access Equity, if racial and ethnic 
disparities persist? Is it OK for people who are “access rich” to get less than they’ve 
grown accustomed to so that others get more? How do we make the ethical and 
practical argument for redistribution given political discomfort with that concept? 
 Measuring, mapping, and comparing equity is an important step toward 
improving equity. I hope that this work has advanced that work in some small way. 
254 
References 
91st United States Congress. Controlled Substances Act, Pub. L. No. 91–513, 84 Stat. 
1236 (1970). Retrieved from 
http://www.fda.gov/regulatoryinformation/legislation/ucm148726.htm#cntlsbe 
109th Congress. A bill to amend the Controlled Substances Act to lift the patient 
limitation on prescribing drug addiction treatments by medical practitioners in 
medical practices, and for other purposes, Pub. L. No. 109–56, 119 STAT. 591 
(2005). Retrieved from https://www.congress.gov/109/plaws/publ56/PLAW-
109publ56.pdf 
109th Congress. Office of National Drug Control Policy Reauthorization Act of 2006, Pub. 
L. No. 109–469, 102 STAT. 3502 (2006). Retrieved from 
https://www.congress.gov/bill/109th-congress/house-bill/6344 
Albright, J., Ciaverelli, R., Essex, A., Tkacz, J., & Ruetsch, C. (2010). Psychiatrist 
characteristics that influence use of buprenorphine medication-assisted 
treatment. Journal of Addiction Medicine, 4(4). 
https://doi.org/10.1097/ADM.0b013e3181c816f3 
Alexandra Nielsen. (2015). Buprenorphine Treatment Capacity: Agent-Based Modeling 
for Policy Analysis. Presented at the American Association for the Treatment of 
Opioid Dependence National Conference, Atlanta, GA. 
American Academy of Physician Assistants. (2014). 2013 AAPA annual survey report. 
American Academy of Physician Assistants. Retrieved from 
https://www.aapa.org/research/national-survey/ 
American Association of Nurse Practitioners. (2013). NP Facts. American Association of 
Nurse Practitioners. Retrieved from 
http://www.aanp.org/images/documents/about-nps/npfacts2013.pdf 
American Association of Nurse Practitioners. (2016). NP Fact Sheet. Retrieved February 
14, 2017, from https://www.aanp.org/all-about-nps/np-fact-sheet 
American Psychiatric Association, & DSM-IV, A. P. A. T. F. on. (1994). Diagnostic and 
statistical manual of mental disorders: DSM-IV. Amer Psychiatric Pub Inc. 
American Society of Addiction Medicine. (2006). Buprenorphine for Opiate Dependence 
and Withdrawal. Retrieved October 7, 2016, from 
http://www.asam.org/advocacy/find-a-policy-statement/view-policy-
statement/public-policy-statements/2011/12/15/buprenorphine-for-opiate-
dependence-and-withdrawal 
Apparicio, P., Gelb, J., Dubé, A.-S., Kingham, S., Gauvin, L., & Robitaille, É. (2017). The 
approaches to measuring the potential spatial access to urban health services 
revisited: distance types and aggregation-error issues. International Journal of 
Health Geographics, 16, 32. https://doi.org/10.1186/s12942-017-0105-9 
Arfken, C. L., Johanson, C.-E., di Menza, S., & Schuster, C. R. (2010). Expanding treatment 
capacity for opioid dependence with office-based treatment with 
255 
buprenorphine: National surveys of physicians. Journal of Substance Abuse 
Treatment, 39(2), 96–104. https://doi.org/10.1016/j.jsat.2010.05.004 
ASAM staff. (2015, December 7). Survey Results: Addiction Specialists Weigh In on the 
DATA 2000 Patient Limits. ASAM Magazine. Retrieved from 
http://www.asam.org/magazine/read/article/2015/12/08/addiction-specialists-
weigh-in-on-the-data-2000-patient-limits 
Association, A. P., & others. (2013). Diagnostic and statistical manual of mental 
disorders, (DSM-5®). American Psychiatric Pub. Retrieved from 
https://books.google.com/books?hl=en&lr=&id=-
JivBAAAQBAJ&oi=fnd&pg=PT18&dq=diagnostic+and+statistical+manual+V&ots=
cdPT55HMsd&sig=2quNpWyfyYCMu8XXgiJTPMPS5ik 
Auriacombe, M., Fatséas, M., Dubernet, J., Daulouede, J.-P., & Tignol, J. (2004). French 
field experience with buprenorphine. American Journal on Addictions, 13(sup1), 
S17–S28. 
Baler, R. D., & Volkow, N. D. (2006). Drug addiction: the neurobiology of disrupted self-
control. Trends in Molecular Medicine, 12(12), 559–566. 
Barbosa, C., Taylor, B., Godfrey, C., Rehm, J., Parrott, S., & Drummond, C. (2010). 
Modelling lifetime QALYs and health care costs from different drinking patterns 
over time: a Markov model. International Journal of Methods in Psychiatric 
Research, 19(2), 97–109. 
Barnett, P. G. (2009). Comparison of costs and utilization among buprenorphine and 
methadone patients. Addiction, 104(6), 982–992. 
Barry, D. T., Jones, E. S., Tetrault, J. M., Becker, W. C., Irwin, K., Sullivan, L. E., … Fiellin, D. 
A. (2008). Integrating buprenorphine treatment of opioid dependence into 
office-based practice: A qualitative study of facilitators and barriers. In JOURNAL 
OF GENERAL INTERNAL MEDICINE (Vol. 23, pp. 331–332). SPRINGER 233 SPRING 
STREET, NEW YORK, NY 10013 USA. 
Beardsley, K., Wish, E. D., Fitzelle, D. B., O’Grady, K., & Arria, A. M. (2003). Distance 
traveled to outpatient drug treatment and client retention. Journal of Substance 
Abuse Treatment, 25(4), 279–285. https://doi.org/10.1016/S0740-
5472(03)00188-0 
Behrens, D. A., Caulkins, J. P., Tragler, G., Haunschmied, J. L., & Feichtinger, G. (1999). A 
dynamic model of drug initiation: implications for treatment and drug control. 
Mathematical Biosciences, 159(1), 1–20. 
Bell, J., Dru, A., Fischer, B., Levit, S., & Sarfraz, M. A. (2002). Substitution therapy for 
heroin addiction. Substance Use & Misuse, 37(8–10), 1149–1178. 
Bell, J., Trinh, L., Butler, B., Randall, D., & Rubin, G. (2009). Comparing retention in 
treatment and mortality in people after initial entry to methadone and 
buprenorphine treatment. Addiction, 104(7), 1193–1200. 
Boero, R., & Squazzoni, F. (2005). Does empirical embeddedness matter? 
Methodological issues on agent-based models for analytical social science. 
256 
Journal of Artificial Societies and Social Simulation, 8(4). Retrieved from 
http://jasss.soc.surrey.ac.uk/8/4/6.html 
Boone, M., Brown, N. J., Moon, M. A., Schuman, D. J., Thomas, J., & Wright, D. L. (2004). 
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid 
Addiction. Treatment Improvement Protocol (TIP) Series 40. Substance Abuse 
and Mental Health Services Administration. Retrieved from 
http://eric.ed.gov/?id=ED491569 
Bridge, T. P., Fudala, P. J., Herbert, S., & Leiderman, D. B. (2003). Safety and health 
policy considerations related to the use of buprenorphine/naloxone as an office-
based treatment for opiate dependence. Drug and Alcohol Dependence, 70(2 
Suppl). 
Brownstein, M. J. (1993). A brief history of opiates, opioid peptides, and opioid 
receptors. Proceedings of the National Academy of Sciences of the United States 
of America, 90(12), 5391. 
Campbell, N. D., & Lovell, A. M. (2012). The history of the development of 
buprenorphine as an addiction therapeutic. Annals of the New York Academy of 
Sciences, 1248(1), 124–139. 
Carl Levin, & Orrin Hatch. Drug Addiction Treatment Act of 2000, Pub. L. No. 106–310 
(2000). Retrieved from https://www.govtrack.us/congress/bills/106/hr2634/text 
Caro, J. J., Briggs, A. H., Siebert, U., & Kuntz, K. M. (2012). Modeling Good Research 
Practices—Overview A Report of the ISPOR-SMDM Modeling Good Research 
Practices Task Force–1. Medical Decision Making, 32(5), 667–677. 
Caulkins, J. P., Dietze, P., & Ritter, A. (2007). Dynamic compartmental model of trends in 
Australian drug use. Health Care Management Science, 10(2), 151–162. 
Caulkins, Jonathan P., Behrens, D. A., Knoll, C., Tragler, G., & Zuba, D. (2004). Markov 
chain modeling of initiation and demand: the case of the US cocaine epidemic. 
Health Care Management Science, 7(4), 319–329. 
Caulkins, Jonathan P., Rydell, C. P., Everingham, S. S., Chiesa, J., & Bushway, S. (1999). An 
Ounce of Prevention, a Pound of Uncertainty: The Cost-Effectiveness of School-
Based Drug Prevention Programs. ERIC. Retrieved from 
http://www.eric.ed.gov/ERICWebPortal/recordDetail?accno=ED430199 
Centers for Disease Control and Prevention, W. (2015, January 22). Multiple cause of 
death, 1999-2013 Querry. Retrieved February 2, 2015, from 
http://wonder.cdc.gov/mcd.html 
Central Intelligence Agency. (2018). The World Factbook — Central Intelligence Agency. 
Retrieved April 13, 2018, from https://www.cia.gov/library/publications/the-
world-factbook/rankorder/2172rank.html 
Charreire, H., Casey, R., Salze, P., Simon, C., Chaix, B., Banos, A., … Oppert, J.-M. (2010). 
Measuring the food environment using geographical information systems: a 
methodological review. Public Health Nutrition, 13(11), 1773–1785. 
Chen, L., Hedegaard, H., & Warner, M. (2013). QuickStats: Number of Deaths From 
Poisoning, Drug Poisoning, and Drug Poisoning Involving Opioid Analgesics — 
257 
United States, 1999–2010. MMWR. Morbidity and Mortality Weekly Report, 
62(12), 234. 
Chisholm, D., Rehm, J., Van Ommeren, M., & Monteiro, M. (2004). Reducing the global 
burden of hazardous alcohol use: a comparative cost-effectiveness analysis. 
Journal of Studies on Alcohol, 65(6), 782–793. 
Comer, S. D., Collins, E. D., Kleber, H. D., Nuwayser, E. S., Kerrigan, J. H., & Fischman, M. 
W. (2002). Depot naltrexone: long-lasting antagonism of the effects of heroin in 
humans. Psychopharmacology, 159(4), 351–360. 
Congress and SAMHSA look at ways to expand buprenorphine. (2014). Alcoholism & 
Drug Abuse Weekly, 2. https://doi.org/DOI: 10.1002/adaw 
Dahan, A., Yassen, A., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., & Danhof, M. 
(2006). Buprenorphine induces ceiling in respiratory depression but not in 
analgesia. British Journal of Anaesthesia, 96(5), 627–632. 
Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, 
B., & Green, J. L. (2015). Trends in Opioid Analgesic Abuse and Mortality in the 
United States. New England Journal of Medicine, 372(3), 241–248. 
https://doi.org/10.1056/NEJMsa1406143 
Dean, J. S., Gumerman, G. J., Epstein, J. M., Axtell, R. L., Swedlund, A. C., Parker, M. T., & 
McCarroll, S. (2000). Understanding Anasazi culture change through agent-based 
modeling. Dynamics in Human and Primate Societies: Agent-Based Modeling of 
Social and Spatial Processes, 179–205. 
Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality 
among clients of a state-wide opioid pharmacotherapy program over 20 years: 
Risk factors and lives saved. Drug and Alcohol Dependence, 105(1–2), 9–15. 
https://doi.org/10.1016/j.drugalcdep.2009.05.021 
Delamater, P. L. (2013). Spatial accessibility in suboptimally configured health care 
systems: A modified two-step floating catchment area (M2SFCA) metric. Health 
& Place, 24, 30–43. https://doi.org/10.1016/j.healthplace.2013.07.012 
Dick, A. W., Pacula, R. L., Gordon, A. J., Sorbero, M., Burns, R. M., Leslie, D. L., & Stein, B. 
D. (2015). Increasing Potential Access to Opioid Agonist Treatment in US 
Treatment Shortage Areas. Health Affairs (Project Hope), 34(6), 1028. 
Division of Pharmacologic Therapies. (2015). Opioid Treament Program Directory. 
Retrieved September 18, 2015, from 
http://dpt2.samhsa.gov/treatment/directory.aspx 
Doescher, M. P., Andrilla, C. H. A., Skillman, S. M., Morgan, P., & Kaplan, L. (2014). The 
Contribution of Physicians, Physician Assistants, and Nurse Practitioners Toward 
Rural Primary Care: Findings From a 13-State Survey. Medical Care, 52(6), 549–
556. 
Drug Enforcement Administration. (2008). Changes to Patient Limitation for Dispensing 
or Prescribing Approved Narcotic Controlled Substances for Maintenance or 
Detoxification Treatment by Qualified Individual Practitioners (Final Rule No. 73 
FR 29685). Drug Enforcement Administration. Retrieved from 
258 
https://www.federalregister.gov/documents/2008/05/22/E8-11471/changes-to-
patient-limitation-for-dispensing-or-prescribing-approved-narcotic-controlled-
substances 
Egan, J. E., Casadonte, P., Gartenmann, T., Martin, J., McCance-Katz, E. F., Netherland, J., 
… Fiellin, D. A. (2010). The Physician Clinical Support System-Buprenorphine 
(PCSS-B): a novel project to  expand/improve buprenorphine treatment. Journal 
of General Internal Medicine, 25(9), 936–941. https://doi.org/10.1007/s11606-
010-1377-y 
Epstein, J. M., & Axtell, R. (1997). Artificial societies and generative social science. 
Artificial Life and Robotics, 1(1), 33–34. 
Eschenbach, T. G. (1992). Spiderplots versus tornado diagrams for sensitivity analysis. 
Interfaces, 22(6), 40–46. 
Fatseas, M., & Auriacombe, M. (2007). Why buprenorphine is so successful in treating 
opiate addiction in France. Current Psychiatry Reports, 9(5), 358–364. 
Federal Register. (2016). 42 CFR Part 8 RIN 0930-AA22 Medication Assisted Treatment 
for Opioid Use Disorders (final rule) (No. 81 FR 44711). Department of Health and 
Human Services. Retrieved from https://federalregister.gov/a/2016-16120 
Feldstein, P. J. (2012). Health care economics (7th ed). Clifton Park, NY: Delmar Cengage 
Learning. 
Fiellin, D. A. (2007). The first three years of buprenorphine in the United States: 
experience to date and future directions. Journal of Addiction Medicine, 1(2), 62–
67. 
Fiellin, D. A., & O’Connor, P. G. (2002a). New federal initiatives to enhance the medical 
treatment of opioid dependence. Annals of Internal Medicine, 137(8), 688–692. 
Fiellin, D. A., & O’Connor, P. G. (2002b). Office-based treatment of opioid-dependent 
patients. New England Journal of Medicine, 347(11), 817–823. 
Fiellin, D. A., O’Connor, P. G., Chawarski, M., Pakes, J. P., Pantalon, M. V., & 
Schottenfeld, R. S. (2001). Methadone maintenance in primary care: a 
randomized controlled trial. Jama, 286(14), 1724–1731. 
Fiellin, D. A., Pantalon, M. V., Pakes, J. P., O’Connor, P. G., Chawarski, M., & 
Schottenfeld, R. S. (2002). Treatment of heroin dependence with buprenorphine 
in primary care. The American Journal of Drug and Alcohol Abuse, 28(2), 231–
241. 
Fiellin, D. A., Rosenheck, R. A., & Kosten, T. R. (2001). Office-based treatment for opioid 
dependence: reaching new patient populations. American Journal of Psychiatry, 
158(8), 1200–1204. 
Fornili, K., & Burda, C. (2009). Buprenorphine prescribing: Why physicians aren’t and 
nurse prescribers can’t. Journal of Addictions Nursing, 20(4), 218–226. 
Fornili, K., & Burda-Cohee, C. (2006). Buprenorphine Products for the Pharmacologic 
Management of Opioid Addiction: Why Shouldn’t Advanced Practice Nurses 
Prescribe?: Journal of Addictions Nursing, 17(2), 139–145. 
https://doi.org/10.1080/10884600600668518 
259 
Friedmann, P. D., Lemon, S. C., & Stein, M. D. (2001). Transportation and retention in 
outpatient drug abuse treatment programs. Journal of Substance Abuse 
Treatment, 21(2), 97–103. https://doi.org/10.1016/S0740-5472(01)00185-4 
Galea, S., Hall, C., & Kaplan, G. A. (2009). Social epidemiology and complex system 
dynamic modelling as applied to health behaviour and drug use research. 
International Journal of Drug Policy, 20(3), 209–216. 
Garfein, R. S., Doherty, M. C., Monterroso, E. R., Thomas, D. L., Nelson, K. E., & Vlahov, 
D. (1998). Prevalence and incidence of hepatitis C virus infection among young 
adult injection drug users. JAIDS Journal of Acquired Immune Deficiency 
Syndromes, 18, S11–S19. 
Garrison, L. A., & Babcock, D. S. (2009). Alcohol consumption among college students: 
An agent-based computational simulation. Complexity, 14(6), 35–44. 
Genie L. Bailey, Monique Ziebro, Timothy P. Lepak, Richard G. Soper, & Michael M. 
Miller. (2015, April). A Survey of Opioid-Dependent PatientsTreated With 
Buprenorphine—Medication Use and Misuse. Presented at the 46th American 
Society of Addiction Medicine Annual Conference, Austin, Texas. 
Giabbanelli, P., & Crutzen, R. (2012). An Agent-Based Social Network Model of Binge 
Drinking Among Dutch Adults. Journal of Artificial Societies and Social Simulation, 
16(2), 10. 
Gini, C. (1912). Variabilità e mutabilità. Reprinted in Memorie Di Metodologica Statistica 
(Ed. Pizetti E, Salvemini, T). Rome: Libreria Eredi Virgilio Veschi. 
Gordon, A. J., Kavanagh, G., Krumm, M., Ramgopal, R., Paidisetty, S., Aghevli, M., … 
Liberto, J. (2011). Facilitators and barriers in implementing buprenorphine in the 
Veterans Health Administration. Psychology of Addictive Behaviors : Journal of 
the Society of Psychologists in Addictive Behaviors, 25(2), 215–224. 
https://doi.org/10.1037/a0022776 
Gordon, A. J., Trafton, J. A., Saxon, A. J., Gifford, A. L., Goodman, F., Calabrese, V. S., … 
Liberto, J. (2007). Implementation of buprenorphine in the Veterans Health 
Administration: results of the first 3 years. Drug and Alcohol Dependence, 90(2–
3), 292–296. https://doi.org/10.1016/j.drugalcdep.2007.03.010 
Green, C. A., McCarty, D., Mertens, J., Lynch, F. L., Hilde, A., Firemark, A., … Anderson, B. 
M. (2014). A qualitative study of the adoption of buprenorphine for opioid 
addiction treatment. Journal of Substance Abuse Treatment, 46(3), 390–401. 
https://doi.org/10.1016/j.jsat.2013.09.002 
Grimm, V., Berger, U., DeAngelis, D. L., Polhill, J. G., Giske, J., & Railsback, S. F. (2010). 
The ODD protocol: a review and first update. Ecological Modelling, 221(23), 
2760–2768. 
Grimm, V., & Railsback, S. F. (2012). Pattern-oriented modelling: a ‘multi-scope’for 
predictive systems ecology. Philosophical Transactions of the Royal Society B: 
Biological Sciences, 367(1586), 298–310. 
Grumbach, K., Hart, L. G., Mertz, E., Coffman, J., & Palazzo, L. (2003). Who is caring for 
the underserved? A comparison of primary care physicians and nonphysician 
260 
clinicians in California and Washington. The Annals of Family Medicine, 1(2), 97–
104. 
Guagliardo, M. F. (2004). Spatial accessibility of primary care: concepts, methods and 
challenges. International Journal of Health Geographics, 3(1), 3. 
Gutfraind, A., Boodram, B., Prachand, N., Hailegiorgis, A., Dahari, H., & Major, M. E. 
(2015). Agent-based model forecasts aging of the population of people who 
inject drugs in metropolitan Chicago and changing prevalence of hepatitis C 
infections. PloS One, 10(9), e0137993. 
Hall, G., Neighbors, C. J., Iheoma, J., Dauber, S., Adams, M., Culleton, R., … Morgenstern, 
J. (2014). Mobile opioid agonist treatment and public funding expands treatment 
for disenfranchised opioid-dependent individuals. Journal of Substance Abuse 
Treatment, 46(4), 511–515. https://doi.org/10.1016/j.jsat.2013.11.002 
Hansen, H. B., Siegel, C. E., Case, B. G., Bertollo, D. N., DiRocco, D., & Galanter, M. 
(2013). Variation in use of buprenorphine and methadone treatment by racial, 
ethnic, and income characteristics of residential social areas in New York City. 
The Journal of Behavioral Health Services & Research, 40(3), 367–377. 
https://doi.org/10.1007/s11414-013-9341-3 
Hansen, H., Siegel, C., Wanderling, J., & DiRocco, D. (2016). Buprenorphine and 
methadone treatment for opioid dependence by income, ethnicity and race of 
neighborhoods in New York City. Drug and Alcohol Dependence, 164, 14–21. 
Hansen, W. G. (1959). How accessibility shapes land use. Journal of the American 
Institute of Planners, 25(2), 73–76. 
Hansen-Turton, T., Ware, J., Bond, L., Doria, N., & Cunningham, P. (2013). Are managed 
care organizations in the United States impeding the delivery of primary care by 
nurse practitioners? A 2012 update on managed care organization credentialing 
and reimbursement practices. Population Health Management, 16(5), 306–309. 
Heard, D., Bobashev, G. V., & Morris, R. J. (2014). Reducing the complexity of an agent-
based local heroin market model. PloS One, 9(7), e102263. 
Hefei Wen. (2016). Estimating the Impact of Medication Assisted Opioid Treatment. In 
6th Biennial Conference of the American Society of Health Economists. 
Philadelphia, PA: Ashecon. Retrieved from 
https://ashecon.confex.com/ashecon/2016/webprogram/Paper4886.html 
Hirchak, K. A., & Murphy, S. M. (2016). Assessing Differences in the Availability of Opioid 
Addiction Therapy Options: Rural Versus Urban and American Indian Reservation 
Versus Nonreservation. The Journal of Rural Health. Retrieved from 
http://onlinelibrary.wiley.com/doi/10.1111/jrh.12178/full 
Hoffer, L., Bobashev, G., & Morris, R. J. (2012). Simulating patterns of heroin addiction 
within the social context of a local heroin market. In Computational neuroscience 
of drug addiction (pp. 313–331). Springer. Retrieved from 
http://link.springer.com/10.1007%2F978-1-4614-0751-5_11 
Holder, H. (1998). Planning for Alcohol-Problem Prevention through Complex Systems 
Modeling: Results from SimCom. Substance Use & Misuse, 33(3), 669–692. 
261 
Holder, H. D., & Blose, J. O. (1987). Reduction of community alcohol problems: 
computer simulation experiments in three counties. Journal of Studies on 
Alcohol, 48(2), 124–135. 
Homer, J. B. (1993a). A system dynamics model for cocaine prevalence estimation and 
trend projection. Journal of Drug Issues. Retrieved from 
http://psycnet.apa.org/psycinfo/1993-43867-001 
Homer, J. B. (1993b). Projecting the impact of law enforcement on cocaine prevalence: a 
system dynamics approach. Journal of Drug Issues, 23, 281–281. 
Health Resources and Services Administration. (2018). HRSA Data Warehouse - Map 
Services. Retrieved July 25, 2018, from 
https://datawarehouse.hrsa.gov/data/mapservices.aspx 
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., … Ling, W. (2014). 
Treatment retention among patients randomized to buprenorphine/naloxone 
compared to methadone in a multi‐site trial. Addiction, 109(1), 79–87. 
https://doi.org/10.1111/add.12333 
Hulse, G. K., Tait, R. J., Comer, S. D., Sullivan, M. A., Jacobs, I. G., & Arnold-Reed, D. 
(2005). Reducing hospital presentations for opioid overdose in patients treated 
with sustained release naltrexone implants. Drug and Alcohol Dependence, 79(3), 
351–357. 
Hutchinson, E., Catlin, M., Andrilla, C. H. A., Baldwin, L.-M., & Rosenblatt, R. A. (2014). 
Barriers to primary care physicians prescribing buprenorphine. Annals of Family 
Medicine, 12(2), 128–133. https://doi.org/10.1370/afm.1595 
Ingram, D. R. (1971). The concept of accessibility: a search for an operational form. 
Regional Studies, 5(2), 101–107. 
Jaffe, J. H., & O’Keeffe, C. (2003). From morphine clinics to buprenorphine: regulating 
opioid agonist treatment of addiction in the United States. Drug and Alcohol 
Dependence, 70(2 Suppl). 
Join Together. (2003). National poll of physicians finds barriers to widespread 
buprenorphine use. Boston, MA. Retrieved from http://www.drugfree.org/join-
together/national-poll-of-physicians-finds-barriers-to-widespread-
buprenorphine-use/ 
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015). National and 
state treatment need and capacity for opioid agonist medication-assisted 
treatment. American Journal of Public Health, 105(8). Retrieved from 
https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2015.302664 
Joseph, A. E., & Bantock, P. R. (1982). Measuring potential physical accessibility to 
general practitioners in rural areas: a method and case study. Social Science & 
Medicine, 16(1), 85–90. 
Kerr, D., Kelly, A.-M., Dietze, P., Jolley, D., & Barger, B. (2009). Randomized controlled 
trial comparing the effectiveness and safety of intranasal and intramuscular 
naloxone for the treatment of suspected heroin overdose. Addiction, 104(12), 
2067–2074. 
262 
Khan, A. A. (1992). An integrated approach to measuring potential spatial access to 
health care services. Socio-Economic Planning Sciences, 26(4), 275–287. 
Kissin, W., McLeod, C., Sonnefeld, J., & Stanton, A. (2006). Experiences of a national 
sample of qualified addiction specialists who have and  have not prescribed 
buprenorphine for opioid dependence. Journal of Addictive Diseases, 25(4). 
https://doi.org/10.1300/J069v25n04_09 
Knox, P. L. (1978). The intraurban ecology of primary medical care: patterns of 
accessibility and their policy implications. Environment and Planning A, 10(4), 
415–435. 
Krantz, M. J., & Mehler, P. S. (2004). Treating opioid dependence: growing implications 
for primary care. Archives of Internal Medicine, 164(3), 277–288. 
Kraus, M. L., Alford, D. P., Kotz, M. M., Levounis, P., Mandell, T. W., Meyer, M., … Wyatt, 
S. A. (2011). Statement of the American Society Of Addiction Medicine 
Consensus Panel on the use of buprenorphine in office-based treatment of 
opioid addiction. Journal of Addiction Medicine, 5(4), 254–263. 
https://doi.org/10.1097/ADM.0b013e3182312983 
Kreek, M. J., & Vocci, F. J. (2002). History and current status of opioid maintenance 
treatments: blending conference session. Journal of Substance Abuse Treatment, 
23(2), 93–105. 
Kvamme, E., Catlin, M., Banta-Green, C., Roll, J., & Rosenblatt, R. (2013a). Who 
prescribes buprenorphine for rural patients? The impact of specialty, location 
and practice type in Washington State. Journal of Substance Abuse Treatment, 
44(3), 355–360. https://doi.org/10.1016/j.jsat.2012.07.006 
Kvamme, E., Catlin, M., Banta-Green, C., Roll, J., & Rosenblatt, R. (2013b). Who 
prescribes buprenorphine for rural patients? The impact of specialty, location 
and practice type in Washington State. Journal of Substance Abuse Treatment, 
44(3), 355–360. https://doi.org/10.1016/j.jsat.2012.07.006 
Lamy, F., Bossomaier, T., & Perez, P. (2015). An ontologic agent-based model of 
recreational polydrug use: SimUse. International Journal of Simulation and 
Process Modelling, 10(3), 207–222. 
Langford, M., & Higgs, G. (2006). Measuring potential access to primary healthcare 
services: the influence of alternative spatial representations of population. The 
Professional Geographer, 58(3), 294–306. 
Law, A. M. (2013). Simulation modeling and analysis (Fifth edition). Dubuque: McGraw-
Hill Education. 
Lee, G., & Lim, H. (2009). A spatial statistical approach to identifying areas with poor 
access to grocery foods in the city of Buffalo, New York. Urban Studies, 46(7), 
1299–1315. 
Leshner, A. I. (1997). Addiction is a brain disease, and it matters. Science, 278(5335), 45–
47. 
263 
Leslie, T. F., Frankenfeld, C. L., & Makara, M. A. (2012). The spatial food environment of 
the DC metropolitan area: Clustering, co-location, and categorical differentiation. 
Applied Geography, 35(1), 300–307. 
Levin, G., Roberts, E. B., & Hirsch, G. B. (1975). The persistent poppy: a computer-aided 
search for heroin policy. Ballinger Publishing Company Cambridge, 
Massachusetts. Retrieved from 
https://www.ncjrs.gov/App/abstractdb/AbstractDBDetails.aspx?id=25853 
Levy, D. T., Chaloupka, F., Gitchell, J., Mendez, D., & Warner, K. E. (2002). The use of 
simulation models for the surveillance, justification and understanding of 
tobacco control policies. Health Care Management Science, 5(2), 113–120. 
Levy, D. T., & Friend, K. (2001). A computer simulation model of mass media 
interventions directed at tobacco use. Preventive Medicine, 32(3), 284–294. 
Levy, D. T., Friend, K., Holder, H., & Carmona, M. (2001). Effect of policies directed at 
youth access to smoking: results from the SimSmoke computer simulation 
model. Tobacco Control, 10(2), 108–116. 
Li, Z., Serban, N., & Swann, J. L. (2015). An optimization framework for measuring spatial 
access over healthcare networks. BMC Health Services Research, 15(1). 
https://doi.org/10.1186/s12913-015-0919-8 
Ling, W., & Smith, D. (2002). Buprenorphine: blending practice and research. Journal of 
Substance Abuse Treatment, 23(2), 87–92. 
Lockwood, B. (2012). The influence of travel distance on treatment noncompletion for 
juvenile offenders. Journal of Research in Crime and Delinquency, 49(4), 572–
600. 
Lorenz, M. O. (1905). Methods of measuring the concentration of wealth. Publications of 
the American Statistical Association, 9(70), 209–219. 
Lowe, J. M., & Sen, A. (1996). GRAVITY MODEL APPLICATIONS IN HEALTH PLANNING: 
ANALYSIS OF AN URBAN HOSPITAL MARKET*. Journal of Regional Science, 36(3), 
437–461. 
Luo, J. (2014). Integrating the Huff Model and Floating Catchment Area Methods to 
Analyze Spatial Access to Healthcare Services. Transactions in GIS, 18(3), 436–
448. 
Luo, W. (2004). Using a GIS-based floating catchment method to assess areas with 
shortage of physicians. Health & Place, 10(1), 1–11. 
https://doi.org/10.1016/S1353-8292(02)00067-9 
Luo, W., & Qi, Y. (2009). An enhanced two-step floating catchment area (E2SFCA) 
method for measuring spatial accessibility to primary care physicians. Health & 
Place, 15(4), 1100–1107. https://doi.org/10.1016/j.healthplace.2009.06.002 
Luo, W., & Wang, F. (2003). Measures of spatial accessibility to health care in a GIS 
environment: synthesis and a case study in the Chicago region. Environment and 
Planning B: Planning and Design, 30(6), 865–884. 
https://doi.org/10.1068/b29120 
264 
Luo, W., & Whippo, T. (2012). Variable catchment sizes for the two-step floating 
catchment area (2SFCA) method. Health & Place, 18(4), 789–795. 
https://doi.org/10.1016/j.healthplace.2012.04.002 
Mark, T. L., Woody, G. E., Juday, T., & Kleber, H. D. (2001). The economic costs of heroin 
addiction in the United States. Drug and Alcohol Dependence, 61(2), 195–206. 
Martin, W. R., Jasinski, D. R., & Mansky, P. A. (1973). Naltrexone, an antagonist for the 
treatment of heroin dependence: Effects in man. Archives of General Psychiatry, 
28(6), 784–791. 
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2002). Buprenorphine maintenance 
versus placebo or methadone maintenance for opioid dependence. The 
Cochrane Database of Systematic Reviews, (4). 
https://doi.org/10.1002/14651858.CD002207 
McCarty, D., Priest, K. C., & Korthuis, P. T. (2018). Treatment and Prevention of Opioid 
Use Disorder: Challenges and Opportunities. Annual Review of Public Health, 
39(1), 525–541. https://doi.org/10.1146/annurev-publhealth-040617-013526 
McGrail, M. R., & Humphreys, J. S. (2009). Measuring spatial accessibility to primary care 
in rural areas: Improving the effectiveness of the two-step floating catchment 
area method. Applied Geography, 29(4), 533–541. 
https://doi.org/10.1016/j.apgeog.2008.12.003 
Merrill, J. O. (2002). Policy progress for physician treatment of opiate addiction. Journal 
of General Internal Medicine, 17(5), 361–368. 
Molfenter, T., Sherbeck, C., Zehner, M., & Starr, S. (2015). Buprenorphine Prescribing 
Availability in a Sample of Ohio Specialty Treatment Organizations. Journal of 
Addictive Behaviors, Therapy & Rehabilitation, 4(2). Retrieved from 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569134/ 
Mortimer, D., & Segal, L. (2005). Economic evaluation of interventions for problem 
drinking and alcohol dependence: cost per QALY estimates. Alcohol and 
Alcoholism, 40(6), 549–555. 
National Institute on Drug Abuse. (2017, September 15). Overdose Death Rates. 
Retrieved September 19, 2017, from https://www.drugabuse.gov/related-
topics/trends-statistics/overdose-death-rates 
Netherland, J., Botsko, M., Egan, J. E., Saxon, A. J., Cunningham, C. O., Finkelstein, R., … 
others. (2009). Factors affecting willingness to provide buprenorphine 
treatment. Journal of Substance Abuse Treatment, 36(3), 244–251. 
Ngui, A., & Apparicio, P. (2011). Optimizing the two-step floating catchment area 
method for measuring spatial accessibility to medical clinics in Montreal. BMC 
Health Services Research, 11(1), 1. 
Nicholls, S. (2001). Measuring the accessibility and equity of public parks: A case study 
using GIS. Managing Leisure, 6(4), 201–219. 
Ning, J. (2012). Improving the USDA’s Definition of Food Deserts via a Spatial Interaction 
Approach A Case Study of Hamilton County, Ohio. University of Cincinnati. 
Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1337351602 
265 
Novick, D. M., Pascarelli, E. F., Joseph, H., Salsitz, E. A., Richman, B. L., Des Jarlais, D. C., 
… Nyswander, M. E. (1988). Methadone maintenance patients in general medical 
practice: a preliminary report. JAMA, 259(22), 3299–3302. 
Nyabadza, F., & Hove-Musekwa, S. D. (2010). From heroin epidemics to 
methamphetamine epidemics: Modelling substance abuse in a South African 
province. Mathematical Biosciences, 225(2), 132–140. 
O’Connor, A. B. (2011). Nurse practitioners’ inability to prescribe buprenorphine: 
Limitations of the Drug Addiction Treatment Act of 2000. Journal of the American 
Academy of Nurse Practitioners, 23(10), 542–545. 
Office of National Drug Control Policy. (2012). What America’s Users Spend on Illegal 
Drugs, 2000-2006. Washington, D.C.: Executive Office of the President. 
Office of National Drug Control Policy. (2014). 2014 National Drug Control Strategy. 
Retrieved April 22, 2015, from https://www.whitehouse.gov/embeds/footer 
Office of National Drug Control Policy. (2015). 2015 National Drug Control Strategy. 
Retrieved November 7, 2016, from https://www.whitehouse.gov/node/287061 
Páez, A., Scott, D. M., & Morency, C. (2012). Measuring accessibility: positive and 
normative implementations of various accessibility indicators. Journal of 
Transport Geography, 25, 141–153. 
https://doi.org/10.1016/j.jtrangeo.2012.03.016 
Payte, J. T. (1997). Methadone maintenance treatment: the first thirty years. Journal of 
Psychoactive Drugs, 29(2), 149–153. 
Perez, P., Dray, A., Ritter, A., Dietze, P., Moore, T., & Mazerolle, L. (2006). SimDrug: A 
Multi-Agent System Tackling the Complexity of Illicit Drug Markets in Australia. 
Complex Science for a Complex World: Exploring Human Ecosystems with Agents, 
193. 
Peterson, D., Willard, K., Altmann, M., Gatewood, L., & Davidson, G. (1990). Monte Carlo 
simulation of HIV infection in an intravenous drug user community. JAIDS Journal 
of Acquired Immune Deficiency Syndromes, 3(11), 1086–1095. 
Phibbs, C. S., & Luft, H. S. (1995). Correlation of travel time on roads versus straight line 
distance. Medical Care Research and Review, 52(4), 532–542. 
QGIS. (2017). (Version 2.14.19-Essen). Retrieved from https://qgis.org/en/site/ 
Quest, T. L., Merrill, J. O., Roll, J., Saxon, A. J., & Rosenblatt, R. A. (2012). Buprenorphine 
therapy for opioid addiction in rural Washington: the experience of the early 
adopters. Journal of Opioid Management, 8(1). 
Reif, S., Thomas, C. P., & Wallack, S. S. (2007a). Factors determining how early adopter 
physicians use buprenorphine in treatment. Journal of Addiction Medicine, 1(4), 
205–212. https://doi.org/10.1097/ADM.0b013e31814c3fa8 
Reif, S., Thomas, C. P., & Wallack, S. S. (2007b). Factors determining how early adopter 
physicians use buprenorphine in treatment. Journal of Addiction Medicine, 1(4), 
205–212. https://doi.org/10.1097/ADM.0b013e31814c3fa8 
Roman, P. M., Abraham, A. J., & Knudsen, H. K. (2011). Using medication-assisted 
treatment for substance use disorders: evidence of barriers and facilitators of 
266 
implementation. Addictive Behaviors, 36(6), 584–589. 
https://doi.org/10.1016/j.addbeh.2011.01.032 
Roose, R. J., Kunins, H. V., Sohler, N. L., Elam, R. T., & Cunningham, C. O. (2008). Nurse 
practitioner and physician assistant interest in prescribing buprenorphine. 
Journal of Substance Abuse Treatment, 34(4), 456–459. 
Rosenblatt, R. A., Andrilla, C. H. A., Catlin, M., & Larson, E. H. (2015a). Geographic and 
Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder. The 
Annals of Family Medicine, 13(1), 23–26. 
Rosenblatt, R. A., Andrilla, C. H. A., Catlin, M., & Larson, E. H. (2015b). Geographic and 
Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder. The 
Annals of Family Medicine, 13(1), 23–26. 
Rounsaville, B. J., & Kosten, T. R. (2000). Treatment for Opioid Dependence: Quality and 
Access. JAMA, 283(10), 1337. https://doi.org/10.1001/jama.283.10.1337 
Schackman, B. R., Leff, J. A., Polsky, D., Moore, B. A., & Fiellin, D. A. (2012). Cost-
effectiveness of long-term outpatient buprenorphine-naloxone treatment for 
opioid dependence in primary care. Journal of General Internal Medicine, 27(6), 
669–676. https://doi.org/10.1007/s11606-011-1962-8 
Schackman, B. R., Merrill, J. O., McCarty, D., Levi, J., & Lubinski, C. (2006). Overcoming 
policy and financing barriers to integrated buprenorphine and HIV primary care. 
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases 
Society of America, 43 Suppl 4, S247-253. https://doi.org/10.1086/508190 
Schmitt, S. K., Phibbs, C. S., & Piette, J. D. (2003). The influence of distance on utilization 
of outpatient mental health aftercare following inpatient substance abuse 
treatment. Addictive Behaviors, 28(6), 1183–1192. 
https://doi.org/10.1016/S0306-4603(02)00218-6 
Schoenbaum, E. E., Hartel, D., Selwyn, P. A., Klein, R. S., Davenny, K., Rogers, M., … 
Friedland, G. (1989). Risk factors for human immunodeficiency virus infection in 
intravenous drug users. The New England Journal of Medicine. Retrieved from 
http://psycnet.apa.org/psycinfo/1990-07801-001 
Schuurman, N., BéRubé, M., & Crooks, V. A. (2010). Measuring potential spatial access 
to primary health care physicians using a modified gravity model. Canadian 
Geographer / Le Géographe Canadien, 54(1), 29–45. 
https://doi.org/10.1111/j.1541-0064.2009.00301.x 
Schwartz, R. P., Brooner, R. K., Montoya, I. D., Currens, M., & Hayes, M. (1999). A 12-
Year Follow-Up of a Methadone Medical Maintenance Program. The American 
Journal on Addictions, 8(4), 293–299. 
Senay, E. C., Barthwell, A. G., Marks, R., Bokos, P., Gillman, D., White, R., & Pristach, C. A. 
(1993). Medical maintenance: a pilot study. Journal of Addictive Diseases, 12(4), 
59–76. 
Sharkey, J. R., Horel, S., & Dean, W. R. (2010). Neighborhood deprivation, vehicle 
ownership, and potential spatial access to a variety of fruits and vegetables in a 
large rural area in Texas. International Journal of Health Geographics, 9(1), 26. 
267 
Shen, Q. (1998). Location characteristics of inner-city neighborhoods and employment 
accessibility of low-wage workers. Environment and Planning B: Planning and 
Design, 25(3), 345–365. 
Sohler Everingham, S. M., Peter Rydell, C., & Caulkins, J. P. (1995). Cocaine consumption 
in the United States: estimating past trends and future scenarios. Socio-Economic 
Planning Sciences, 29(4), 305–314. 
Spiser, V., & Dumolt, S. (2011). Physician Assistants’ Interest in Prescribing 
Buprenorphine for Opioid Addiction. In Proceedings of 7th Annual GRASP 
Symposium. Wichita State University. Retrieved from 
http://soar.wichita.edu/handle/10057/3617 
Stein, B. D., Gordon, A. J., Dick, A., Burns, R. M., Pacula, R., Farmer, C., & Leslie, D. 
(2015). Physician supply for the treatment of opioid use disorders: The influence 
of state policies. Drug & Alcohol Dependence, 146, e107–e108. 
Stein, B. D., Gordon, A. J., Dick, A. W., Burns, R. M., Pacula, R. L., Farmer, C. M., … 
Sorbero, M. (2015). Supply of buprenorphine waivered physicians: The influence 
of state policies. Journal of Substance Abuse Treatment, 48(1), 104–111. 
Stein, B. D., Pacula, R. L., Gordon, A. J., Burns, R. M., Leslie, D. L., Sorbero, M. J., … Dick, 
A. W. (2015). Where is buprenorphine dispensed to treat opioid use disorders? 
The role of private offices, opioid treatment programs, and substance abuse 
treatment facilities in urban and rural counties. Milbank Quarterly, 93(3), 561–
583. 
Stein BD, Sorbero M, Dick AW, Pacula R, Burns RM, & Gordon AJ. (2016). Physician 
capacity to treat opioid use disorder with buprenorphine-assisted treatment. 
JAMA, 316(11), 1211–1212. https://doi.org/10.1001/jama.2016.10542 
Stewart, J. Q. (1948). Demographic gravitation: evidence and applications. Sociometry, 
11(1/2), 31–58. 
Strobbe, S., & Hobbins, D. (2012). The prescribing of buprenorphine by advanced 
practice addictions nurses. Journal of Addictions Nursing, 23(1), 82–83. 
https://doi.org/10.3109/10884602.2011.649026 
Substance Abuse and Mental Health Services Administration. (2013a). 2011 opioid 
treatment program (OTP) survey: Data on substance abuse treatment facilities 
with OTPs. (SMA No. 14–4807). Rockville, MD: Substance Abues and Mental 
Health Services Administration. 
Substance Abuse and Mental Health Services Administration. (2013b). Results from the 
2012 National Survey on Drug Use and Health: Summary of National Findings. 
Substance Abuse and Mental Health Services  Administration. Retrieved from 
http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFin
dings/NSDUHresults2012.pdf 
Substance Abuse and Mental Health Services Administration. (2014a). National Survey 
of Substance Abuse Treatment Services (N-SSATS): 2013. Data on Substance 
Abuse Treatment Facilities (BHSIS Series S-73 No. HHS Publication No. (SMA) 14-
4890). Rockville, MD: Substance Abuse and Mental Health Services 
268 
Administration. Retrieved from 
http://www.samhsa.gov/data/sites/default/files/2013_N-
SSATS_National_Survey_of_Substance_Abuse_Treatment_Services/2013_N-
SSATS_National_Survey_of_Substance_Abuse_Treatment_Services_Tables.html#
Tbl3.1 
Substance Abuse and Mental Health Services Administration. (2014b). Results from the 
2013 National Survey on Drug Use and Health: Summary of National Findings 
(NSDUH Series H-48 No. HHS Publication No. (SMA) 14-4863). Rockville, MD: 
Substance Abuse and Mental Health Services Administration. 
Substance Abuse and Mental Health Services Administration. (2014c, September 22). 
2014 Buprenorphine Summit: Report of Proceedings. US Department of Health 
and Human Services. Retrieved from 
http://www.samhsa.gov/sites/default/files/proceedings_of_2014_buprenorphin
e_summit_030915_508.pdf 
Substance Abuse and Mental Health Services Administration. (2016a). Medication 
Assisted Treatment for Opioid Use Disorders (Rule No. 81 FR 44711) (pp. 44711–
44739). Substance Abuse and Mental Health Services Administration. Retrieved 
from https://www.federalregister.gov/documents/2016/07/08/2016-
16120/medication-assisted-treatment-for-opioid-use-disorders 
Substance Abuse and Mental Health Services Administration. (2016b, August 10). 
Number of DATA-Certified Physicians. Retrieved August 10, 2016, from 
http://www.samhsa.gov/medication-assisted-treatment/physician-program-
data/certified-physicians?field_bup_us_state_code_value=All 
Substance Abuse and Mental Health Services Administration. (2017). Results from the 
2016 National Survey on Drug Use and Health. Bethesda, MD. Retrieved from 
https://www.samhsa.gov/sites/default/files/sites/default/files/2016_ffr_1_slide
show_v5.pdf 
Substance Abuse and Mental Health Services Administration. (2018, January 18). 
Physician and Program Data. Retrieved May 23, 2018, from 
http://www.samhsa.gov/programs-campaigns/medication-assisted-
treatment/physician-program-data 
Sullivan, L. E., Chawarski, M., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2005). 
The practice of office-based buprenorphine treatment of opioid dependence: is 
it associated with new patients entering into treatment? Drug and Alcohol 
Dependence, 79(1), 113–116. 
Talen, E., & Anselin, L. (1998). Assessing spatial equity: an evaluation of measures of 
accessibility to public playgrounds. Environment and Planning A, 30(4), 595–613. 
Thomas, C. P., Reif, S., Haq, S., Wallack, S. S., Hoyt, A., & Ritter, G. A. (2008). Use of 
buprenorphine for addiction treatment: perspectives of addiction specialists and 
general psychiatrists. Psychiatric Services (Washington, D.C.), 59(8), 909–916. 
https://doi.org/10.1176/appi.ps.59.8.909 
269 
Thorpe, L. E., Ouellet, L. J., Hershow, R., Bailey, S. L., Williams, I. T., Williamson, J., … 
Garfein, R. S. (2002). Risk of hepatitis C virus infection among young adult 
injection drug users who share injection equipment. American Journal of 
Epidemiology, 155(7), 645–653. 
Timothy P. Lepak. (2014, June). Patient matching system frequently asked questions. 
Retrieved September 18, 2015, from 
http://www.treatmentmatch.org/patients/patient_faq.cfm#p1a 
Tomintz, M. (2009). Modelling Best Locations for Stop Smoking Services at the Small 
Area Level in Leeds, UK. Retrieved from 
http://www.agit.at/php_files/myagit/papers/2009/7488.pdf 
U.S. Department of Health and Human Services, Health Resources and Services 
Administration. (2016a). Health Professional Shortage Areas (HPSAs): 
Designation Criteria and Guidelines. Retrieved September 26, 2016, from 
http://bhpr.hrsa.gov/shortage/hpsas/designationcriteria/index.html 
U.S. Department of Health and Human Services, Health Resources and Services 
Administration. (2016b). Medically Underserved Areas/Populations: Guidelines 
for MUA and MUP Designation. Retrieved September 26, 2016, from 
http://www.hrsa.gov/shortage/mua/index.html 
US Drug Enforcement Administration, Office of Diversion Control. (2013). National 
Forensic Laboratory Information System 2013 Annual Report (National Forensic 
Laboratory Information System). SpringField, VA: US Department of Justice, Drug 
Enforcement Administration. 
Ver Ploeg, M., Dutko, P., & Breneman, V. (2014). Measuring Food Access and Food 
Deserts for Policy Purposes. Applied Economic Perspectives and Policy, ppu035. 
Volkow, N. D., Fowler, J. S., & Wang, G.-J. (2004). The addicted human brain viewed in 
the light of imaging studies: brain circuits and treatment strategies. 
Neuropharmacology, 47, 3–13. 
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-Assisted 
Therapies — Tackling the Opioid-Overdose Epidemic. New England Journal of 
Medicine, 370(22), 2063–2066. https://doi.org/10.1056/NEJMp1402780 
Volkow, N. D., & Li, T.-K. (2004). Drug addiction: the neurobiology of behaviour gone 
awry. Nature Reviews Neuroscience, 5(12), 963–970. 
Wakeland, W., Nielsen, A., & Geissert, P. (2015). Dynamic model of nonmedical opioid 
use trajectories and potential policy interventions. The American Journal of Drug 
and Alcohol Abuse, 41(6), 508–518. 
Wakeland, W., Nielsen, A., Schmidt, T. D., McCarty, D., Webster, L. R., Fitzgerald, J., & 
Haddox, J. D. (2013). Modeling the Impact of Simulated Educational 
Interventions on the Use and Abuse of Pharmaceutical Opioids in the United 
States A Report on Initial Efforts. Health Education & Behavior, 40(1 suppl), 74S–
86S. 
270 
Walker, R. E., Keane, C. R., & Burke, J. G. (2010). Disparities and access to healthy food in 
the United States: A review of food deserts literature. Health & Place, 16(5), 
876–884. 
Wan, N., Zhan, F. B., Zou, B., & Chow, E. (2012). A relative spatial access assessment 
approach for analyzing potential spatial access to colorectal cancer services in 
Texas. Applied Geography, 32(2), 291–299. 
Wan, N., Zou, B., & Sternberg, T. (2012). A three-step floating catchment area method 
for analyzing spatial access to health services. International Journal of 
Geographical Information Science, 26(6), 1073–1089. 
Wang, F. (2012). Measurement, Optimization, and Impact of Health Care Accessibility: A 
Methodological Review. Annals of the Association of American Geographers, 
102(5), 1104–1112. https://doi.org/10.1080/00045608.2012.657146 
Wang, F., & Tang, Q. (2013). Planning toward Equal Accessibility to Services: A Quadratic 
Programming Approach. Environment and Planning B: Planning and Design, 
40(2), 195–212. https://doi.org/10.1068/b37096 
Were, D. L. (2014). Advanced Nurses’ Perspectives on the Drug Addiction Treatment Act, 
13 Years Later. WALDEN UNIVERSITY. Retrieved from 
http://scholarworks.waldenu.edu/cgi/viewcontent.cgi?article=1078&context=dis
sertations 
West, J. C., Kosten, T. R., Wilk, J., Svikis, D., Triffleman, E., Rae, D. S., … Regier, D. A. 
(2004). Challenges in increasing access to buprenorphine treatment for opiate 
addiction. The American Journal on Addictions / American Academy of 
Psychiatrists in Alcoholism and Addictions, 13 Suppl 1, S8-16. 
https://doi.org/10.1080/10550490490440753 
WESTAT, & The Avisa Group. (2006). The SAMHSA Evaluation of the impact of the DATA 
waiver program: Summary report. 
White, E., & Comiskey, C. (2007). Heroin epidemics, treatment and ODE modelling. 
Mathematical Biosciences, 208(1), 312–324. 
Wilenski, U., & others. (1999). Netlogo. Center for Connected Learning and Computer-
Based Modeling. 
Wisniewski, A. M., Dlugosz, M. R., & Blondell, R. D. (2013). Reimbursement and practice 
policies among providers of buprenorphine-naloxone treatment. Substance 
Abuse : Official Publication of the Association for Medical Education and 
Research in Substance Abuse, 34(2), 105–107. 
https://doi.org/10.1080/08897077.2012.677753 
Yang, D.-H., Goerge, R., & Mullner, R. (2006). Comparing GIS-based methods of 
measuring spatial accessibility to health services. Journal of Medical Systems, 
30(1), 23–32. 
Yücel, G., & van Daalen, E. (2009). An objective-based perspective on assessment of 
model-supported policy processes. Journal of Artificial Societies and Social 
Simulation, 12(4), 3. 
271 
Zarkin, G. A., Cowell, A. J., Hicks, K. A., Mills, M. J., Belenko, S., Dunlap, L. J., … Keyes, V. 
(2011). Benefits and costs of substance abuse treatment programs for state 
prison inmates: results from a lifetime simulation model. Health Economics. 
Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/hec.1735/full 
Zarkin, G. A., Dunlap, L. J., Hicks, K. A., & Mamo, D. (2005). Benefits and costs of 
methadone treatment: results from a lifetime simulation model. Health 
Economics, 14(11), 1133–1150. 
  
272 
Appendix A Patient Willingness to Travel Based on Zip Code 2006-May 2013 
The histograms below chart frequency of stated willingness to travel in 5 mile 
increments for residents who live in regions with population densities within the stated 
range.  People who used the NAABT.org physician locator website entered information 
about themselves including zip code, age and email address to the website, and might 
be contacted directly by buprenorphine providers.  I received de-identified data, and 
grouped individuals according to the population density of their zip code.  I then 
generated histograms of miles willing to travel for different population density ranges.  
Rather than fitting histograms with probability distributions, I used them directly in 
simulation because several distributions were multimodal. 
 
Figure A-1: Miles willing to travel for people residing in areas with population density > 5000 
people/square mile 
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Figure A-2: Miles willing to travel for people residing in areas with population density 2500-5000 
people/square mile 
 
Figure A-3: Miles willing to travel for people residing in areas with population density 1000-2500 
people/square mile 
 
Figure A-4: Miles willing to travel for people residing in areas with population density 500-1000 
people/square mile 
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Figure A-5: Miles willing to travel for people residing in areas with population density 250-500 
people/square mile 
 
Figure A-6: Miles willing to travel for people residing in areas with population density 100-250 
people/square mile 
 
Figure A-7: Miles willing to travel for people residing in areas with population density 50-100 
people/square mile 
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Figure A-8: Miles willing to travel for people residing in areas with population density 25-50 people/square 
mile 
 
Figure A-9: Miles willing to travel for people residing in areas with population density 10-25 people/square 
mile 
 
Figure A-10: Miles willing to travel for people residing in areas with population density 0-10 people/square 
mile
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 Model code 
 Code tab 
__includes ["GeoSetup1.nls" "ProviderSetup1.nls" "PtSetup1.nls" 
"Declarations1.nls" "ProviderGo1.nls" "PtGo1.nls"  "Reporters1.nls"  
"SetupCommands1.nls" "GoCommands1.nls" "otp1.nls" ] 
 
;;;;;;;;;;;;;;;;;;;;;;; 
;;; SETUP PROCEDURES ;; 
;;;;;;;;;;;;;;;;;;;;;;; 
 
to setup 
  clear-all 
  setup-globals 
  set-initials 
  setup-geography 
  setup-OTPs 
  setup-providers 
  ask OTPs [init-OTPs] 
  set-capacity 
  if equity-experiments = "high-capacity-provider-closure"[ 
    repeat large-capacity-n[ 
      ask one-of real-providers with-max [total-capacity] 
      [ 
        set total-capacity 0 
      ] 
    ] 
  ] 
  if equity-experiments = "rural-provider-closure"[ 
    let rxing-providers real-providers with [total-capacity > 0] 
    repeat rural-provider-n [ 
      ask one-of rxing-providers with-min [[pop-den] of patch-here] 
      [ 
        set total-capacity 0 
        die 
      ] 
    ] 
  ] 
  if double-capacity?[ 
    ask real-providers [set total-capacity 2 * total-capacity] 
  ] 
  setup-people 
  set lorenz-with-weights-2SFCA [] 
  set lorenz-with-weights-E2SFCA [] 
  set lorenz-with-weights-logistic [] 
  set lorenz-with-weights-gaussian [] 
  set lorenz-with-weights-exponential [] 
  set gini-index-weights-2SFCA 0 
  set gini-index-weights-E2SFCA 0 
  set gini-index-weights-logistic 0 
  set gini-index-weights-gaussian 0 
  set gini-index-weights-exponential 0 
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  if gini-at-setup? [ 
  do-gini 
  ] 
  reset-ticks 
end 
 
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;; 
;;; GO PROCEDURES                   ;; 
;;; walk through time week by week. ;; 
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;; 
to go 
  tick 
;set testlist[] 
  do-street-market 
  grow-deps 
  chance-OD 
  if model-year = 2016 and ticks = 34 [set high-cap 275 ask real-providers 
[if patients-per-provider > 100[set capped-patients-per-provider min list 
patients-per-provider high-cap set total-capacity capped-patients-per-
provider + MTH-spots ]]] 
  if model-year = 2015 and ticks = 85 [set high-cap 275 ask real-providers 
[if patients-per-provider > 100[set capped-patients-per-provider min list 
patients-per-provider high-cap set total-capacity capped-patients-per-
provider + MTH-spots]]] 
  age-patients 
  age-providers 
  compute-IQR 
  if ticks = 59 or ticks = 111  [ 
    do-gini 
  ] 
  reset-flagged-vars 
end 
 
 
 
 
to do-gini 
  do-two-step 
 
  do-lorenz-2SFCA 
  do-lorenz-E2SFCA 
  do-lorenz-logistic 
  do-lorenz-gaussian 
  do-lorenz-exponential 
 
  update-plots 
end 
 
to do-two-step 
  do-step-one 
  do-step-two 
 
 do-step-one-E2SFCA 
 do-step-two-E2SFCA 
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end 
 
to do-step-one 
;  print "2SFCA" 
  ask real-providers [ 
    let sum-of-weights-2SFCA 0 
    let sum-of-weights-logistic 0 
   let sum-of-weights-gaussian 0 
    let sum-of-weights-exponential 0 
    let catchment-deps nobody 
    let current-dep nobody 
    set catchment-deps deps with [my-travel-distance > distance myself] 
 
 
    ask catchment-deps[ 
      let my-weight-2SFCA 1 
      let my-weight-logistic 1 - (1 / (1 + e ̂  ((-10 / my-travel-distance) 
* ((distance myself) - (my-travel-distance / 2))))) 
      let my-weight-gaussian e ^ ( - ((distance myself) * (distance 
myself)/(0.3 * my-travel-distance * my-travel-distance))) 
      let my-weight-exponential e ^ ( - (distance myself) / (.3 * my-
travel-distance)) 
      set sum-of-weights-2SFCA sum-of-weights-2SFCA +  my-weight-2SFCA 
      set sum-of-weights-logistic sum-of-weights-logistic + my-weight-
logistic 
      set sum-of-weights-gaussian sum-of-weights-gaussian + my-weight-
gaussian 
      set sum-of-weights-exponential sum-of-weights-exponential + my-
weight-exponential 
    ] 
    ifelse sum-of-weights-2SFCA != 0 [ 
      set weighted-ratio-2SFCA total-capacity / sum-of-weights-2SFCA 
    ] 
    [ 
      set weighted-ratio-2SFCA 0 
    ] 
    ifelse sum-of-weights-logistic != 0 [ 
      set weighted-ratio-logistic total-capacity / sum-of-weights-
logistic 
    ] 
    [ 
      set weighted-ratio-logistic 0 
    ] 
    ifelse sum-of-weights-gaussian != 0 [ 
      set weighted-ratio-gaussian total-capacity / sum-of-weights-
gaussian 
    ] 
    [ 
      set weighted-ratio-gaussian 0 ;show "no-demand" 
    ] 
    ifelse sum-of-weights-exponential != 0 [ 
      set weighted-ratio-exponential total-capacity / sum-of-weights-
exponential 
    ] 
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    [ 
      set weighted-ratio-exponential 0 ;show "no-demand" 
    ] 
  ] 
end 
 
to do-step-one-E2SFCA 
   ask real-providers [ 
    let sum-of-weights-E2SFCA 0 
    let catchment-deps nobody 
    let current-dep nobody 
    set catchment-deps deps with [distance myself < 60] 
 
    ask catchment-deps[ 
      let my-weight-E2SFCA 1 
      if distance myself < 60[ 
        set my-weight-E2SFCA .123 
      ] 
      if distance myself < 30[ 
        set my-weight-E2SFCA .6 
      ] 
      if distance myself < 10[ 
        set my-weight-E2SFCA 1 
      ] 
      set sum-of-weights-E2SFCA sum-of-weights-E2SFCA +  my-weight-E2SFCA 
    ] 
    ifelse sum-of-weights-E2SFCA != 0 [ 
      set weighted-ratio-E2SFCA total-capacity / sum-of-weights-E2SFCA 
    ] 
    [ 
      set weighted-ratio-E2SFCA 0 ;show "no-demand" 
    ] 
  ] 
end 
 
to do-step-two-E2SFCA 
  ask deps[ 
    set reachable-providers real-providers with [distance myself < 60] 
    let my-weight-E2SFCA 1 
    set weighted-sum-of-ratios-E2SFCA 0 
    let current-provider nobody 
    ask reachable-providers[ 
      let my-dist distance myself 
      ask myself [ 
        if my-dist < 60[ 
          set my-weight-E2SFCA .123 
        ] 
        if my-dist < 30[ 
          set my-weight-E2SFCA .6 
        ] 
        if my-dist < 10[ 
          set my-weight-E2SFCA 1 
        ] 
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        set weighted-sum-of-ratios-E2SFCA weighted-sum-of-ratios-E2SFCA 
+ ([weighted-ratio-E2SFCA] of myself * my-weight-E2SFCA) 
 
      ] 
    ] 
  ] 
end 
 
 
to do-step-two 
  ask deps[ 
    set reachable-providers real-providers with [distance myself < [my-
travel-distance] of myself] 
 
    let my-weight-2SFCA 1 
    let my-weight-logistic 1 
    let my-weight-gaussian 1 
    let my-weight-exponential 1 
    set weighted-sum-of-ratios-2SFCA 0 
    set weighted-sum-of-ratios-logistic 0 
    set weighted-sum-of-ratios-gaussian 0 
    set weighted-sum-of-ratios-exponential 0 
    let current-provider nobody 
    ask reachable-providers[ 
      let my-dist distance myself 
      ask myself [ 
        set my-weight-logistic 1 - (1 / (1 + e ^ ((-10 / my-travel-
distance) * ((my-dist) - (my-travel-distance / 2))))) 
        set my-weight-gaussian e ^ ( - ((distance myself) * (distance 
myself)/(0.3 * my-travel-distance * my-travel-distance))) 
        set my-weight-exponential e ^ ( - (distance myself) / (.3 * my-
travel-distance)) 
        set weighted-sum-of-ratios-2SFCA weighted-sum-of-ratios-2SFCA + 
([weighted-ratio-2SFCA] of myself * my-weight-2SFCA) 
        set weighted-sum-of-ratios-logistic weighted-sum-of-ratios-
logistic + ([weighted-ratio-logistic] of myself * my-weight-logistic) 
        set weighted-sum-of-ratios-gaussian weighted-sum-of-ratios-
gaussian + ([weighted-ratio-gaussian] of myself * my-weight-gaussian) 
        set weighted-sum-of-ratios-exponential weighted-sum-of-ratios-
exponential + ([weighted-ratio-exponential] of myself * my-weight-
exponential) 
 
      ] 
    ] 
  ] 
end 
 
to do-lorenz-2SFCA 
  let num-patients (count deps) 
  let sorted-ratios sort [weighted-sum-of-ratios-2SFCA] of deps 
  let total-ratios sum sorted-ratios 
  let ratio-sum-so-far 0 
  let index 0 
  set gini-index-weights-2SFCA 0 
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  set lorenz-with-weights-2SFCA [] 
  repeat num-patients[ 
   set ratio-sum-so-far (ratio-sum-so-far + item index sorted-ratios) 
   set lorenz-with-weights-2SFCA lput ((ratio-sum-so-far / total-ratios) 
* 100) lorenz-with-weights-2SFCA 
   set index (index + 1) 
   set gini-index-weights-2SFCA gini-index-weights-2SFCA + (index / num-
patients) - (ratio-sum-so-far / total-ratios ) 
  ] 
  set gini-index-weights-2SFCA (gini-index-weights-2SFCA / num-patients) 
* 2 
end 
 
to do-lorenz-logistic 
  let num-patients (count deps) 
  let sorted-ratios sort [weighted-sum-of-ratios-logistic] of deps 
  let sorted-deps [] 
  if show-log-map? [ 
    set sorted-deps sort-on [weighted-sum-of-ratios-logistic] deps 
    ask patches [set pcolor black] 
    ask otps [set shape "circle" set size 2 set color white] 
    ask providers [set shape "circle" set size 2 set color white] 
  ] 
  let total-ratios sum sorted-ratios 
  ;show total-ratios 
  let ratio-sum-so-far 0 
  let prev-ratio-sum-so-far 0 
  let index 0 
  set gini-index-weights-logistic 0 
  set lorenz-with-weights-logistic [] 
  repeat num-patients[ 
   set ratio-sum-so-far (ratio-sum-so-far + item index sorted-ratios) 
   set lorenz-with-weights-logistic lput ((ratio-sum-so-far / total-
ratios) * 100) lorenz-with-weights-logistic 
      if show-log-map?[ 
      ask item index sorted-deps 
      [ 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients = 0 ) [set size 3 set color red] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= .25 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > 0) [set size 3 set color ORANGE] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= .5 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > .25) [set size 3 set color brown] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= .9 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > .5) [set size 3 set color yellow] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 1.1 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > .9) [set size 3 set color green] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 1.25 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > 1.1) [set size 3 set color turquoise] 
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        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 1.5 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > 1.25) [set size 3 set color cyan] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 2 and (ratio-sum-so-far - prev-ratio-sum-so-far) / total-
ratios  * num-patients > 1.5) [set size 3 set color sky ] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients > 2) [set size 3 set color blue] 
 
        if (ratio-sum-so-far / total-ratios < 1) [set decile 10] 
        if (ratio-sum-so-far / total-ratios < .9) [set decile 9] 
        if (ratio-sum-so-far / total-ratios < .8) [set decile 8] 
        if (ratio-sum-so-far / total-ratios < .7) [set decile 7] 
        if (ratio-sum-so-far / total-ratios < .6) [set decile 6] 
        if (ratio-sum-so-far / total-ratios < .5) [set decile 5] 
        if (ratio-sum-so-far / total-ratios < .4) [set decile 4] 
        if (ratio-sum-so-far / total-ratios < .3) [set decile 3] 
        if (ratio-sum-so-far / total-ratios < .2) [set decile 2] 
        if (ratio-sum-so-far / total-ratios < .1) [set decile 1] 
 
      ] 
   ] 
   set prev-ratio-sum-so-far ratio-sum-so-far 
   set index (index + 1) 
   set gini-index-weights-logistic gini-index-weights-logistic + (index 
/ num-patients) - (ratio-sum-so-far / total-ratios ) 
  ] 
  set gini-index-weights-logistic (gini-index-weights-logistic / num-
patients) * 2 
   if show-log-map?[ 
    show word "1st " (precision (count deps with [decile = 1] / count 
deps) 3) 
    show word "2nd " (precision (count deps with [decile = 2] / count 
deps) 3) 
    show word "3rd " (precision (count deps with [decile = 3] / count 
deps) 3) 
    show word "4th " (precision (count deps with [decile = 4] / count 
deps) 3) 
    show word "5th " (precision (count deps with [decile = 5] / count 
deps) 3) 
    show word "6th " (precision (count deps with [decile = 6] / count 
deps) 3) 
    show word "7th " (precision (count deps with [decile = 7] / count 
deps) 3) 
    show word "8th " (precision (count deps with [decile = 8] / count 
deps) 3) 
    show word "9th " (precision (count deps with [decile = 9] / count 
deps) 3) 
    show word "10th " (precision (count deps with [decile = 10] / count 
deps) 3) 
  ] 
end 
 
to do-lorenz-gaussian 
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  let num-patients (count deps) 
  let sorted-ratios sort [weighted-sum-of-ratios-gaussian] of deps 
  let sorted-deps [] 
  if show-gaussian-map? [ 
    set sorted-deps sort-on [weighted-sum-of-ratios-gaussian] deps 
    ask patches [set pcolor black] 
    ask otps [set shape "circle" set size 2 set color white] 
    ask providers [set shape "circle" set size 2 set color white] 
  ] 
  let total-ratios sum sorted-ratios 
  ;show total-ratios 
  let ratio-sum-so-far 0 
  let prev-ratio-sum-so-far 0 
  let index 0 
  set gini-index-weights-gaussian 0 
  set lorenz-with-weights-gaussian [] 
  repeat num-patients[ 
   set ratio-sum-so-far (ratio-sum-so-far + item index sorted-ratios) 
   set lorenz-with-weights-gaussian lput ((ratio-sum-so-far / total-
ratios) * 100) lorenz-with-weights-gaussian 
    if show-gaussian-map?[ 
      ask item index sorted-deps 
      [ 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients = 0 ) [set size 3 set color red] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= .25 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > 0) [set size 3 set color ORANGE] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= .5 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > .25) [set size 3 set color brown] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= .9 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > .5) [set size 3 set color yellow] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 1.1 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > .9) [set size 3 set color green] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 1.25 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > 1.1) [set size 3 set color turquoise] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 1.5 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > 1.25) [set size 3 set color cyan] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 2 and (ratio-sum-so-far - prev-ratio-sum-so-far) / total-
ratios  * num-patients > 1.5) [set size 3 set color sky ] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients > 2) [set size 3 set color blue] 
 
        if (ratio-sum-so-far / total-ratios < 1) [set decile 10] 
        if (ratio-sum-so-far / total-ratios < .9) [set decile 9] 
        if (ratio-sum-so-far / total-ratios < .8) [set decile 8] 
        if (ratio-sum-so-far / total-ratios < .7) [set decile 7] 
        if (ratio-sum-so-far / total-ratios < .6) [set decile 6] 
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        if (ratio-sum-so-far / total-ratios < .5) [set decile 5] 
        if (ratio-sum-so-far / total-ratios < .4) [set decile 4] 
        if (ratio-sum-so-far / total-ratios < .3) [set decile 3] 
        if (ratio-sum-so-far / total-ratios < .2) [set decile 2] 
        if (ratio-sum-so-far / total-ratios < .1) [set decile 1] 
      ] 
    ] 
    set prev-ratio-sum-so-far ratio-sum-so-far 
    set index (index + 1) 
    set gini-index-weights-gaussian gini-index-weights-gaussian + (index 
/ num-patients) - (ratio-sum-so-far / total-ratios ) 
  ] 
  set gini-index-weights-gaussian (gini-index-weights-gaussian / num-
patients) * 2 
    if show-gaussian-map?[ 
    show word "1st " (precision (count deps with [decile = 1] / count 
deps) 3) 
    show word "2nd " (precision (count deps with [decile = 2] / count 
deps) 3) 
    show word "3rd " (precision (count deps with [decile = 3] / count 
deps) 3) 
    show word "4th " (precision (count deps with [decile = 4] / count 
deps) 3) 
    show word "5th " (precision (count deps with [decile = 5] / count 
deps) 3) 
    show word "6th " (precision (count deps with [decile = 6] / count 
deps) 3) 
    show word "7th " (precision (count deps with [decile = 7] / count 
deps) 3) 
    show word "8th " (precision (count deps with [decile = 8] / count 
deps) 3) 
    show word "9th " (precision (count deps with [decile = 9] / count 
deps) 3) 
    show word "10th " (precision (count deps with [decile = 10] / count 
deps) 3) 
  ] 
end 
 
to do-lorenz-exponential 
  let num-patients (count deps) 
  let sorted-ratios sort [weighted-sum-of-ratios-exponential] of deps 
  let total-ratios sum sorted-ratios 
  ;show total-ratios 
  let ratio-sum-so-far 0 
  let index 0 
  set gini-index-weights-exponential 0 
  set lorenz-with-weights-exponential [] 
  repeat num-patients[ 
   set ratio-sum-so-far (ratio-sum-so-far + item index sorted-ratios) 
   set lorenz-with-weights-exponential lput ((ratio-sum-so-far / total-
ratios) * 100) lorenz-with-weights-exponential 
   set index (index + 1) 
   set gini-index-weights-exponential gini-index-weights-exponential + 
(index / num-patients) - (ratio-sum-so-far / total-ratios ) 
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  ] 
  set gini-index-weights-exponential (gini-index-weights-exponential / 
num-patients) * 2 
end 
 
to do-lorenz-E2SFCA 
  let num-patients (count deps) 
  let sorted-ratios sort [weighted-sum-of-ratios-E2SFCA] of deps 
  let sorted-deps [] 
  if show-e2-map? [ 
    set sorted-deps sort-on [weighted-sum-of-ratios-E2SFCA] deps 
    ask patches [set pcolor black] 
    ask otps [set shape "circle" set size 2 set color white] 
    ask providers [set shape "circle" set size 2 set color white] 
  ] 
  let total-ratios sum sorted-ratios 
  let ratio-sum-so-far 0 
  let prev-ratio-sum-so-far 0 
  let index 0 
  set gini-index-weights-E2SFCA 0 
  set lorenz-with-weights-E2SFCA [] 
  repeat num-patients[ 
   set ratio-sum-so-far (ratio-sum-so-far + item index sorted-ratios) 
   set lorenz-with-weights-E2SFCA lput ((ratio-sum-so-far / total-ratios) 
* 100) lorenz-with-weights-E2SFCA 
   if show-e2-map?[ 
      ask item index sorted-deps 
      [ 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients = 0 ) [set size 3 set color red] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= .25 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > 0) [set size 3 set color ORANGE] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= .5 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > .25) [set size 3 set color brown] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= .9 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > .5) [set size 3 set color yellow] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 1.1 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > .9) [set size 3 set color green] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 1.25 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > 1.1) [set size 3 set color turquoise] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 1.5 and (ratio-sum-so-far - prev-ratio-sum-so-far) / 
total-ratios  * num-patients > 1.25) [set size 3 set color cyan] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients <= 2 and (ratio-sum-so-far - prev-ratio-sum-so-far) / total-
ratios  * num-patients > 1.5) [set size 3 set color sky ] 
        if ((ratio-sum-so-far - prev-ratio-sum-so-far) / total-ratios  * 
num-patients > 2) [set size 3 set color blue] 
 
287 
        if (ratio-sum-so-far / total-ratios < 1) [set decile 10] 
        if (ratio-sum-so-far / total-ratios < .9) [set decile 9] 
        if (ratio-sum-so-far / total-ratios < .8) [set decile 8] 
        if (ratio-sum-so-far / total-ratios < .7) [set decile 7] 
        if (ratio-sum-so-far / total-ratios < .6) [set decile 6] 
        if (ratio-sum-so-far / total-ratios < .5) [set decile 5] 
        if (ratio-sum-so-far / total-ratios < .4) [set decile 4] 
        if (ratio-sum-so-far / total-ratios < .3) [set decile 3] 
        if (ratio-sum-so-far / total-ratios < .2) [set decile 2] 
        if (ratio-sum-so-far / total-ratios < .1) [set decile 1] 
      ] 
   ] 
   set index (index + 1) 
    set prev-ratio-sum-so-far ratio-sum-so-far 
   set gini-index-weights-E2SFCA gini-index-weights-E2SFCA + (index / 
num-patients) - (ratio-sum-so-far / total-ratios ) 
  ] 
  if show-e2-map?[ 
  show word "1st " (precision (count deps with [decile = 1] / count deps) 
3) 
  show word "2nd " (precision (count deps with [decile = 2] / count deps) 
3) 
  show word "3rd " (precision (count deps with [decile = 3] / count deps) 
3) 
  show word "4th " (precision (count deps with [decile = 4] / count deps) 
3) 
  show word "5th " (precision (count deps with [decile = 5] / count deps) 
3) 
  show word "6th " (precision (count deps with [decile = 6] / count deps) 
3) 
  show word "7th " (precision (count deps with [decile = 7] / count deps) 
3) 
  show word "8th " (precision (count deps with [decile = 8] / count deps) 
3) 
  show word "9th " (precision (count deps with [decile = 9] / count deps) 
3) 
  show word "10th " (precision (count deps with [decile = 10] / count 
deps) 3) 
  ] 
  set gini-index-weights-E2SFCA (gini-index-weights-E2SFCA / num-
patients) * 2 
end 
 
to compute-IQR 
  let nonOTPproviders providers with [otp-doc? = false] 
  let RxingnonOTPproviders nonOTPproviders with [(count BUP-patients + 
count tele-patients) > 0] 
  let sortedDocList sort-on [count tele-patients + count BUP-patients] 
RxingnonOTPproviders 
  let firstQIndex round (length sortedDocList / 4) - 1 
  let thirdQIndex round (length sortedDocList * .75) - 1 
  let medianIndex round (length sortedDocList / 2) - 1 
  let firstDoc item firstQIndex sortedDocList 
  let thirdDoc item thirdQIndex sortedDocList 
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  let medianDoc item medianIndex sortedDocList 
 
  set firstQuartile [count tele-patients + count BUP-patients] of 
firstDoc 
  set thirdQuartile [count tele-patients + count BUP-patients] of 
thirdDoc 
  set medianPts [(count BUP-patients + count tele-patients)] of medianDoc 
  set OneToThree round (100 * count RxingnonOTPproviders with [(count 
BUP-patients + count tele-patients) > 0 and (count BUP-patients + count 
tele-patients) < 4] / (count RxingnonOTPproviders)) 
  set FourTo30 round (100 * count RxingnonOTPproviders with [(count BUP-
patients + count tele-patients) >= 4 and (count BUP-patients + count tele-
patients) <= 30] / (count RxingnonOTPproviders)) 
  set ThirtyoneTo75 round (100 * count RxingnonOTPproviders with [(count 
BUP-patients + count tele-patients) >= 31 and (count BUP-patients + count 
tele-patients) <= 75] / (count RxingnonOTPproviders)) 
  set MoreThan75 round (100 * count RxingnonOTPproviders with [(count 
BUP-patients + count tele-patients) >= 76] / (count 
RxingnonOTPproviders)) 
end 
 
 Declarations.nls 
breed [providers provider] 
breed[deps dep] 
breed[OTPs OTP] 
 
globals[ 
  filename 
  lorenz-points 
  untreated-dependent  
  open-capacity 
  number-docs 
  number-patients 
  max-patch-density 
  total-number-dependent 
  weekly-add-docs 
  weekly-add-APN 
  dead-number 
  diverted-medicine 
  all-insurance 
  gini-index-reserve 
  ods-deps 
  ods-pats 
  in-tx 
  n 
  men 
  women  
  gini-index-weights-2SFCA 
  gini-index-weights-E2SFCA 
  gini-index-weights-logistic 
  gini-index-weights-gaussian 
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  gini-index-weights-exponential 
  lorenz-with-weights-2SFCA 
  lorenz-with-weights-E2SFCA 
  lorenz-with-weights-logistic 
  lorenz-with-weights-gaussian 
  lorenz-with-weights-exponential  
  firstQuartile 
  thirdQuartile 
  medianPts 
  OneToThree 
  FourTo30 
  ThirtyOneto75 
  MoreThan75 
  dummy-doc 
  rural-areas 
  small-cities 
  large-cities 
  patches-with-pills 
  initial-pct-patients-in-tx 
  low-spec 
  high-spec 
  non-high-list 
  non-low-list 
  non-low-nolist 
  low-spec-random 
  high-spec-random 
  non-high-list-random 
  non-low-list-random 
  non-low-nolist-random 
  pa-pop 
  pa-pcp-pct 
  dep-incidence 
  seeking-incidence 
  initial-pct-deps-seeking-or-in-tx 
  remote-dep-pct 
  np-pop 
  np-pcp-pct 
  MUA-pct 
  remote-pct 
  APN-discount 
  lowest-cost 
  APN-random 
  small-city-pct 
  rural-threshold 
  small-city-threshold 
  divertAfford 
  wanted$ 
  percentSayYes 
  colleague-radius 
  rural-dep-pct 
  pct-of-income 
  pct-poverty 
  pct-twox-poverty 
  coinsurance-base 
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  coinsurance-random 
  never-abstain-pct 
  abstinence-floor 
  abstinence-mean 
  dose-sixteen 
  dose-eight 
  dose-tfour 
  mth-cost 
  pct-try-bup-first 
  mth-weekly-quit-rate 
  first-week-bup-quit 
  second-week-bup-quit 
  show-street-market? 
  my-wait-time 
  total-population 
  docs-per-pop 
  pts-dependent 
  poverty-level 
  female-pct 
  num-otps 
  va-pct 
  gvt-pct 
  pnp-pct 
  ods-pts-in-tx 
  post-tx-die 
] 
 
providers-own [ 
  patients-per-provider           
  capped-patients-per-provider    
  BUP-years                       
  wait-list                      
  colleagues                      
  specialist?                     
  onList?                         
  Rxing?                          
  CapHigh?                        
  willAdd?                        
  provider-type                   
  accepted-insurance-list 
  visit-cost 
  OTP-doc? 
  MTH-spots 
  total-capacity 
  no-pay? 
  do-telemedicine? 
  weighted-ratio-2SFCA 
  weighted-ratio-E2SFCA 
  weighted-ratio-logistic 
  weighted-ratio-gaussian 
  weighted-ratio-exponential 
  tele-patients 
  BUP-patients 
  MTH-patients 
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  rxerType 
] 
 
deps-own[ 
  pt? 
  seeking-BUP? 
  getting-BUP-weeks  
  stable-abstinence? 
  abstinence-threshold 
  provider-group 
  provider-list  
  my-provider 
  my-travel-distance 
  waitlisted? 
  my-wait-threshold 
  indexprovider 
  too-far? 
  weeks-waiting 
  no-access-flag? 
  sought? 
  have-purchased-pills? 
  pill-source 
  dose 
  weeks-of-pills 
  total-tx-cost 
  have-diverted? 
  divert-reason 
  insurance 
  coinsurance 
  cantAfford? 
  monthly-out-of-pocket-payment 
  monthly-medication-cost 
  poverty 
  income 
  sex 
  relapse? 
  recipient-flag? 
  got-any-tx-flag? 
  weighted-sum-of-ratios-2SFCA 
  weighted-sum-of-ratios-E2SFCA 
  weighted-sum-of-ratios-logistic 
  weighted-sum-of-ratios-gaussian 
  weighted-sum-of-ratios-exponential 
  reachable-providers 
  decile 
] 
 
patches-own[ 
 pop-den  
 lambda 
 nn-distance 
 xP 
 yP 
 MUA? 
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 pills-here  
] 
 
OTPs-own 
[ 
  OTP-type 
  accepted-insurance-list 
  no-pay? 
  OTP-docs 
  give-BUP? 
  MTH-spots 
  MTH-pts 
] 
 GeoSetup.nls 
to setup-geography 
  set small-city-pct 35.5 
  set rural-threshold 35.0 
  set small-city-threshold 1000 
  make-MUA 
  make-real-map 
  set show-street-market? false 
end 
 
to make-MUA 
  let mapfilename (word "map" map-number "MUA.png") 
  import-pcolors mapfilename 
  ask patches [set pcolor round pcolor ifelse pcolor = 109 or (pcolor > 
14 and pcolor < 20) [set MUA? true][ set MUA? false]] 
  ask patches [set pcolor black]     
end 
 
to make-real-map 
  let mapfilename (word "map" map-number ".png") 
  import-pcolors mapfilename 
  ask patches [set pcolor round pcolor] 
  ask patches [remove-lines] 
  ask patches [set-density] 
  diffuse pop-den .2 
  ask patches [set pop-den round pop-den] 
  set max-patch-density  max [pop-den] of patches 
  set rural-areas patches with [pop-den < rural-threshold] 
  set small-cities patches with [pop-den < small-city-threshold and 
pop-den > rural-threshold] 
  set large-cities patches with [pop-den > small-city-threshold] 
  set patches-with-pills patch-set nobody 
end 
    
to remove-lines 
   if pcolor = 4 or pcolor = 5 or pcolor = 133 [set pcolor [pcolor] of 
one-of patches in-radius 3 with [pcolor > 5] remove-lines] 
end 
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to set-density 
  if pcolor = 74 [set pop-den 1] 
  if pcolor = 55 [set pop-den (1 + random 10)] 
  if pcolor = 56 [set pop-den (10 + random 15)] 
  if pcolor = 57 [set pop-den (25 + random 25)] 
  if pcolor = 58 [set pop-den (50 + random 50)] 
  if pcolor = 47 [set pop-den (100 + random 150)] 
  if pcolor = 28 [set pop-den (250 + random 250)] 
  if pcolor = 27 [set pop-den (500 + random 500)] 
  if pcolor = 26 [set pop-den (1000 + random 1500)] 
  if pcolor = 16 [set pop-den (2500 + random 2500)] 
  if pcolor = 15 [set pop-den (5000 + random 2000)] 
end 
 
 SetupCommands.nls 
to set-initials 
  set all-insurance ["public" "private" "none"] 
  set diverted-medicine 0 
  if model-year = 2013  
    [ 
      set total-population 316500000  
      set docs-per-pop (22631 / total-population)  
      set pts-dependent 3556000 
      set initial-pct-patients-in-tx .6 
      set od-deps-CMR 8 
  ]  
  if model-year = 2014  
    [ 
      set total-population 318600000  
      set docs-per-pop (22218 / total-population)  
      set pts-dependent 3400000 
      set initial-pct-patients-in-tx .7 
      set od-deps-CMR 10.5 
  ]  
  if model-year = 2015  
    [ 
      set total-population 320900000  
      set docs-per-pop (25504 / total-population)  
      set pts-dependent 3418000 
       set initial-pct-patients-in-tx .8 
      set od-deps-CMR 12 
  ]  
  if model-year = 2016  
    [ 
      set total-population 323100000  
      set docs-per-pop (29961 / total-population)  
      set pts-dependent 3538000 
      set initial-pct-patients-in-tx .8 
      set od-deps-CMR 12 
  ]  
end 
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to setup-people 
 
  set total-number-dependent floor (pts-dependent * total-pop / total-
population)  
  calculate-number-patients (total-number-dependent / 1)     
  ifelse dep-locations = "baseline-model" or dep-locations = "random-
location"[ 
    create-deps (total-number-dependent / 1)  
  ] 
  [ 
    ask patches [sprout-deps (round (pop-den * total-number-dependent / 
total-pop))]  
  ] 
  ask deps[ 
    set-initial-dep-stats 
    set-initial-pt-location   
    set-distance 
    if dep-locations = "random-location" [move-to one-of patches] 
    if [pop-den] of patch-here = 0 [move-to one-of patches with [pop-
den = 1]] 
  ] 
  if equity-experiments = "rural-hotspot" or equity-experiments = 
"rural-hotspot-low-transport" 
  [ 
    let hotspot-pop sum [pop-den] of patches with [pxcor >= 75 and 
pxcor <= 100 and pycor >= 75 and pycor <= 100]  
    create-deps hotspot-pop / 5 [ 
      move-to one-of patches with [pxcor >= 75 and pxcor <= 100 and 
pycor >= 75 and pycor <= 100] 
      set-initial-dep-stats 
      set color orange 
      ifelse equity-experiments = "rural-hotspot"[ 
        set-distance 
      ] 
      [ 
        set my-travel-distance 10 + random 20 
      ] 
    ] 
  ] 
  if equity-experiments = "urban-hotspot" 
  [ 
    let hotspot-pop sum [pop-den] of patches with [pxcor >= 130 and 
pxcor <= 145 and pycor >= 35 and pycor <= 50]  
    create-deps hotspot-pop / 10 [ 
      move-to one-of patches with [pxcor >= 130 and pxcor <= 145 and 
pycor >= 35 and pycor <= 50] 
      set-initial-dep-stats 
      set color orange 
      set-distance 
    ] 
  ] 
  setup-patients 
end 
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to set-initial-dep-stats 
  ht 
  set pt? false 
  set abstinence-threshold 0 
  set abstinence-mean 200 
  set seeking-BUP? FALSE 
  set getting-BUP-weeks -1 
  set stable-abstinence? FALSE 
  set my-provider NOBODY 
  set provider-list [] 
  set provider-group nobody  
  set indexprovider 0  
  set waitlisted? false 
  set relapse? false  
  set too-far? false 
  set my-wait-threshold random-exponential my-wait-time 
  set weeks-waiting 0 
  set cantAfford? false 
  set weeks-of-pills 0 
  set dose 0 
  set monthly-out-of-pocket-payment 0 
  set monthly-medication-cost 0 
  set my-travel-distance my-travel-distance  / 1.3 ;;converting crows 
fly distance to taxicab distance 
 
  set have-purchased-pills? false 
  set pill-source [] 
  set have-diverted? false 
  set divert-reason [] 
   
  set recipient-flag? false 
  set got-any-tx-flag? false 
  set no-access-flag? false 
  set sought? false 
 
  set-sex 
  init-poverty-insurance  
  set-abstinence-thresholds 
   
   
end 
 
to calculate-number-patients [total-deps] 
  set number-patients floor (total-deps * initial-pct-deps-seeking-or-
in-tx) 
end 
 
to set-initial-pt-location 
  ifelse random 100 < rural-dep-pct  
  [ 
    move-to one-of rural-areas 
    let big-neighborhood patches in-radius 5 
    if random 100 < remote-dep-pct [move-to max-one-of big-neighborhood 
[pop-den]] 
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  ] 
  [ 
    ifelse random 100 < small-city-pct 
    [move-to one-of small-cities] 
    [if large-cities != nobody [move-to one-of large-cities]] 
  ] 
end 
 
to set-sex 
  ifelse random 100 < female-pct[set sex "female"][set sex "male"] 
end 
 
to init-poverty-insurance 
let m random 100 
if m < pct-poverty [set poverty 1]                                                          
if m >= pct-poverty AND m < pct-poverty + pct-twox-poverty [set poverty 
2]                                             
if m >= pct-poverty + pct-twox-poverty [set poverty 3]                                                         
if poverty = 1 [ 
  let q random 100 
  if q < 47 [set insurance "public" set coinsurance 100]                           
  if q >= 47 and q < 67 [set insurance "private" set coinsurance 
coinsurance-base + random coinsurance-random]   
  if q >= 67 [set insurance "none" set coinsurance 0]                            
] 
 if poverty = 2 [ 
  let q random 100 
  if q < 30 [set insurance "public" set coinsurance 100]                           
  if q >= 30 and q < 64 [set insurance "private" set coinsurance 
coinsurance-base + random coinsurance-random]  
  if q >= 64 [set insurance "none" set coinsurance 0]                            
] 
if poverty = 3 [ 
  let q random 100 
  if q < 11 [set insurance "public" set coinsurance 100]                          
  if q >= 11 and q < 83 [set insurance "private" set coinsurance 
coinsurance-base + random coinsurance-random]   
  if q >= 83 [set insurance "none" set coinsurance 0]                             
] 
set income (poverty - 1) * poverty-level + random poverty-level                 
if medicaid-expansion? [if random 100 < pct-uninsured-now-have-medicaid        
    [if insurance = "none" and poverty = 1 
      [set insurance "public" set coinsurance 100]]]                             
end                                                                                
 
to set-abstinence-thresholds 
  ifelse random 100 < never-abstain-pct ;;data?  
    [set abstinence-threshold 10000] 
    [while [abstinence-threshold <= abstinence-floor] ; 
      [set abstinence-threshold round random-normal abstinence-mean 
abstinence-mean]  
    ]  
end 
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to setup-globals 
  set ods-deps 0 
  set ods-pats 0 
   
  set initial-pct-deps-seeking-or-in-tx .36 
  set remote-dep-pct 52.0 
  set low-spec .046 
  set high-spec .12 
  set non-high-list .2040 
  set non-low-list .0780 
  set non-low-nolist .48 
  set low-spec-random 2 
  set high-spec-random 2 
  set non-high-list-random 2 
  set non-low-list-random 2 
  set non-low-nolist-random 2 
  set pa-pop 101318 
  set pa-pcp-pct .265 
  set dep-incidence .1 
  set seeking-incidence .4 
  set np-pop 220000 
  set np-pcp-pct .710 
  set MUA-pct .3 
  set remote-pct .25 
  set APN-discount .7 
  set lowest-cost 60 
  set APN-random 2 
  set divertAfford 54 
  set wanted$ 14 
  set percentSayYes 35 
  set colleague-radius 5 
  set rural-dep-pct 14.5 
  set pct-of-income .30 
  set pct-poverty 30 
  set pct-twox-poverty 26 
  set coinsurance-base 50 
  set coinsurance-random 19 
  set never-abstain-pct 50 
  set abstinence-floor 10 
   
  set dose-sixteen 63 
  set dose-eight 18 
  set dose-tfour 15 
  set mth-cost 20 
  set pct-try-bup-first 80 
  set mth-weekly-quit-rate .0070 
  set first-week-bup-quit 24 
  set second-week-bup-quit 12 
  set my-wait-time 4 
  set poverty-level 1000 
  set female-pct 30 
 
  set ods-pts-in-tx 3 
  set post-tx-die 8 
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end 
    
 ProviderSetup.nls 
to setup-providers 
  setup-docs 
  if NP-PAs? [setup-APN] 
  ask providers[ 
    set colleagues other providers in-radius colleague-radius 
    if not any? colleagues [let other-guys min-n-of 2 providers 
[distance myself] set other-guys other other-guys set colleagues other-
guys ] 
  ] 
create-dummy-doc 
end 
 
to setup-docs 
  set-doc-pop 
  ifelse doc-locations = "baseline-model" or doc-locations = "random-
location"[ 
    create-providers number-docs  
  ] 
  [ 
    while [count providers < number-docs][ 
      ask one-of patches [if random-float 1 > (pop-den * number-docs / 
total-pop) [sprout-providers (ceiling (pop-den * number-docs / total-
pop))]] 
    ] 
  ] 
  ask providers[   
    set size 4 
    set color red 
    set provider-type "doc" 
    set OTP-doc? FALSE  
    set do-telemedicine? FALSE 
    set BUP-patients turtle-set nobody 
    set tele-patients turtle-set nobody 
    set MTH-patients turtle-set nobody 
    set-practice-characteristics 
    set-doc-characteristics 
    set-initial-doc-location  
  ]  
end 
 
to set-doc-pop  
  set number-docs floor (docs-per-pop  * total-pop)                           
  set weekly-add-docs  growth-rate-docs / 52 * (total-pop / total-
population)  
end 
 
to set-practice-characteristics 
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  while [visit-cost < lowest-cost] [set visit-cost visit-cost-mean + 
random-normal visit-cost-mean visit-cost-mean]                                                        
  set-insurance 
  if accepted-insurance-list = 0 [set accepted-insurance-list ["none"]] 
end 
 
to set-insurance 
set accepted-insurance-list [] 
if random 100 < accept-cash [set accepted-insurance-list ["none"]] 
if random 100 < accept-private [set accepted-insurance-list lput 
"private" accepted-insurance-list] 
if random 100 < accept-public [set accepted-insurance-list lput 
"public" accepted-insurance-list] 
if accepted-insurance-list = [] [set accepted-insurance-list ["none"]] 
end 
 
to set-doc-characteristics 
  set willAdd? FALSE                                                                             
  let r random-float 1 
  ;set rxerType 0 
  
  if r <=  low-spec 
  [ 
    set BUP-years random-float 1 
    set specialist? TRUE set onList? TRUE set Rxing? TRUE set capHigh? 
FALSE set willAdd? TRUE 
    ifelse low-spec-random = 4 [set patients-per-provider high-cap] 
    [ 
      ifelse low-spec-random = 2[set patients-per-provider 30 + round 
random-exponential 250] 
      [ifelse low-spec-random = 1 [set patients-per-provider random 
150][set patients-per-provider random 1000]] 
    ] 
    set-telemedicine                                                                                              
    set rxerType 1   
  ] 
  if r > low-spec and r <= (low-spec + high-spec) 
  [ 
    set BUP-years 1 + random-float 12 
    set specialist? TRUE set onList? TRUE set Rxing? TRUE set capHigh? 
TRUE set willAdd? TRUE 
    ifelse high-spec-random = 4 [set patients-per-provider high-cap] 
    [ 
      ifelse high-spec-random = 2[set patients-per-provider 30 + round 
random-exponential 250] 
    [ifelse high-spec-random = 1 [set patients-per-provider random 
150][set patients-per-provider random 1000]] 
    ] 
    set-telemedicine 
    set rxerType 2   
  ] 
  if r > (low-spec + high-spec) and r <= (low-spec  + high-spec + non-
high-list) 
  [ 
300 
    set BUP-years 1 + random-float 12 
    set specialist? FALSE set onList? TRUE set Rxing? TRUE set capHigh? 
TRUE set willAdd? TRUE 
    ifelse non-high-list-random = 4 [set patients-per-provider high-
cap] 
    [ 
    ifelse non-high-list-random = 2[ set patients-per-provider 30 + 
round random-exponential 220 ] ;; goosing high end 
   [ifelse non-high-list-random = 1 [set patients-per-provider random 
100][set patients-per-provider random 1000]] 
    while [patients-per-provider < 30 and non-high-list-random = 2] 
[set patients-per-provider 20 + round random-exponential 40] 
    ] 
  set rxerType 3   
  ] 
  if r > (low-spec + high-spec + non-high-list) and r <= (low-spec +  
high-spec + non-high-list + non-low-list)  
  [ 
    set specialist? FALSE set onList? TRUE set Rxing? TRUE set capHigh? 
FALSE  
    ifelse random 100 < pct-get-high-cap  
    [ 
      ifelse non-low-list-random = 4 [set patients-per-provider high-
cap] 
    [ 
      ifelse non-low-list-random = 2[set patients-per-provider 20 + 
round random-exponential 40] 
      [ifelse non-low-list-random = 1 [set patients-per-provider random 
100][set patients-per-provider random 200]] 
      while [patients-per-provider < 30 and non-low-list-random = 2] 
[set patients-per-provider 20 + round random-exponential 40] 
      ] ;; 7% will go on to get 100 
      set BUP-years random-float 1 
      set willAdd? TRUE 
    ] 
    [ 
       ifelse non-low-list-random = 4 [set patients-per-provider low-
cap] 
      [ 
      ifelse non-low-list-random = 2[set patients-per-provider round 
random-normal 20 7 ] ;; calibrate to lower  
      [ifelse non-low-list-random = 1 [set patients-per-provider random 
10][set patients-per-provider random 30]] 
      while [(patients-per-provider < 0 or patients-per-provider > 30) 
and non-low-list-random = 2] [set patients-per-provider round random-
normal 20 7] 
      ] 
      set BUP-years random-float 13 
      ] 
    set rxerType 4   
  ] 
   ifelse (low-spec +  high-spec + non-high-list + non-low-list + non-
low-nolist) > (1 - pct-not-rxing) [ 
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    if r > (low-spec +  high-spec + non-high-list + non-low-list) and r 
<= (low-spec +  high-spec + non-high-list + non-low-list + non-low-
nolist )  
    [ 
      set specialist? FALSE set onList? FALSE set Rxing? TRUE set 
capHigh? FALSE  
      ifelse random 100 < pct-get-high-cap  
      [ 
         ifelse non-low-nolist-random = 4 [set patients-per-provider 
high-cap] 
      [ 
        ifelse non-low-nolist-random = 2[set patients-per-provider 20 + 
round random-exponential 40]  
        [ifelse non-low-nolist-random = 1 [set patients-per-provider 
random 100][set patients-per-provider random 200]] 
        while [patients-per-provider < 30 and non-low-nolist-random = 
2] [set patients-per-provider 20 + round random-exponential 40] 
        ] ;; 7% will go on to get 100 
        set BUP-years random-float 1 
        set willAdd? TRUE 
      ] 
      [ 
         ifelse non-low-nolist-random = 4 [set patients-per-provider 
low-cap] 
      [ 
        ifelse non-low-nolist-random = 2[set patients-per-provider 
round random-normal 20 7]  
        [ifelse non-low-nolist-random = 1 [set patients-per-provider 
random 10][set patients-per-provider random 30]] 
          while [patients-per-provider < 0 or patients-per-provider > 
30] [set patients-per-provider round random-normal 20 7] 
        ] 
        set BUP-years random-float 13 
      ] 
       set rxerType 5 
    ] 
    if r > (low-spec +  high-spec + non-high-list + non-low-list + non-
low-nolist ) 
    [ 
      set BUP-years random-float 13 
      set specialist? FALSE set onList? FALSE set Rxing? FALSE set 
capHigh? FALSE 
      set patients-per-provider 0 
      set rxerType 6 
    ]  
  ] 
  [ 
   if r > (low-spec +  high-spec + non-high-list + non-low-list) and r 
<= (1 - pct-not-rxing ) 
    [ 
      set specialist? FALSE set onList? FALSE set Rxing? TRUE set 
capHigh? FALSE  
      ifelse random 100 < pct-get-high-cap  
      [ 
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         ifelse non-low-nolist-random = 4 [set patients-per-provider 
high-cap] 
      [ 
        ifelse non-low-nolist-random = 2[set patients-per-provider 20 + 
round random-exponential 40] 
        [ifelse non-low-nolist-random = 1 [set patients-per-provider 
random 100][set patients-per-provider random 200]] 
        while [patients-per-provider < 30 and non-low-nolist-random = 
2] [set patients-per-provider 20 + round random-exponential 40] 
        ] 
        set BUP-years random-float 1 
        set willAdd? TRUE 
      ] 
      [ 
         ifelse non-low-nolist-random = 4 [set patients-per-provider 
low-cap] 
      [ 
        ifelse non-low-nolist-random = 2[set patients-per-provider 
round random-normal 20 7]  
        [ifelse non-low-nolist-random = 1 [set patients-per-provider 
random 10][set patients-per-provider random 30]] 
          while [patients-per-provider < 0 or patients-per-provider > 
30] [set patients-per-provider round random-normal 20 7] 
        ] 
        set BUP-years random-float 13 
      ] 
       set rxerType 5 
    ] 
      if r > (1 - pct-not-rxing) 
      [ 
      set BUP-years random-float 13 
      set specialist? FALSE set onList? FALSE set Rxing? FALSE set 
capHigh? FALSE 
      set patients-per-provider 0 
      set rxerType 6 
      ]  
    ]  
   
  if specialist? = 0 ;; anyone left over goes in this pile 
  [ 
    set specialist? FALSE set onList? FALSE set Rxing? TRUE set 
capHigh? FALSE 
    ifelse random 100 < pct-get-high-cap  
    [ 
      set patients-per-provider 20 + round random-exponential 40  
      while [patients-per-provider < 30] [set patients-per-provider 20 
+ round random-exponential 40]  
      set BUP-years random-float 1 
      set willAdd? TRUE 
    ] 
    [ 
      set patients-per-provider round random-normal 20 7   
      while [patients-per-provider < 0 or patients-per-provider > 30] 
[set patients-per-provider round random-normal 20 7] 
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      set BUP-years random-float 13 
      ] 
    set rxerType 7 
    ] 
     
   
end 
 
to set-telemedicine 
if telemedicine?[ 
 if random 100 < pct-specialists-telemedicine[set do-telemedicine? 
true] 
]  
end 
 
to set-initial-doc-location 
  if doc-locations = "random-location"[ 
    move-to one-of patches 
  ] 
  if doc-locations = "baseline-model" 
  [ 
    ifelse capHigh? = false[ 
      let temp-my-patch-den random-lognormal 46300 9460 
      while [temp-my-patch-den > max-patch-density] [set temp-my-patch-
den random-lognormal 46300 9460] 
      let density-low-bound temp-my-patch-den - .4 * temp-my-patch-den 
      let density-upper-bound temp-my-patch-den + 4 * temp-my-patch-den 
      let move-to-patch one-of patches with [pop-den > density-low-
bound AND pop-den < density-upper-bound] 
      if move-to-patch != nobody[  move-to move-to-patch] 
    ] 
    [     
      let temp-my-patch-den random-lognormal 19600 5570 
      while [temp-my-patch-den > max-patch-density] [set temp-my-patch-
den random-lognormal 19600 5570] 
      let density-low-bound temp-my-patch-den - .4 * temp-my-patch-den 
      let density-upper-bound temp-my-patch-den + 4 * temp-my-patch-den 
      let move-to-patch one-of patches with [pop-den > density-low-
bound AND pop-den < density-upper-bound] 
      if move-to-patch != nobody[  move-to move-to-patch] 
    ] 
  ] 
end 
 
to set-capacity 
  ask providers with [BUP-years < 1 and provider-type != "MTH-doc"][ 
   ifelse (patients-per-provider > low-cap) 
     [set capped-patients-per-provider low-cap] 
     [set capped-patients-per-provider patients-per-provider] 
   if OTP-doc? = false [set total-capacity capped-patients-per-
provider] 
 ] 
 ask providers with [BUP-years >= 1 and provider-type != "MTH-doc"][ 
   ifelse (patients-per-provider > high-cap) 
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     [set capped-patients-per-provider high-cap] 
     [set capped-patients-per-provider patients-per-provider] 
   if OTP-doc? = false [set total-capacity capped-patients-per-
provider] 
 ] 
 set open-capacity (sum [capped-patients-per-provider] of providers) - 
(sum [count my-links] of providers) 
end 
 
to setup-APN 
  setup-PAs 
  setup-NPs 
end 
 
to setup-PAs 
  let number-PAs pa-pop * (total-pop / total-population) * pa-pcp-pct * 
pct-NPs-PAs-rxing / 100 
  create-providers number-PAs[ 
    set size 3 
    set color black  
    set provider-type "PA" 
    set OTP-doc? FALSE  
    set do-telemedicine? FALSE 
    set BUP-patients turtle-set nobody 
    set tele-patients turtle-set nobody 
    set MTH-patients turtle-set nobody 
    set-APN-characteristics 
    set-initial-APN-location  
    set-APN-practice-characteristics 
  ]  
end 
 
to setup-NPs 
  let number-NPs np-pop * (total-pop / total-population) * np-pcp-pct * 
pct-NPs-PAs-rxing / 100 
  create-providers number-NPs[ 
    set size 3 
    set color black 
    set OTP-doc? FALSE  
    set do-telemedicine? FALSE 
    set BUP-patients turtle-set nobody 
    set tele-patients turtle-set nobody 
    set MTH-patients turtle-set nobody 
    set provider-type "NP" 
    set-APN-characteristics 
    set-initial-APN-location 
    set-APN-practice-characteristics 
  ] 
end 
 
to set-APN-characteristics 
  set BUP-years 0.02 
  set specialist? FALSE set onList? TRUE set Rxing? TRUE set capHigh? 
FALSE  
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    ifelse random 100 < pct-get-high-cap  
    [ 
      if APN-random = 2[set patients-per-provider 30 + round random-
exponential 220] 
       
      while [patients-per-provider < 0] [set patients-per-provider 30 + 
round random-exponential 220]  
      set willAdd? TRUE 
    ] 
    [ 
      if APN-random = 2[set patients-per-provider 20 + round random-
exponential 40 ] 
       
      while [patients-per-provider < 0 or patients-per-provider > 30] 
[set patients-per-provider 20 + round random-exponential 40 ] 
      set willAdd? FALSE 
    ] 
end 
 
to set-APN-practice-characteristics 
  while [visit-cost < lowest-cost] [set visit-cost visit-cost-mean + 
random-normal visit-cost-mean visit-cost-mean]                                                         
  set visit-cost APN-discount * visit-cost  
  set-insurance 
  if accepted-insurance-list = 0 [set accepted-insurance-list ["none"]] 
end 
 
to set-initial-APN-location 
  let t random-float 1 
                                                                           
  ifelse t < MUA-pct [                                                          
    ifelse random-float 1 < remote-pct                                           
    [move-to one-of patches with [MUA? and pop-den < rural-threshold 
and pop-den > 0]]  
    [move-to one-of patches with [MUA? and pop-den >= rural-threshold]] 
      
  ] 
  [ 
    move-to one-of patches with [MUA? = FALSE and count providers-here 
> 0]  
  ]                                                                             
end 
 
 
to create-dummy-doc 
  create-providers 1 [ 
  ht 
  set provider-type "dummy"  
  set OTP-doc? FALSE  
  set do-telemedicine? FALSE  
  set accepted-insurance-list (list "none" "public" "private") 
  set total-capacity 100000 
  set capped-patients-per-provider 100000 
  set patients-per-provider 10000 
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  set rxing? false 
  set willAdd? false 
  set specialist? false 
  set capHigh? false 
  set onList? false 
  set BUP-patients turtle-set nobody 
  set tele-patients turtle-set nobody 
  set MTH-patients turtle-set nobody 
  set BUP-years 10 
  set dummy-doc self 
] 
end 
 
 Otp.nls 
to setup-OTPs 
  set num-otps 1368 
  set va-pct 3 
  set gvt-pct 6 
  set pnp-pct 36 
  let number-OTPs floor (num-otps  * (total-pop / total-population)) 
  create-OTPs number-OTPs  
  [ 
    set accepted-insurance-list (list) 
    set-OTP-location  
    set size 4  
    set shape "square"  
    set color 125 
    set-OTP-type-insurance 
  ] 
end 
 
to set-OTP-type-insurance 
  let pct random 100 
  let cash-pct random 100 
  let private-pct random 100 
  let public-pct random 100 
  let nopay-pct random 100 
  let give-bup random 100 
  if pct < va-pct  
  [ 
    set OTP-type "VA"  
    if cash-pct < 64 [set accepted-insurance-list lput "none" accepted-
insurance-list] 
    if private-pct < 91 [set accepted-insurance-list lput "private" 
accepted-insurance-list] 
    if public-pct < 35[set accepted-insurance-list lput "public" 
accepted-insurance-list] 
    ifelse nopay-pct < 94 [set no-pay? true][set no-pay? false] 
    ifelse give-bup < 94[set give-BUP? true][set give-BUP? false] 
    if empty? accepted-insurance-list [set accepted-insurance-list lput 
"none" accepted-insurance-list] 
    while [MTH-spots <= 0][set MTH-spots round (random-normal 103 89)] 
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  ] 
  if pct >= va-pct and pct < va-pct + gvt-pct  
  [set OTP-type "gvt"  
    if cash-pct < 92 [set accepted-insurance-list lput "none" accepted-
insurance-list] 
    if private-pct < 49 [set accepted-insurance-list lput "private" 
accepted-insurance-list] 
    if public-pct < 71 [set accepted-insurance-list lput "public" 
accepted-insurance-list] 
    ifelse nopay-pct < 70 [set no-pay? true][set no-pay? false] 
    ifelse give-bup < 35[set give-BUP? true][set give-BUP? false] 
    if empty? accepted-insurance-list [set accepted-insurance-list lput 
"none" accepted-insurance-list] 
    while [MTH-spots <= 0][set MTH-spots round (random-normal 362 469 
)] 
    ]  
  if pct >= va-pct + gvt-pct and pct < va-pct + gvt-pct + pnp-pct 
  [set OTP-type "PNP"  
    if cash-pct < 96 [set accepted-insurance-list lput "none" accepted-
insurance-list] 
    if private-pct < 58 [set accepted-insurance-list lput "private" 
accepted-insurance-list] 
    if public-pct < 92 [set accepted-insurance-list lput "public" 
accepted-insurance-list] 
    ifelse nopay-pct < 44 [set no-pay? true][set no-pay? false] 
    ifelse give-bup < 44[set give-BUP? true][set give-BUP? false] 
    if empty? accepted-insurance-list [set accepted-insurance-list lput 
"none" accepted-insurance-list] 
    while [MTH-spots <= 0][set MTH-spots round (random-normal 235 213)] 
  ] 
  if pct >= va-pct + gvt-pct + pnp-pct  
  [set OTP-type "PFP"  
    if cash-pct < 100[set accepted-insurance-list lput "none" accepted-
insurance-list] 
    if private-pct < 33[set accepted-insurance-list lput "private" 
accepted-insurance-list] 
    if public-pct < 46 [set accepted-insurance-list lput "public" 
accepted-insurance-list] 
    ifelse nopay-pct < 8 [set no-pay? true][set no-pay? false] 
    ifelse give-bup < 48[set give-BUP? true][set give-BUP? false] 
    if empty? accepted-insurance-list [set accepted-insurance-list lput 
"none" accepted-insurance-list] 
    while [MTH-spots <= 0][set MTH-spots round (random-normal 255 204)]  
    ]  
end 
 
to set-OTP-location 
  ifelse doc-locations = "random-location" [ 
    move-to one-of patches 
  ] 
  [ 
    let OTP-location-den 3 + random-lognormal 32900 9050 
    let max-den  max [pop-den] of patches 
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    while [OTP-location-den > max-den] [set OTP-location-den random-
lognormal 32900 9050] 
    let density-low-bound OTP-location-den - .4 * OTP-location-den 
    let density-upper-bound OTP-location-den + 4 * OTP-location-den 
    if one-of patches with [pop-den > density-low-bound AND pop-den < 
density-upper-bound] != nobody[  move-to one-of patches with [pop-den > 
density-low-bound AND pop-den < density-upper-bound]]  
  ] 
end  
 
to init-OTPs 
  let temp-list accepted-insurance-list 
  let my-patch patch-here 
  let temp-MTH-spots MTH-spots 
  let temp-no-pay? no-pay? 
  ifelse give-BUP? 
  [ 
    ask n-of 2 providers with [specialist? and capHigh?] 
    [ 
      move-to my-patch 
      set onList? TRUE set Rxing? TRUE 
      set OTP-doc? TRUE                    
      set MTH-spots round (temp-MTH-spots / 2) 
      set capped-patients-per-provider high-cap 
      set total-capacity (capped-patients-per-provider + MTH-spots) 
      set do-telemedicine? FALSE  
      set BUP-patients turtle-set nobody 
      set tele-patients turtle-set nobody 
      set MTH-patients turtle-set nobody                                                       
      set accepted-insurance-list (list)   
      set colleagues other providers in-radius colleague-radius                                               
      foreach temp-list[x -> set accepted-insurance-list fput x 
accepted-insurance-list] 
      set no-pay? temp-no-pay?] 
    set OTP-docs providers-here 
  ] 
  [ 
   let num-doc 1 + random 2 
   hatch-providers num-doc  
   [ 
     set specialist? true                    
     set onList? false                     
     set Rxing? false                      
     set CapHigh? false                    
     set willAdd? false                        
     set provider-type  "MTH-doc"   
     set do-telemedicine? false 
     set BUP-patients turtle-set nobody 
     set tele-patients turtle-set nobody 
     set MTH-patients turtle-set nobody     
     set patients-per-provider 0 
     set capped-patients-per-provider 0 
     set MTH-spots round (temp-MTH-spots / num-doc) 
     set total-capacity MTH-spots    
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     set accepted-insurance-list (list) 
     foreach temp-list[x -> set accepted-insurance-list fput x 
accepted-insurance-list] 
     set visit-cost 40 + random 60 
     set OTP-doc? true 
     set colleagues other providers in-radius colleague-radius 
     if not any? colleagues [let other-guys min-n-of 2 providers 
[distance myself] set other-guys other other-guys set colleagues other-
guys ] 
     set no-pay? temp-no-pay? 
   ] 
   set OTP-docs providers-here with [provider-type = "MTH-doc"] 
  ] 
end 
 
 PtSetup.nls 
to setup-patients 
 ask n-of (number-patients) deps [init-patient] 
 ask patients[set-initial-intreatment] 
 ask patients with [getting-bup-weeks > -1][get-provider] 
end 
 
to init-patient 
  set pt? true 
  set-dose 
  set monthly-medication-cost dose * medication-cost-base 
  set-provider-groups 
  set color blue 
  st 
end 
 
 
to set-dose 
  ifelse random 100 < dose-sixteen [set dose 16] 
  [ifelse random 100 < dose-eight [set dose 8] 
    [ifelse random 100 < dose-tfour [set dose 24] 
      [set dose 32] 
    ] 
  ] 
  if dose = 0 [set dose 16]   
end 
 
to set-provider-groups 
  let inradius-OTP-docs providers with [provider-type = "MTH-doc" and 
member? [insurance] of myself accepted-insurance-list and distance 
myself < [my-travel-distance] of myself] 
  let inradius-providers providers  with [onList? and member? 
[insurance] of myself accepted-insurance-list and distance myself < 
[my-travel-distance] of myself] 
  set inradius-providers (turtle-set inradius-OTP-docs inradius-
providers) 
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  let ref-OTP-provider min-one-of inradius-providers with [otp-
doc?][distance myself] 
  let ref-provider min-one-of inradius-providers with [otp-doc? = 
false][distance myself] 
  if ref-OTP-provider != nobody 
    [ 
      set my-provider ref-OTP-provider 
      set indexprovider 0 
      set too-far? FALSE 
      set provider-group (turtle-set my-provider provider-group) 
    ] 
    ifelse ref-provider != nobody 
      [ 
        if my-provider = nobody or ref-OTP-provider =  nobody or 
distance ref-provider < distance ref-OTP-provider [set my-provider ref-
provider] 
        set indexprovider 0 
        set too-far? FALSE 
        set provider-group (turtle-set ref-provider ref-OTP-provider) 
      ] 
      [ 
        if telemedicine?[  set provider-group turtle-set providers with 
[do-telemedicine? and onList? and member? [insurance] of myself 
accepted-insurance-list = TRUE]]    
        ifelse provider-group = nobody [set my-provider dummy-doc ] 
                                       [set my-provider one-of 
provider-group] 
        if my-provider = nobody [set my-provider dummy-doc] 
      ] 
    set seeking-BUP? true   
    set sought? TRUE  
end 
 
 
to set-initial-intreatment 
    if random-float 1 < initial-pct-patients-in-tx    
    [ 
      set seeking-BUP? false  
      set sought? false                                                               
      set getting-BUP-weeks ceiling random-exponential 10  
      if my-provider != dummy-doc[ 
        set provider-group  
        (turtle-set my-provider  
          ([colleagues] of my-provider) with [member? [insurance] of 
myself accepted-insurance-list = TRUE]  
      providers with [do-telemedicine? and member? [insurance] of 
myself accepted-insurance-list = TRUE])                                                                             
      ]  
    ] 
end 
 
to set-distance ;; plug for data on willingness to travel. 
   if [pop-den] of patch-here > 5000 [draw-5000] 
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   if [pop-den] of patch-here < 5000 and [pop-den] of patch-here > 2500 
[draw-2500] 
   if [pop-den] of patch-here < 2500 and [pop-den] of patch-here > 1000 
[draw-1000] 
   if [pop-den] of patch-here < 1000 and [pop-den] of patch-here > 500 
[draw-500] 
   if [pop-den] of patch-here < 500 and [pop-den] of patch-here > 250 
[draw-250] 
   if [pop-den] of patch-here < 250 and [pop-den] of patch-here > 100 
[draw-100] 
   if [pop-den] of patch-here < 100 and [pop-den] of patch-here > 50 
[draw-50]  
   if [pop-den] of patch-here < 50 and [pop-den] of patch-here > 25 
[draw-25]  
   if [pop-den] of patch-here < 25 and [pop-den] of patch-here > 10 
[draw-10]  
   if [pop-den] of patch-here < 10 and [pop-den] of patch-here > 0 
[draw-0] 
   if my-travel-distance = 0 [set my-travel-distance 5]  
end 
 
 
to draw-5000 
  let nn random-float 1 
  if nn < 1 [set my-travel-distance 100] 
  if nn < .985085 [set my-travel-distance 95] 
  if nn < .9849 [set my-travel-distance 90] 
  if nn < .9843 [set my-travel-distance 85] 
  if nn < .9841 [set my-travel-distance 80] 
  if nn < .9835 [set my-travel-distance 75] 
  if nn < .9820 [set my-travel-distance 70] 
  if nn < .9813 [set my-travel-distance 65] 
  if nn < .9808 [set my-travel-distance 60] 
  if nn < .9757 [set my-travel-distance 55] 
  if nn < .9749 [set my-travel-distance 50] 
  if nn < .9567 [set my-travel-distance 45] 
  if nn < .9525 [set my-travel-distance 40] 
  if nn < .94012 [set my-travel-distance 35] 
  if nn < .931733 [set my-travel-distance 30] 
  if nn < .8922 [set my-travel-distance 25] 
  if nn < .85049 [set my-travel-distance 20] 
  if nn < .7391 [set my-travel-distance 15] 
  if nn < .5769 [set my-travel-distance 10 ] 
  if nn < .218 [set my-travel-distance 5] 
end 
 
to draw-2500 
   let nn random-float 1 
  if nn < 1 [set my-travel-distance 100] 
  if nn < .97884343 [set my-travel-distance 95] 
  if nn < 0.978667137 
 [set my-travel-distance 90] 
  if nn < 0.977697461 
 [set my-travel-distance 85] 
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  if nn < 0.977433004 
 [set my-travel-distance 80] 
  if nn < 0.975141044 
 [set my-travel-distance 75] 
  if nn < 0.97196756 
 [set my-travel-distance 70] 
  if nn < 0.969851904 
 [set my-travel-distance 65] 
  if nn < 0.967295487 
 [set my-travel-distance 60] 
  if nn < 0.954777856 
 [set my-travel-distance 55] 
  if nn < 0.951428068 
 [set my-travel-distance 50] 
  if nn < 0.91969323 
 [set my-travel-distance 45] 
  if nn < 0.911583216 
 [set my-travel-distance 40] 
  if nn < 0.888751763 
 [set my-travel-distance 35] 
  if nn < 0.871385755 
 [set my-travel-distance 30] 
  if nn < 0.79698519 
 [set my-travel-distance 25] 
  if nn < 0.719058533 
 [set my-travel-distance 20] 
  if nn < 0.527062764 
 [set my-travel-distance 15] 
  if nn < 0.298748237 
 [set my-travel-distance 10 ] 
  if nn < 0.052803244 
  [set my-travel-distance 5] 
   
end 
 
to draw-1000 
   let nn random-float 1 
  if nn < 1 [set my-travel-distance 100] 
  if nn < 0.980004957 
 [set my-travel-distance 95] 
  if nn < 0.979426588 
 [set my-travel-distance 90] 
  if nn < 0.977939354 
 [set my-travel-distance 85] 
  if nn < 0.977360985 
 [set my-travel-distance 80] 
  if nn < 0.974221267 
 [set my-travel-distance 75] 
  if nn < 0.968602826 
 [set my-travel-distance 70] 
  if nn < 0.963480129 
 [set my-travel-distance 65] 
  if nn < 0.959431546 
 [set my-travel-distance 60] 
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  if nn < 0.941832603 
 [set my-travel-distance 55] 
  if nn < 0.936296786 
 [set my-travel-distance 50] 
  if nn < 0.896554573 
 [set my-travel-distance 45] 
  if nn < 0.884491448 
 [set my-travel-distance 40] 
  if nn < 0.849458812 
 [set my-travel-distance 35] 
  if nn < 0.820457738 
 [set my-travel-distance 30] 
  if nn < 0.71759068 
 [set my-travel-distance 25] 
  if nn < 0.603734611 
 [set my-travel-distance 20] 
  if nn < 0.387341981 
 [set my-travel-distance 15] 
  if nn < 0.175989424 
 [set my-travel-distance 10 ] 
  if nn < 0.025448236 
 [set my-travel-distance 5] 
   
end 
 
to draw-500 
  let nn random-float 1 
  if nn < 1 [set my-travel-distance 100] 
  if nn < 0.970779221 
 [set my-travel-distance 95] 
  if nn < 0.97038961 
 [set my-travel-distance 90] 
  if nn < 0.967662338 
 [set my-travel-distance 85] 
  if nn < 0.965844156 
 [set my-travel-distance 80] 
  if nn < 0.961038961 
 [set my-travel-distance 75] 
  if nn < 0.954415584 
 [set my-travel-distance 70] 
  if nn < 0.947922078 
 [set my-travel-distance 65] 
  if nn < 0.93974026 
 [set my-travel-distance 60] 
  if nn < 0.916753247 
 [set my-travel-distance 55] 
  if nn < 0.906363636 
 [set my-travel-distance 50] 
  if nn < 0.843766234 
 [set my-travel-distance 45] 
  if nn < 0.820649351 
 [set my-travel-distance 40] 
  if nn < 0.76987013 
 [set my-travel-distance 35] 
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  if nn < 0.717012987 
 [set my-travel-distance 30] 
  if nn < 0.578961039 
 [set my-travel-distance 25] 
  if nn < 0.436103896 
 [set my-travel-distance 20] 
  if nn < 0.231688312 
 [set my-travel-distance 15] 
  if nn < 0.09012987 
 [set my-travel-distance 10 ] 
  if nn < 0.015064935 
 [set my-travel-distance 5] 
   
end 
 
to draw-250 
   let nn random-float 1 
  if nn < 1 [set my-travel-distance 100] 
  if nn < 0.952435312 
 [set my-travel-distance 95] 
  if nn < 0.951674277 
 [set my-travel-distance 90] 
  if nn < 0.945459158 
 [set my-travel-distance 85] 
  if nn < 0.941146626 
 [set my-travel-distance 80] 
  if nn < 0.932648402 
 [set my-travel-distance 75] 
  if nn < 0.917047184 
 [set my-travel-distance 70] 
  if nn < 0.900431253 
 [set my-travel-distance 65] 
  if nn < 0.887747336 
 [set my-travel-distance 60] 
  if nn < 0.846905124 
 [set my-travel-distance 55] 
  if nn < 0.829020802 
 [set my-travel-distance 50] 
  if nn < 0.745560629 
 [set my-travel-distance 45] 
  if nn < 0.70890411 
 [set my-travel-distance 40] 
  if nn < 0.643708777 
 [set my-travel-distance 35] 
  if nn < 0.581557585 
 [set my-travel-distance 30] 
  if nn < 0.428589548 
 [set my-travel-distance 25] 
  if nn < 0.297945205 
 [set my-travel-distance 20] 
  if nn < 0.14028412 
 [set my-travel-distance 15] 
  if nn < 0.063926941 
 [set my-travel-distance 10 ] 
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  if nn < 0.013191273 
 [set my-travel-distance 5] 
   
end 
 
to draw-100 
   let nn random-float 1 
  if nn < 1 [set my-travel-distance 100 ] 
  if nn < 0.925048411 
 [set my-travel-distance 95] 
  if nn < 0.92322588 
 [set my-travel-distance 90] 
  if nn < 0.916733113 
 [set my-travel-distance 85] 
  if nn < 0.912632418 
 [set my-travel-distance 80] 
  if nn < 0.898849527 
 [set my-travel-distance 75] 
  if nn < 0.877206971 
 [set my-travel-distance 70] 
  if nn < 0.855222691 
 [set my-travel-distance 65] 
  if nn < 0.832896685 
 [set my-travel-distance 60] 
  if nn < 0.770816722 
 [set my-travel-distance 55] 
  if nn < 0.74074496 
 [set my-travel-distance 50] 
  if nn < 0.612826062 
 [set my-travel-distance 45] 
  if nn < 0.56133956 
 [set my-travel-distance 40] 
  if nn < 0.47385807 
 [set my-travel-distance 35] 
  if nn < 0.402323727 
 [set my-travel-distance 30] 
  if nn < 0.256065611 
 [set my-travel-distance 25] 
  if nn < 0.163116528 
 [set my-travel-distance 20] 
  if nn < 0.071989976 
 [set my-travel-distance 15] 
  if nn < 0.032577742 
 [set my-travel-distance 10 ] 
  if nn < 0.009112655 
 [set my-travel-distance 5] 
   
end 
 
to draw-50 
  let nn random-float 1 
  if nn < 1  
  [set my-travel-distance 100] 
  if nn < 0.952435312 
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 [set my-travel-distance 95] 
  if nn < 0.951674277 
 [set my-travel-distance 90] 
  if nn < 0.945459158 
 [set my-travel-distance 85] 
  if nn < 0.941146626 
 [set my-travel-distance 80] 
  if nn < 0.932648402 
 [set my-travel-distance 75] 
  if nn < 0.917047184 
 [set my-travel-distance 70] 
  if nn < 0.900431253 
 [set my-travel-distance 65] 
  if nn < 0.887747336 
 [set my-travel-distance 60] 
  if nn < 0.846905124 
 [set my-travel-distance 55] 
  if nn < 0.829020802 
 [set my-travel-distance 50] 
  if nn < 0.745560629 
 [set my-travel-distance 45] 
  if nn < 0.70890411 
 [set my-travel-distance 40] 
  if nn < 0.643708777 
 [set my-travel-distance 35] 
  if nn < 0.581557585 
 [set my-travel-distance 30] 
  if nn < 0.428589548 
 [set my-travel-distance 25] 
  if nn < 0.297945205 
 [set my-travel-distance 20] 
  if nn < 0.14028412 
 [set my-travel-distance 15] 
  if nn < 0.063926941 
 [set my-travel-distance 10 ] 
  if nn < 0.013191273 
 [set my-travel-distance 5] 
   
end 
 
to draw-25 
  let nn random-float 1 
  if nn < 1  
  [set my-travel-distance 100] 
  if nn < 0.842581661 
 [set my-travel-distance 95] 
  if nn < 0.839433294 
 [set my-travel-distance 90] 
  if nn < 0.826446281 
 [set my-travel-distance 85] 
  if nn < 0.807949626 
 [set my-travel-distance 80] 
  if nn < 0.780401417 
 [set my-travel-distance 75] 
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  if nn < 0.733175915 
 [set my-travel-distance 70] 
  if nn < 0.690279418 
 [set my-travel-distance 65] 
  if nn < 0.662337662 
 [set my-travel-distance 60] 
  if nn < 0.556080283 
 [set my-travel-distance 55] 
  if nn < 0.50806769 
 [set my-travel-distance 50] 
  if nn < 0.346713892 
 [set my-travel-distance 45] 
  if nn < 0.303423849 
 [set my-travel-distance 40] 
  if nn < 0.225108225 
 [set my-travel-distance 35] 
  if nn < 0.174734357 
 [set my-travel-distance 30] 
  if nn < 0.093663912 
 [set my-travel-distance 25] 
  if nn < 0.058638331 
 [set my-travel-distance 20] 
  if nn < 0.029515939 
 [set my-travel-distance 15] 
  if nn < 0.018103109 
 [set my-travel-distance 10 ] 
  if nn < 0.008658009 
 [set my-travel-distance 5] 
   
end 
 
to draw-10 
     let nn random-float 1 
  if nn < 1  
  [set my-travel-distance 100] 
  if nn < 0.72 
 [set my-travel-distance 95] 
  if nn < 0.714545455 
 [set my-travel-distance 90] 
  if nn < 0.691818182 
 [set my-travel-distance 85] 
  if nn < 0.680909091 
 [set my-travel-distance 80] 
  if nn < 0.647272727 
 [set my-travel-distance 75] 
  if nn < 0.595454545 
 [set my-travel-distance 70] 
  if nn < 0.551818182 
 [set my-travel-distance 65] 
  if nn < 0.515454545 
 [set my-travel-distance 60] 
  if nn < 0.431818182 
 [set my-travel-distance 55] 
  if nn < 0.394545455 
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 [set my-travel-distance 50] 
  if nn < 0.26 
 [set my-travel-distance 45] 
  if nn < 0.222727273 
 [set my-travel-distance 40] 
  if nn < 0.166363636 
 [set my-travel-distance 35] 
  if nn < 0.132727273 
 [set my-travel-distance 30] 
  if nn < 0.072727273 
 [set my-travel-distance 25] 
  if nn < 0.054545455 
 [set my-travel-distance 20] 
  if nn < 0.023636364 
 [set my-travel-distance 15] 
  if nn < 0.015454545 
 [set my-travel-distance 10 ] 
  if nn < 0.008181818 
 [set my-travel-distance 5] 
   
end 
 
to draw-0 
   let nn random-float 1 
  if nn < 1  
  [set my-travel-distance 100] 
  if nn < 0.48372093 
 [set my-travel-distance 95] 
  if nn < 0.479069767 
 [set my-travel-distance 90] 
  if nn < 0.460465116 
 [set my-travel-distance 85] 
  if nn < 0.446511628 
 [set my-travel-distance 80] 
  if nn < 0.41627907 
 [set my-travel-distance 75] 
  if nn < 0.381395349 
 [set my-travel-distance 70] 
  if nn < 0.360465116 
 [set my-travel-distance 65] 
  if nn < 0.334883721 
 [set my-travel-distance 60] 
  if nn < 0.272093023 
 [set my-travel-distance 55] 
  if nn < 0.255813953 
 [set my-travel-distance 50] 
  if nn < 0.202325581 
 [set my-travel-distance 45] 
  if nn < 0.186046512 
 [set my-travel-distance 40] 
  if nn < 0.16744186 
 [set my-travel-distance 35] 
  if nn < 0.162790698 
 [set my-travel-distance 30] 
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  if nn < 0.125581395 
 [set my-travel-distance 25] 
  if nn < 0.104651163 
 [set my-travel-distance 20] 
  if nn < 0.072093023 
 [set my-travel-distance 15] 
  if nn < 0.06744186 
 [set my-travel-distance 10 ] 
  if nn < 0.034883721 
 [set my-travel-distance 5] 
   
end 
 
 ProviderGo.nls 
to age-providers 
  let short-tick 1 / 52 
  add-docs 
  ask providers [ 
    set BUP-years BUP-years + short-tick 
    if BUP-years > 1 AND BUP-years < 2 and willAdd? 
    [ 
      set capped-patients-per-provider patients-per-provider 
      if patients-per-provider > high-cap [set capped-patients-per-
provider high-cap] 
    ] 
  ] 
end 
 
to add-docs 
  let weekrate 0 
  let randomizer weekly-add-docs - floor weekly-add-docs 
  ifelse random-float 1 < randomizer [set weekrate floor weekly-add-
docs + 1][set weekrate floor weekly-add-docs] 
  create-providers weekrate [ 
    set color black  
    set-initial-doc-location  
    set BUP-years 0 
    set provider-type "doc" 
    set OTP-doc? FALSE 
    set do-telemedicine? FALSE 
    set BUP-patients turtle-set nobody 
    set tele-patients turtle-set nobody 
    set MTH-patients turtle-set nobody  
    set-practice-characteristics 
    set-doc-characteristics 
    set-capacity 
    set colleagues other providers in-radius colleague-radius 
    if not any? colleagues [let other-guys min-n-of 2 providers 
[distance myself] set other-guys other other-guys set colleagues other-
guys ] 
  ] 
  set number-docs count providers with [provider-type = "doc"] 
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end 
 
 GoCommands.nls 
to do-street-market 
  diffuse pills-here (8 / 9) 
  set patches-with-pills patches with [pills-here > 0] 
  if show-street-market? [ 
    ask turtles [ht]  
    ask patches [set pcolor scale-color green pills-here 0 20] 
  ] 
end 
 
to grow-deps            
 let num-new-deps ((pts-dependent * dep-incidence * total-pop / (total-
population * 52)))  
 create-deps  num-new-deps [set-initial-dep-stats]  
end 
 
to chance-OD 
  ask nonpats  [ 
   let m random-float 1 
    ifelse weeks-of-pills >= 1 [ 
      set weeks-of-pills weeks-of-pills - 1 
      if m < (ods-pts-in-tx / (1000 * 52 ))[ 
       set ods-deps ods-deps + 1 die 
      ] 
    ] 
    [ 
     if weeks-of-pills > 0 
      [ 
        set weeks-of-pills 0  
      ] 
      if m < (od-deps-CMR / (1000 * 52))[ 
        set ods-deps ods-deps + 1 die 
      ] 
    ] 
  ] 
end 
 
to reset-flagged-vars 
 if ticks mod 52 - 8 = 0  
  [ 
    ask deps with [no-access-flag? and recipient-flag? = FALSE][ht] 
    ask deps with [seeking-bup? = false and getting-bup-weeks = -1][ht] 
    ask deps with [recipient-flag?][set recipient-flag? FALSE] 
    ask deps with [got-any-tx-flag?][set got-any-tx-flag? FALSE] 
    ask deps with [getting-BUP-weeks >= 0][set recipient-flag? TRUE set 
got-any-tx-flag? TRUE] 
    ask deps with [getting-BUP-weeks = -200][set got-any-tx-flag? TRUE 
]   
    ask deps with [getting-BUP-weeks = -1] [set recipient-flag? FALSE 
set got-any-tx-flag? FALSE] 
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    ask deps [set no-access-flag? FALSE] 
    ask deps [set sought? FALSE] 
  ] 
  reset-counters 
end 
 
to reset-counters 
  if ticks mod 52 - 8 = 0 [ 
    set ODs-pats 0 
    set ODs-deps 0 
    set diverted-medicine 0 
  ] 
end 
 
 PtGo.nls 
to age-patients 
let current-patients patients 
 
ask current-patients with [(getting-BUP-weeks != -1 or stable-
abstinence?) ][if random-float 1 < (ods-pts-in-tx / (1000 * 52 ))  
[stop-provider-link set-dead]]  
ask current-patients with [weeks-waiting > my-wait-threshold ][do-
relapse];; 
ask current-patients with [getting-bup-weeks = -200][do-methadone] 
ask current-patients with [getting-bup-weeks >= 0][do-buprenorphine]                      
ask current-patients with [waitlisted? and getting-bup-weeks = -
1][initiate-tx] 
ask current-patients with [waitlisted? = false and getting-bup-weeks = 
-1][initiate-tx] 
start-seeking-tx 
end 
 
 
to stop-provider-link 
  ifelse getting-bup-weeks = -200 [  
    let local-mth-set [MTH-patients] of my-provider 
    set local-mth-set other local-mth-set 
    ask my-provider [ 
      set MTH-patients local-mth-set 
    ] 
  ] 
  [ 
    let local-BUP-set [BUP-patients] of my-provider 
    let local-TELE-set [tele-patients] of my-provider 
    if member? self local-BUP-set [ 
      set local-BUP-set other local-BUP-set 
      ask my-provider [ 
      set BUP-patients local-BUP-set 
      ] 
    ] 
    if member? self local-TELE-set [ 
      set local-TELE-set other local-TELE-set 
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      ask my-provider [ 
        set tele-patients local-TELE-set 
      ] 
    ] 
  ] 
end 
 
to set-dead 
  ifelse getting-bup-weeks = -1 and stable-abstinence? = false  
  [set ods-deps ods-deps + 1] 
  [set ods-pats ods-pats + 1] 
die  
end 
 
 
 
to do-relapse 
  set relapse? true 
  set pt? false 
  set getting-bup-weeks -1 
  set seeking-bup? false 
  set indexprovider 0 
  set color white 
   
  if weeks-of-pills > 0 and getting-bup-weeks > 4  
  [ask patch-here [set pills-here pills-here + [weeks-of-pills] of 
myself * [dose] of myself]] 
  if weeks-of-pills > 0 and getting-bup-weeks < 4  
  [ask patch-here [set pills-here pills-here + (([weeks-of-pills] of 
myself * [dose] of myself) / 4)]] 
 
end 
 
to do-methadone 
  if random-float 1 < mth-weekly-quit-rate [ 
    stop-provider-link 
    if random-float 1 < (post-tx-die / (1000 * 52 )) [set getting-bup-
weeks -1 set-dead] 
    do-relapse 
  ] 
end 
 
to do-buprenorphine  
   ifelse (getting-BUP-weeks = 0 AND random 100 < first-week-bup-quit)                              
   or (getting-BUP-weeks = 1 AND random 100 < second-week-bup-quit)                                  
   or (getting-BUP-weeks >= 2 AND random 500 < (100 / getting-BUP-
weeks))          
   [ 
       stop-provider-link                                                          
       if random-float 1 < (post-tx-die / (1000 * 52 )) [set getting-
bup-weeks -1 set-dead] 
       do-relapse                                                                 
   ]  
   [ 
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     ifelse getting-BUP-weeks >= abstinence-threshold  
       [ 
         stop-provider-link  
         set getting-BUP-weeks -1  
         set relapse? false  
         set stable-abstinence? true  
         set color pink  
    ]                        
       [ 
         get-pills 
         divert-pills 
         use-pills                                                             
         set getting-BUP-weeks getting-BUP-weeks + 1  
         set relapse? false 
       ]  
   ]  
end 
 
to get-pills 
  if getting-BUP-weeks mod 4 = 0  
  [ 
    set weeks-of-pills 4 
    ifelse getting-BUP-weeks != 0  
    [ 
      ifelse [accepted-insurance-list] of my-provider = ["none"] 
      [set monthly-out-of-pocket-payment [visit-cost] of my-provider + 
monthly-medication-cost * (100 - coinsurance) / 100 ]                              
      [set monthly-out-of-pocket-payment [visit-cost] of my-provider * 
(100 - coinsurance) / 100 + monthly-medication-cost * (100 - 
coinsurance) / 100 ]   
      set total-tx-cost total-tx-cost + [visit-cost] of my-provider + 
monthly-medication-cost 
    ]   
    [ 
      ifelse [accepted-insurance-list] of my-provider = ["none"] 
      [set monthly-out-of-pocket-payment [visit-cost] of my-provider * 
2 + monthly-medication-cost * (100 - coinsurance) / 100 ]                              
      [set monthly-out-of-pocket-payment [visit-cost] of my-provider * 
2 * (100 - coinsurance) / 100 + monthly-medication-cost * (100 - 
coinsurance) / 100 ]   
      set total-tx-cost total-tx-cost + [visit-cost] of my-provider * 2  
+ monthly-medication-cost 
    ] 
    ifelse monthly-out-of-pocket-payment > income * pct-of-income [set 
cantAfford? TRUE][set cantAfford? FALSE] 
  ] 
end 
 
to divert-pills 
 
  let need-money false 
   
  if poverty < 3 and wanted$ > random 5200 [set need-money true] 
  ifelse cantAfford? = true and random 5200 < divertAfford 
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  [   
    let m one-of [ .14 .28 .35]  
    if weeks-of-pills - m > 0[ 
      set weeks-of-pills weeks-of-pills - m 
      set diverted-medicine diverted-medicine + (m * dose) 
      set have-diverted? True 
      set divert-reason lput "afford" divert-reason 
      ask patch-here [set pills-here m * [dose] of myself ] 
    ] 
  ] 
  [ 
    if need-money = true 
    [ 
      let m one-of [ .14 .28 .35] 
      if weeks-of-pills - m > 0[ 
        set weeks-of-pills weeks-of-pills - m 
        set diverted-medicine diverted-medicine + (m * dose) 
        set have-diverted? True 
        set divert-reason lput "money" divert-reason 
        ask patch-here [set pills-here m * [dose] of myself ] 
      ] 
    ] 
  ] 
 
end 
 
to use-pills 
  set weeks-of-pills weeks-of-pills - 1 
  if weeks-of-pills <= 0 [set weeks-of-pills 0]   
end 
 
to initiate-tx 
  if seeking-BUP?  
    [ 
      get-provider    
    ] 
end 
 
 
to get-provider ;;  
  ifelse [provider-type] of my-provider = "dummy"  
    [ 
      ifelse any? insurance-not-dummies with [distance myself < [my-
travel-distance] of myself]      
      [set-provider-groups] 
      [ 
        set no-access-flag? TRUE 
        set too-far? true 
        set getting-BUP-weeks -1  
        set seeking-BUP? true  
        set sought? true 
        set got-any-tx-flag? false  
        set recipient-flag? false 
        set color yellow 
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        st 
        set size 1 
        get-diverted-bup    
      ] 
    ]   
    [  
      ifelse provider-group != nobody and (indexprovider < count 
provider-group) 
      [ 
        if indexprovider = 1 or waitlisted?[set provider-list sort-on 
[distance myself] provider-group] 
        if indexprovider != 0 [set my-provider item indexprovider 
provider-list] 
        ifelse my-travel-distance < distance my-provider 
        [ 
          set no-access-flag? TRUE 
          set getting-BUP-weeks -1  
          set seeking-BUP? true  
          set sought? true 
          set got-any-tx-flag? false  
          set color orange + 2 
          set waitlisted? true 
          st 
          set size 1  
          try-telemedicine                                                                         
          if getting-BUP-weeks = -1 [   get-diverted-bup   ]                       
        ] 
        [ 
          ifelse ([provider-type] of my-provider = "MTH-doc"  and 
([count MTH-patients] of my-provider < ([total-capacity] of my-
provider) ))   ; 
          [                                                      
            try-to-start-mth-tx                                     
            if getting-bup-weeks = -200                           
            [                                                     
              set color red                                       
              add-to-MTH-list                                     
            ]                                                       
          ]                                                       
        [   
          ifelse(getting-bup-weeks != -200 and ([count tele-patients] 
of my-provider + [count BUP-patients] of my-provider) < ([total-
capacity] of my-provider))            
          [ 
            set color black 
            start-tx  
            if getting-bup-weeks >= 0  and recipient-flag? [ 
              add-to-BUP-list 
            ] 
            if getting-bup-weeks = -200  
            [ 
              set color red 
              add-to-MTH-list                   
            ] 
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          ] 
         [ 
            set indexprovider indexprovider + 1                                    
            get-provider 
         ] 
        ] 
        ]  
      ] 
      [                                                                                  
        if getting-bup-weeks = -1  
        [set color orange 
          st 
          set size 1 
          set no-access-flag? TRUE 
          set waitlisted? true 
          set provider-group  
          (turtle-set my-provider  
            ([colleagues] of my-provider) with [member? [insurance] of 
myself accepted-insurance-list = TRUE]  
            providers with [do-telemedicine? and member? [insurance] of 
myself accepted-insurance-list = TRUE] 
            ) 
          set indexprovider 0 
          get-diverted-bup                                                                     
          set seeking-BUP? true set sought? true 
          set getting-BUP-weeks -1 
          set my-provider min-one-of  provider-group [distance myself] 
        ] 
      ] 
    ] 
end 
 
 
 
to try-telemedicine 
  let teledocs turtle-set provider-group with [do-telemedicine? and 
capped-patients-per-provider - (count BUP-patients + count tele-
patients) > 0] 
  if any? teledocs 
  [ 
    set my-provider one-of teledocs 
    start-tx 
    ifelse getting-bup-weeks >= 0 and seeking-bup? = FALSE  
    [ 
      add-to-tele-list 
      ] 
    [set getting-bup-weeks -1 set waitlisted? true] 
  ]  
end 
 
to get-diverted-bup 
  if random-float 5200 < percentSayYes  [ 
    if ask-friends-for-pills = true                                               
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    [set have-purchased-pills? true set pill-source lput "friends" 
pill-source ] 
  ] 
  ifelse weeks-of-pills >= 1 [set relapse? false ] 
    [ 
     let street-market patches-with-pills with [distance myself < [my-
travel-distance] of myself]   
      
      let pills-on-street sum [pills-here] of street-market 
      if pills-on-street > 0[ 
        ifelse pills-on-street <= dose * 7 * (1 - weeks-of-pills)                                         
        [ 
          set weeks-waiting weeks-waiting + 1 
          set weeks-of-pills weeks-of-pills + (pills-on-street / (dose 
* 7)) 
        ] 
        [                                                            
          set weeks-of-pills 1 
          set relapse? false 
        ] 
        buy-street-pills street-market pills-on-street 
        set have-purchased-pills? true 
        set pill-source lput "street" pill-source 
 
      ] 
    ] 
    if have-purchased-pills? = false [set weeks-waiting weeks-waiting + 
1] 
end 
 
 
 
to-report ask-friends-for-pills 
  let purchased-pills? false 
  let my-radius min list 5 my-travel-distance 
  let candidate-friends other patients with [weeks-of-pills > 0 and 
distance myself < my-radius ] 
  let friends n-of min list 5 count candidate-friends candidate-friends 
  let total-pills sum [weeks-of-pills] of friends  
 
  while [any? friends and purchased-pills? = FALSE and total-pills > 
0][  
    ask one-of friends [                          
      let m ([dose] of myself / dose)  
      if m > 1 [set m 1]    
      if weeks-of-pills - m > 0       
      [ 
        set weeks-of-pills weeks-of-pills - m 
        set diverted-medicine diverted-medicine + (m * dose) 
        set have-diverted? true 
        set divert-reason lput "friends" divert-reason 
        set purchased-pills? true 
        ask myself [set weeks-of-pills m] 
      ] 
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      set friends turtle-set other friends 
    ] 
  ] 
  ifelse purchased-pills? [report TRUE] 
  [report FALSE] 
end 
 
to buy-street-pills [street-market pills-on-street] 
let purchased-pills 0 
let pill-need dose * 7 * (1 - weeks-of-pills) 
 
ifelse pills-on-street > pill-need 
[ 
  while [purchased-pills < pill-need]  
    [ 
      if any? street-market with [pills-here > 0] [ 
        ask one-of street-market with [pills-here > 0] 
        [ 
          ifelse pills-here < ([pill-need] of myself - purchased-pills) 
          [ set purchased-pills purchased-pills + pills-here set pills-
here 0  set street-market other street-market ]  
          [ set pills-here pills-here - purchased-pills set purchased-
pills [pill-need] of myself ]  
        ] 
      ] 
    ] 
] 
[set purchased-pills pills-on-street ask street-market [set pills-here 
0 ]] 
end 
 
 
to start-tx  
  ifelse [OTP-doc?] of my-provider = true ; 
  [ 
    ifelse [provider-type] of my-provider = "MTH-doc"  
    [try-to-start-mth-tx]                              
    [try-to-start-bup-or-mth-tx]  
  ]  
  [start-bup-tx] 
end 
 
 
to try-to-start-mth-tx 
  let temp-no-pay? [no-pay?] of my-provider  
  let cantAffordMTH? FALSE 
  let have-MTH-spots [MTH-spots] of my-provider 
  let number-MTH-pts [count MTH-patients] of my-provider 
 
  ifelse [accepted-insurance-list] of my-provider = ["none"] 
    [set monthly-out-of-pocket-payment mth-cost ]                                                     
    [set monthly-out-of-pocket-payment mth-cost * (100 - coinsurance) / 
100] 
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  if monthly-out-of-pocket-payment > income * pct-of-income [set 
cantAffordMTH? TRUE] 
   
  ifelse ((cantAffordMTH? = FALSE or (cantAffordMTH? and temp-no-pay?))  
    and ((have-MTH-spots - number-MTH-pts) > 0))                                                 
    [ 
      ifelse [otp-doc?] of my-provider = false  
      [error "methadone error here" start-mth-tx] 
      [start-mth-tx] 
      ] 
    [ 
      set getting-bup-weeks -1  
      set waitlisted? TRUE  
      set cantAfford? TRUE 
      set provider-group  
      (turtle-set my-provider  
        ([colleagues] of my-provider) with [member? [insurance] of 
myself accepted-insurance-list = TRUE]  
        providers with [do-telemedicine? and member? [insurance] of 
myself accepted-insurance-list = TRUE] 
      )  
      set indexprovider indexprovider + 1 
      get-provider 
    ]                 
end 
 
 
 
to start-mth-tx 
  set recipient-flag? false   
  set getting-BUP-weeks -200 
  set got-any-tx-flag? TRUE 
  set seeking-BUP? false  
  set relapse? false  
  set stable-abstinence? false  
  set cantAfford? false  
  set waitlisted? FALSE 
  set color green - 2 
  set too-far? FALSE 
  set weeks-waiting 0 
end 
 
 
to try-to-start-bup-or-mth-tx 
  let number-bup-pts (count ([BUP-patients ] of my-provider) + count 
([tele-patients] of my-provider)) 
   
  ifelse [accepted-insurance-list] of my-provider = ["none"] 
    [set monthly-out-of-pocket-payment [visit-cost] of my-provider + 
monthly-medication-cost * (100 - coinsurance) / 100]  
    [set monthly-out-of-pocket-payment [visit-cost] of my-provider  * 
(100 - coinsurance) / 100 + monthly-medication-cost * (100 - 
coinsurance)/ 100]  
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  if monthly-out-of-pocket-payment > income * pct-of-income [set 
cantAfford? TRUE] 
  ifelse number-bup-pts < [capped-patients-per-provider] of my-provider 
and cantAfford? = FALSE and random 100 < pct-try-bup-first 
    [start-bup-tx] 
    [if [otp-doc?] of my-provider = TRUE[try-to-start-mth-tx]] 
end 
 
to start-bup-tx 
  set recipient-flag? TRUE  
  set getting-BUP-weeks getting-BUP-weeks + 1 
  set got-any-tx-flag? TRUE  
  set seeking-BUP? false  
  set relapse? false  
  set stable-abstinence? false  
  st  
  set color green  
  set size 1 
  set waitlisted? FALSE 
  set weeks-waiting 0 
   
  ifelse [accepted-insurance-list] of my-provider = ["none"] 
    [set monthly-out-of-pocket-payment [visit-cost] of my-provider  + 
monthly-medication-cost * (100 - coinsurance) / 100]                             
    [set monthly-out-of-pocket-payment [visit-cost] of my-provider  * 
(100 - coinsurance) / 100 + monthly-medication-cost * (100 - 
coinsurance)/ 100] 
  set total-tx-cost total-tx-cost + [visit-cost] of my-provider  + 
monthly-medication-cost 
  if monthly-out-of-pocket-payment > income * pct-of-income [set 
cantAfford? TRUE] 
end 
 
to start-seeking-tx 
  ask n-of (round (count deps * seeking-incidence / 52)) deps [  
    init-patient 
    set sought? true    
      ] 
  
end 
 
to add-to-BUP-list 
  ask my-provider[set BUP-patients (turtle-set BUP-patients myself)]  
end 
 
to add-to-MTH-list 
 ask my-provider[set MTH-patients (turtle-set MTH-patients myself)] 
end 
 
to add-to-tele-list 
  ask my-provider[set tele-patients (turtle-set tele-patients myself)] 
end  
331 
 Reporters.nls 
to-report random-lognormal[densd denmean] 
  let sigmaden sqrt (ln (((densd * densd) / (denmean * denmean)) + 1))  
  let mu ln (denmean) - (sigmaden / 2)  
  report (exp (random-normal mu sigmaden) ) 
; show mu 
; show sigmaden 
end 
 
to-report patients 
  report deps with [pt?] 
end 
 
to-report nonpats 
  report deps with [pt? = false] 
end 
 
to-report not-dummies 
   report providers with [provider-type != "dummy"] 
end 
 
to-report insurance-not-dummies 
  report providers with [provider-type != "dummy" and member? 
[insurance] of myself accepted-insurance-list = TRUE] 
end 
 
to-report real-providers 
  report providers with [provider-type != "dummy"] 
end 
 
to-report total-pop 
report sum [pop-den] of patches   
end  
 
 
